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Preface
Those already familiar with the content of a PhD thesis might notice that this particular one is not
written like most others. My research during my PhD contained two big topics that are outlined
in Part III and Part IV. However, to not directly throw around field-specific terms and equations,
this thesis starts with some chapters introducing (some of) these subjects to the reader and give
them a feeling what it is all about. As it was my intention to make my work more reachable to my
friends and family as well as scientists in less related fields, I’ve tried to write these introductory
chapters in lighter layman’s terms. I wanted them - and other people not specialized in these
subjects - to know and understand the general content of my work, or at least get a grasp of it.
DON’T PANIC if you do not understand everything (especially in the later sections)! The aim
here was to step out of the black box and show what I’ve been up to these last four years. I hope
you enjoy reading it and that it can convince you that your tax money was very well-spent!
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1
Research goals
As the title of this thesis already quite well reveals, the objective of my PhD was to develop
(bioinformatics) methods to handle the analysis of next-generation sequencing data, particulary
in an epigenetics context. DNA methylation, a chemical modification whereby a methyl group is
added on top of the DNA sequence, is the best kown and most studied epigenetic process and is
the focus of this thesis. It has been shown to be involved in gene regulation mechanisms such as
expression and splicing. Apart from its ‘normal’ biallelic state, DNA methylation can also occur
in an allele-specific state, termed monoallelic DNA methylation and is likely to be involved in
monoallelic gene expression. When this latter phenomenon is parental-dependent, it is labeled
as imprinting. Although imprinting is a familiar concept, only a handful of imprinted regions
are well-characterized. However, given the prevalent involvement of imprinted genes in growth
regulation, their disruption can result in disease phenotypes such as cancer, underlining the need
for methods to characterize imprinted loci and address their instability in tumor formation.
With the availability of next-generation sequencing technologies, it is now possible to screen
genomes for such features in a genome-wide manner. Indeed, for genome-wide DNA methylation
profiling, bisulfite sequencing is the gold standard and allows to readily identify monoallelically
methylated alleles at base pair resolution. Drawbacks however are the cost and di culties/com-
plexities in the post-analysis. Fortunately, there exist alternative enrichment-based sequencing
methods such as MethylCap-seq. But, although these methods are cost-e ective, they do not
provide the same resolution and are not directly applicable to detect monoallelic events. There-
fore, the first goal of the doctoral work was to devise a method that circumvents these
issues and that by solely using data from enrichment-based sequencing is still able to
identify imprinted regions.
Although additional validation proved the e ectiveness and reliability of the developed method,
we felt that there was still room for further optimization. Therefore, in a second stage, a
methodology was hatched that starts from the same rationale as the former method, but includes
major improvements and additional features, and was here applied on RNA-seq data. As second
4aim of this doctoral work, we wanted to identify the imprintome of human breast, and
how it is deregulated in cancer.
Next to imprinting and the development of methods to detect monoallelic events, the focus of
my PhD was interweaved with another topic, i.e. neuroepigenetics. This rather new research field
concerns the link between epigenetics and brain plasticity. Given the rapidly growing attention to
this latter research area - highlighted by the prevalent occurence in popular media (e.g. BRAIN
initiative) - an interuniversity collaboration was set up (IUAP programme) funded by the Belgian
Science Policy O ce in which we also participated. This network combines researchers of di erent
expertises questioning how brain plasticity is regulated at the cellular level and exploring the role
of hormones and the environment in brain plasticity through epigenetic changes. Therefore,
teamed up with experts in behavioral neuroendocrinology and using a songbird (= zebra finch)
as our model organism, our goal was to explore the role of DNA methylation in the establishment
and control of brain plasticity. A third aim of this doctoral work was therefore to map
the zebra finch functional methylome. This map was subsequently used for further research,
which was still ongoing when this doctoral thesis was completed, yet some preliminary results are
presented in the conclusions and perspectives chapter.
2
Outline
This thesis consists of five di erent parts. Part I describes some general concepts of molecular
biology. Although these sections can be considered as basic knowledge to anyone familiar with
genetics, I wanted to include them as they are crucial for understanding the concepts and tech-
niques used in further chapters and to provide the ‘whole’ background story (see Preface). After
introducing the reader to DNA, the central dogma of molecular biology and gene regulation, the
focus is shifted towards epigenetics with the main emphasis on DNA methylation and two of its
applications: imprinting and neuroepigenetics.
Part II gives an overview of the history of sequencing technologies and describes the emergence
of second and third generation sequencing technologies with a comprehensive discussion of the
Illumina sequencing technology and its applications. The second part dives into available methods
to detect DNA methylation together with their benefits and caveats. Finally, part II closes with
an overview of the data-analytical methods and most frequently used tools that are needed to
analyze next-generation sequencing data.
Part III concers the first objective of my PhD, namely the development of methods to de-
tect imprinting events using enrichment-based sequencing data. The first chapter describes the
first bioinformatics pipeline I developed to identify monoallelic DNA methylation starting from
MethylCap-seq samples. After discussing this pipeline and the obtained results, a brief intermezzo
links this part to the next and final chapter of this part. This chapter outlines the recent devel-
oped framework that includes further optimizations and extra features together with an extended
proof-of-concept using public RNA-seq datasets.
Part IV switches to the second research topic, i.e. the influence of DNA methylation in neuro-
plasticity. This part describes the pilot study performed on zebra finch cell lines in order to obtain
a first draft of the zebra finch methylome together with a list of genes putatively regulated by
DNA methylation. In addition, the link between these results and the extrapolation to the brain
are briefly discussed.
Part V is the final part and o ers a general conclusion and some future perspectives.

SUMMARY & SAMENVATTING
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3
Summary
Epigenetics is defined as the collection of heritable changes in gene expression of organisms that
are not encoded in the DNA sequence itself. DNA methylation is the best known epigenetic
process and involves the addition of a methyl group to the carbon 5’-position of cytosine by
methyltransferases, mainly in a CpG context (at least for mammals). In promoters, DNA methy-
lation generally leads to transcriptional silencing of the corresponding gene and is a major means
to regulate gene expression during development. Monoallelic DNA methylation is known to play
an important role in the regulation of monoallelic gene expression, a biological event in which
only one of the two gene copies is active and transcribed. An important example of monoallelic
methylation is the regulation of the parent-dependent monoallelic expression, a phenomenon
called imprinting, where the silenced allele is more methylated than the active, expressed allele.
Dysregulation of imprinted regions is associated with many diseases. Although imprinting is a
well-investigated topic, only a few imprinted regions are well-characterized in humans. Taking
advantage of the recent advent of next-generation sequencing platforms, here, we developed two
methodologies to screen for imprinted regions.
The first part introduces a data-analytical framework to screen for genes that exhibit monoallelic
DNA methylation and thus might regulate monoallelic expression. Using enrichment-based se-
quencing data, e.g. MethylCap-seq, the methodology screens for regions that exhibit monoallelic
DNA methylation based on classic population genetic theory, i.e. Hardy-Weinberg equilibrium, in
a genome-wide manner. After qualitative filtering of associated SNP loci in the MethylCap-seq
data, for each single SNP locus, the Hardy-Weinberg theorem is applied to evaluate whether
the observed frequency of samples featured by a biallelic event is lower than randomly expected.
Indeed, as it can be assumed that biallelic DNA methylation results in (enrichment-based) se-
quencing data which is in Hardy-Weinberg equilibrium for each locus - i.e. if SNPs are present,
both homozygous and heterozygous samples will be detected at a predictable rate - the search for
monoallelic methylation translates into the identification of loci where the observed fraction of
heterozygotes is significantly reduced (= deviation from Hardy-Weinberg equilibrium). Applied
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on 334 MethylCap-seq samples of diverse origin and using an FDR of 0.1, this resulted in the
identification of 80 genomic regions featured by monoallelic DNA methylation, of which 25 have
already been linked to imprinting. Further analysis revealed enrichment of these loci in promoter
regions demonstrating the relevance of our method. Additional validation was done using both
whole-genome bisulfite sequencing data and RNA-seq data, further establishing that the proposed
methodology allowed the identification of loci known to be imprinted as well as novel candidate
imprinted genes. Importantly, because of the general rationale of the developed approach, it can
be easily applied to other enrichment-based sequencing technologies, such as the ChIP-seq-based
identification of monoallelic histone modifications.
Although the developed framework was able to accurately detect imprinted loci, it also has some
downsides, with its computational load as the biggest disadvantage. In order to tackle these
drawbacks, a novel methodology was developed that starts from the previous framework, but
includes some improvements. This methodology models the data as a mixture distribution of
homozygous and heterozygous samples and uses Maximum Likelihood Estimation and the Like-
lihood Ratio Test to identify significant imprinting. Importantly, while the ‘old’ model does not
explicitly model imprinting, this novel framework also enables the detection of partial imprinting.
Using this methodology on 113 healthy control RNA-seq samples, we were able to identify 140 im-
printed SNP loci, corresponding with 60 genes, including both some of the well-known imprinted
loci as well as several novel loci not yet detected by other methods. Additional validation by
comparing our found imprinted set with (i) imprinted loci found by other methods and/or present
external references and (ii) our previously reported monoallelically methylated loci together with
methylation data matching our used sample set, demonstrated the e cacy of our method. Ad-
ditionally, the method was extended to study di erential imprinting between control and cancer
samples. By applying this on 506 breast cancer RNA-seq samples, putative deregulation of 3
imprinted loci was observed, particularly in HER2-positive tumors. In conclusion, using RNA-seq
data of breast samples, we provide an overview of both known and novel imprinted loci in normal
breast tissue as well as regions that are putatively deregulated in breast cancer.
Although methylation has traditionally been regarded as a highly stable epigenetic mark, it has
been observed that the postnatal brain shows stimulus-induced de novo CpG methylation or active
DNA demethylation at specific loci during the process of learning and memory formation. Due to
the presence of multiple behavioral parallels between song learning and human speech learning and
striking homologies between the brains of birds and mammals, songbirds - and in particular the
zebra finch (Taeniopygia guttata) - became a widely used model organism in neuroscience. How-
ever, until now, a genome-wide DNA methylation pattern of this species is still lacking. Therefore,
we aimed at establishing a genome-wide DNA methylation map of the zebra finch genome, as
well as identifying putatively epigenetically regulated genes. MethylCap-seq experiments were
performed on two zebra finch cell lines in presence and absence of AZA-induced demethylation.
However, as MethylCap-seq has been primarily used for human and mouse epigenomic studies,
in a first step the MethylCap-seq methodology was validated in zebra finch by comparison with
data generated by the species neutral (yet less genome-wide) RRBS methodology. In addition,
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to assess the influence of (variable) methylation on gene expression, RNA-seq experiments were
performed as well. Comparison of this expression data with MethylCap-seq results showed that at
least 357 genes are putatively regulated by promoter methylation, for which an additional pathway
analysis showed clear enrichment for neurological networks. A subset of genes was validated using
Exon Arrays, quantitative RT-PCR and CpG pyrosequencing on bisulfite-treated samples. Using
this approach, we provide the first genome-wide DNA methylation map of the zebra finch genome
as well as a comprehensive set of genes of which transcription is under putative DNA methylation
control, including many neurobiologically relevant genes. As such, this study can be an important
starting point for future epigenetic studies in zebra finch and an attractive data-mining tool for
(neuro)epigenetic studies in songbirds.
Source: [1].

4
Samenvatting
Epigenetica is gedefinieerd als de collectie van overerfbare veranderingen in genexpressie die niet
gecodeerd zitten in de DNA sequentie zelf. DNA methylatie is het best gekende epigenetische
proces en omvat de additie van een methylgroep door methyltransferases op de 5’-positie van
cytosine, hoofdzakelijk in een CpG context (althans bij zoogdieren). DNA methylatie in promoter-
regio’s is een belangrijk onderdeel bij de regulatie van genexpressie tijdens de ontwikkeling en leidt
over het algemeen tot transcriptionale silencing van het overeenkomstige gen. Van monoallelische
DNA methylatie is reeds geweten dat het een cruciale rol speelt bij de regulatie van monoallelische
genexpressie, een biologische gebeurtenis waarbij slechts één van de twee genkopijen actief is en
vertaald wordt. Een belangrijk voorbeeld in deze context is de regulatie van parentaal afhanke-
lijke monoallelische expressie, imprinting genoemd, waar het stilgelegde allel meer gemethyleerd
is dan het actieve, geexpresseerde allel. Deregulatie van imprinted regio’s is reeds geassocieerd
met vele ziektes. Echter, hoewel imprinting een druk onderzocht onderwerp is, zijn er tot dusver
slechts enkele imprinted regio’s die goed in kaart zijn gebracht. Voordeel halend uit de recente
opkomst van next-generation sequeneringsplatformen, hebben we hier, in dit proefschrift, twee
methodologieën ontwikkeld om te screenen naar imprinted regio’s.
Het eerste deel introduceert een data-analytisch kader om te screenen voor genen gemarkeerd
met monoallelische methylatie, en die dus mogelijks ook monoallelische expressie reguleren. Door
het gebruik van sequenerings data gebaseerd op een aanrijkingsstap, zoals o.a. MethylCap-seq,
en op basis van een klassieke populatie genetica theorie, namelijk het Hardy-Weinberg even-
wicht, gaat de methodologie op zoek naar monoallelisch gemethylateerde regio’s, en dit op een
genoomwijde manier. Na kwalitatieve filtering van geassocieerde SNP loci in de MethylCap-seq
data, wordt voor elk individueel SNP locus de Hardy-Weinberg theorie toegepast om te eval-
ueren of de geobserveerde fractie van stalen, gekenmerkt door een biallelische gebeurtenis, lager
is dan wat at random zou verwacht worden. Inderdaad, doordat er kan aangenomen worden dat
biallelische DNA methylatie resulteert in (aangerijkte) sequeneringsdata dat in Hardy-Weinberg
evenwicht is voor elk locus - m.a.w. als er SNPs aanwezig zijn, worden zowel homozygote als
heterozygote stalen gedetecteerd met een voorspelde hoeveelheid - vertaalt de zoektocht naar
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monoallelische methylatie zich naar de identificatie van loci waarbij de geobserveerde heterozy-
gotenfractie significant gereduceerd is (= afwijking van Hardy-Weinberg evenwicht). Toegepast
op 334 MethylCap-seq stalen van diverse oorsprong en bij een FDR van 0.1, resulteerde dit in
de identificatie van 80 genomische regio’s met potentiële monoallelische methylatie, waarvan er
25 reeds gelinkt zijn aan imprinting. Verdere analyse onthulde de aanrijking van deze loci in
promoterregio’s, wat de relevantie van onze methode aantoont. Met behulp van genoomwijde
bisulfiet sequenering en RNA-seq data werden deze resultaten verder gevalideerd, wat nog eens
extra aantoont dat de vooropgestelde methode e ectief de detectie toelaat van zowel gekende
als nieuwe kandidaat imprinted genen. Belangrijk hierbij is dat, door de generieke gedachtengang
van de ontwikkelde aanpak, dit ook eenvoudig kan toegepast worden op andere soortgelijke se-
queneringstechnologieën, zoals bijvoorbeeld de ChIP-seq gebaseerde detectie van monoallelische
histonmodificaties.
Hoewel het ontwikkelde kader in staat was om op een accurate manier imprinted loci te detecteren,
had het echter ook wat minpunten, met de grote computationale vereisten als koploper. Omwille
van deze nadelen werd een nieuwe methodologie ontwikkeld met als basis de vorige methode, maar
met een paar verbeteringen. Ditmaal wordt de data gemodeleerd als een ‘gemixte’ distributie
van homozygote en heterozygote stalen en wordt gebruik gemaakt van de ‘Maximum Likelihood’
schatting en de ‘Likelihood Ratio Test’ om significant imprinting te detecteren. Waar het ‘oude’
model geen rekening houdt met de specifieke graad van imprinting, laat dit nieuwe model wel de
detectie toe van partiële/intermediaire imprinting. Dit model werd getest op 113 RNA-seq stalen
van gezonde controles resulterend in de identificatie van 140 imprinted SNP loci, wat overeen komt
met 60 genen, inclusief reeds gekende imprinted regio’s alsook sommige nieuwe loci. Vervolgens
werd deze gevonden imprinted set van genen vergeleken met (i) imprinted loci gevonden door
andere methodes en/of aanwezig in externe referenties en (ii) met onze reeds gerapporteerde
monoallelische loci in combinatie met bijhorende methylatie data van onze gebruikte RNA-seq
stalen. Deze tweeledige validatie demonstreerde eveneens de doeltre ende van onze methode.
Deze methodologie werd vervolgens nog verder uitgebreid om als extraatje ook nog mogelijke
di erentiële imprinting op te sporen tussen controle en kankerstalen. Na toepassing van deze
uitbreiding op 506 RNA-seq stalen afkomstig van borstkanker, werd de mogelijke deregulatie van
3 imprinted loci waargenomen, en dit voornamelijk in HER2-positieve tumoren. Dus, door onze
nieuwe methode los te laten op RNA-seq stalen afkomstig van borstweefsel, brengen we een
overzicht van zowel gekende als nieuwe imprinted loci in normaal borstweefsel alsook regio’s die
hypothetisch gedereguleerd zijn in borstkanker.
Alhoewel methylatie traditioneel gezien werd als een uiterst stabiele epigenetische merker, werd
stimulatie geïnduceerde de novo CpG methylatie of actieve DNA demethylatie reeds geobserveerd
in postnatale hersenen op specifieke loci gedurende de ontwikkeling van het geheugen en leerpro-
ces. Gegeven de verschillende gelijkenissen tussen het leren zingen bij de zangvogels en praten
bij de mens, en de frapante homologieën tussen de hersenen van vogels en zoogdieren worden
zangvogels - en in het bijzonder de zebravink (Taeniopygia guttata) - zeer frequent gebruikt
als modelorganisme in de neurowetenschappen. Alhoewel, momenteel is het genoomwijde DNA
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methylatiepatroon van deze soort (nog) niet beschikbaar. Daarom was het onze doelstelling om
zo’n genoomwijde DNA methylatiemap van de zebravink op te stellen, en putatief epigenetisch
gereguleerde genen te identificeren. MethylCap-seq experimenten werden uitgevoerd op twee ze-
bravink cellijnen in de aanwezigheid of afwezigheid van AZA-geïnduceerde demethylatie. Gezien
MethylCap-seq tot nu toe hoofdzakelijk gebruikt werd in humane en muis epigenomische stud-
ies, werd in een eerste stap de MethylCap-seq methodologie gevalideerd in de zebravink door de
vergelijking van data gegenereerd door een species-neutrale (maar minder genoomwijde) RRBS
methodologie. Aanvullend, om de invloed van (variable) methylatie op genexpressie in kaart te
brengen, werden eveneens RNA-seq experimenten uitgevoerd. De vergelijking tussen expressie
data en MethylCap-seq resultaten toonde aan dat op z’n minst 357 genen putatief gereguleerd
worden door promotermethylatie, de daaropvolgende pathway-analyse toonde een duidelijke aan-
rijking voor neurale netwerken aan. Een subset van genen werd gevalideerd met behulp van
Exon Arrays, quantitative RT-PCR en CpG pyrosequenering op bisulfiet behandelde stalen. Met
behulp van deze methodologie, stelden we voor het eerst een genoomwijde DNA methylatiemap
op van het zebravink genoom en detecteerden we een uitgebreide set van genen waarvan de
transcriptie gecontroleerd wordt door putatieve DNA methylatie, inclusief vele neurobiologisch
relevante genen. Bijgevolg kan deze studie een belangrijk startpunt betekenen voor toekomstige
epigenetische studies in zebravinken en eveneens een aantrekkelijke data-mining tool vormen voor
(neuro)epigenetische studies in zangvogels.
Source: [2].

PART I
INTRODUCTION TO GENETICS,
EPIGENETICS AND IMPRINTING
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1
Molecular biology, genetics & genomics
‘Almost all aspects of life are engineered at the molecular level, and without understanding
molecules we can only have a very sketchy understanding of life itself.’ - Francis Crick
What is molecular biology? The term has multiple definitions, but one restrictive, workable
definition is that it attempts to explain genes and their activities in molecular terms. One of its
major disciplines is genetics, the branch of science concerned with the function and molecular
structure of genes, heredity, and variation in living organisms. But before going to the world of
genetics, let us first take a look at the structure of the cell.
1.1 The cell
Living things, including you, the reader, are made up of cells. Eukaryotic cells are the basic
structural, functional and biological unit of all known life forms and are therefore often referred
to as ‘the building blocks of life’. They provide structure to the body, convert nutrients to energy
and carry out specialized functions. Cells also carry the genetic, hereditary information and can
make copies of themselves. A cell is made up of many smaller parts (e.g. cytoskeleton, multiple
organelles), each with their own functions, and is kept together by the cell membrane (Figure 1.1).
Inside the cell, there are two major compartments: (i) the cytoplasm and (ii) the nucleus. While
the cytoplasm contains the structures that perform the cell’s functions, the nucleus contains the
structures that control cell division and the cell’s genetic material, i.e. DNA (with some minor
exceptions, see further).
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Figure 1.1: Although there are many di erent types of cells, most cells have the same components.
A cell consists of a nucleus and cytoplasm and is contained within the cell membrane. The nucleus
contains the cell’s genetic material and a nucleolus, which produces ribosomes. Ribosomes produce
proteins, which are packaged by the Golgi apparatus. The cytoplasm consists of a fluid material
and organelles. The endoplasmatic reticulum transports materials within the cell. Mitochondria
generate energy for the cell’s activities. Lysosomes harbor enzymes that can break down particles
in the cell. Centrioles participate in cell division. Source: [3].
1.2 Genes & DNA
The cell nucleus harbors the genetic, hereditary information. The functional, molecular unit of
heredity is a gene that in normal situations encodes for a functional product (RNA or protein).
Genes are made of deoxyribonucleic acid (DNA), the molecule that stores our biological informa-
tion and encodes the genetic instructions used in the development and functioning of most living
organisms. Although already identified and isolated in 1869, its now well-known double helix
structure was only first discovered by Watson, Crick and Franklin in 1953 (Figure 1.2(a)) [4, 5].
The double helix consists of two anti-parallel strands, whereby each single stranded DNA (ssDNA)
molecule is a long biopolymer of nucleotides composed of four repeating bases - adenine (A),
cytosine (C), thymine (T) and guanine (G) - linked to the 1’-position of the sugar (deoxyribose)
of a sugar-phosphate backbone. The sugar and phosphate residues are bound in an asymmetric
fashion, giving the ssDNA molecule a specific orientation, the head generally referred to as the
5’-end and the tail as the 3’-end. Two ssDNA molecules are arranged in opposite directions
(anti-parallel) into a double helix, stabilized by hydrogen bonds between the bases of each strand
- where A always pairs with T (two hydrogen bonds) and C always pairs with G (three hydrogen
bonds) (Figure 1.2(b)) [4].
Eukaryotic organisms store most of their DNA inside the cell nucleus, while a small amount
of DNA can also be found in some cell organelles, such as mitochondria/chloroplasts. Nuclear
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(a) (b)
Figure 1.2: (a) Watson and Crick. Source: [6]. (b) Structure of DNA. Source: U.S. National
Library of Medicine.
DNA does not appear in free linear strands, but is highly condensed and wrapped around specific
proteins, forming a chromatin structure. In its extended form chromatin looks like beads on a
string. The beads are called nucleosomes, each composed of DNA wrapped around proteins called
histones [7, 8]. This chromatin structure is even further condensed by several levels of packing
eventually forming the famous chromosomes (Figure 1.3). The diploid human genome consists
of twenty-two autosomal chromosome pairs and one pair of sex chromosomes [9].
Due to the recent advent of rapid and relatively inexpensive sequencing platforms, researchers
have been able to obtain the sequences of entire genomes instead of one gene at a time, thereby
creating a new subdiscipline called ‘genomics’, the study of complete genomes. The haploid
human genome (i.e. twenty-three chromosomes) consists of approximately three billion bases in
a specific order. Human genomes include both ‘(protein-)coding’ and ‘non-coding’ DNA. The
human genome holds more or less 30,000 genes and one gene has an average coding length of
1,000 base pairs (bp). This means that human cells contain about 100 times more DNA than they
apparently need. This extra, non-coding fraction of the DNA used to be dismissed as ‘junk DNA’
[10, 11], but recent evidence has revealed that this ‘junk DNA’ actually contains a landscape of
genetic elements important for gene regulation [11, 12]. So although its sequence has already
been completely determined, the function of at least half of the genomic regions is not yet fully
understood.
1.3 The central dogma of molecular biology
DNA to RNA to protein: this is the central dogma, a term first coined by Francis Crick in 1958
and re-stated in 1970 [5, 14]. It provides the basic framework explaining how genetic information
flows in a sequential nature between the three classes of information-carrying molecules, i.e. DNA,
Adenine Thymine 
Guanine Cytosine 
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Figure 1.3: The DNA of a cell is tightly packed into chromosomes. DNA is wrapped around small
proteins called histones. The beady histones are then further organized and folded into chromatin
aggregates that eventually make up the chromosomes. Source: [13].
RNA and protein. The dogma states that in general only three information transfers occur within
a cell (Figure 1.4(a)).
• DNA replication
The information stored in a DNA molecule can be passed on to another DNA molecule.
This is maybe the most important transfer, as it is needed to sustain the genetic material
in the progeny of any cell during cell division.
• Transcription
The information stored in a DNA molecule - corresponding to a gene - can also be passed
to a di erent molecule named ribonucleic acid (RNA). The main di erences between RNA
and DNA are that RNA uses ribose as a sugar in its sugar-phosphate backbone and that
thymine is replaced by uracil (U). Importantly, unlike DNA, it is more often found as a
single stranded molecule (instead of paired double stranded). There are di erent types
of RNA molecules, but the RNA copy destined to be translated into a protein is called
‘messenger RNA’ (mRNA). Before the subsequent translation process to a protein, the
pre-mRNA undergoes some preprocessing steps (e.g. protective measures (capping, poly-A
tailing) and splicing). The DNA sequence of a gene is not entirely protein-coding. During
splicing, the intronic (= non-coding) regions are removed from the mRNA by a protein
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complex that recognizes splice sites, the spliceosome, and joins the remaining exons to
form a mature mRNA molecule, the actual transcript. Apart from the introns, genes also
contain di erent regulatory elements which are not transcribed. In most cases, the actual
protein-coding part of gene makes up only a very small fraction of the gene’s total length.
• Translation
After successful transcription and subsequent mRNA preprocessing, the information stored
in the RNA molecule can be tranlated to a sequence of amino acids, the building blocks of
proteins. The mature mRNA is transferred outside the nucleus to the ribosomes, protein
complexes that read the mRNA-sequence of A, U, C and Gs and translate the large majority
of them into a sequence of amino acids. Three consecutive mRNA bases are defined as
a ‘codon’, and every codon is recognized by a specific amino acid, which is attached to a
corresponding transfer RNA (tRNA). In total, there are twenty amino acids that are encoded
by the mRNA codons, including start and stop codons. Thus, there are 43 (= 64) possible
codons for twenty amino acids, meaning that some amino acids can be encoded by more
than one codon. After translation, the protein undergoes some extra post-translational
modifications and is folded into its three-dimensional functional structure. The resulting
protein is now ready to perform its function inside or outside the cell.
(a) (b)
Figure 1.4: (a) Diagram of the central dogma, showing how information flows between the three
classes of information-carrying molecules, i.e. DNA, RNA and proteins via the fundamental pro-
cesses of replication, transcription and translation. (b) Same diagram of central dogma, but now
also with indication of unusual flows of information (green arrows). i) Reverse transcription: a
process known to occur in retroviruses and eukaryotes (retrotransposons) by which genetic infor-
mation from RNA gets transcribed into new DNA. ii) RNA replication: the copying of one RNA
to another by a specific enzyme called RNA-dependent RNA polymerase. Many viruses replicate
this way, but it also found in eukaryotes involved in RNA silencing. Source: [15].
However, today we know that the central dogma does not capture the full complexity and that
many exceptions exist (Figure 1.4(b)) [11]. For example, certain viruses can create DNA from
an RNA template in a process called reverse transcription [12, 16].
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1.4 Gene regulation
Transcription and translation are two consecutive steps of the general process termed gene ex-
pression, i.e. the process by which the genetic code stored in DNA is interpreted and used in the
synthesis of functional gene products (RNA and/or protein). The body is composed of many
di erent cell types, each with its own structure and functionality (e.g. blood cells, muscle cells
and skin cells), so cells need a tight regulation of gene expression to preserve their cell type char-
acteristics. In order to do this, the cell has multiple control mechanisms, of which transcriptional
regulation is the first in line to control the rate of gene transcription, and thus the amount of
RNA that is ‘transcribed’, as well as the specific variant of the RNA molecule [11]. The rate of
gene transcription is mainly orchestrated by proteins called ‘transcription factors’ that recognize
specific DNA sequences (protein-binding sites) in or near a genic region, thereby stimulating or
impeding gene transcription.
For example, a promoter region is a DNA region (10-1,000bp long) found before the start of a
gene’s coding region (transcription start site (TSS)) that, when bound by activating transcription
factors, initiates transcription through recruitment of RNA polymerase, the enzyme that copies
the DNA into an RNA molecule [17]. Many eukaryotic genes have a conserved promoter sequence
called the TATA box, located 25 to 35bp upstream of the transcription start site. Transcription
factors bind to the TATA box and initiate the formation of the RNA polymerase transcription
complex, which promotes transcription. Although the promoter structure was originally thought
to be invariant, a remarkable degree of diversity has become apparent. Generally, a promoter
exists of three elements: the core promoter, the proximal promoter and the distal promoter. The
former is the minimal portion required to properly initiate transcription and includes the TSS, the
TATA box and a binding site for RNA polymerase. The latter two promoter elements are further
upstream of the TSS and contain extra regulatory elements (e.g. additional specific transcription
factor binding sites) [18]. Next to these promoter-specific regulatory elements, gene promot-
ers can have additional regulatory elements that are sometimes several kilobases away from the
TSS. These regions, termed enhancers, can be bound by specific proteins (activators) thereby
increasing the likelihood of the transcription of the corresponding gene [19].
Apart from transcription, other steps in the gene expression process can be modulated as well,
namely translation as well as post-transcriptional and -translational regulation [11]. As the
name suggests, post-transcriptional regulation occurs after transcription, but before translation,
and a ects the stability and distribution of the resulting RNA transcript through certain RNA-
modifications. Generally, (pre-m)RNA processing includes five processes: (i) 5’-end capping, (ii)
RNA editing, in which individual RNA residues are converted to alternative bases to produce
mRNAs encoding distinct protein products (iii) splicing, in which introns are removed and exons
are ligated together by the spliceosome, (iv) 3’-end formation, which involves cleavage and syn-
thesis of the poly-A tail, and finally (v) degradation. Interestingly, research showed that some of
these pre-mRNA processes occur in tight regulation with transcription, i.e. before RNA synthesis
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is complete (= co-transcriptional) or at least begin during RNA synthesis by RNA polymerase
and continue post-transcriptionally [20, 21]. Examples are R-loop formation and (alternative)
splicing. An R-loop is a structure in which an RNA molecule is partially or completely hybridized
with one strand of a dsDNA, leaving the other strand unpaired, forming RNA-DNA hybrids.
Such R-loop structures have long been reported from bacteria to yeast and mammals and are
shown to be involved in genomic stability as well as in the (prevention of) DNA methylation
process of the underlying sequence [22]. Although most RNA splicing occurs after the complete
synthesis and 3’-end formation of the pre-mRNA, transcripts with many exons can be spliced
co-transcriptionally. The nature of co-transcriptional splicing suggests that changes in transcrip-
tion can dramatically a ect splicing, and that splicing can, in turn, influence transcription. It has
been shown to play a part in coordinating both constitutive and alternative splicing. Importantly,
recent evidence suggests that DNA methylation also prominently a ects the splicing process (see
next Chapter section 2.3) [23, 24].
Likewise, post-translational modifications influence the stability and amount of active proteins
in the protein pool after translation. For example, the addition of a covalently bound phos-
phate group (phosphorylation) may alter the protein’s structural conformation, leading to its
(de)activation. In some cases, protein phosphorylation can also modify the protein’s function.
Ubiquitination on the other hand, i.e. the addition of ubiquitin, marks the protein for degrada-
tion thus altering its stability [9]. Many other post-translational mechanisms exist, yet these are
beyond the scope of this dissertation and will therefore not be further discussed.
Another major player in gene regulation is epigenetics. As this is a very important concept in
order to understand the next parts of this PhD thesis, it has the privilege to be elaborated below
in its own chapter.
Source: [25].
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Epigenetics
‘Epigenetics doesn’t change the genetic code, it changes how that’s read. Perfectly normal genes
can result in cancer or death. Vice-versa, in the right environment, mutant genes won’t be
expressed. Genes are equivalent to blueprints; epigenetics is the contractor. They change the
assembly, the structure.’ - Bruce Lipton
The central dogma described above sketches our DNA as the carrier of our genetic and inheritable
material. However, genetics alone - thus, taking only the genes into account - is not able to explain
all observed events. For example, although identical twins are genetically identical, i.e. have the
same DNA sequence, they often exhibit di erent physical characteristics and during life one can
develop a disease while the other stays una ected. Also, while every cell in our body has the same
set of genes, obviously, not all cells are the same: the cells in our heart, for instance, work very
di erently from the cells in our eyes. The same is true for our skin and our liver cells, or our brain
and muscle cells, or any of the other 300 di erent cell types. These cells are dissimilar because they
use the same set of genes di erently. Some of these di erences can be explained by epigenetics,
which literally means ‘on top of genetics’. Epigenetics was first described by Waddington in
1942 and describes the study of heritable (both mitotically and meiotically) alterations in gene
expression not mediated by changes in the underlying DNA sequence [26]. Thus, epigenetics adds
an extra layer of information on top of the DNA - usually in the form of proteins or chemical
modifications - without altering the DNA sequence itself and is regarded as the bridge between
genotype and phenotype. The most widely studied players in epigenetic regulation are histone
modifications, some classes of non-coding RNA such as micro RNA (miRNA) or long non-coding
RNA (lncRNA), and finally DNA methylation. Importantly, these and other regulators interact
and the final state is the combined result of the three mutual e ects [27].
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2.1 Histone modifications
Section 1.2 and Figure 1.3 already explained that nuclear DNA is found in a complex of DNA
and histones called chromatin. Chromatin is the template of the epigenetic scenery with the
nucleosome as its basic structural repeating unit. Each nucleosome is composed of about 146bp
of DNA wrapped around eight histone proteins (two times H2A, H2B, H3 and H4), the ‘histone
octamer’ (Figure 2.1). Histones are a family of small, positively charged proteins. DNA, on the
other hand, is negatively charged ensuring that the DNA is very tightly bound to the histone
octamer. These nucleosomes are joined by the DNA between them, referred to as ‘linker DNA’
(+≠ 20bp), eventually forming the chromatin string. On top of the nucleosome bead, one histone
H1 is bound to the linker DNA between nucleosomes stabilizing the chromatin fiber and keeping
in place the DNA wrapped around the nucleosome. Chromatin is a very dynamic molecule and
although there are a lot of possible configurations, generally only two global conformations are
considered: ‘euchromatin’ and ‘heterochromatin’. The latter being a tightly packed form (in
the nucleosomes) silencing gene expression, while the former refers to an open, non-condensed
chromatin form enabling gene expression [8, 28].
Figure 2.1: Schematic representation of chromatin structure. Nucleosomes are represented by
DNA (grey) wrapped around eight histone proteins, H2A, H2B, H3, and H4 (colored circles).
N-terminal histone tails (blue) are shown protruding from H3 and H4. Source: [29].
Histones have long N-terminal tails that stick out of the nucleosome and can undergo several
post-translational modifications, such as acetylation, methylation and phosphorylation (Figure
2.1). They are regulated by specific enzymes and enzyme complexes such as histone acetyltrans-
ferases (HATs), histone deacetylases (HDACs) and histone methyltransferases (HMTs). Di erent
modifications can be present simultaneously, together composing the ‘histone code’. These mod-
ifications take place on specific amino acids in the N-terminal histone tails and the e ect depends
upon the specific amino acid that is modified. Furthermore, histones can be modified simulta-
neously by diverse modifications and at di erent sites, so that cross-talk - either at the same
site, at di erent sites on the same histone or even between di erent histone tails - can occur.
Depending on the type and exact location of the modifications, the chromatin will be open (eu-
chromatin) or closed (heterochromatin). The latter can be further subdivided into parts which are
always repressed, called constitutive heterochromatin, and parts which can be active depending on
amongst others tissue type, called facultative heterochromatin. Each of these di erent chromatin
environments is identified by a specific set of post-translational modifications, ultimately forming
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distinct regions that will be transcribed or silenced. For example, the presence of euchromatin
is often associated with hyperacteylation of lysine residues in the histone tails as well as with
less histone and DNA methylation and less histone H1 binding. In contrast, heterochromatin is
characterized with deacetylation of histone proteins, methylation on the lysine 9 and 27 residues
of H3 and lysine 20 of H4, DNA methylation and attraction of heterochromatin protein 1. In
addition, these modifications attract other proteins which can bind or are blocked from binding
depending on the specific modifications [28]. It is important to remember that these processes
are reversible, so modified or remodeled chromatin can sometimes be returned to its compact
state after transcription and/or replication is complete.
2.2 RNA
Multiple studies on model organisms of plants and animals yielded evidence that RNA, and in
particular non-coding RNA (ncRNA), also plays a significant role in the epigenetic regulation of
gene expression. In general, ncRNAs function to regulate gene expression at the transcriptional
and post-transcriptional level, with silencing of repetitive DNA sequences and dosage compensa-
tion as well-known examples. Non-coding RNAs involved in epigenetic processes can be divided
into two main groups, namely the short ncRNAs (<30bp, i.e. microRNAs (miRNAs), short inter-
fering RNAs (siRNAs), and piwi-interacting RNAs (piRNAs)) and the long ncRNAs (>200bp).
Both major groups are shown to play a role in heterochromatin formation, histone modification,
DNA methylation targeting, and gene silencing [30, 31]. Note that since the RNA sequence is
already fully contained in the DNA code, these ncRNA moieties are often considered as an extra
epigenetic mechanism (next to histone modifications and DNA methylation) ‘in the broad sense’.
2.3 DNA methylation
DNA methylation is the best known and most studied epigenetic process and involves the addition
of a methyl group to a cytosine residue. In plants, methylation takes place in a CG, CHG or CHH
(H = A, C or T) context, while in mammals this almost exclusively occurs at cytosine residues
within a CG dinucleotide [32]. This symmetric dinucleotide is often indicated as CpG, where the
‘p’ represents the phosphodiester link between the two bases. Since the work in this thesis is
performed in the context of vertebrates, we will only consider the latter type of DNA methylation.
There are two di erent mechanisms that establish the DNA methylation pattern: (i) de novo
methylation and (ii) maintenance methylation. In both forms, the reaction is catalyzed by en-
zymes called DNA methyltransferases (DNMTs), which use S-adenosyl-L-methionine (SAM) as
a substrate. By converting it to S-adenosyl-L-homocysteine (SAH) DNMTs can transfer the
methyl group to the 5’-position of a cytosine, ultimately forming 5’-methylcytosine (5-mC) (Fig-
ure 2.2(a)). Maintenance methylation, i.e. maintenance of the DNA methylation pattern after
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DNA replication, is catalyzed by DNMT1 on hemi-methylated DNA. Other methyltransferases
(DNMT3A and DNMT3B) mainly establish de novo methylation, i.e. the addition of methyl
groups to previously unmethylated DNA (Figure 2.2(b)) [33–35].
(a)
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Figure 2.2: (a) Methylation of a cytosine residue by a DNMT using SAM as a substrate. Source:
[36] (b) Genomic DNA (gDNA) is shown as a horizontal black line with CpG sites marked as vertical
lines. Unmethylated DNA (upper part) is de novo methylated by DNMT3A and DNMT3B resulting
in symmetric methylation on some of the CpG dinucleotides. After DNA replication (lower part), a
DNA double strand is formed composed of one - still unmethylated - newly shaped strand and one -
already methylated - strand originating from the parental cell. DNMT1, the maintenance DNMT,
makes sure that symmetric methylation stays conserved on those loci where, after replication,
only one strand (parental) is methylated (= hemi-methylated), but does not perform de novo
methylation. Source: [37].
Approximately 60-70% of our CpGs are methylated, which accounts for roughly 3-6% of all
cytosines in the human genome. Methylated cytosines are widely spread across the genome, with
particularly high densities in repetitive DNA sequences, transposons and promoters of retroviruses
[38]. The remaining unmethylated CpGs are usually found in so-called CpG islands, which are
DNA regions with a high CpG frequency and distributed in a non-random way, namely in regulatory
genic regions with a preference for the promoter and the first exon of genes [39]. About 60%
of known promoters are linked to a CpG island. The majority of CpG islands remain free of
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methylation and are associated with transcriptionally active genes, such as housekeeping genes.
However, in promoter CpG islands, DNA methylation generally leads to transcriptional silencing
of the corresponding gene. Gene bodies like exons and introns can be methylated as well. Yet,
here methylation is associated with active transcription and, importantly, with alternative splicing
events. Indeed, although DNA methylation was originally thought to only a ect transcription,
emerging evidence shows that it also regulates alternative splicing. Exons, and especially splice
sites, have higher levels of DNA methylation than flanking introns, and the splicing of about 22%
of alternative exons is regulated by DNA methylation [40].
Next to DNA methylation, also DNA demethylation can occur, either in a passive or in an active
fashion. Passive demethylation takes place when the ‘normal’ maintenance methylation pathway
is disturbed, and the present amount of DNA methylation becomes diluted after DNA replication.
In other cases, methylation is removed through enzymes that directly target and modify the methyl
group, i.e. active demethylation [40]. For example, it has recently been shown that the ten-eleven
translocation (TET) protein converts 5-mC into 5’-hydroxymethylation (5-hmC) which can be
further processed to demethylated cytosines with the aid of enzymes involved in DNA repair [41].
DNA methylation is a major means to regulate gene expression during development. In mammals,
it plays an important role in processes like embryo- and gametogenesis, stem cell di erentiation,
genomic imprinting, X-chromosome inactivation and silencing of repetitive elements. As it is a
defining feature of cellular identity and essential for normal development, its dysregulation is often
associated with diseases, such as cancer and mental retardation, through aberrant activation or
silencing of genes [32]. But how does DNA methylation actually interfere with gene expression?
In most cases, promoter methylation leads to silencing (= blocking expression) of the corre-
sponding gene. However, this is a slight oversimplification of the reality. Initially, it was assumed
that methylation prevented or altered the correct binding of certain transcription factors to the
DNA, thus hindering normal transcription (Figure 2.3a). In a number of cases, this mechanism is
indeed involved, but, generally, there are two other mechanisms by which promoter methylation
can interfere with gene expression [40, 42]. A first alternative is one where specific transcriptional
repressors bind directly to methylated CpGs with a Methyl-CpG Binding Domain (MBD). When
bound to methyl groups, these MBD-containing proteins can repress gene transcription through
the recruitment of histone deacetylases (HDACs). Subsequently, these HDACs deacetylate the
histones, causing the chromatin to condense thereby becoming inaccessible for the transcription
machinery (Figure 2.3). Lastly, the chromatin structure of methylated and unmethylated DNA
is di erent. Dense DNA methylation has been shown to trigger histone hypoacetylation, leading
to a more closed chromatin structure. Depending on the exact location of the methylated re-
gion, this can directly decrease the expression rate by a decreased e ciency of RNA polymerase.
Importantly, these three mechanisms do not exclude each other: the final silencing e ect is the
joint result of the three [43].
Thus, during the process of cell division (mitosis), the symmetric DNA methylation patterns
are re-established in the daughter cells and therefore stably maintained. During gametogenesis,
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Figure 2.3: If a gene promoter is not methylated, the transcription factors can bind and sub-
sequently initiate the transcription process (upper DNA strand). If however, the promoter is
methylated, transcription factor binding is hindered, thus blocking the normal transcription pro-
cess. Alternatively, MBD-containing proteins like MeCP2 bind to the methylated DNA and attract
HDACs and sometimes other co-repressors. The latter proteins reform the chromatin, making it
more dense thereby hindering transcription of the corresponding gene (lower DNA strand). Source:
[43].
epigenetic reprogramming of the cell occurs. In the early germ cells, genomes are wiped clean
of most of their DNA methylation and of other covalent chromatin modifications that are as-
sociated with somatic gene regulation, so that germ cells can acquire the (totipotent) capacity
to support post-fertilization development. This process also removes DNA methylation imprints
from imprinted loci (see next chapter). After the initiation of sex determination, the germ cells
are progressively de novo remethylated. Here, a fascinating aspect of gametogenesis is the di er-
ential marking of some genes and chromosomes in male and female germ cells, observed in both
insects and in mammals. These DNA methylation and chromatin imprints are transmitted to the
developing embryo and mediate expression depending on the gene inheritance from the sperm or
the oocyte [44]. This topic is extensively discussed in the next chapter.
Intriguingly, a small fraction of DNA regions can escape the first demethylation step occuring in
the early germ cells and can in principle be stably transmitted to the next generation. Importantly,
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these inheritance patterns can be influenced by both environmental and genetic variation. Indeed,
a number of environmental triggers have been shown to a ect an organism’s epigenome, in
particular the methylation pattern (or lack thereof), and thus tipping the balance between genes
that are o  and those that are on [45, 46]. For example, ‘diet’ is one of the more easily studied
environmental factors in epigenetic change. Diets high in methyl-donating nutrients, such as folic
acid or B vitamins, can rapidly alter gene expression, especially during early development when
the epigenome is first being established. A diet deprived of methyl-donating nutrients can cause
certain regions of your genome to be under-methylated for life. As a result, your mother’s diet
during pregnancy and your diet as an infant can a ect your epigenome in ways that stick with
you into adulthood [45–47]. To illustrate this, consider the following experiment performed on
two genetically identical mice strains, but with a di erence in the methylation of their agouti
gene - a gene common in all mammals. In one strain the agouti gene is completely unmethylated
resulting in fat, yellow mice prone to diabetes and cancer, while in the other strain this gene is
methylated (= normal case) and the mice have a brown coat color, are skinny and have a low
disease risk (Figure 2.4). In the control case, the o spring of the former strain was fat and yellow,
while for the latter the babies obtained a normal brown color. However, when researchers fed
pregnant yellow mice a methyl-rich diet, most of her pups were brown and stayed healthy for life.
These results underline the influence of external factors on gene expression. Note that also as
an adult, a methyl-deficient diet lowers your global DNA methylation. However, this is mostly
reversible when switching again to a methyl-rich diet [45, 48, 49].
Figure 2.4: Shown are two genetically identical mice. When a mouse’s agouti gene is completely
unmethylated, the mouse is obese with a yellow coat color and prone to diabetes and cancer (left).
However, when the agouti gene is methylated (as it is in normal mice), the coat color is brown and
the skinnier mouse has a low disease risk (right). Source: [49].
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Hydroxymethylation (5-hmC), which involves the addition of a hydroxymethyl group to a nu-
cleotide residue, is found in many organisms and is particularly present at high levels in neuro-
logical tissue. As described above, it is an important intermediate in the active oxidative DNA
demethylation pathway. However, levels of 5-hmC are often much higher than expected for an
intermediate modification and appear to recruit transcriptional, chromatin and splicing regula-
tors that are distinct from those recruited by 5-mC, feeding the speculation that it could itself
constitute a new layer of epigenetic regulation. Indeed, 5-hmC appears to be enriched in gene
bodies, concentrated at transcriptional regulatory elements (e.g. promoters and transcription fac-
tor binding sites) and is positively correlated with transcriptional activity [39, 50, 51]. In addition,
5-hmC is found to be a prognostic indicator in some cancers and diseases. For example, tumors
originating in various human tissues often have strongly depleted levels of 5hmC and mutations
in a TET gene are commonly observed in human myeloid malignancies [52]. Global levels of
5-hmC are highest in the brain where it has been shown to play an important role in neurological
development and memory formation, suggesting a far-reaching impact [53]. As a result, 5-hmC
has gained much attention over the past several years as a potential epigenetic factor in fields like
stem cell renewal, cancer development and neurological disorders. However, its biological role is
still not completely understood and further research is needed to increase our knowledge.
Source: [54].
3
Imprinting & Allele-specific expression
‘But DNA isn’t really like that. It’s more like a script. Think of Romeo and Juliet, for example.
In 1936, George Cukor directed Leslie Howard and Norma Shearer in a film version. Sixty years
later Baz Luhrmann directed Leonardo DiCaprio and Claire Danes in another movie version of
this play. Both productions used Shakespeare’s script, yet the two movies are entirely di erent.
Identical starting points, di erent outcomes.’ - Nessa Carey
Mammals are diploid organisms whose cells possess two matched sets of chromosomes, one
inherited from the mother and one from the father. Thus, both your father and your mother con-
tributed a single chromosome to each of your 23 chromosome pairs. For one special chromosome
pair, the sex chromosomes, you don’t necessarily end up with a matching pair. Typically, females
have two X-chromosomes, while males have one X- and one Y-chromosome. A mother always
passes one of her X-chromosomes on to her children, a father on the other hand can pass on
either his X- or his Y- chromosome, thus determining the sex of his o spring. For the remaining
22 pairs, the two chromosomes contain the same genetic content, leaving us with two copies for
each gene [55, 56]. However, due to small di erences such as single nucleotide polymorphisms
(SNPs) - a variation in a single nucleotide at a specific position in the genome - maternal and
paternal copies of a gene still tend to di er. In diploid eukaryotic organisms, including humans,
the maternally and paternally derived copies of each gene are usually assumed to be simultane-
ously expressed at similar levels. But, in some cases, only a single allele is transcribed, while
the other allele is transcriptionally silent, a phenomenon denoted as monoallelic or allele-specific
expression. The expressed allele can be randomly selected (e.g X-chromosome inactivation and
some autosomal genes) or predetermined by parental imprinting (Figure 3.1) [55, 57, 58].
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Figure 3.1: Types of monoallelic expression: (i) non-random, predetermined allele-specific ex-
pression (imprinting) and (ii) random allele-specific expression (further divided into X-chromosome
inactivation and autosomal genes). For the autosomal monoallelically expressed subgroup, land-
mark gene classes are shown along with the respective dates when their monoallelic expression was
discovered. Source: [59].
3.1 Parent-of-origin allele-specific expression
In this type of monoallelic expression - also known as parent-of-origin imprinting, genomic im-
printing or just imprinting - all cells for which a given gene is imprinted have the same active
allele. Which allele is expressed is solely determined by the parent of origin of the allele due
to di erent epigenetic marks placed during gametogenesis in the male and female germline. A
fertilized egg thus has di erent marks on some genes originating from the father or the mother.
This di erential marking ultimately leads to monoallelic expression, where some imprinted genes
are expressed exclusively from the maternally or paternally inherited chromosomes (Figure 3.2)
[57, 59]. While many imprinted genes are ubiquitously imprinted, e.g. Igf2/H19, some exhibit
tissue-specific patterns, such as for example Slc22a2 and Slc22a3, which are exclusively imprinted
in the placenta [60].
To date, approximately 100 imprinted genes have been described in mammals, about 100 in
mice and 50 in humans, and are often conserved among mammals. Importantly, most (not all!)
imprinted human genes are also imprinted in mice, but as there are more imprinted genes in
mice, logically, not all of them are imprinted in humans. Imprinted genes are located in ≥1
megabase clusters throughout the genome, although singletons have been described. Each of
these clusters is under the control of a discrete region, termed an imprinting control region (ICR)
[57, 59]. How does the transcription machinery distinguish between maternally and paternally
inherited alleles? It seems that DNA methylation is the major epigenetic parent-of-origin-specific
modification that is set up in the germline and that di erentially marks the two alleles of an
imprinted gene [57, 61]. These di erentially methylated regions are called DMRs, and many
DMRs are also ICRs. Unclustered imprinted genes are generally regulated by germline-derived
di erential promoter methylation [55]. Interestingly, in the female germline, methylation marks
always act at the promoters of imprinted genes (which are also often characterized by CpG
islands) resulting in their heritable maternally repressed state, while methylation in the paternal
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germline is not placed at promoter regions but rather within intergenic regions (Figure 3.2(b)).
Curiously, many more maternally than paternally methylated DMRs/ICRs have been identified
[57]. Therefore, it has been hypothesized that imprinting originated from a ‘parental conflict’,
also known as the kinship theory of genomic imprinting. This hypothesis states that the interests
of the maternal and paternal genome are opposite. The former aims at dividing resources over
all of her o spring (potentially of di erent fathers) and increasing overall fitness by decreasing
embryonic growth. The father’s genome, however, aims for instant success and the highest fitness
possible, thus expressing genes that increase growth [62].
(a)
Maternally methylated DMRs and ICRs are located at promoters
Paternally methylated DMRs and ICRs are located in intergenic regions
(b)
Figure 3.2: (a) Imprinted genes are expressed in a parent-of-origin-specific manner. Here, a cell
is shown with the maternally and paternally inherited chromosome labeled in red and blue, respec-
tively, together with one ‘normal’ biallelically expressed gene (blue rectangle) and two imprinted
genes, A and B. Gene A is exclusively transcribed from the maternal allele and repressed on the
paternal allele, while gene B on the contrary is transcribed from the paternal allele and repressed
on the maternal allele (arrow indicating expression). (b) DNA methylation is essential for estab-
lishment and maintenance of imprinting. Shown here are the two major types of DNA methylation
present at imprinted loci. For loci associated with maternal-specific methylation, DNA methyla-
tion (black lollipops) is associated with the promoter of a repressed gene, whereas hypomethylation
(white lollipops) in the promoter region is associated with the expression of that gene (upper figure).
Paternal-specific methylation on the other hand is associated with DNA methylation in intergenic
regions (lower figure). Adapted from: [57].
Indeed, imprinted genes seem to play essential roles in the growth and development of the fetus,
as well as in post-natal behavior, cell type specificity, normal brain function and metabolism.
Generally, imprinted genes are widely and highly expressed during pre-natal stages and are mostly
down-regulated after birth. Especially the placenta and the brain are sites of imprinted tran-
scription and are predominantly involved in the nutritional and growth control of the embyro as
well as with behavior, learning and maternal care. Most of our understanding of imprinted gene
function comes from studies in mutated mice and genotype-phenotype studies in humans with
imprinting disorders. Indeed, deregulation of imprinting has already been associated with many
diseases including the behavioral and neurodevelopmental disorders Prader-Willi and Angelman
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syndromes and the growth disorders Beckwith-Wiedemann and Silver-Russel. Furthermore, as
loss of imprinting (LOI) has been found in high frequency in various tumors (e.g. Wilm’s tu-
mor), imprinting most likely plays an important role in cancer as well. Although imprinting is a
well-investigated topic, the mechanisms underlying genomic imprinting are only slowly being elu-
cidated and only a few imprinted regions are well characterized in humans, such as the Igf2/H19
region, which is also linked to the Beckwith-Wiedemann syndrome and Wilm’s tumor. The ICR
located far upstream of the H19 gene modulates the transcription of Igf2 and H19 genes in an
allele-specific manner: on paternal inheritance, the methylated ICR silences the H19 gene and
indirectly facilitates transcription from the distant Igf2 promoter, whereas on the maternal chro-
mosome the unmethylated ICR, together with enhancers (= short DNA region that when bound
by proteins increases the likelihood that transcription will occur at a specific gene), activates
transcription of H19 and thereby contributes to the repression of Igf2. Central to this model is
the site-specific binding of CTCF, a versatile protein that regulates gene expression by binding
to DNA functioning as a transcriptional activator (Figure 3.3) [63, 64].
Figure 3.3: Imprinting at the Igf2-H19 locus resulting in the maternally expressed H19 and
paternally expressed Igf2. On the maternally inherited allele, the ICR (red parallelogram) re-
mains unmethylated allowing CTCF and its cofactors to bind. This interaction mediates enhancer
blocking allowing downstream enhancers (black circle) to access the H19 promoter and drive its
expression. Paternal methylation (black lollipops) at the ICR prevents CTCF binding and together
with methylation at the H19 promoter enables the enhancers to access and stimulate expression of
Igf2. Black flags represent additional repressive histone marks. Source: [65].
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3.2 Random allele-specific expression
The remaining class covers genes showing random allele-specific expression and includes X-
inactivated and autosomal random monoallelically expressed genes. Recall that human females
typically get two X-chromosomes (one from each parent), whereas males inherit a single copy
of the X-chromosome from their mother, along with a Y-chromosome from their father. In or-
der to obtain equal levels of transcription of X-linked genes in both sexes, most genes of one
X-chromosome are inactivated in females - a phenomenon known as X-chromosome inactivation
or dosage compensation. X-chromosome inactivation takes place early in development and is
completely random, i.e. each cell makes an independent and random choice which chromosome it
inactivates. Once this initial decision is made, it is irreversible and all the cell’s descendants will
inactivate that same X-chromosome. This finally leads to a mosaic expression pattern, in which
patches of cells have an inactive maternal X-chromosome, while other patches have an inactive
paternal X-chromosome [55, 59].
A nice illustrating example are tortoiseshell cats, which are almost exclusively female. In these
cats, the primary gene for coat colors like brown and chocolate can be masked by the gene O
that is located on the X-chromosome and has two alleles, Oo and Ono, coding for orange or
non-orange coat color variations, respectively. Male cats only have one X-chromosome - thus
carrying only one of these alleles - resulting in an entirely orange of non-orange coat. Female cats
on the other hand have two X-chromosomes and can either have two Oo alleles, two Ono alleles
or one of each. However, due to X-chromosome inactivation, this latter genotype gives rise to a
mixture of an orange and non-orange (black) coat: cells where the X-linked Oo allele is silenced
have an active Ono whereas cells where Ono is inactive express the Oo allele. As a result, these
cats are coated with a ‘tortoiseshell-like’ color pattern [56].
In the 1990s it started to emerge that next to imprinted genes, there was another class of auto-
somal genes that showed monoallelic expression, but in a random manner and thus not parent-
of-origin specific. In other words, they share similarities with genes subject to X-chromosome
inactivation in that some cells express the maternal allele and some cells express the paternal al-
lele. These autosomes include for example some immune response genes, such as those coding for
various immunoglobin receptors and cytokines, and olfactory receptor genes. Importantly, in ad-
dition to the cells with monoallelic expression, some of these randomly monoallelically expressed
genes also have some cells with biallelic expression. As this leads to three distinct expression
states for each gene - expression of both alleles, expression of only the maternal allele and expres-
sion of only the paternal allele - autosomal random monoallelic expression can impact biological
function and can give a unique identity to individual cells. Improvements in technology have led
to an appreciation of the widespread nature of random monoallelic expression across the genome
beyond chemosensory and immune system genes. Recent studies indicate that at least 1% of all
autosomal genes show monoallelic expression.
As for imprinted and X-inactivated genes, monoallelic expression of these autosomal loci is gener-
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ally accompanied by di erences in DNA methylation and some histone modifications. However, as
opposed to the permanent silencing seen in X-chromosome inactivation, expression of monoallel-
ically expressed autosomal genes can be sometimes ‘stochastic’ (= variable). For example, some
cytokines are expressed from only one allele in latent T-cells, but when a particular stimulation
the global level of transcription rises, both alleles may be expressed. Additionally, allele-specific
silencing of autosomal genes also di ers from silencing of the entire X-chromosome in that the
silencing of one specific allele appears to occur independently of other monoallelically expressed
genes present on that chromosome [56, 59].
Source: [66].
4
Neuroepigenetics
Over the last decade, a lot of papers have been published concerning epigenetic mechanisms in
the nervous system. These recent discoveries have forced a redefinition of the term epigenetics,
especially regarding the epigenetic mechanisms found in adult neurons [67].
4.1 The emergence of a new epigenetic subdiscipline
Brains of all species are primarily composed of two classes of cells: neurons and glial cells.
The latter class comes in several types and acts as the nervous system’s supporting players
providing structural and metabolic support, insulation, and guidance of development. Neurons
are specialized nerve cells that both process and transmit information through electrical and
chemical signals. The property that makes neurons unique is their ability to send signals to
specific target cells over very long distances by means of an axon, a fiber extending from the
neuron’s cell body. Neurons were initially regarded as the most important cells in the brain,
although the last couple of years the importance of glial cells became more and more apparent,
redirecting the spotlight now onto both cell classes [68] .
As mentioned earlier (Chapter 2), cells use epigenetic markers to regulate gene expression, which
are later inherited by their daughter cells during cell division or can sometimes even be passed
down to future generations. It was initially believed that neurons did not undergo these epigenetic
processes due to their highly di erentiated and post-mitotic nature. However, numerous recent
studies display evidence of epigenetic mechanisms in neurons as well and it is now known that there
are many ways a neuron can utilize epigenetic markers to regulate its gene expression. Note that
since neurons do not divide, these epigenetic markers are not mitotically inherited. This sets the
roles of epigenetic mechanisms in adult neurons apart from their roles in developmental biology,
such as setting of cell fate determination, heritability, genomic imprinting, etc. For this reason,
Day and Sweatt proposed to adopt the term neuroepigenetics to capture this distinction [69]. The
primary (neuro)epigenetic mechanisms include DNA methylation and histone acetylation. Evenly
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important is the e ective removal of these modifications (i.e. demethylation and deacetylation),
which gives neurons their ‘plastic’ nature, namely the ability to change gene expression based
on neuronal activity and/or environmental influences. These epigenetic mechanisms (or actually
their dysregulation) have already been associated with several neurological and neurodegenerative
diseases such as Rett’s syndrome [70]. With this in mind, current research often examines the
involvement of these epigenetic mechanisms - as well as the processes through which these
mechanisms are regulated - in brain development, memory formation and consolidation.
4.1.1 Neuroplasticity
Emerging evidence underlines epigenetic modifications, and in particular methylation and hydroxy
DNA methylation, as key players in brain plasticity. For example, they seem to be predominantly
involved in a variety of fundamental processes in the central nervous system (CNS), from neuronal
stem cell di erentiation to environmental (re)programming of molecular, hormonal and behavioral
responses and synaptic plasticity. Epigenetics seems to be the perfect explanation/modulator for
the processes underlying one of the most intriguing brain characteristics: its plasticity. Experience-
dependent plasticity is the ability of neuronal circuits to remodel themselves (on a molecular,
structural and functional basis) based on changes in neural activity. The recent discovery that
5-(h)mC is particularly dynamic in brain cells has strongly increased the interest of neuroscientists
in understanding the role of these DNA modifications in activity-induced remodeling of neuronal
circuits [71].
4.1.2 Dynamic & distinct DNA methylation in the brain
Evidence that DNA methylation has a uniquely important role in the brain emerged with the dis-
covery of the prominent methyl-DNA–binding protein, methyl-CpG binding protein 2 (MeCP2),
and the later identification that mutations in MeCP2 give rise to Rett’s syndrome, an X-linked
neurological disorder [72]. Subsequent studies also identified neurodevelopmental disorders as-
sociated with mutations in DNMTs [73], suggesting that both the enzymatic ‘writers’ of DNA
methylation patterns and the ‘readers’ of these marks have important roles in the brain.
DNA methylation has been thought to be a static epigenetic mark for over 20 years. Recent evi-
dence demonstrated that it is dynamically regulated both through passive and active mechanisms
(see section 2.3). The most interesting pathway proposed to participate in active demethylation
of DNA is the oxidative demethylation. Here, TET enzymes (TET1, TET2 and TET3) catalyze
the (oxidative) conversion of 5-mC to 5-hmC. Moreover, 5-hmC can be further oxidized to 5’-
formylcytosine (5-fC) and 5’-carboxycytosine (5-caC), although their levels are significantly lower
than that of 5-hmC [71, 74].
Genome-wide analysis of methylation patterns in multiple mammalian tissues indicates that the
CpG methylation profile is generally similar in post-mitotic neurons and other cell types [53, 75].
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Thus, also in neurons 5’ methylation of CpG dinucleotides is thought to silence the transcription of
repeats and to regulate gene expression by promoting transcriptional repression [76]. Indeed, mod-
ulation in DNMT expression together with changes in CpG methylation in the promoter of specific
plasticity genes have shed new light on the role of experience-dependent methylation of DNA in
the brain. For example, there is activity-dependent DNA demethylation in the promoter region
of brain-derived neurotrophic factor (BDNF ) and fibroblast growth factor 1 (FGF1), two critical
genes involved in adult neurogenesis [77]. Also, fear conditioning, i.e. the behavioral paradigm
where organisms learn to predict aversive events, is linked with rapid methylation (and transcrip-
tional silencing) of the memory suppressor gene protein phosphatase 1 (PP1) and demethylation
(and transcriptional activation) of the synaptic plasticity gene reelin (RELN) [78]. This desig-
nates dynamic and opposite 5-mC changes during memory consolidation, indicating that DNA
methylation might be exploited by neurons to achieve dynamic changes in transcriptional activity
during memory formation.
However, although 5-mCG certainly exists and has been characterized in brain cells, also other
types of methylation, namely 5-hmC and non-CpG, appear to significantly expand the role of DNA
methylation in the neuronal genome relative to other cell types. Interestingly, current evidence
shows that most 5-hmC in the brain occurs in CpG context, accounting for 25% and 40% of all
modified CpG dinucleotides in the frontal cortex and cerebellum, respectively. Genome-wide, 5-
hmC is generally enriched in gene bodies of highly expressed genes and depleted in transcriptional
start sites. In addition, an accumulation of 5-hmC occurs broadly across intergenic regions of the
neuronal genome [53]. Indeed, hydroxymethylation is particularly abundant in the CNS relative
to many other tissues, even 10-fold higher in brain than in embryonic stem cells, highlighting a
possible role for 5-hmC in the epigenetic control of neuronal function [79]. TET1 and TET3 levels
have been found to respond to neuronal activity raising the possibility that neuronal activity in
newly formed circuits helps to drive the increase in 5-hmC in the brain and shapes its profile across
the neuronal genome. Furthermore, manipulation of TET activity to alter 5-hmC levels implicated
that its regulation is tightly involved in learning and memory, neurogenesis and neuronal activity-
regulated gene expression. Together with the finding that a redistribution of 5-hmC accompanies
some forms of neuronal plasticity, this suggests that hydroxymethylation and its regulation is
intimately involved in brain function [70, 80, 81].
Until a few years ago, cytosine methylation was thought to be restricted to CpG sites. Recent
research on embryonic and pluripotent cells reported also methylation in some non-CpG cytosines,
i.e. 5-mCH (with H = A, T or C) [71], but its functional relevance was initially underappreciated
due to its low frequency. Indeed, although present in almost all tissues, 5-mCH is nearly absent
from non-neuronal adult cells. However, significant levels of 5-mCH were detected, first in
embryonic stem cells and then in adult brains of mice and humans. Frequency of methylation at
CH-sites in the latter is roughly 2-6% and is estimated to account for at least half of the total
fraction of methylated cytosines [53, 82, 83].
Preliminary research of its functional role shows that at a genome-wide level, neuronal 5-mCH is
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depleted in expressed genes, with 5-mCH levels in the genic region (= gene body and up/down-
stream regions) inversely correlated with the abundance of the associated transcript. Remarkably,
5-mCH is strongly enriched in neurons but sparse in glia suggesting that this form of DNA methy-
lation might be more relevant for neuron-specific functions. Moreover, gene ontology analysis
shows that genes hypermethylated in CH in glial cells are implicated in neuronal and synaptic
development and function. On the other hand, the same genes are hypomethylated in both CH
and CpG context in neurons, indicating that 5-mCH might have a transcriptional repressive role
for neuronal-specific genes in the glial genome. Unlike the overall level of CpG methylation which
remains unchanged during development, 5-mCH ramps up significantly in the brain during the
first two years of life (early post-natal development) and especially during synaptogenesis, i.e. the
period when connections between neurons are rapidly forming. It then increases through adoles-
cence until it finally plateaus in early adulthood, when the development of the frontal cortex (=
a brain region associated with behavior and decision making) is essentially complete (Figure 4.1)
[53].
Figure 4.1: Global methylation profile of neurons and glia in the frontal cortex of humans. At
birth, 5-mCH (purple stars) is almost non-existent, but added rapidly during the first few years
of life and then more slowly until about the age of 30. After age 50, the number of 5-mCH
modifications declines. Source: [53].
It is important to note that 5-mCH is not clearly associated with silencing in all cell types,
e.g. in embryonic stem cells it is correlated with gene expression. These distinct roles of 5-mCH
in di erent cell types may be related to the unique complement of writers and/or readers of
DNA methylation: (i) DNMT3A and DNMT3B are both highly expressed in embryonic stem
cells, whereas DNMT3A, but not DNMT3B, is highly expressed in neurons, in addition (ii) the
predominant form of 5-mCH in embryonic stem cells occurs within the context of the CAG
trinucleotide, whereas in neurons it occurs largely within the CAC trinucleotide [53, 70, 71].
Thus, the di erential distribution, i.e. expression of DNMTs, and the specific sequence context
of 5-mCH may have important implications for readers of DNA methylation and whether they
function as activators or repressors of gene expression.
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4.2 An avian model for investigating the neurobiological basis of
learning
Songbirds o er a unique opportunity for us to understand the genetics behind the wiring and
re-wiring of our brains when we learn and memorize. Songbirds evolved the ability to learn
vocalizations by copying a singing adult. They have one important thing in common with humans:
they learn how to converse with one another, which is very rare in other animals. As such, in the
past few decades, songbirds became a widely used model system for the behavioral neurobiology
of learning [84], evolutionary genetics [85], neuroendocrinology [86] – particularly the sexual
di erentiation of the brain – and adult neurogenesis [86].
One songbird in particular, the zebra finch (Taeniopygia guttata (Figure 4.2)) has been the focus
of many studies. This songbird species from Australia is very popular, owing to its attractive
plumage patterns, highly social behavior and the ease with which they can be bred in captivity. In
addition, zebra finches readily sing in captivity and can be considered aseasonal as their singing,
breeding and anatomical organization remains largely unchanged throughout the year, o ering
distinct advantages over other songbirds [87].
Figure 4.2: Picture depicting an adult pair (male on the left, female on the right) of zebra finches.
Source [88].
Since their first use in experimental biology, zebra finches have become a choice model organism
in neurobiology, particularly in the study of learned vocalizations [87]:
• Vocal learning
Zebra finches (and other songbirds) learn to vocalize by imitating an adult male tutor,
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usually their father. Vocal learning is a trait that songbirds share with humans, where it
forms the basis of spoken language acquisition, but which is absent in traditional model
organisms like rodents and nonhuman primates. There exist marked similarities between
birdsong and human speech acquisition, including the presence of ‘babbling’-like immature
vocalizations, crucial periods for learning, auditory feedback and individual vocal variabil-
ity and dialects. As in humans, also social factors influence the vocal learning process,
i.e. conditions resem- bling the natural setting and/or learning is improved by a live tutor
[87, 89].
• Brain activity and gene expression
Songbirds and humans use a similar brain circuitry during both acquisition and production
of learned vocalizations [90]. Due to the specific nuclear organization of the avian fore-
brain, areas that control birdsong (the song nuclei) are distinct [91]. This feature makes
it possible and more straightforward to study the connectivity and map the location of
neuronal projections within this song system, i.e. without the influence of other systems.
Importantly, this distinct brain organization allows directly linking gene activity/expression
in the song nuclei with subsequent behavior and vice versa. By means of high-throughput
methods, several hundreds of genes have been identified that are regulated during singing
[92].
• Adult neurogenesis
Importantly, it has been shown that songbirds exhibit adult neurogenesis within song control
nuclei, again establishing that an adult (vertebrate) brain is plastic and can generate novel
neuronal cells [93].
Although the full extent of the transcriptional response to singing and the regulatory mechanisms
only started to be unravelled by microarray (Zebrafinch Agilent array from SoNG Consortium)
and Illumina RNA sequencing approaches, preliminary research showed that some of the singing
induced genes revealed epigenetic regulation [94]. Various studies now reveal that acute expo-
sure to hormones (glucocorticoids, estrogens, androgens, thyroid hormones) triggers persistent
changes in histone acetylation/methylation and DNA (de)methylation in various tissues or brain
regions. For example, epigenetic changes have already been reported in brain for BDNF, RELN
and serotonin neurotransmitters, hormone responsive target genes involved in the song control sys-
tem and behavior [95]. At another level hormones control expression levels of various epigenetic
modifier enzymes (acetylases, deacetylases, methylases, demethylases, etc.), which perpetuate
epigenetic reprogramming [96]. RNA sequencing approaches further demonstrated involvement
of non-coding RNAs, miRNAs and alternative spliced transcripts some of which may control the
initiation of specific cell signaling cascades [97].
Thus, it has become apparent that there are striking homologies between the brains of birds
and mammals, leading to the identification of common neuronal and molecular substrates [98].
Nowadays, several genomic resources and tools have become available to further investigate these
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phenomena, highlighted by the recent assembly of the zebra finch’ genome sequence. The zebra
finch genome includes 33 chromosomes and is marked by two sex chromosomes designated as
Z and W. Compared to humans, males and females now carry two and one copies of the Z sex
chromosome, respectively. Indeed, in birds, males are homogametic (ZZ) while females are the
heterogametic sex (ZW) [99].
Source: [100].
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1
DNA sequencing
‘If you thought that science was certain - well, that is just an error on your part’ - Richard Feynman
Knowledge of DNA sequences has become indispensable for biological and medical research and
applied fields such as biotechnology. The process to determine the order of individual nucleotides
within a DNA molecule is termed ‘DNA sequencing’ and includes any method or technology that
is used to discover the precise order of adenine, guanine, cytosine and thymine in a strand of
DNA. DNA sequencing can be used to determine the sequence of individual genes, larger genetic
regions, full chromosomes or entire genomes. However, after the discovery of the double helix
structure by Watson, Crick and Franklin in 1953 [4] it took about twenty more years before the
specific sequence of nucleotide fragments could be reliably analyzed. RNA sequencing (RNA-seq)
was one of the earliest forms of nucleotide sequencing and using a RNA-seq method, Walter Fiers
and his colleagues identified the first complete gene (1972) [101] and complete genome (1976)
of Bacteriophage MS2 [102], here at Ghent university.
The true era of DNA sequencing started with the development of the ‘Sanger sequencing’ tech-
nology in 1977, named after its inventor Frederick Sanger [103]. Sanger sequencing - also termed
first-generation sequencing - was the most widely used sequencing method for approximately
three decades until around 2005 it got supplanted by ‘next-generation sequencing’ - or second-
generation sequencing - methods. Compared to Sanger sequencing, next-generation sequencing
is easier, faster and cheaper, making it better suited for large-scale automated genome analyses.
Since 2008, even newer sequencing technologies have been developed and the development is
still ungoing. These new technologies are collectively named next-next-generation sequencing or
third-generation sequencing [104, 105].
As we move into an era of personalized medicine and complex genomic databases, the demand
for the (further) development of new and existing sequencing technologies is constant and novel
approaches are reducing the cost per base and increasing throughput and quality on a daily basis
[105].
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1.1 Sanger sequencing
In 1977, Frederick Sanger and his co-workers presented the ‘chain-termination method’, better
known as ‘Sanger sequencing’. In a classical Sanger sequencing experiment a ssDNA template,
obtained by in vivo (= into bacterial vectors) or in vitro (= PCR amplification) cloning, is am-
plified using a DNA primer, a DNA polymerase and both deoxynucleosidetriphosphates (dNTPs)
and dideoxynucleosidetriphosphates (ddNTPs). dNTPs are normal nucleotides used in cells for
DNA synthesis, whereas ddNTPs, the chain-terminating nucleotides, lack a 3’-hydroxyl group
making them incapable of forming a phosphodiester bond with other nucleotides, thereby e ec-
tively terminating the extension of the DNA strand by DNA polymerase. This whole process is
repeated four times (using a mixture of all dNTPs in the four reactions and ddATPs only in the
first, ddGTPs in the second, ddTTPs in the third and ddGTPs in the final, fourth reaction) with
the chain-terminating molecules radioactively labeled. The template elongates by incorporation
of dNTPs and ddNTPs in random positions. This process generates DNA fragments of any size
terminated at di erent positions. After running the four reactions, terminated DNA fragments
of di erent lengths are separated using electrophoresis, a gel-based technique that can separate
the negatively charged DNA molecules based on length by applying an electric field (Figure 1.1).
The closer the ddNTP was incorporated at the 5’-end, the smaller the resulting DNA fragment
and the faster the fragment elutes on the gel. Thus, by analyzing the gels of the four reactions
together, the original sequence of the ssDNA template can be deduced from the positions of the
bands in the gel, leading to sequences up to a few hundred bases [103, 105].
Over time, this technique was further improved by (i) the introduction of fluorescently labeled
ddNTPs [107], (ii) the use of better (polyacrylamide instead of acrylamide) gels [108] and (iii)
automated laser fluorescent detection [109]. Instead of running four reactions, the use of fluores-
cently labeled ddNTPs enables sequencing in one single reaction: each ddNTP can now be labeled
with a specific dye and all four labeled chain-terminator nucleotides are combined together with
the normal dNTPs. Afterwards, the obtained terminated DNA fragments are separated again
using electrophoresis, yet can now be analyzed on a single lane. Using polyacrylamide gels in-
stead of acrylamide gels significantly shortens run times. An overview of the Sanger sequencing
workflow is depicted in Figures 1.1 and 1.2(a).
1.2 Next-generation sequencing
Next-generation sequencing (NGS) has been evolving since 2005 and provides the ability to
dramatically increase the speed at which DNA can be sequenced at a fraction of the cost of
older sequencing technologies. To illustrate this, in 2001 the Human Genome Project used the
first-generation Sanger sequencing technology to sequence the human genome, taking 13 years
and $2.7 billion to achieve its goal. This project greatly stimulated the development of powerful
novel sequencing technology to increase speed and accuracy, while simultaneously reducing cost
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Figure 1.1: Illustration of Sanger sequencing using the dideoxy chain-termination method where
DNA is replicated in the presence of chemically altered versions of A, C, T and G. (a) A ssDNA
template is obtained after dissociation of dsDNA. Next, a radioactively- or fluorescently-labeled
primer is added for amplification. (b) Four separate reactions are performed to synthesize new
DNA. Each reaction contains an excess of all four deoxynucleotides (= dNTPs) and a small portion
of one of the dideoxynucleotide bases (= ddNTPs). (c) DNA is synthesized, terminating each time
a ddNTP is incorporated. (d) DNA from all four reactions is separated on a gel in side-by-side
lanes. The sequence of the original read can subsequently be read from the bottom up as the
compliment of bases identified in the gel. Adapted from: [106].
and manpower. Second- or next-generation sequencing can now sequence an individual genome
in under 2 weeks for approximately $1,000-3,000, representing remarkable progress [110, 111].
NGS is based on the principle of massively parallel sequencing. This essentially means that
by physically separating (parallelizing) the reactions to be performed, thousands or millions of
pieces of DNA can be sequenced at the same time. Following the human genome project, 454
sequencing was launched by 454 Life Sciences/Roche in 2005, and Solexa/Illumina released the
Genome Analyzer IIx the next year (Illumina sequencing), followed by the (Sequencing by Oligo
Ligation Detection) SOLiD-platform provided by Agencourt, which were at the time the three
biggest players in NGS massively parallel sequencing systems [111]. Their sequencing strategy
is also known as ‘cycle-array sequencing’, i.e. sequencing of a dense array of DNA features by
iterative cycles of enzymatic manipulation and imaging-based data collection [104].
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Figure 1.2: Workflow of Sanger versus next-generation sequencing. (a) In Sanger sequencing,
gDNA is first enzymatically fragmented and cloned into bacteria, e.g. E. Coli, to obtain single
DNA fragments. For each sequencing reaction, a single bacterial colony is used. Many copies of
a given initial DNA fragment are collected from each bacterial clone. Chain-termination relies
on the ability of ddNTPs to stop chain-elongation by DNA polymerase. For each sequencing
reaction, the resulting di erently-sized DNA fragments are loaded onto a gel and separated by
electrophoresis generating a ladder of ddNTP-terminated, dye-labeled products. Signal detection
can be automated by the use of a laser/computer: each ddNTP is specifically fluorescently labeled
and after the fragments of di erent lengths pass a detector, the four-channel emission spectrum
is used to generate the original DNA sequence. (b) In NGS cycle-array sequencing, common
adapters are ligated to the fragmented gDNA ultimately leading to spatially separated collections of
unique DNA fragments, dubbed polonies (refering to the equivalent colonies for Sanger sequencing).
Successive cyclic iterations of enzymatic interrogation and imaging-based detection of fluorescent
labels incorporated with each extension are used to build up a contiguous sequencing read for each
array feature in parallel. Source: [104].
Although these three platforms are quite diverse in sequencing biochemistry as well as in how the
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array is generated, their workflows are conceptually similar (Figure 1.2(b)). Briefly, initially DNA
is fragmented into multiple short segments called a shotgun library, followed by in vitro ligation
of adapters. Adapters are short sequences of DNA that include priming sites for the subsequent
amplification steps. These adapter-ligated DNA fragments are then subjected to one of several
protocols to generate PCR colonies or ‘polonies’. Each PCR colony consists of many copies of a
single shotgun library fragment and are spatially clustered on an array. Once each PCR colony is
tethered to the planar array, fluorescent nucleotides are added, together with DNA polymerase and
sequencing primers. As fluorescently tagged bases are incorporated to each strand in each cluster
in real time, imaging-based detection of incorporated fluorescent labels can be used to acquire
sequencing data from all features in parallel. Successive cycles of enzyme-driven biochemistry
and imaging-based data acquisition construct a contiguous sequencing read for each PCR cluster
[104].
Several factors are key in the definition and evaluation of any technology platform: (i) read
length, (ii) throughput, (iii) read accuracy (typically indicated by the so-called ‘Phred Score’),
(iv) read depth (number of times each base is sequenced in independent events) and (v) cost per
base [105]. The advantages of second-generation DNA sequencing with regard to (ii), (iv) and
(v) are however also o set by several disadvantages, particularly regarding (i) and (iii). The main
weakness of NGS is that the (accurate) read length is not as long as with the previous techniques,
mainly due to the progressive decline in e ciency of the sequencing chemistry as well as raw
accuracy during the run (these new platforms are tenfold less accurate than base-calls by Sanger
sequencing) [104, 105]. Another weakness of NGS is the use of PCR for amplification which
can itself potentially introduce bias for quantitative applications [112]. In addition, whilst huge
quantities of sequencing data can be produced relatively cheaply and quickly, data analysis can
be lengthy and di cult [111]. Although these limitations create important algorithmic challenges
for the immediate future, we should bear in mind that these technologies will continue to improve
[104].
As Illumina sequencing is used to generate all of the sequencing data discussed in the following
parts, the following paragraph takes a closer look at the specific steps and biochemistry of this
technology.
1.2.1 Illumina Sequencing
Large-scale parallel sequencing-by-synthesis from Solexa/Illumina, commonly named Illumina se-
quencing, is at the moment the most frequently used NGS technology. In 2006, Solexa released
the Genome Analyzer and in 2007 the company was purchased by Illumina [111]. Currently,
the company sells a number of di erent sequencing instruments, namely the MiniSeq, MiSeq,
NextSeq, HiSeq and HiSeq X series, available for studies in small laboratories to large genome
centers, respectively, making NGS technology highly flexible and scalable [113]. Illumina sequenc-
ing uses relatively simple library preparation followed by a bridge amplification step to amplify
1.2 NEXT-GENERATION SEQUENCING 56
DNA fragments. A reversible dye-terminator sequencing-by-synthesis process enables reading of
the actual sequence of the DNA fragment [114]. In summary, the Illumina workflow includes 4
basic steps (Figure 1.3) [113]:
• Library preparation
After fractionating the gDNA into smaller fragments of typically 100-300bp (though some
instruments can handle longer fragments), libraries can be constructed by any method
that gives rise to a mixture of adapter-flanked fragments. Adapter-ligated fragments are
subsequently size-selected and gel purified [115].
• Cluster generation
After succesful library preparation, the fragments are ready to undergo cluster generation by
‘bridge amplification’. In this approach, both forward and reverse primers complementary
to the ligated adapters are tethered to a solid substrate, i.e. the flow cell, to which the
DNA fragments hybridize. As a result, all amplicons arising from any single DNA template
during amplification remain immobilized and clustered to a single physical location on the
array. After synthesis of a complementary strand starting from the primer, the original
DNA strand is denatured and washed away, resulting in a ssDNA molecule being covalently
bound to the silica flow cell. In a next step, the actual bridge amplification occurs. First,
the bound molecules hybridize with their free adapter end to a neighboring complementary
primer, e ectively forming a U-bridge, followed by DNA extension from the primer onwards
to create a dsDNA molecule. Subsequently, this dsDNA molecule is denatured, hybridized
to a neighboring primer on the flow cell to form a new U-bridge and extended once again.
This bridge amplification is repeated 35 times to create a dense cluster of at least 1,000
clonal amplicons. Finally, the reverse strands are washed away and sequencing primers are
annealed to the DNA template (Figure 1.3(a)) [116].
• Sequencing
Next, the generated clusters on the flow cell surface are sequenced simultaneously (i.e. in
parallel). Illumina sequencing utilizes a reversible dye-terminator sequencing-by-synthesis
method that detects single bases as they are incorporated into the DNA template strands.
Each sequencing cycle consists of a single-base extension with a mixture of the four nu-
cleotides which are slightly modified: (i) each nucleotide is fluorescently labeled with its
own dye and (ii) they are reversibly blocked at their 3’-end so that only one base is in-
corporated. Unbound nucleotides are washed away and the clusters are excited by a laser
resulting in nucleotide-specific fluorescence of the last incorporated base which is captured
by the imaging system. After cleaving both the fluorescent labels and the 3’-terminator
group, this process is cyclically repeated in order to obtain the desired read length. Read
lengths up to 50-75bp are currently routine, although longer reads are also possible but
may incur a higher error rate at their 3’-end due to a progressive decline in for example
cleavage e ciency of fluorescent and terminator groups (Figure 1.3(b)) [104, 117, 118].
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• Data analysis
During data preprocessing, images are converted into sequence reads, complemented with
reliability measures (Phred scores). Additional preprocessing steps typically include removal
of adapter sequences, trimming of low quality fragments, and several application specific
steps. When no reference genome(s) for the species under study is/are available, a de
novo approach typically uses sequence overlap to infer functional units for further analysis.
More often, a reference genome is available, and the genomic origin (chromosome, exact
position) for each newly sequenced fragment is traced in a step called ‘mapping’ or ‘align-
ment’. Subsequently, depending on the research question, many variations of analysis are
possible such as SNP identification, expression analysis, metagenomic analysis etc. Given
the relevance of this step to the research in this thesis, it is more elaborated in Chapter 3
[113].
(a) (b)
Figure 1.3: Overview of two important steps of the Illumina sequencing technology. (a) Cluster
generation. Source: [119]. (b) Sequencing. Source: [105]. A detailed description of both can be
found in the main text.
1.2.2 NGS advances & applications
While nowadays a lot of commercial kits are available and sequencing runs are pretty standardized,
customization is necessary when determining the run parameters to achieve specific experimental
goals.
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• Sequencing libraries
NGS requires the preparation of libraries in which (fragments of) DNA (or RNA) molecules
are fused with adapters followed by PCR amplification and sequencing. Choosing the right
library preparation strategy is essential for each sequencing project as picking the wrong
library preparation can lead to bias, amplification artefacts, uneveness of coverage, poor
mapping and uninformative reads. The two most common library types are single-end
(SE) and paired-end (PE) sequencing libraries. In SE sequencing, considered the default
methodology, only one end of the DNA template is sequenced from the 5’-end towards the
3’-end, yielding only the 5’-end of the sequenced fragment. In PE sequencing, although the
initial library preparation is similar to SE sequencing, both ends of the same DNA template
are sequenced. Eventually, two sequence reads, ‘a read pair’, with a known approximate
distance - typically 200-600bp - in between is obtained. SE sequencing runs are faster,
cheaper and are often su cient for profiling or counting studies such as RNA-seq or ChIP-
seq. PE runs on the other hand are more costly and time consuming, but produce twice
the number of reads (though in pairs) for the same e ort in library preparation without
doubling the sequencing cost. PE reads produce additional positioning information in the
genome enabling more accurate read alignment and making it easier to resolve genomic
rearrangements such as indels. In addition, analysis of di erential read pair spacing also
allows removal of PCR duplicates, a common artefact from the PCR amplification step
[113, 120, 121].
In addition to the rise of data output per sequencing run, the sample throughput per
run in NGS has also increased over time. With multiplexed libraries, unique sample in-
dex sequences are added to each DNA fragment during library preparation allowing large
numbers of samples to be pooled and sequenced simultaneously during a single sequencing
run. Afterwards, each read can be identified and sorted prior to the final data analysis
[113, 120, 121].
• Read length & depth of coverage
Some sequencing instruments provide flexibility in choosing the number of base pairs that
are read per fragment during sequencing. For example, each read may have a length of
50bp, 100bp or more. While longer reads can provide more reliable information about the
relative locations of specific base pairs, they are generally more prone to sequencing errors
at the 3’-end and more expensive to generate.
Each sequencing platform, instrument and run yields di erent number of reads. By in-
creasing or decreasing the number of sequencing reads, researchers can tune the sensitivity
of an experiment to accommodate various study objectives with respect to the scale of
the study. A sequencing run generates reads that are not uniformily distributed across the
entire genome: some bases are covered by fewer reads and some by more reads than the
average coverage. The depth of coverage is a measure of the number of times that a
specific genomic site is sequenced during a sequencing run. If the coverage is 100X, this
means that on average each base was sequenced 100 times. This is especially important for
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approaches such as genotyping, where the more frequently a base is sequenced, the more
reliable a base is called, resulting in better quality of your data [120, 121].
NGS platforms enable a wide variety of methods allowing researchers to study almost any organism
with questions related to their genome, transcriptome and even epigenome. These methods di er
primarily by how the DNA (or RNA) samples are obtained - organism, tissue type, etc. - and by the
final data analysis. After library preparation, the actual sequencing stage remains fundamentally
the same for each method. Although the number of NGS methods is constantly growing, a brief
overview of some important methods is presented here [113].
• Genomics
Genomics is the study of heritable or acquired alterations in the genomic DNA sequence.
This application has been instrumental in identifying inherited disorders, characterizing
mutations that drive cancer progression, and tracking disease outbreaks. While microarrays
can interrogate over 4 million markers per sample, whole-genome sequencing (WGS) is far
more comprehensive and delivers a view of virtually the entire genome. NGS technologies
are now challenging microarrays as the tool of choice for genome analyses. The rapid drop
in sequencing cost and the ability of WGS to rapidly produce large volumes of data make it
a powerful tool for genomics research. Even when there is no reference sequence available,
NGS enables de novo sequencing of any species, largely contrasting microarrays, which
require knowledge of the genome for probe design [113, 122, 123].
For example, with the decrease in sequencing costs, researchers are now developing and
using NGS approaches for genotyping, thereby replacing array-based approaches to screen
for SNPs. Genotyping-by-sequencing (GBS) - or next-generation genotyping - is a screening
method to discover novel SNPs and to perform genotyping studies, such as genome-wide
association studies (e.g. 1000 Genomes Project [124]). As prior to sequencing, GBS involves
a digestion step with a restriction enzyme, it reduces genome complexity and can thus be
applied to large genomes. In addition, it also enables the identification of variants other than
SNPs, including small insertions, deletions, and microsatellites. As it also allows variants to
be compared when no reference genome is available, it is often used for genotyping of non-
model organisms (e.g. plant genotyping in breeding programs). GBS thus represents a cost-
e ective alternative for populations with complex genomes or limited resources available
[125, 126].
Targeted sequencing also proves invaluable to research. Here, a subset of genes or regions
of the genome are isolated and sequenced. This ‘targeting’ allows researchers to focus
time, expenses, and data analysis on specific target zones and enables sequencing at much
higher coverage levels. For example, WGS studies usually achieve a 30x-50x coverage of
the genome, while a targeted sequencing approach can easily cover the areas of interest
at coverage levels of 500x-1,000x or higher, allowing the identification of possible rare
variants. With exome sequencing, the protein coding portion of the genome is selectively
captured and sequenced. The exome represents less than 2% of the human genome, but
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contains the majority of known disease-causing variants, making whole-exome sequencing
a cost-e ective alternative to WGS [113].
• Transcriptomics
Transcriptomics - the study of RNA transcripts that are produced by the genome - using
NGS allows the genome-wide identification of genes that are (di erentially) expressed in
specific tissues or cells both in normal and diseased circumstances. RNA-seq starts with
total RNA extraction from the sample followed by an additional step to remove highly
abundant (particularly ribosomal) RNA, either directly or through selection of mRNA. In a
next step the RNA sample is converted back to complementary dsDNA (cDNA), which is
subsequently used for standard NGS library preparation. RNA-seq is very diverse and can
be focused on either the total RNA, or on a specific RNA subset, e.g. mRNA, small RNA,
noncoding RNA and microRNA, by including additional purification/enrichment steps prior
to the actual cDNA conversion [113, 127].
Ribosome profiling is a novel NGS method that is actually at the interphase between
transcriptomics and proteomics: it involves the sequencing of ribosome-protected mRNA
fragments (transcriptomics part) and thus presents a ‘snapshot’ of the actively translated
mRNA in a cell at a specific point (proteomics part). NGS ribosome profiling provides a
detailed in vivo analysis of protein production. Consequently, as this application enables the
determination of genes which are actually being translated into proteins, i.e. the ‘coding’
fraction of RNA transcripts, it is very useful for investigating translational control, rate
of protein synthesis and protein abundance, although it should be noted that there is no
perfect one-on-one relationship between ribosomal binding and translation [113, 128].
• Epigenomics
As already discussed in the previous chapter (section 2.2), ncRNAs play a role in gene ex-
pression, both at the transcriptional and post-transcriptional level. Likewise, the interaction
between DNA/RNA and proteins plays a fundamental role in in many biological processes,
e.g. gene expression. These latter interactions include histone modifications (section 2.1)
and can be surveyed with a NGS method called ChIP-seq, which combines chromatin im-
munoprecipitation (ChIP) assays and NGS [113, 122].
Given the prevalent roles and abundance of DNA methylation, the genome-wide profiling
of DNA methylation, i.e. methylation sequencing, is of critical importance in the study of
epigenetics. There are a couple of commonly used methods suitable for di erent experi-
mental settings. Given the relevance to this thesis, a more detailed overview is provided in
the next chapter.
The further development of NGS relies heavily on statistical methods and bioinformatics tools
for the subsequent data analysis. Indeed, bioinformatics analysis has become one of the main
bottlenecks for NGS applications. As described above, data throughput has increased with several
orders of magnitude compared to older methods. It is therefore necessary to keep developing
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suitable algorithms that can handle this and organize/interpret the output so it can be managed
by researchers, patients, etc. It is also important to consider the huge computational power and
data storage needed to process and maintain the data.
1.3 Next-next-generation sequencing
While NGS is now in full swing, even newer technologies known as third-generation sequencing or
next-next-generation sequencing (NNGS) are starting to appear. The main advantage of NNGS
is its ability to sequence single molecules of DNA without the need of a prior amplification step,
thereby requiring less sample manipulations and avoiding possible PCR artefacts. NNGS usually
involves a sequencing-by-synthesis strategy comparable to NGS, but is now based on physical
recognition of unmodified bases instead of imaging-based detection of nucleotide incoporation. In
addition, as there are no washing/imaging steps, time- and reagent-consuming steps are avoided.
This type of sequencing is currently being developed by a large number of companies, each using
a quite di erent approach. Without going into much detail, a small description of the four most
promising technologies is given below.
1.3.1 Pacific Biosciences SMRT sequencing
Pacific Biosciences developed a technology called Single-Molecule Real-Time (SMRT) sequencing
(Figure 1.4(a)). SMRT sequencing is built upon two key innovations: (i) zero-mode waveguides
(ZMWs) and (ii) phospholinked nucleotides. The platform uses single DNA polymerases anchored
to the bottom surface of an individual ZMW which is illuminated from below. In each ZMW,
a single molecule of DNA template is bound to the immobilized DNA polymerase and each
SMRT cell contains tens of thousands of these ZMWs. As a ZMW is only 100 nm in diameter,
the wavelength of the used light (532 and 643 nm) is too large to e ciently pass through the
waveguide. Thus, these ZMWs produce an evanescent wave that substantially reduces the volume
of observation at the surface of the polymerase reaction, enabling single-fluorophore detection
despite the relatively high labeled dNTP concentrations required by DNA polymerase for fast,
accurate and progressive synthesis. Di erentially labeled dNTPs enter the ZMW via di usion
and occupy the detection volume below for microseconds. During an incorporation event, the
labeled nucleotide is held within the detection volume by the polymerase for tens of milliseconds.
As each nucleotide is incorporated the label is cleaved o  and di uses out of the ZMW. Finally,
these ZMWs are continuously scanned thereby imaging the ongoing incorporation of dye-labeled
dNTPs in real-time during DNA synthesis. The technology is already fully commercially available
and implies that very long reads (average >10 kb) can be sequenced [129–131].
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Figure 1.4: Overview of the most promising third-generation sequencing platforms. (a) Pacific
Biosciences Single-Molecule Real-Time (SMRT) sequencing. (b) Life Technologies Single-Molecule
Fluorescence Resonance Energy Transfer (FRET) sequencing. (c) Oxford Nanopore Technologies
sequencing. (d) Ion Torrent Semiconductor sequencing. Source: [131].
1.3.2 Life Technologies FRET sequencing
The key element of this third-generation sequencing technology from Life Technologies is its
use of single-molecule fluorescence resonance energy transfer (FRET). Again, this sequencing
platform uses fluorescently labeled dNTPs, but here the DNA templates are immobilized on a
solid surface and the DNA polymerase for the sequencing-by-synthesis process is modified with
a quantum dot (Figure 1.4(b)). During an incorporation event, energy is transferred from the
quantum dot to a nucleotide-specific acceptor fluorescent moiety on each labeled nucleotide.
Light emission can only emanate from labeled nucleotides as they are being incorporated and it
is this burst of fluorescence energy that is recorded by the imaging system [132].
1.3.3 Oxford Nanopore Technologies
Nanopore sequencing is an NNGS technique consisting of a nanopore through which a ssDNA
template is forced (Figure 1.4(c)). The nanopore (purple in Figure 1.4(c)) can have a biological
origin, i.e. –-hemolysin bacterial protein, or can be artificially created, i.e. solid state, and is
positioned (immobilized) within a synthetic lipid bilayer. A current, which is constantly measured,
is applied to the interior of the nanopore. When a molecule passes through the nanopore, the
applied current is disrupted. This disruption is specific for each of the four nucleotides making it
possible to identify the passing nucleotides by looking at the current disruption profile. One of
the most important advantages of nanopore sequencing is its inexpensive sample preparation due
to the use of unmodified DNA and the application of a nanopore sensor, which eliminates the
need for dNTPs and DNA polymerases. As with Pacific Biosciences, this technology also implies
that very long reads can be sequenced. It is anticipated to be fully commercially available in the
very near future [131, 133, 134].
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1.3.4 Ion Torrent Semiconductor sequencing
The Ion Torrent technology directly translates chemically encoded information into digital infor-
mation on a semiconductor chip (Figure 1.4(d)). In nature, the incorporation of a nucleotide at
the 3’-end of a DNA strand by polymerase involves the formation of a covalent bond between the
two adjacent nucleotides thereby releasing a pyrophosphate and a hydrogen ion as byproducts
[135, 136]. Ion Torrent sequencing exploits this latter feature, namely that the release of positively
charged hydrogen ions will change the pH of the solution. Practically, wells on a semiconductor
chip, each containing one ssDNA template and one DNA polymerase, are sequentially flooded
with dATPs, dGTPs, dTTPs and dCTPs. Only when one of these dNTPs is complementary
to the nucleotide on the template strand, it is added to it by DNA polymerase. Upon such an
incorporation event, a hydrogen ion will be released changing the pH of the solution which can
be detected by an ion sensor (= pH-electrode). In a next step the unattached dNTPs are washed
away and a next sequencing cycle is started [137]. Because this is direct detection - no scanning,
no cameras, no light - each nucleotide incorporation is recorded in seconds. Despite the fact that
this technology is still limited in the provided length of sequencing reads, this major reduction in
sequencing time from days to hours has already led to many clinical applications [131].
Source: [138].

2
Detection of DNA methylation
‘From the growth of the Internet through to the mapping of the human genome and our un-
derstanding of the human brain, the more we understand, the more there seems to be for us to
explore.’ - Martin Rees
There exists a plethora of techniques to detect DNA methylation at specific loci. Generally, these
can be divided into three major groups: (i) chemical modification with bisulfite, (ii) methylation-
sensitive restriction endonucleases and (iii) a nity-based isolation of methylated DNA. On top of
that, various experimental methods have been developed to look at DNA methylation in a genome-
wide manner, each with their own advantages and challenges, of which bisulfite sequencing,
bisulfite microarrays and enrichment-based methods are the most popular. Which approach is
the most appropriate depends on the goal of the study. In other words: the method of choice
should deliver an unbiased answer to the biological question asked by the researcher [139–141].
2.1 Bisulfite-based methods
Bisulfite genomic sequencing is regarded as the ‘gold standard’ for detection of DNA methylation
because it provides a qualitative and quantitative approach to identify 5-mC at single base pair
resolution. As a methylated cytosine has the same base pairing characteristics as unmethylated
cytosine, they are indistinguisable from each other by current NGS technologies. However, prior
treatment of the DNA with bisulfite deaminates cytosine into uracil, which will be read as thymine
upon sequencing, whereas 5-mC is resistant and will remain read as cytosine. Thus, comparing
the sequence of the same read (or the reference sequence) before and after bisulfite treatment
enables detection of methylated cytosines (Figure 2.1). Here it is important to remark that also
hydroxymethylated cytosines are resistant to treatment, implying that 5-mC and 5-hmC cannot be
discriminated by this assay. As DNA methylation is far more prominent than hydroxymethylation,
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this is typically not problematic and ignored in applied DNA methylation studies (except in the
brain, see section 4.1.2). Luckily, alternative methods such as oxidative bisulfite sequencing and
oxidative Reduced Representation Bisulfite Sequencing (RRBS) have recently been developed to
discriminate between these two modifications [139, 140, 142].
Figure 2.1: gDNA is denatured and treated with bisulfite to convert unmethylated cytosine into
uracil, which is converted into thymine by PCR. Sequencing of DNA before and after bisulfite
treatment allows determining the methylation state of a DNA sample. Source: [143].
Bisulfite sequencing can be challenging: (i) Bisulfite conversion of unmethylated cytosines reduces
the genome complexity to three abundantly present nucleotides (A, T & G) and one relatively
rare 5-mC. This makes the alignment of the reads to the reference genome a more di cult task.
However, a couple of tools and mappers exist that try to tackle this complexity. (ii) Bisulfite
treatment also leads to DNA fragmentation, making investigation of long fragments di cult
[140, 142].
Bisulfite conversion is often the first step for methods that study the methylation status of spe-
cific genes or loci of interest. For example, bisulfite-converted DNA can be used for amplification
of a specific region followed by sequencing. Firstly, primers are designed around a known re-
gion of interest and amplified with PCR after bisulfite treatment. In a next step the resulting
PCR products are sequenced. However, due to reduced complexity of the DNA, primer design
and subsequent amplification can be problematic. Also, amplification of long fragments from
bisulfite-treated DNA is di cult and often limited to 100-300bp [140].
Another classical method that uses bisulfite-treated DNA is methylation-specific PCR (MSP).
Here, two pairs of primers are designed: (i) one methylation-specific primer pair that favors
amplification of methylated DNA (= not converted by the bisulfite treatment) and (ii) one
unmethylated-specific primer pair that only binds to unmethylated DNA. By looking at the re-
sulting PCR products the methylation status of the region can be determined. Pyrosequencing of
bisulfite-treated DNA is another technology suited for low-throughput projects. For this method,
primers are designed, PCR products for the locus of interest are obtained (using primers for
CpG-poor regions, i.e. putatively aspecific towards methylation) and short-read pyrosequencing is
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performed. The level of methylation of each sequenced cytosine can subsequently be estimated
in a quantitative manner based on the signal intensities - detection of pyrophospate release upon
nucleotide inclusion - of incorporated dGTP and dATP [140].
With the advent of NGS technology, this approach can be extended to methylation analysis across
an entire genome. Whole-Genome Bisulfite Sequencing (WGBS) is similar to WGS, except for one
additional step: a bisulfite treatment of the fragmented DNA. Key advantages are its (putatively)
full genomic coverage, reproducibility, quantitative and qualitative accuracy and single-base pair
resolution. Drawbacks however are the cost and di culties in post-NGS analysis, e.g. alignment.
Fortunately, WGBS can be (partiallly) substituted by methods that sequence only a part of the
genome. Evidently, this approach is less expensive, thereby also allowing for a higher coverage of
the sequenced fraction. One such method is RRBS. In RRBS, restriction enzymes and bisulfite
sequencing are combined to enrich for genomic loci with a high CpG content. First, gDNA is
digested using a methylation-insensitive restriction enzyme, i.e. MspI, which recognizes CCGG-
sites and cuts the DNA upstream of the CG (whether methylated or not), resulting in fragments
of di erent sizes. These fragments often undergo subsequent size-selection keeping only frag-
ments between 40-220bp, representative for the majority of CpG islands and promoter regions
(85%). Finally, the same bisulfite treatment and library preparation as for WGBS is performed.
This prior digestion and enrichment reduces the amount of nucleotides to be sequenced to only
approximately 1% of the genome [140, 142, 144, 145].
Upon bisulfite treatment, DNA methylation analysis can also be performed using microarrays.
Arrays are cost-e cient and valuable to look at specific regions of interest. Ilumina developed
an array methodology that is based on bisulfite conversion and whole-genome amplification: The
Infinium HumanMethylation Bead Chip. It is probably the most popular and widely used genome-
scale assay for methylation profiling [140]. There exist two di erent assays: the Infinium I and
the Infinium II. In the former assay, the converted and amplified DNA is hybridized against two
di erent types of beads for each specific CpG site: (i) one that contains a probe that matches the
unmethylated form of the CpG site (thymine), and (ii) one with a probe matching the methylated
form (cytosine), respectively the U- and M-probe. Only if a probe perfectly matches the CpG
site single-base extension can occur, resulting in a fluorescent signal (Figure 2.2). The Infinium
II assay consists of only one probe per CpG site and, depending on the single-base extension
with a labelled adenosine or guanine (complementary to thymine and cytosine, respectively), the
methylation status is determined [146]. While the Illumina 27K methylation array only contains
Infinium I probes, the newer 450K methylation array as well as the most recent microarray chip
of Illumina, i.e. the 850K methylation array, combine these two assays. This latter array, also
known as the HumanMethylationEPIC Bead Chip, can detect the methylation status of 850,000
individual CpGs in 99% of known genes, including miRNA promoters, 5’- and 3’-ends of genes
(referred to as untranslated regions (UTRs)), coding regions, transcription factor binding sites
and island shores (= 2kb upstream of CpG islands). However, this chip is only suited to study
human gDNA. Alternative kits with custom non-human panels exist, but are limited to only 384
CpGs [140, 142, 147].
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Figure 2.2: (a) Visualization of the Infinium I assay technology. Only if a probe perfectly matches
the CpG site single-base extension can occur resulting in a fluorescent signal. Thus, in case an M-
probe hybridizes to the methylated form of ‘its’ CpG, subsequent single-base extension will result
in a fluorescent signal. In case this M-probe would have hybridized to the unmethylated form of the
CpG site, the resulting mismatch hinders extension and no signal would occur. The same reasoning
can be applied for the U-probe, where a signal will be detected for a match with an unmethylated
CpG. (b) The Infinium II design uses 1 bead type, with the methylated state determined at the
single base extension step after hybridization. Source: [146].
2.2 Enrichment-based methods
Although RRBS already decreases costs by sequencing a limited (yet reproducible) part of the
genome, even more cost-e cient alternative genome-wide methods exist that also avoid the dis-
advantages of bisulfite-treated methods. These methods are based on prior enrichment of methy-
lated DNA fragments by methylation-specific antibodies or proteins containing methyl binding
domains (MBD) followed by sequencing. In the latter, MBD - usually recombinant versions of
the MBD found in MBD (and sometimes MCEP2) proteins - is used to capture methylated CpGs
of fragmented gDNA, and after a washing-and-elution-step, the enriched DNA is analyzed and
quantified (Figure 2.3). As in bisulfite sequencing, the MBD-captured DNA can be quantified by
microarrays or sequencing. However, developing microarray probes requires prior knowledge of
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the genome and/or genomic locations, making de novo sequencing more flexible. On top of that,
sequencing-based approaches require less DNA, have a far higher genome-wide character and
provide higher resolution. When followed by sequencing, MBD-enrichment methods are known
by several names: MBD-seq, MethylCapture sequencing (MethylCap-seq) and MBD-isolated ge-
nomic sequencing (MIGS) [142, 148].
As an alternative to MBDs, methylation-specific antibodies can be used (methylated DNA im-
munoprecipitation (MeDIP)). Although it is generally stated that MethylCap-seq targets biolog-
ically more relevant methylated DNA fragments, the a nity of MeDIP-seq is less dependent on
the CpG-content and even non-CpG methylation can be picked up.
Generally, both MethylCap- and MeDIP-seq are not able to capture 5-hmC. However, some results
with the MBD of MCEP2 indicate potential a nity for 5-hmC. Recently, the MeDIP method has
been adjusted to serve this need by using antibodies specifically targeting 5-hmC (hMeDIP-seq).
Source: [142].
Figure 2.3: Enrichment-based sequencing for DNA methylation profiling. (a, b, c) gDNA is frag-
mented and methylated DNA fragments are captured using antibodies or specific protein domains
(e.g. MBD). (d) Next, unbound fragments are washed away and bound, methylated fragments are
obtained through elution. (e, f) After library preparation, the fragments are sequenced and re-
sulting sequence reads are aligned to a reference genome to identify the methylated regions [142].
Although enrichment-based methods reduce the overall cost of sequencing while still providing a
genome-wide profile, there are some drawbacks as well. Firstly, in contrast to bisulfite sequencing,
they do not provide single base pair resolution nor information regarding the unmethylated fraction
of the genome [149]. Secondly, the CpG-density and GC-content of the target fragment can a ect
the a nity and e ciency of purification, potentially creating major biases. As a consequence,
several methylated loci are virtually impossible to capture and sequence when using MethylCap-
and MeDIP-seq [142].
2.3 OTHER METHODS 70
2.3 Other methods
Another bisulfite-free alternative to profile DNA methylation is the usage of particular endonucle-
ases, i.e. restriction enzymes that cut DNA at or near an enzyme-specific recognition nucleotide
sequence known as ‘restriction site’. By combining endonucleases that only cut when (i) the
DNA is methylated and/or when (ii) DNA is unmethylated together with endonucleases whose
function is una ected by presence of methylation a selective digestion of the DNA is obtained.
For example, the endonuclease HpaII recognizes the CCGG sequence and is able to digest it, but
only when it is unmethylated. In contrast, the MspI enzyme recognizes the same CCGG site and
cuts the sequence, whether methylated or not. Hence, combining both HpaII and MspI on the
same sample - and subsequent (electrophoretic) analysis of the sizes of the digestion products -
makes it possible to reveal the location of methylated sites. Nowadays, there are a number of
methods that incorporate this digestion approach, some of which enable whole-genome methy-
lation profiling (e.g. endonuclease digestion followed by sequencing), while others are suitable to
profile methylation of individual genes [140].
Less common is the detection of methylated bases directly through sequencing of unmodified
DNA without the need of prior enrichment or bisulfite conversion. Considering the disadvantages
of bisulfite- and enrichment-based methods, direct detection of methylated cytosines would be a
preferred approach. Pacific Biosciences has developed a way to detect methylated bases directly
by monitoring the kinetics of polymerase during SMRT and already o ers a commercial product
for such sequencing. The applicability of this technology for DNA methylation analysis was
demonstrated for 5-mC, however, so far, not at single nucleotide resolution. Also, as discussed
in the previous chapter, there have been recent advances in the use of nanopores, which are able
to detect modified bases directly. These new findings will hopefully lead to future sequencing
instruments with even better sensitivity and specificity [140].
Source: [150]
3
NGS data analysis
‘Bioinformaticians are not anti-social; we’re just genome friendly.’ - Unknown
NGS technologies are revolutionizing the way to generate genomic data. NGS uses massively par-
allel sequencing to obtain relatively short reads, generating enormous datasets. Therefore, com-
putational methods need to keep up in order to analyze a wide range of genetic information and to
assist in data interpretation and downstream applications, such as genome mapping, gene/protein
prediction, variant detection, functional genomics and transcriptome/epigenetic analysis. Given
the continuously decreasing cost of sequencing, it is no surprise that the complexity of bioin-
formatics has been making data analysis a larger and larger portion of the total cost of a given
study project. Indeed, the total cost of storing and analyzing sequence data will soon be greater
than the cost of obtaining the raw data from sequencing machines. Following sections give an
overview of some basic steps in the analysis of genome-wide NGS data. As the performed work in
this thesis almost exclusively involves the analysis of data originating from (Illumina) sequencing
platforms rather than microarrays, only the former will be discussed.
3.1 Primary analysis
NGS experiments result in platform-specific images of emitted signals. In a primary analysis,
these images are processed to call base pairs with associated quality scores. In most cases, this
results in a FASTQ file, which is just a combination of the sequence data as a string of A, C, T
and G characters (= the base calls) together with their respective quality score. The standard
and most widely used quality score is Phred. Phred quality scores are logarithmically related to
the probability that the base call is wrong, i.e. a score of 10 means a 10% error probability, 20
means a 1% chance, etc. [151]
Before these called reads are reassembled, it is often suggested to first check the raw reads
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from the machine for quality. Quality control generally includes an overview of the base qual-
ity distributions, read lengths, GC content, possible artefacts/contaminations, sequencing bias
and degree of (PCR-)duplication. A couple of good tools, such as FastQC [152] and PICARD
[153], are available for this initial quality assessment and help to remove low quality or aberrant
sequences. Also, following initial quality control, it is essential to remove adapter sequences
(‘adapter clipping’) from reads as they can profoundly a ect downstream analysis. If necessary,
an extra quality trimming of the reads can be performed. Trimming refers to the removal of bases
from either the 5’- or the 3’-ends of a read whose quality does not pass user settings. Unlike
adapter clipping, trimming is not mandatory, but is often recommended to improve accuracy and
performance in subsequent steps such as alignment and assembly. A good open-source tool for
both clipping and trimming of NGS reads is FASTX [154, 155].
3.2 Secondary analysis
Next, the preprocessed reads are reassembled. If the genome sequence of the studied species is
unknown, the genome has to be reassembled from scratch by assessing overlap of reads, a process
referred to as de novo assembly. If on the other hand a reference genome is available, the process
is much simpler as the reads ‘only’ have to be aligned to this reference. However, the short
length of the reads together with the occurence of sequencing errors and genomic variations,
such as SNPs and indels (= insertion and deletions), make mapping to the reference genome not
straightforward [151, 155]. Luckily, many di erent algorithms - each with their specific strenghts
and drawbacks - have been developed to tackle this problem. Examples of popular short read
DNA mappers are SOAP [156], BWA [157] and BOWTIE [158]. The process of RNA splicing
makes mapping of cDNA reads from RNA-seq data even more challenging. RNA-seq alignment
algorithms need to take this potential splicing into account by allowing large gaps to include
introns. Two of such splice-aware ‘transcriptome mappers’ are TopHat [159] and STAR [160].
Prior bisulfite treatment of DNA to profile methylation patterns also complicates standard map-
ping because of the following reasons: (i) The search space for mapping is significantly in-
creased relative to the original reference sequence. Unlike normal sequencing, the two strands
of bisulfite-treated sequences are not complementary due to the bisulfite conversion that only
a ects cytosines. As a result, there will be four distinct strands after PCR amplification. (ii)
There is a reduced sequence complexity. Although the mammalian genome consists of approxi-
mately 19% cytosines, only 1.8% of dinucleotides are CpGs. As 5-mC predominantly occurs at
CpG dinucleotides, the vast majority of cytosines, i.e. the unmethylated fraction, will be con-
verted to thymines. As a consequence, the overall C content of bisulfite reads is expected to
be reduced by 50%. (iii) Cytosine to thymine mapping is asymmetric, meaning that thymine in
the bisulfite reads can be mapped to either cytosine or thymine in the reference, but not vice
versa. Apart from increasing the searching space, this also complicates the matching process
[161]. BSMAP and Bismark are two e cient bisulfite mappers addressing these issues. While
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the former uses a bitwise masking algorithm - masking Ts in the bisulfite reads as Cs (i.e. reverse
bisulfite conversion) only at C positions in the original reference while keeping all other Ts in the
bisulfite reads unchanged - to subsequently map masked reads directly to the reference genome,
the latter mapper first transforms the bisulfite reads into a C-to-T and G-to-A version, after
which each of them is aligned to equivalently pre-converted forms of the reference genome using
four parallel alignment processes. Both algorithms support alignment of WGBS and RRBS reads
[161, 162]. Most tools report mapping results in the Sequence Alignment Map (SAM) format or
its binary sister BAM. A SAM file is a tab-delimited text file that contains the sequence align-
ment data in pre-specified ASCII columns as well as the sequence and quality information of the
original FASTQ file. While the SAM format is human-readable, BAM stores the same data in a
compressed, indexed binary form [163].
3.3 Tertiary analysis
Upon alignment, it is time to make some sense of the data. Data visualization is an essential
component of genomics data analysis. There are a couple of publicly available tools/websites,
e.g. UCSC browser, which allow users to upload their custom tracks - such as for example sample-
specific alignment files - and browse entire genomes with annotated data. This provides some
useful information about the mapped reads such as the visualization of highly expressed regions,
detection of structural variants or even overlap with other data types or samples. However, if one
wants to find all structural variants or high/low/di erentially expressed genomic regions, manually
browsing the entire genome would be a real ine cient, time-consuming task. In addition, decisions
based solely on personal judgment about the visual look of mapped reads would not be very
‘scientific’, let alone be consistent. Fortunately, there exists a plethora of tools and algorithms to
summarize your aligned data and analyze them in a statistically appropriate manner without the
need of visualization. As such, data visualization is rather meant to initially assess the quality of
your alignment and importantly, to verify the outcome of subsequent statistical analyses (with or
without other existing data). As the post-sequencing analyses of variant detection and di erential
analysis are relevant for the remaining chapters of this thesis, the next sections will mainly focus
on the di erent aspects of these analyses [151, 155].
3.3.1 Genotype calling
Given the aligned sequence data, an informative next step is to look at possible sequence variants.
In other words, the identification of SNPs, indels, copy number variations (CNVs) and other types
of structural variation (e.g. inversions and translocations). Generally, this requires a reference
genome to compare the sequence data against. However, the occurrence of areas of low coverage,
sequencing errors, misalignments and library preparation biases (PCR-duplication) complicates the
variant calling process. Therefore, specialized variant calling tools are needed that use Bayesian
3.3 TERTIARY ANALYSIS 74
probabilistic models for correctly inferring variants. Typically, these models are based on the
calculated probabilities of the genotypes given the data, and take into account allele frequencies
(either known or empirically determined), finally selecting the genotype with the highest posterior
probability [151, 155]. Examples of variant discovering pipelines with build-in probabilistic models
are Samtools Mpileup [163], Genome Analysis ToolKit (GATK) [164] and SeqEM [165]. These
tools mostly report called variants in the Variant Call Format (VCF). A VCF file is a text file
with a specific intuitive format developed for storing genomic sequence variations. It contains
meta-information lines, a header line, and then data lines each containing information about
a (variant) position in the genome [166]. After producing such a list of detected SNPs, it is
highly recommended to compare it to dbSNP, the largest repository of SNP data found within
the National Center for Biotechnology Information (NCBI) database. These variations can result
in biological e ects through introduction of di erent amino acids into protein sequences, early
termination of coding sequences and alteration of regulatory elements and splice sites. A natural
step following the variant calling process is annotating the detected variants and elucidating their
e ect as well as biological significance [155].
3.3.2 Differential expression analysis
For many applications, we are interested in measuring the absolute or relative expression of each
mRNA in the cell. In most experimental setups, expression profiles of two or preferably more
samples are compared to identify di erentially expressed (DE) genes across di erent conditions.
A gene is declared DE if the observed di erence or change in read counts between the di erent
samples is statistically significant, i.e. if the di erence is greater than what would be expected
just by random variation. Therefore, statistical methods are needed to analyze the respective
sample-specific read count distributions. Generally, a DE analysis exists of the following critical
steps (Figure 3.1): (i) define experimental setup, (ii) import the count data, (iii) normalize the
data between samples/groups and remove sample-specific variation, (iv) fit a model/distribution
to the data that accounts for both technical and biological variability, (v) statistical testing to
find biologically DE genes and (vi) summarize and visualize results.
A common study design is a two-group comparison (e.g. one experimental/treated group and
one control group). However, also more complex designs (e.g. with more than one experimental
factor of interest) are possible. For the latter, however, a design matrix that specifies all factors
expected to a ect expression levels, including biological factors of interest as well as other factors
such as batch e ects, is needed to describe the design mathematically. Before any analysis or
statistical modeling, it is usually recommended to start from a sample table containing metadata
such as sample identifiers, experimental conditions, additional factors, etc.
After initial checks on sequence quality, reads are mapped to the reference with a splice-aware
aligner (e.g. TopHat and STAR) and organized. However, in case no reference genome is available
for the species under study, one must first determine a set of transcript sequences via de novo
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transcriptome assembly, which is the reconstruction of transcript sequences from RNA-seq reads
without the aid of genome sequence information. Here, the sequence reads are assembled into
transcripts via a short read transcript assembly program. A number of assembly programs are
available, of which Velvet and Trinity are most frequently used [167, 168]. Without going into
detail, both algorithms are based on De Bruijn graphs - directed graphs representing overlaps
between sequences of symbols - to assemble transcripts De novo transcriptome assembly is often
the preferred method to studying non-model organisms, since it is cheaper and easier than building
a genome, and reference-based methods are not possible without an existing genome. Importantly,
also reference-based de novo transcriptome assembly tools exist, such as the TopHat/Cu inks
pipeline [169]. Using this approach, alternative splicing events and/or novel transcripts can be
identified in the sequencing data by examining their alignments to the genome.
But, whatever method was used, in a next step the numbers of mapped reads are counted and
summarized per genomic feature - with or without available annotation files - in order to measure
their activity. A possible tool for counting reads in a feature of interest (e.g. genes and exons)
is HTseq, which assembles the count data into a table (rows for features (i.e. genes/transcripts)
and columns for samples) [170]. Two widely-used statistical tools, DESeq and edgeR, start from
such a feature count table [171, 172].
After this preliminary work, it is time for the ‘real’ di erential analysis. As the di erent samples (=
libraries) will be sequenced to di erent depths, the count data has to be scaled to be comparable,
a process called ‘normalization’. Normalization is one of the crucial steps in DE analysis: it
removes non-biological sources of systematic variation between samples. In addition to variation
in library sizes, this also includes other between-samples variation such as (preferably minor) batch
e ects, though some approaches also adjust for within-sample di erences caused by gene length
and GC-content.
However, it should be noted that in practice, the raw reads are not actually altered, but that the
data is scaled in the statistical models. Indeed, by default edgeR first uses the number of mapped
reads per sample and estimates an additional normalization factor to account for sample-specific
e ects. In a next step, these two items are combined and used as an ‘o set’ in the negative
binomial model. Likewise, DESeq defines a virtual reference sample by taking the median across
samples for each gene and then computes ‘size factors’, i.e. the median of ratios of each sample
to the reference sample. Thus, although the packages di er in their default normalization, in
practice the normalization factors of both approaches are often very similar. Instead of using
the default normalization methods, users are also allowed to give in own normalization factors
resulting from custom normalization methods [172].
Note however that, although intuitively it makes sense, standard library size normalization meth-
ods are mostly not appropriate for RNA-seq. Problems arise when datasets with major di erences
in sample composition are compared, such as samples with large di erences in expressed mRNA
populations. If, for example, a particular set of mRNAs is very highly expressed in one condition,
but not in the other, normalizing by a library size factor makes it appear that non-DE genes are
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in fact consistently downregulated, while minimizing the genuine di erences between the more
highly expressed genes. Therefore, it is preferable to use alternative, more advanced methods
that try to handle outliers (DE genes) prior to normalization to minimize their impact [173].
Both edgeR and DESeq use a count-based framework and implement general di erential analyses
based on a negative binomial distribution. However, estimation of the corresponding variance is
often problematic for experiments with few replicates (see below). To deal with this di culty, both
methods are ‘moderated’ methods, meaning they use all loci to estimate variance/overdispersion
and share information between similarly expressed genes to shrink (= ‘moderate’) the gene-wise
variances to a fitted common variance. Although they have a similar strategy, edgeR and DESeq
slightly di er in the extent of the moderation and their common variance estimate, i.e. the
variance estimate that the procedure is moderating towards [174]. In addition, they also di er
in the way they estimate the dispersion, a parameter describing how much of the variance in
expression deviates from the mean. Without going much into detail, in practice, DEseq will
be more stringent (but less powerful) while edgeR will be somewhat more sensitive to outliers.
There have been lots of comparative studies, but ultimately no single method dominates across
all settings.
Finally, both return fold changes, counts as well as raw and adjusted P-values. Indeed, obtained
P-values need to be adjusted for multiple testing. By default, the Benjamini-Hochberg (False
Discovery Rate (FDR)) procedure is applied [175], but also other options are available, such as
Bonferroni [170, 172, 176].
Two - also popular - alternatives to the negative binomial model to identify DE genes are LIMMA-
VOOM and PoissonSeq. The former method transforms the data (= read counts) to the more
tangible normal distribution after which the RNA-seq data can be analyzed as if it was microarray
data [177]. PoissonSeq on the other hand transforms the data to a Poisson distribution, where
mean per definition equals the variance [178].
Several variations of workflows with slightly di erent approaches with respect to these aspects
have been presented in the literature, of which a popular one covering both DESeq and edgeR is
shown in (Figure 3.1) [171, 172, 179]. Note that these methods are general and flexible, making
that this counting approach can be applied to other situations where observations are counts and
the goal is to discover changes in abundance (e.g. ChIP-seq and MethylCap-seq) [172].
There are a couple of critical points that need to be considered regarding the experimental design.
Before one even begins an RNA-seq experiment, they should have an understanding of each step
and should put together a carefully devised experimental plan. When designing such an experiment
researchers are faced with choosing between many experimental options. Some of these will have
little impact, but in other cases inappropriate decisions can result in spending a great deal of
time and money only to obtain nearly useless data. This stage is arguably the most important
but often receives the least attention (Figure 3.2). Experiments that are designed to measure
quantitative changes have requirements that di er from those that are designed for qualitative
purposes, e.g. annotation, and it would be di cult and expensive to design a single experiment
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Figure 3.1: A possible di erential expression pipeline for RNA-seq data using a count-based
approach with edgeR and/or DESeq. While one can start from the raw sequence data as input
data (purple box), alternative entry points to this pipeline are shown in orange boxes. Green
boxes indicate needed annotation files, the purple box the input data and the light orange box the
required steps for adequate software installation. Source: [172].
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that satisfies the requirements of both. Here, we highlight some important considerations with
detection of di erential expression as an experimental objective.
Figure 3.2: It is imperative that one carefully considers di erent experimental options before
launching into a time-consuming and costly RNA-seq experiment. While this is thé most crucial
step in the pipeline, its importance is often undervalued or even neglected. Source: [180].
DE experiments must be designed to accurately measure counts of each transcript. However,
as there is no way to know how accurately these counts reflect what was really present in the
sample nor how widely expression normally varies in a given group (with and without treatment),
simple read counts alone are not su cient to identify DE genes, let alone to quantify the degree
of di erences. Therefore, next to accurately measuring read counts, it is equally important to
measure the variances associated with those numbers.
Several types of variances contribute to RNA-seq data including: (i) sampling variance, (ii)
technical variance (= unintended variation in library preparation and sequencing procedures) and
(iii) biological variance (= inherent/nascent biological variability within a treatment or control
group) [172, 179, 181]. To account for these di erent sources of variances and obtain accurate
measures, DE experiments need to focus time and expense on replicates. The number of replicates
per group directly a ects statistical power, i.e. the likelihood that a study will detect an e ect when
there is an e ect to be detected. Decisions about the number and types of replicates (individual
units of statistical inference) are driven by both extrinsic and intrinsic factors. The former relates
to e.g. costs and sample availability, the latter includes the degree of transcriptional variability
among samples, possible low expression levels of genes of interest, amount of experimental factors
(= complexity of experimental design) [172, 181]. Also, when one wants to identify a treatment
e ect on genes with shallow coverage, depth of sequencing per sample has to be taken into
account. In addition, for more complex designs it is important that su cient replication occurs
at every level of comparison [182]. Note that, when the amount of available material (e.g. DNA
and RNA) is rather low, it is often possible to pool samples from the same condition/treatment
to obtain su cient material for sequencing. Importantly, pooling samples does not only increase
the amount of material, but also reduces biological variation between samples.
In conclusion, replication levels of two or three are often a practical compromise between cost
and benefit for well-designed experiments (i.e. with very low amounts of non-relevant biological
variation) for which inexpensive validation is possible. However, for observational studies, where
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the objective is to obtain a comprehensive overview, typically much larger group sizes (dozens
or hundreds) are needed to reliably detect biologically meaningful results. In contrast, studies
aiming to identify clinically relevant biomarkers often need less samples, as the aim is to find a
very clear di erence between di erent groups [172].
Source: [183].
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SNP-guided identification of monoallelic
DNA methylation events from
enrichment-based sequencing data
1.1 Abstract
Monoallelic gene expression is typically initiated early in the development of an organism. Dysreg-
ulation of monoallelic gene expression has already been linked to several non-Mendelian inherited
genetic disorders. In humans, DNA methylation is deemed to be an important regulator of mono-
allelic gene expression, but only few examples are known. One important reason is that current,
cost-a ordable truly genome-wide methods to assess DNA methylation are based on sequencing
post-enrichment. Here, we present a new methodology based on classical population genetic the-
ory, i.e. the Hardy-Weinberg theorem, that combines methylomic data from MethylCap-seq with
associated SNP profiles to identify monoallelically methylated loci. Applied on 334 MethylCap-seq
samples of very diverse origin, this resulted in the identification of 80 genomic regions featured by
monoallelic DNA methylation. Of these 80 loci, 49 are located in genic regions of which 25 have
already been linked to imprinting. Further analysis revealed statistically significant enrichment of
these loci in promoter regions, further establishing the relevance and usefulness of the method.
Additional validation was done using both 14 WGBS data sets and 16 mRNA-seq data sets.
Importantly, the developed approach can be easily applied to other enrichment-based sequencing
technologies, like the ChIP-seq-based identification of monoallelic histone modifications.
1.2 Introduction
For diploid organisms, gene expression is denoted as allele-specific or monoallelic if only one allele
is transcriptionally active. The expressed allele can be randomly selected (e.g. X-chromosome
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inactivation and some autosomal genes) or predetermined by parental imprinting [61, 184, 185].
Erroneous allele-specific expression has been associated with several genetic disorders, like the
Prader-Willi syndrome, as well as with certain forms of cancer, like Wilm’s tumor. Both diseases
are caused by loss of imprinting of some genes in the 15q11-q13 and 11p15.5 region, respectively
[27].
Epigenetics is defined as the study of inheritable modifications on both chromatin and DNA
that have an influence on gene expression without changing the underlying DNA sequence [186].
Mammalian DNA methylation is an epigenetic mark that is predominantly found in a CpG se-
quence context [187]. This methylation mark has been linked with gene expression and when
located in the promoter region, it generally leads to transcriptional silencing of the corresponding
gene [40]. As it is a defining feature of cellular identity and essential for normal development,
its dysregulation is often associated with disease [27]. Monoallelic DNA methylation is likely to
bear an important role in the regulation of monoallelic expression [188]. In addition to DNA
methylation, histone modifications also contribute to the maintenance of monoallelic expression.
The methylated, silenced allele is mostly sustained with the repressive histone H3 trimethylation
at lysine 9 (H3K9me3) while the active allele is characterized by the permissive histone marker
H3 trimethylation at lysine 4 (H3K4me3) [189].
An important example of monoallelic DNA methylation is the regulation of the parental-dependent
monoallelic expression at imprinted loci, where the silenced allele is significantly more methylated
than the active, expressed allele [61]. Although imprinting is a well-investigated topic and sev-
eral studies already provided evidence (e.g. computational predictions based on DNA sequence
characteristics or detection of monoallelic expression) of some regions with monoallelic DNA
methylation [61, 185, 190–196], only a few imprinted regions are well characterized in humans,
like, for example, the Igf2/H19 region. Furthermore, monoallelic methylation has recently been
recognized as very common at non-imprinted loci a ecting autosomal genes, regulating, for ex-
ample, the production of specific antibodies and receptors in the immune system as well as the
selection of olfactory receptors [197, 198]. While monoallelic methylation has been shown to play
an important role in the di erentiation between tissues, little is known about the specific location
of these loci as well as the genome-wide character of monoallelic DNA methylation.
The recent advent of next-generation massively parallel sequencing platforms has introduced the
possibility of genome-wide DNA methylation profiling. Bisulfite sequencing, which combines
bisulfite treatment of gDNA with the high-throughput sequencing of the entire genome, is the
gold standard and allows to readily identify monoallelic methylated alleles [199], but is very
costly and therefore out of reach for smaller projects. Fortunately, cost-e ective alternatives
based on the specific enrichment of methylated portions of the genome (i.e. enrichment-based
methods) such as MeDIP-seq and MethylCap-seq exist. Yet, these methods neither provide
single base pair resolution nor information regarding unmethylated alleles and are therefore not
directly applicable to detect monoallelic events [148]. While some approaches already tried
to tackle this issue, they rely on the combination of multiple sequencing technologies, like for
example, the integrative method of Harris et al. [200], which tries to find regions with intermediate
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and potentially monoallelic events by combining data originating from MeDIP-seq, methylation-
sensitive restriction enzyme sequencing (MRE-seq), RNA-seq and ChIP-seq.
To circumvent these issues we developed a data-analytical framework that solely uses data from
enrichment-based sequencing, and screens for regions that exhibit monoallelic DNA methylation
based on classical population genetic theory, i.e. the Hardy-Weinberg equilibrium, in a parental-
independent and genome-wide manner. This theory states that in a large random-mating popu-
lation with no selection, mutation or migration both the allele and genotype frequencies of a gene
locus with two alleles are constant from generation to generation, and furthermore, that there
is a simple relationship between these allele and genotype frequencies: if the alleles are A and a
with frequencies p and q (= 1-p), respectively, then at equilibrium the genotype frequencies of
AA, Aa and aa are p2, 2pq and q2, respectively [201].
The developed pipeline first compares enrichment-based sequencing data of multiple samples
to the public NCBI SNP-archive dbSNP in order to screen the obtained non-duplicate, uniquely
mappable sequence reads for SNPs. Only SNP loci with an adequate coverage and allele frequency
are retained and the e ect of sequencing errors is further reduced by comparing the chance of
a sequencing error with the chance of detecting genuine SNPs. For each single SNP locus, the
Hardy-Weinberg theorem is then applied to evaluate whether the observed frequency of samples
featured by a biallelic event is lower than randomly expected [201]. Using a permutation approach,
confidence limits are simulated and genomic regions with a P-value smaller than the P-value
corresponding with a given false discovery rate (FDR) can be assumed to harbor a monoallelic
event.
Starting from MethylCap-seq data of a mixture of 334 Caucasian human samples and an FDR of
0.1, this methodology allowed the identification of 80 monoallelically methylated loci, significantly
more than expected in promoter regions. Of these 80 loci, 25 have previously been linked to
imprinting. Additional validation was done using both 14 WGBS data sets of diverse origin and
mRNA-seq data of 16 normal tissues. Here, the analysis was performed on available samples
originating from a variety of tissues, mostly cancer tumors, providing a challenging data set to
identify monoallelic methylation events (see Discussion). However, even in this set-up generally
known imprinted regions were identified as well as putative novel imprinted genes, demonstrating
the robustness of our method. Finally, because of the general rationale of the developed approach,
it can be applied to enrichment-based sequencing applications to detect monoallelic features other
than DNA methylation. A possible application could be ChIP-seq [202] to screen for monoallelic
histone modifications [203–207].
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1.3 Materials & Methods
Samples
A total of 334 human samples, mostly cancer samples of various tissues, was used to detect
monoallelically methylated loci (Appendix A.1.1). Of these 334 samples, 215 samples were of
female origin and only these were used to analyze the X-chromosome. gDNA was extracted from
these samples with the Easy DNA kit (Invitrogen K1800-01) using protocol #4 from the manu-
facturer manual. The DNA concentration was measured on a Nanodrop ND-1000. Subsequently,
the gDNA was sheared on the Covaris S2 with following settings: duty cycle 10%, intensity 5,
200 cycles per burst during 180 s to obtain fragments with an average length of 200bp. The
power mode was frequency sweeping, temperature 6-8°C and water level of 12. A total of 500 ng
was loaded in 130 µl TE (1:5) in a microtube with Adaptive Focused Acoustics (AFA) intensifier.
MethylCapture sequencing
MethylCap-seq [148], which combines enrichment of methylated DNA fragments by MBD-based
a nity purification with massively parallel sequencing, was used to profile the DNA methylation
pattern of the 334 samples. The samples were sequenced according to the protocol described in
the paper of De Meyer et al. [208] with some additional modifications: (i) After DNA fragmen-
tation, the methylated fragments were captured using Diagenode’s MethylCap kit starting from
a DNA concentration of 500 ng instead of 200 ng. (ii) PE sequencing was done on either the
Illumina GAIIx or the HiSeq platform. Depending on the sequencing platform, the obtained PE
sequence reads were 45 or 50bp, respectively.
Data preprocessing
The rationale behind the proposed methodology is that biallelic DNA methylation results in
MethylCap-seq data which is in Hardy-Weinberg equilibrium for each locus, i.e. if SNPs are
present for a locus, both homozygous and heterozygous subjects will be detected at a predictable
rate [201]. However, in case of monoallelic methylation, heterozygous samples will no longer be
detected, resulting in deviation from the Hardy-Weinberg equilibrium, which can be measured.
For a detailed description of the statistical framework, see Additional Methods Appendix A.1.2.
Figure 1.1 gives an overall representation of the workflow starting from MethylCap-seq data.
Mapping
For each of the 334 samples, the MethylCap-seq PE reads were mapped using BOWTIE (v1.0.0)
[209]. The mapping parameters were chosen so that only those PE reads that mapped uniquely
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Figure 1.1: Overview of bioinformatics pipeline to detect putatively monoallelically SNP loci
starting from MethylCap-seq data. After mapping with BOWTIE the non-duplicate, uniquely
mapped reads are screened for SNPs using dbSNP. To reduce the computational load SNP loci
with a too high MAF and/or a too low overall coverage are filtered. In this reduced data set,
an additional sequencing error correction was performed with two iterations. Next, the corrected
data was put in the newly developed data-analytical framework with 1,000 and 1,000,000 iterations,
respectively. Only loci that obtained a P-value smaller than or equal to 0.005 after the first iteration
were kept as input for the second iteration. If the P-value obtained for a locus was smaller than the
P-value corresponding with an FDR of 0.1, the monoallelic methylation on this locus was called
significant. After determining the functional annotation of these SNP positions, an enrichment
analysis was performed. Finally, the resulting loci were validated using both literature and WGBS
data.
on the human hg19/GRCh37 reference assembly within a maximum of 400bp of each other
were retained. In order to both reduce the presence of sequencing errors as well as to allow
the occurrence of real SNPs, a maximum of three mismatches was allowed. As suggested by
Stevenson et al. [210], allowing three mismatches during the alignment step significantly reduces
the reference allele bias at SNP loci while still enabling an ample amount of uniquely mapped
reads. Duplicate fragments, i.e. fragments with the exact same location of both paired-end
reads, were disposed as these are most likely the result of amplification of the same sequence
reads during library preparation.
SNP tracing
The non-duplicate, uniquely mappable reads were subsequently screened for SNPs. Only positions
that showed a mismatch in the mapping of one or more samples and that overlapped known single
nucleotide variations (SNVs) of dbSNP (version 137) were withheld. Not keeping all the mis-
matches reduces both the e ect of sequencing errors (false positives) and the computational load
1.3 MATERIALS & METHODS 88
in the further analyses. Also, for each locus, the coverage of each SNP variant was determined,
and the allele frequencies were estimated.
Additional data filtering and correction
Both for computational reasons and as a first filtering step for sequencing errors, SNP loci with
a very high major allele frequency (MAF) were filtered (threshold 0.9). Additionally, a minimal
total coverage threshold, i.e. across all samples, for each SNP locus was imposed (350 ≥ 1◊
per sample). Note that loci not fulfilling both criteria are unlikely to provide su cient power for
the subsequent statistical analysis. As analysis of the X-chromosome involved fewer samples, the
threshold for the coverage was set to a less stringent value, namely 250 instead of 350, which
roughly corresponded to the number of female subjects.
In this reduced data set, an additional sequencing error correction was performed. For compu-
tational reasons, a simple Bayesian methodology was implemented. Basically, for each sample
and locus, the chance of obtaining a certain profile was calculated under (i) the assumption of
heterozygosity and (ii) the assumption of homozygosity but with additional sequencing errors.
The option with the largest a posteriori chance was withheld (with alleles representing putative
sequencing errors being removed from the data set). As the prior chances of homozygosity and
heterozygosity were based on the allele frequencies, which are updated upon each round of the
Bayesian algorithm, this method was performed twice (See Appendix A.1.2.1). This approach can
be considered to be conservative (i.e. to disfavor the presence of monoallelic DNA methylation),
as (i) only two rounds of correction were applied and (ii) the sequencing error estimate (0.25%,
based on Quail et al. [211]) is on the lower bound of estimates reported and is based on the
performance of the Illumina HiSeq, whereas also more error prone GAIIx data was included in
this study.
Detection of monoallelically methylated loci
After additional filtering and data correction, the remaining data was used as input of the new
data-analytical framework developed in the R statistical environment (v2.15.2). The statistical
strategy and practical implementation are elaborated in the Additional Methods Appendix A.1.2.
In summary, based on the observed allele frequencies, theoretically expected genotype frequencies
can be calculated assuming Hardy-Weinberg equilibrium in the overall data set. If the observed
frequency of heterozygote individuals is significantly reduced relative to Hardy-Weinberg expec-
tations, this indicates significant monoallelic methylation. Null distributions were generated using
random data with the same allele frequencies and sample coverages (for that locus) as in the
original data. This approach accounts for the increased likelihood of erroneously calling loci with
a low coverage homozygous. P-values were determined by comparison of the observed frequency
of heterozygotes with the generated null distributions.
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Only loci that obtained a P-value smaller than or equal to 0.005 after the first iteration were
kept as input for the second iteration. Thus, after the first iteration round, loci that were in
all probability not monoallelically methylated, were filtered out as to reduce the computational
time in the second iteration. At the end of the second iteration the algorithm obtained a P-value
for each locus. If this P-value was smaller than the P-value corresponding with an FDR of 0.1,
monoallelic methylation on this locus was called significant. This procedure was also performed
two times, a first time with 1,000 and a second time with 1,000,000 iterations. To summarize
results, significant loci were visualized on a circular plot with the Circos tool [212].
Functional annotation and enrichment analysis
Succesful completion of the monoallelically methylated loci detection pipeline resulted in a list of
significant SNPs. The functional annotation (i.e. promoter, exon, intron and intergenic) of these
SNP positions was determined using Ensembl (release 66), with the promoter defined as starting
from 2,000bp upstream until the TSS.
We tested for enrichment in one or more of these functional categories. A null distribution was
generated by random sampling from the total amount of detected SNPs (after filtering) and
counting the occurrences of the respective annotations. During this sampling procedure, the
number of SNPs sampled for each chromosome was equal to the number of significant SNPs on
that chromosome. This sampling was repeated 1,000 times. With the null distribution obtained
for each of these functional locations (i.e. promoter, exon, intron and intergenic), it was possible
to calculate a two-sided P-value for each functional location. For loci that were featured by more
than one functional annotation (i.e. overlapping genes and/or di erent transcripts and/or sense
and antisense strand) the score for the functional location was divided by the amount of di erent
functional locations that this locus has (the sum always being one). For example, if a locus is
located in an exon on the sense strand, but is also in an intron on the other strand, both the
exon and intron were attributed a score of 0.5.
Validation of putative loci using 14 WGBS data sets
In order to evaluate the loci detected by this novel methodology, an extra validation step was
performed using 14 publicly available WGBS data sets comprising a range of tissue types. The
WGBS data sets were downloaded from the Gene Expression Omnibus repository [213]. A sum-
mary of the data sets including accession numbers is provided in Appendix A.1.3. The 14 samples
were aligned in a window of 2,000bp (1,000bp upstream and 1,000bp downstream) around the
candidate SNP positions (hg19/GRCh37 reference assembly) using BISMARK [162]. A maximum
of three non-bisulfite mismatches was permitted in the seed (70bp) to (i) lower the presence of
sequencing errors while still allowing the detection of real SNPs, but also to (ii) circumvent a
possible bias alignment to the reference allele while keeping a substantial unique alignment rate
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[210]. After excluding duplicates, only reads mapping onto one of the candidate monoallelically
methylated SNPs positions were kept. Next, for each SNP position and each sample the methy-
lation calls, i.e. methylated or unmethylated, of all CpGs were summarized from the mapped
bisulfite reads per SNP allele (covered by the reads on the specific SNP position). To assess
monoallelic DNA methylation in the SNP loci, a Pearson’s chi-square test was performed. With
a chi-square test, it could be assessed if each allele has an equal distribution of methylation
calls, i.e. degree of methylation. Samples that were not covered or were homozygous for the
particular locus were excluded. In summary, for each heterozygous sample a chi-square value
was calculated based on the degree of (non-) methylation obtained for each SNP allele, with a
high chi-square value indicating that the methylation degree is allele dependent, i.e. one SNP
allele featuring a high degree of methylation while the other allele is characterized with no or
a low degree of methylation. Null distributions were made by a permutation approach (using
the chisq.test function of the R Stats package) generating 2,000 random chi-square values for
each sample, making it possible to determine a sample-specific P-value for each SNP locus. By
summing the chi-square values over all heterozygous samples for a specific SNP locus and again
generating null distributions of random chi-square values, also a global P-value for a SNP locus
could be obtained. Note that this test does not require absolute absence of methylation of one
allele, which would be too strict given the possibility of incomplete bisulfite conversion and the
presence of both sequencing errors and sequencing bias.
Validation of allele-specific expression using 16 RNA-seq data sets
As an additional validation and to evaluate the e ect of the found monoallelic methylated loci on
gene expression, the results were combined with publicly available mRNA-seq data sets from 16
normal human tissues (Illumina’s Human BodyMap 2.0 project), including adipose, adrenal, brain,
breast, colon, heart, kidney, liver, lung, lymph, ovary, prostate, skeletal muscle, testes, thyroid
and leukocyte cells originating from di erent individuals (15 Caucasians and 1 African American,
see Appendix A.1.4). The data are accessible from ArrayExpress, ArrayExpress accession: E-
MTAB-513, actual sequence files are in ENA archive with accession number: ERP000546 (linked
from ArrayExpress page as ‘ENA-ERP000546’ tag in links section.
For each tissue, the raw PE sequence reads (2x50bp) were aligned using the transcriptome
mapper STAR (v2.3.1) [160]. In order to tackle possible mapping bias to the reference allele,
reads were aligned using the method of Degner et al. [214], i.e. using the human hg19/GRCh37
as a reference genome which was masked for known dbSNP positions. Reads mapping up to 10
places were allowed with a maximum of 8 mismatches per fragment, i.e. read pair. Only uniquely
mapped reads were kept and duplicate fragments were removed with Picard’s MarkDuplicates
command-line tool (v1.97) [153].
By assessing if some of the found loci are allele-specifically expressed, allele-specific expression
was determined on a per-heterozygote-site per-tissue basis. In a likewise manner as other allele-
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specific expression studies [210, 215, 216], Samtools mpileup/bcftools (v0.1.19) [163] was used
to call possible variants in the non-duplicate, uniquely mapped reads, whereby variant sites with
a raw read depth lower than 10 were filtered out and only bases with a minimum base quality
(MAQ) of 13 were considered. Next, only SNP positions called by Samtools mpileup and present
in dbSNP were kept. Additionally, known dbSNP sites called as homozygous for the reference
allele, but where at least two high quality (MAQ Ø 13) alternate (i.e. non-reference) bases
mapped, were also added to the list of variant sites.
After observing the amount of high quality mapped reference versus non-reference bases for each
variant site in each tissue, allele-specific expression was assessed by performing an exact binomial
statistical test with the null hypothesis that each allele is equally expressed. To correct for multiple
testing, an FDR of 1% was used. In a next step, the variant sites showing a significant deviation
from the binomial distribution were mapped to their corresponding genes. Only genes with at
least two significant variant sites were assumed to be allele-specific expressed.
1.4 Results
Mapping
For the 334 samples, the mapping resulted in 2,995,375,490 uniquely mapped reads and an av-
erage mapping percentage of 63.05% (Appendix A.1.1). After removing the duplicate fragments
a total of 2,688,409,588 non-duplicate, uniquely mapped reads was acquired.
SNP tracing and data filtering
After parsing the mapping output for SNPs (= mapping mismatches), 19,850,891 SNPs over-
lapped with already known SNV positions from dbSNP. These 19,850,891 loci represent 41.61%
of the total number of SNVs present in dbSNP and only these SNPs were used in the remainder
of the analysis. Appendix A.1.5 details the number of SNPs that overlapped with dbSNP per
chromosome.
After preprocessing the data, the corresponding coverage and allele frequencies were calculated
for each of the 19,850,891 loci and subsequently used to filter the data. Only positions with a
MAF smaller than 0.90 and coverage larger than or equal to 350 (250 for chromosome X) were
retained. A total of 486,090 out of 19,850,891 loci (2.45%) complied with these thresholds.
Appendix A.1.5 shows the number of SNP positions that were retained after filtering as well as
the fraction per chromosome.
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Table 1.1: Monoallelic DNA methylation per chromosome. The first two columns show the specific
chromosome (Chr) and the number of input entries for the statistical analysis. The third and fourth
columns show the amount of loci, which obtained a P-value smaller than (or equal to) 0.005 (after
first iteration) and 0.000016 (after second iteration, corresponding with FDR = 0.1), respectively.
Chr Input entries P Æ 0.005 P Æ 0.000016
1 37,259 98 3
2 34,184 113 10
3 22,065 73 4
4 26,442 68 3
5 20,500 54 1
6 25,708 112 3
7 31,450 153 8
8 20,868 63 0
9 19,908 78 0
10 30,138 108 7
11 19,255 82 8
12 20,484 51 0
13 11,709 88 3
14 12,297 40 1
15 11,829 47 2
16 29,432 64 4
17 24,824 158 3
18 11,783 29 1
19 25,066 96 8
20 16,201 45 7
21 11,977 40 2
22 15,012 70 2
X 7,699 27 0
TOTAL 486,090 1,757 80
Detection of monoallelically methylated loci
Likely sequencing errors in the list of filtered loci were adjusted (see Materials & Methods).
Corrected data was subsequently analyzed using the developed statistical methodology. If the
P-value obtained for a locus was smaller than the P-value corresponding with an FDR of 0.1
(P-value = 0.000016), the monoallelic methylation on this locus was called significant. This was
true for 80 loci (Table 1.1). Figure 1.2 and Appendix A.1.6 depict the genomic distribution of
these 80 monoallelically methylated loci.
In a next step, the functional location of the 80 loci with significant monoallelic DNA methylation
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Figure 1.2: Genomic distribution of the 80 loci for which the monoallelic DNA methylation was
called significant. Chromosomes are shown on a circular representation and divided in regions of
5,000,000bp. The inner circle shows the histogram of all SNPs found in a specific region, whereas
the outer circle shows the histograms of the significant SNPs in that same region, normalized to
the number of SNPs found in that region. The same figure without prior normalization of the outer
circle is shown in Appendix A.1.6.
was determined. These results are shown in Appendix A.1.7. Table 1.2 provides an overview of
the genes in which a significant SNP position was found. Thus, of the 80 detected loci, 49 are
located in a genic region (i.e. promoter, exon, intron) of which 25 are located in regions with
(some) evidence, i.e. monoallelic expression, of imprinting [195, 196, 217].
Functional enrichment of loci with significant monoallelic DNA methylation
Figure 1.3(a) represents the relative number of the di erent functional annotations of these 80
loci. No significant enrichment was found when genic regions were compared to the intergenic
regions (data not shown). The majority of the significant SNP positions are located in intronic
(43.33%) and intergenic regions (37.5%). Additionally, a significant number was found in the
Table 1.2: SNPs featured by monoallelic methylation located in a gene-associated region. Following parameters are indicated: Location (chromo-
some:location), (Ensembl) GeneID, Gene symbol, Description and Biotype. *: known imprinted gene; **: predicted gene.
GeneID Gene symbol Description Biotype Location
ENSG00000183929 DUSP5P Dual specificity phosphatase 5 pseudogene Pseudogene 1:228757936
ENSG00000200624 RN5S6 RNA, 5S ribosomal 6 rRNA 1:228757936
ENSG00000169604 ANTXR1 Anthrax toxin receptor 1 Protein coding 2:69347244
ENSG00000233786 CDC27P1 Cell division cycle 27 homolog (S.cerevisiae) pseudogene 1 Pseudogene 2:133018988,133020085
ENSG00000163975 MFI2 Antigen p97 (melanoma associated) Protein coding 3:196722009
ENSG00000184985 SORCS2 Sortilin-related VPS10 domain containing receptor 2 Protein coding 4:7635629
ENSG00000138641 HERC3 Hect domain and RLD 3 Protein coding 4:89618837
ENSG00000177432 NAP1L5* Nucleosome assembly protein 1-like 5 Protein coding 4:89618837
ENSG00000087116 ADAMTS2 ADAM metallopeptidase with thrombospondin type 1 motif, 2 Protein coding 5:178650557
ENSG00000145945 FAM50B* Family with sequence similarity 50, member B Protein coding 6:3849305
ENSG00000238158 RP11-420L9.4.1 Processed transcript Processed transcript 6:3849305
ENSG00000184465 WDR27 WD repeat domain 27 Protein coding 6:170055316
ENSG00000223838 AC007091.1.1 lncRNA lncRNA 7:19534519
ENSG00000155093 PTPRN2 Protein tyrosine phosphatase, receptor type, N polypeptide 2 Protein coding 7:158041459,158041458,157923845
ENSG00000075826 SEC31 SEC31 homolog B (S.cerevisiae) Protein coding 10:102279295,102279294
ENSG00000255339 NDUFB8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 8, mitochondrial Nonsense mediated decay 10:102279295,102279294
ENSG00000166136 NDUFB8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8, 19kDa Protein coding 10:102279295,102279294
ENSG00000053918 KCNQ1* Potassium voltage-gated channel, KGT-like subfamily, member 1 Protein coding 11:2721568
ENSG00000258492 KCNQ10T1* KCNQ1 opposite strand/antisense transcript 1 Antisense 11:2721568
ENSG00000211502 MIR675** microRNA 675 miRNA 11:2019496,2019618
ENSG00000130600 H19* H19, imprinted maternally expressed transcript Processed transcript 11:2021164,2019496,2019618,2021206,2021980,2022023
ENSG00000102802 C13ORF33 Chromosome 13 open reading frame 33 Protein coding 13:31481030
ENSG00000226317 LINC00351 Long intergenic non-protein coding RNA 351 lncRNA 13:85969909,85969941
ENSG00000258807 RP11-1152H15.1.1 lncRNA lncRNA 14:88237822
ENSG00000214265 SNURF* SNRPN upstream reading frame Protein coding 15:25201659
ENSG00000128739 SNRPN* Small nuclear ribonucleoprotein polypeptide N Protein coding 15:25201659,25123472
ENSG00000122390 NAA60** N(alpha)-acetyltransferase 60, NatF catalytic subunit Protein coding 16:3493495
ENSG00000167981 ZNF597* Zinc finger protein 597 Protein coding 16:3493495
ENSG00000175643 RMI2 RecQ mediated genome instability 2, homolog (S.cerevisiae) Protein coding 16:11415785
ENSG00000207986 AC136932.1 miRNA ncRNA miRNA 16:33960762
ENSG00000108684 ACCN1 Amiloride-sensitive cation channel 1, neuronal Protein coding 17:31340444
ENSG00000074181 NOTCH3 Notch 3 Protein coding 19:15279411
ENSG00000251948 AC092279.1 miRNA ncRNA miRNA 19:24184564
ENSG00000198300 PEG3/ZIM2* Zinc finger, imprinted 2 Protein coding 19:57350463
ENSG00000259486 ZIM2.1* Zinc finger, imprinted 2 Protein coding 19:57350463
ENSG00000130844 ZNF331 Zinc finger protein 331 Protein coding 19:54057515,54057777,54041242,54057156,54040861
ENSG00000235590 GNAS-AS1/SANG* GNAS antisense RNA 1 Antisense 20:57427132,57414110,57426449,57426726
ENSG00000087460 GNAS* GNAS complex locus Protein coding 20:57427132,57414110,57426449,57426726,57431165
ENSG00000160183 TMPRSS3 Transmembrane protease, serine 3 Protein coding 21:40757887
ENSG00000182093 WRB Tryptophan rich basic protein Protein coding 21:40757887
ENSG00000183486 MX2 Myxovirus (influenza virus) resistance 2 (mouse) Protein coding 21:44011806
ENSG00000100138 NHP2L1 NHP2 non-histone chromosome protein 2-like 1 (S.cerevisiae) Protein coding 22:42078666
ENSG00000219438 FAM19A5 Family with sequence similarity 19, member A5 Protein coding 22:49077801
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promoter regions (13.96%). A minority of 5.21% mapped to exonic regions. In order to investigate
whether one of these functional locations was under- or overrepresented compared to random
data, we also performed an enrichment analysis. Figure 1.3(b) shows the mean classification of
SNPs after 1,000 random samplings. By comparing the outcome of this random sampling with
the functional locations of the 80 significant loci, the analysis indicated a significant enrichment
in promoter methylation (P-value = 0.002), but not in other functional locations.
Promoter 13.96%
Exon 5.21%
Intron 43.33%
Intergenic 37.5%
(a)
Promoter 5.99%
Intergenic 39.96%
Exon 5.55%
Intron 48.5%
(b)
Figure 1.3: Piecharts representing the relative number of significant SNPs in the di erent func-
tional classes. (a) Functional classification (i.e. promoter, exon, intron and intergenic) of the sig-
nificant SNPs (i.e. loci with significant monoallelic DNA methylation. (b) Functional classification
of random SNPs resulting from 1,000 iterations.
Validation of putative loci using 14 WGBS data sets
After preprocessing the 14 WGBS data sets as outlined in the Materials & Methods section, 44
out of 80 significant loci were covered by at least one heterozygous sample. Table 1.3 summarizes
both the global and the sample-specific P-values obtained for each of these 44 loci. Note that
29 loci (65.9%) had a global P-value virtually equal to 0 suggesting monoallelic methylation in
at least one of the 14 samples.
Validation of allele-specific expression using 16 RNA-seq data sets
To validate if the found monoallelically methylated loci are associated with allele-specific expres-
sion, publicly available mRNA-seq data sets from 16 di erent individuals and tissues were searched
for allele-specific expression. After preprocessing the data for each variant site, binomial tests
were performed. Using an FDR of 1% and requiring the presence of at least two significant variant
sites per gene, in total 19,840 genes showed allele-specific expression, ≥1190 genes per tissue
(Appendix A.1.4), in line with the amount of loci identified in previous studies [184, 218–220].
Table 1.3: Outcome of the additional validation on 14 WGBS data sets. Global and sample-specific P-values are shown for the 44 SNP loci (Chr:SNP location) that were covered by at least one heterozygous
WGBS sample. Value ‘-’ in the sample columns indicates that the sample did not cover or was not heterozygous for the corresponding SNP loci. *: known imprinted genomic region; **: predicted imprinted genomic
region. Samples: colon adjacent normal (Colon), colon primary tumor (Colon Tumor), mid frontal cortex normal (Cortex Normal1/2), mid frontal cortex Alzheimer (Cortex AD1/2), newborn foreskin fibroblasts (fFF),
human foetal lung cell line (IMR90), human liver carcinoma cell line (HepG2), hematopoietic stem cell progenitors (HSCP), human B cells (bcell), H1 derived mesenchymal stem cells (dMesenschy), H1 derived neuronal
progenitor cells (dNPC) and H1+BPM4 derived mesendoderm cells (dMEEN).
Chr:SNP Global Colon Cortex Cortex Cortex Cortex
position P-value Colon tumor normal1 normal2 AD1 AD2 fFF IMR90 HepG2 HSCP bcell dMesenchy dNPC dMEEN
1:228757936 0 0.0195 - 0.387 - 0.2695 0 0 0 0 0 0.122 0 0 0
2:133018988 0.248 1 0.5405 0.525 1 1 0.1735 - - - - - 0.0685 - 0.482
2:133020085 0.0005 0.002 0.7665 0.7875 0.117 0.2655 1 1 1 - 0.029 0.124 0.0925 - 0.3705
2:207122438** 0 0.1345 0.325 0.002 0.4405 - 0.0125 0.3495 0.1685 0.0015 0.5 - 0.03 0.155 0.0015
2:69347244 0.582 - - 1 - 0.541 - - - - - - - - -
2:133033524 0.2535 - - - - - - 0.28 - - 0.6135 - - - -
2:133029769 0.4335 1 - - - - 1 0.175 - - - - - - -
2:133032580 0 0 0 0.7585 0.119 0.5695 0.034 0 0 0 0 0 0 - 0
3:162561619 0 - - - 0 - - 0 - - 0.0265 - - - 0.5525
4:7635629 0 0.0355 - 0.6355 - - 0 0.004 - - - - 0.00555 - 0.0005
4:89618837* 0 - - - 0.0005 0 0.001 0.33 0 - - 0.0035 0 - 0.0035
4:49099668 0 0.002 0.0015 0.034 0.0755 0.151 0 0 0.0595 0.0015 0.004 0.3295 0.089 - -
5:178650557 0 - - - 0 - - - - - 0.3215 - 0.0045 0.226 -
6:170055316 0 - - 0 - - - 0.002 - 0.2125 0.4965 0.566 0 - 0.2345
6:3849305* 0 0 0 0 0.0065 0 0.0025 0.6925 0.48 0.0025 - 0 1 0.1505 -
6:168784228 0 0 0.04 - - 0.0315 0 0.0005 0.0025 0 - - 0.003 - -
7:64895556 0.0265 - 0.38 - - - 1 0.0005 - - - - - 0.075 -
7:157923845 0.3995 - - - - - - 0.3995 - - - - - - -
7:61080848 1 - - - - - - - - - 1 1 - - -
7:56437045 0 - - 0 - - - 0 - - - - - 0.001 0.0775
7:19534519 0.307 - - - - - - 1 - - 0.3905 - - - 0.33
7:57554497 0.0205 - - - - - - 0.0275 - - 0.269 - - - 0.574
10:42800026 0.5405 - - - - - - 1 - - - 1 - - 0.27
11:2721568* 0 0 0 0 0 - 0 0 - - 0 0.1275 - - -
11:51579458 0.5285 - - - - - - 0.5285 - - - - - - -
13:31481030 0.096 0.1905 - - - - - - 0.174 - - - - - -
14:88237822 0.17 0.184 - - 0.2815 1 - 0.1725 - - - 0.0445 - - 0.6605
15:25123472* 0 0 0 0.0475 0.003 0 0 0.4215 0.314 - 0.0045 0 - - -
15:25201659* 0 - - 0 0 - - 0.5625 - - 0.4805 0.012 0 0 0
16:46411729 0 1 0.6475 - - - - 0 - 0.546 - - - - -
16:3493495* 0 - - 0 0 - 0.0355 0 0 - 0.861 0.0095 0 - 0.001
16:11415785 0.002 - - - - - - 0.0475 0 - - - - - -
17:22252007 0.74 1 - 0.6095 - - 0.627 - - - 0.6155 - - - -
17:22259640 0.7215 0.8215 0.7795 0.3425 1 1 0.613 0.3785 0.6265 - 0.212 0.7165 1 - -
18:18517029 0 - 0.0415 - 0.017 0.1795 0.0045 0 - - 0 0.307 - - 0
19:15279411 0 - - 0.299 0.054 0 0.0005 0 - 0.568 0.839 0.0155 0 - 0.016
19:57350463* 0 0 0.0005 0 0 0 - 0.004 - 0 0.2945 0.0095 0 0 0
19:24184564 0 - - - - - - 1 - - - - - 0 0.0005
20:57415110* 0 - - 0.016 0 - 0 0 0.0095 0.4675 - 0 0 - 0
20:57431165* 0.0625 - - 0.5545 - - - 0.011 0.8245 - - - - - -
21:44011806 0.0145 - - - - - - 0.0145 - - - - - - -
21:40757887 0 0 0 - - - - 0.0255 - - 0 - 1 - -
22:42078666 0 0 0.005 - 0 - - - - - - - 0 - 0.013
22:49077801 0.715 - - - - - - 0.715 - - - - - - -
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In a next step, it was examined if some genes from Table 1.2 - the genes with one (or more)
monoallelic methylated SNP(s) in their genic regions - were also characterized by allele-specific
expression. Indeed, 21 of the 43 genes were covered by at least two variant sites in some tissues of
which 19 showed allele-specific expression in one or more tissues (Table 1.4). Of these 19 genes,
13 also showed biallelic expression in other tissues. For the remaining two genes, GNAS-AS1
and ADAMTS2 - although covered by two or more variant sites in some tissues - allele-specific
expression could not be validated and thus showed evidence of biallelic expression. Of the 19
allele-specifically expressed genes, 6 have already been linked to imprinting [195, 196, 217]. The
other 13 genes represent novel candidate imprinted genes. In addition, for WRB, NHP2L1,
NAA60, ZNF331, H19 and GNAS the found monoallelic methylated loci were located in their
respective promoter region. Appendix A.2.2 also lists the results for genes called allele-specific
expressed if at least one significant variant site was present.
1.5 Discussion
Monoallelic gene expression is typically initiated early in the development of an organism and stably
maintained. Erroneous monoallelic expression has been related to several non-Mendelian inherited
genetic disorders. DNA methylation plays a significant role in the regulation of monoallelic
expression. The choice of the allele to be monoallelically expressed can be either random or a
priori defined by imprinting. Here, we introduced a methodology to screen for genes that exhibit
monoallelic DNA methylation and thus might regulate monoallelic expression.
Using MethylCap-seq, methylome profiles of 334 samples, mostly human cancer samples of diverse
origin, were obtained. In summary, upon extra filtering and data correction, for each SNP locus
the Hardy-Weinberg theorem was applied to evaluate whether the observed frequency of samples
featured by biallelic methylation is lower than randomly expected. Using a permutation approach,
loci with a P-value smaller than the P-value corresponding with a selected FDR of 0.1 were
assumed to be monoallelically methylated. Finally, this resulted in the identification of 80 loci
that showed significant monoallelic DNA methylation.
Functional location of these monoallelic events might provide deeper insight in the unraveling
of monoallelic mechanisms and are provided in Table 1.2 and Appendix A.1.7. It is common
that imprinted genes are present within clusters and share common regulatory elements, such as
non-coding RNAs and DMRs. If these DMRs control the imprinting of one or more genes, these
regions are called imprinting control regions (ICRs). It is known that many of these ICRs are
located in intergenic regions. As some of the found loci are located within intergenic regions as
well as in known (long) non-coding RNAs (see Table 1.2 and Appendix A.1.7), it is possible that
these regions present new regulatory elements involved in imprinting. Furthermore, when we take
a closer look at the intergenic regions, the SNP on chromosome 2 with position 207,122,438 also
shows significant monoallelic methylation. This is interesting, because this locus falls in GPR1AS,
a recently found imprinted lncRNA in the GPR1-ZDBF2 intergenic region [221], corroborating the
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Table 1.4: Validation of allele-specific expression (ASE). Results are shown for the 21 genes with
one (or more) monoallelic methylated SNP(s) in their genic regions and reached the thresholds
to investigate putative ASE. 6 genes exclusively show ASE in one or multiple tissues, 13 genes
have both ASE and biallelic expression (BE) in di erent tissues and 2 genes only show BE. The
following columns are indicated: (Ensembl) GeneID, Gene symbol, number and annotation of
tissues for which ASE/BE could be examined (# Tissues and Tissues, respectively) and the Type
of expression found for these tissues (ASE or BE). *: known imprinted genomic region; **: predicted
imprinted genomic region.
GeneID Gene symbol # Tissues Tissues Type of expression
ENSG00000219438 FAM19A5 1 testis ASE
ENSG00000184985 SORCS2 1 brain ASE
ENSG00000169604 ANTXR1 1 adipose ASE
ENSG00000255339 NDUFB8 1 heart ASE
ENSG00000166136 NDUFB8 10 adipose, adrenal, brain, breast, colon,
heart, ovary, prostate, testis, thyroid ASE
ENSG00000130600 H19* 10 adipose, adrenal, breast, colon, kidney,
ovary, prostate, skeletal muscle, testis,thyroid ASE
ENSG00000175643 RMI2 1 testis ASE
1 ovary BE
ENSG00000122390 NAA60** 1 brain ASE
10 adipose, adrenal, breast, colon, heart,
kidney, liver, lymph node, ovary, thyroid BE
ENSG00000138641 HERC3 1 brain ASE
4 heart, leukocyte, ovary, prostate BE
ENSG00000155093 PTPRN2 1 brain ASE
1 prostate BE
ENSG00000182093 WRB 2 brain, liver ASE
7 adrenal, heart, leukocyte, ovary,
skeletal muscle, testis, thyroid BE
ENSG00000198300 PEG3/ZIM2* 2 brain, ovary ASE
1 testis BE
ENSG00000183486 MX2 2 adipose, leukocyte ASE
4 breast, ovary, testis, thyroid BE
ENSG00000130844 ZNF331 2 brain, ovary ASE
1 lung BE
ENSG00000074181 NOTCH3 4 adipose, adrenal, breast, testis ASE
6 colon, heart, lymph node, ovary,
skeletal muscle, thyroid BE
ENSG00000214265 SNURF* 4 brain, lymph node, prostate, testis ASE
2 heart, thyroid BE
ENSG00000128739 SNRPN* 7 adrenal, colon, leukocyte,
lymph node, ovary, prostate, testis ASE
1 brain BE
ENSG00000100138 NHP2L1 8 adrenal, brain, heart, kidney,
leukocyte, ovary, prostate, testis ASE
7 adipose, breast, colon, liver,
lung, lymph node, thyroid BE
ENSG00000087460 GNAS* 13 adipose, adrenal, brain, breast,
heart, kidney, eukocyte, lung, ASE
lymph node, ovary, prostate, testis, thyroid
1 colon BE
ENSG00000235590 GNAS-AS1/SANG* 1 testis BE
ENSG00000087116 ADAMTS2 3 adipose, breast, ovary BE
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outcome of this study and indicating that the so-called ‘intergenic’ regions are also of interest for
further analyses. Of the 80 loci, 49 were located in genic regions of which 25 are already linked to
imprinting. For example, on chromosome 11 (2.01-2.03 mega base (Mb)), the IGF2/H19 region
was highlighted with 6 SNPs (Figure 1.2). This locus is a well-known imprinted region that is
also linked to the Beckwith-Wiedemann syndrome and Wilm’s tumor [27, 222–224]. The H19
gene codes for a lncRNA of which expression is negatively correlated with the expression of the
neighboring gene insulin-like growth factor 2 (IGF2). Usually the paternal copy is methylated and
silent, while the maternal copy is hypo- or unmethylated and expressed. The same is true for the
imprinted region on chromosome 15 that is correlated to the Prader-Willi syndrome (20.7-30.3
Mb) [27].
In SNRPN, one of the genes in this region where loss of imprinting is linked to the Prader-
Willi syndrome, 2 significant SNPs were identified. For a couple of genes (or regions), like, for
example, H19, more than one significant SNP locus was found. Because some of these SNPs
are at a distance of more than 400bp (the cut-o  length of sequence reads during mapping)
of each other, these independently prove the presence of monoallelic DNA methylation in that
particular region. These SNPs thus provide ‘multiple proof’ in the identification of the particular
monoallelically methylated region and lend added value to the results. Not unexpectedly, Figure
1.3 and the enrichment analysis clearly demonstrated enrichment for monoallelic methylation in
promoter regions, although it should be noted that this enrichment is rather limited in absolute
numbers.
In females, most of the genes on one X-chromosome are transcriptionally silenced by monoallelic
epigenetic events like DNA methylation and histone modifications. Early in development - more
specifically at about the time of the gastrulation phase in the epiblast, which reorganizes the
blastula to the three-layered (= mesoderm, ectoderm and endoderm) gastrula [225] - each cell
makes an independent, random choice which chromosome to inactivate. Once this decision is
set, all further descendants of that cell keep the same pattern. As our method is designed to
specifically detect a deviation from the Hardy-Weinberg equilibrium, it is necessary that for one
sample, the same allele is (un)methylated for all cells - and thus not randomly chosen. In summary,
as random monoallelic methylation would lead to the detection of more heterozygotes, the fact
that no monoallelic methylated loci were found on the X-chromosome reassures the detection of
stable monoallelic methylation with our method.
Further validation was performed using 14 publicly available WGBS data sets, comprising 10
normal samples and 4 samples derived from non-normal tissue, including two samples of cancerous
origin (colon tumor tissue and a human liver carcinoma cell line) and two brain samples from
Alzheimer patients. Of the 80 significant loci, 44 were covered by a heterozygous sample and
could thus be further examined. Twenty-nine of the 44 loci (65.9%) obtained a global P-value
lower than 0.05 of which 24 (54.5%) had a global P-value of virtually 0, indicating monoallelic
methylation in one or more samples. For only 9 of these 24 SNP loci evidence of imprinting already
exists, so that with this subset of 14 WGBS samples at least 15 new monoallelically methylated
regions, found with our new data-analytical framework, are validated. Furthermore, from the
1.5 DISCUSSION 100
sample-specific P-values in Table 1.3 it can be seen that these 24 loci are mainly validated in
multiple normal samples - and thus not or not only in cancerous/diseased samples.
In addition, with the allele-specific expression analysis of 16 di erent tissues of normal origin, it
was possible to investigate if (some of) the found monoallelically methylated regions are associated
with allele-specific expression - and thus might regulate this monoallelic expression. Of the 43
genes featured by one or more of the detected monoallelic methylated loci, 21 had variants
with su cient coverage and base quality and were further examined. Of these 21, 13 genes
showed both allele-specific as well as biallelic expression in di erent tissues, while 6 genes were
only featured by allele-specific expression (Table 1.4). The remaining two genes could not be
validated as allele-specifically expressed in a tissue. Of the 19 genes featured by allele-specific
expression, only 6 have already been linked to imprinting, suggesting the identification of novel
candidate imprinted genes. In fact, for two of these ‘novel’ imprinted genes, WRB and NHP2L1,
recent evidence by Docherty et al. strongly suggests that these are indeed putatively imprinted
as (i) they show allele-specific expression in some tissues and (ii) their methylation patterns are
consistent with allelic maternal methylation [226]. Furthermore, for WRB and NHP2L1 as well
as NAA60, ZNF331, H19 and GNAS, monoallelic promoter methylation was found.
There are a couple of important remarks that come with the proposed methodology:
(i) The basic assumption that MethylCap-seq data from biallelically methylated loci are generally
in Hardy-Weinberg equilibrium only holds for samples originating from a panmictic popula-
tion (i.e. a single population that is long-term randomly mating). If this is not the case and
the samples are not panmictic, this could possibly give rise to some false positives. Thus,
for samples that slightly deviate from the assumption of panmixia, an extra validation of
the resulting loci is necessary to assure qualitative results (as was done in this study).
(ii) The approach does not take into account that loci with monoallelic methylation will be
picked up less e ciently than biallelic loci, resulting in less power leading to a less e cient
detection of monoallelically methylated loci. By consequence, the methodology is less
sensitive and thus too conservative, though this has no e ect on the reliability of those
results deemed significant.
(iii) It is known that aligning to a reference genome at sites of DNA variants generates a bias
towards higher mapping rates of the reference allele compared with the alternative allele
[214]. Recently, Stevenson et al. [210] showed that increasing the number of mismatches
significantly improved measures of allelic abundance, and demonstrated that a maximum of
three mismatches provides a good trade-o , as implemented in this study. Also, as the SNP
density in the human genome is approximately one SNP per kilobase [227], this trade-o  is
deemed to be su cient to both allow the occurrence of real SNPs as well as to lower the
presence of possible sequencing errors. By not calculating the observed allele frequencies
from sample-specific allelic abundances but from the observed genotypes (see Materials
& Methods), the possible influence of an allelic bias is further minimized. In conclusion,
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these precautions, together with the fact that our method is conservative, ensure that our
method is not a ected by possible bias alignment. Indeed, an extra quality control of the
monoallelically methylated loci showed no di erence in sample coverage between samples
homozygous for the reference and the alternative allele (Wilcoxon rank-sum test, P-value
= 0.21, data not shown).
(iv) To eliminate sequencing errors as well as to reduce the computational time and e ort a
filtering step was performed. Consequently, some data will not be analyzed and this could
interfere with the detection of monoallelic DNA methylation. However, the benefits of
filtering outweigh the possible drawbacks: the computational load reduces significantly and
the power to detect loci that do not pass the filter cut-o  will be typically insu cient.
(v) The approach used to correct for possible sequencing errors disfavors the presence of mono-
allelic DNA methylation: only two correction rounds were performed and the sequencing
error estimate of 0.25% is the lowest estimate reported [211]. But although the correction
method can be considered a bit too stringent, it will assure a better quality of the obtained
results and will possibly reduce the amount of false negatives and thus allows a more sen-
sitive identification of monoallelically methylated loci that would otherwise not have been
detected.
(vi) The analysis was performed with samples originating from di erent tissues that were mostly
cancer tumors. The fact that tumors are epigenetically less stable than healthy tissue [83],
makes it probably more di cult to detect monoallelic methylation. On the other hand,
it is known that chromosomal deletions and loss of heterozygosity frequently happen in
cancer, both leading to possible ‘monoallelic’ methylation events. However, as a mixture of
di erent cancer tumors was used and as it is very unlikely that these are all characterized
by the same chromosomal deletion, this latter phenomenon will have had little e ect on
our stringent analysis. To justify this, additional analyses were performed on 14 WGBS
data sets (of which 10 were of normal origin) as well as on mRNA-seq data of 16 tissues
of normal origin, validating a notable number of the identified loci and detecting putatively
imprinted genes.
Although the employed experimental set-up to test our methodology is somewhat challenging
- using a mixture of samples originating from di erent tissues, mostly cancer tumors - the
proposed methodology allowed the identification of loci known to be generally imprinted and
involved in genetic and/or imprinting disorders (e.g. IGF2/H19, KCNQ10T1, SNURF/SNRPN,
GNAS, ...), demonstrating the robustness and biological relevance of our method. Additionally,
the extra allele-specific expression analysis identified monoallelic methylated loci associated with
allele-specific expression, thereby identifying 6 known and 13 novel candidate imprinted genes
(e.g. WRB, NHP2L1, ...). As we opted to use a stringent approach, the outcome further demon-
strates that our methodology is still sensitive enough and produces satisfying results.
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As recent evidence suggests that monoallelic DNA methylation is often tissue- or cell-type specific
[199, 228], it would be particularly interesting to apply the methodology on MethylCap-seq
samples of normal, single-tissue origin, ideally from a single population. Next to MethylCap-
seq, our approach also opens the door to other applications, like ChIP-seq-based detection of
monoallelic protein-DNA binding events and histone modifications.
1.6 Additional Data
Additional data (filtered and sequence error corrected SNP loci of the 334 samples, i.e. starting
data of the data-analytical framework) as well as corresponding scripts of the developed statistical
methodology are available on the authors website: http://www.biobix.be/MAM/.
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2
INTERMEZZO
Disadvantages of the pipeline for
SNP-guided identification of monoallelic
DNA methylation events
2.1 Rationale & bioinformatics pipeline
In the previous chapter, the data-analytical framework developed to screen for loci characterized by
monoallelic methylation was introduced. To recapitulate, the rationale behind the methodology
is based on a population genetics theorem, namely the Hardy-Weinberg principle [201]. This
theorem states that, under certain conditions, the allele and genotype frequencies will remain
constant from generation to generation in a long-term randomly mating population, better known
as a panmictic population. In addition, it declares that allele and genotype frequencies are linked
by a very simple set of formulas: if two alleles A and a are present with allele frequencies p
and q, respectively, at equilibrium the genotype frequencies of AA, Aa and aa will be p2, 2pq
and q2, respectively [201]. This equilibrium only holds if the panmictic population is free of
migration, inbreeding and genetic drift. In practice however, these assumptions are expected to
generally hold for appropriate study designs, even to the extent that deviation of Hardy-Weinberg
equilibrium is an indication for genotyping errors rather than assumption violation [229].
In theory, for loci exhibiting monoallelic methylation, only single alleles will be picked up by
MethylCap-seq (or other enrichment-based methodologies), making that these loci will be ob-
served as homozygous. Thus, in contrast to biallelic methylation, enrichment data for monoallelic
methylated loci will display apparent deviation from the Hardy-Weinberg equilibrium which can
be exploited: testing for monoallelic methylation translates into screening for regions showing a
significant decrease in the observed fraction of heterozygotes.
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The bioinformatics pipeline is shown in Figure 1.1 of the previous chapter. Note that this original
pipeline was used for enrichment-based sequencing data, but that also other types of data such
as RNA-seq and ChIP-seq can be used as input to detect monoallelic expression and monoallelic
histone modifications, respectively.
2.2 Disadvantages
Although the developed framework was able to accurately detect imprinted loci, it also has some
downsides:
• The biggest disadvantage is its computational load. In order to reduce this partly, extensive
qualitative filtering of the data was performed (see Additional data filtering and correction
in section 1.3 of the previous chapter). However, this consequently leads to discarding some
(potentially) ‘good’ data which will not be analyzed, making it more challenging to detect
monoallelic DNA methylation. As it is the intention to include more and more samples in
the future, computational intensity and time will increase even further.
• As sequencing errors mask homozygous samples, an iterative sequencing error correction
step was added. However, for computational reasons, the used approach is conservative,
i.e. biased towards heterozygous phenotypes, thereby disfavoring the detection of mono-
allelic DNA methylation (also explained in Additional data filtering and correction in section
1.3 of the previous chapter).
• The framework does not take into account that loci featured by monoallelic DNA methy-
lation will be picked up less e ciently by MethylCap-seq than biallelic loci (as there are
twice as much methylated fragments available). This results in less power leading to a
less e cient and less sensitive methodology that is again too conservative. This problem
is however intrinsic to imprinting, and should be particularly solved by using su cient se-
quencing depth rather than pursuing a complex data analytical solution (see Discussion
section 1.5 of the previous chapter).
• Lastly, the method particularly tests for deviation from Hardy-Weinberg equilibrium, and
does not explicitly model imprinting. Though validation demonstrated otherwise, low qual-
ity loci may be incorrectly identified.
Nevertheless, even as the methodology is too conservative or computationally intense, this has
no e ect on the reliability of those results deemed significant. Indeed, the identification of
both known (e.g. IGF2/H19, KCNQ10T1, SNURF/SNRPN and GNAS) and novel candidate
(e.g. WRB and NHP2L1) imprinted genes, proved the robustness of the developed framework as
well as its biological relevance (see Results section 1.4 of previous chapter).
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2.3 Optimization
In order to tackle the above raised drawbacks, further optimization is necessary. Therefore, a novel
methodology was developed that starts from the same rationale as the previous one, but includes
some improvements. First, to reduce computational load a more e cient genotype/SNP calling
step was added. Also, the new methodology largely avoids the need to correct for sequencing
errors as these are explicitly taken into account in the model. Next, the statistical framework
was further optimized thereby also enabling the detection of partial imprinting - a phenomenon
that might arise when the studied tissue sample consists of a mixture of imprinted and non-
imprinted cell types. Additionally, this methodology was extended to allow detection of di erential
imprinting. Finally, the framework was tested on RNA-seq data to both prove its e cacy and
applicability on other data types. This methodology and its utility is the subject of the next
chapter.
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3
A mixture model for the omics-based
identification of monoallelically expressed
loci and their deregulation in breast cancer
3.1 Abstract
Imprinting is an epigenetic phenomenon leading to the expression of a single allele in a parent-
of-origin specific manner. Inadequate computational techniques restrict insight in imprinting and
diseases associated with imprinting deregulation, such as cancer. Hence, we introduce a mixture
model for the identification of monoallelically expressed loci based on large scale omics data and
a method to identify loci featured by loss of imprinting. Our rationale is that RNA-seq (or similar
omics data) for monoallelically expressed loci will exhibit apparent deviation from the Hardy-
Weinberg equilibrium. As only a single allele is expressed or epigenetically modified, heterozygous
samples will ideally be recognized as homozygous. The model hence detects those loci in which
the observed heterozygous fraction is shifted towards the homozygous fractions. Furthermore, it
does not rely on prior genotyping and explicitly takes into account sequencing errors and possible
partial imprinting. Once imprinted loci have been identified in control data, loci featured by loss
of imprinting in the pathology under study can be identified. The model enabled the identification
of 140 imprinted SNPs in 113 healthy control samples of the TCGA breast cancer RNA-seq data,
corresponding to 60 genes. Interestingly, these included some well-known imprinted loci such
as IGF2 and PEG3 as well as novel loci such as BCR. Additionally, (putative) deregulation of
these loci was investigated in 506 breast cancer samples from TCGA. Loss of imprinting - i.e. re-
expression of the silenced allele - was observed in MEST (adj P-value < 0.05), whereas borderline
evidence could be found for H19 and HM13 (adj P-value < 0.1).
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3.2 Introduction
In diploid eukaryotic organisms, the maternally and paternally derived copies of each gene are
usually expressed at similar levels. However, a subset of genes are subject to a process termed
allele-specific or monoallelic expression by which only one allele is transcriptionally active and
functional. The expressed allele can be randomly selected (e.g. X-chromosome inactivation and
some autosomal genes) or can depend entirely on the parental origin of the allele, a phenomenon
called imprinting [61, 184, 185]. To date, approximately 100 autosomal imprinted genes have been
identified in mouse, of which most are imprinted in humans as well, with H19, IGF2 (insulin-like
growth factor 2), IGF2R (IGF2 receptor) and PEG3 (Paternally Expressed Gene 3) as well-known
examples [27, 230].
The majority of these imprinted genes are arranged in ≥1 megabase clusters, although singletons
have been described [186]. Each of these clusters is under the control of a discrete region,
termed an imprinting control region (ICR), i.e. essential DNA sequence elements that can be
up to several kb in size. ICRs are CpG-rich regions where the methylation di ers between the
parental alleles and are therefore often referred to as di erentially methylated regions (DMRs).
In addition, also di erential histone modifications can occur in imprinted genes at these DMRs
[231–233]. Although the epigenetic imprinting mark is set up in the germline, parent-of-origin
di erential expression does not necessarily occur in all cells and in some cases may be tissue and
even developmental stage specific [234].
It has long been known that imprinted genes play an important role in development and placental
biology both before and after birth [235]. Allele-specific gene expression in mammals has been
proposed to be the outcome of an evolutionary conflict between the parents of the two alleles
of an o spring: in most cases maternally expressed imprinted genes are growth suppressors while
paternally inherited genes promote growth. This conflict arrises because the father wants to gain
greater evolutionary fitness through the success of the o spring, at the expense of the mother.
Whereas the mother’s evolutionary imperative is to conserve resources for her own survival while
providing su cient nourishment not only to her current, but also to potential subsequent o spring
[236]. However, as the majority of imprinted genes are involved in growth regulation, disruption
of imprinting can result in a number of human imprinting syndromes and predisposes to cancer
by promoting or suppressing antitumor mechanisms [237].
Loss of imprinting (LOI) results in either biallelic expression due to activation of the silent al-
lele or complete silencing due to suppression of the active allele. Indeed, recent experiments
in mice showed that demethylation at imprinted genes leading to LOI made cells susceptible to
cellular transformation and tumorigenesis [238]. For instance, aberrant biallelic expression of the
imprinted IGF2 locus is thought to promote tumorigenesis by inhibiting apoptosis in colorectal
cancer [239], while PEG3, P57 and IGF2R all display LOI resulting in their silencing in oligoden-
drogliomas, breast cancer and hepatocellular carcinomas, respectively [240–242].
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Although allele-specific expression is a well-investigated topic, only a few regions are well char-
acterized in humans. Furthermore, monoallelic expression (and methylation) has already been
recognized as very common at non-imprinted loci a ecting autosomal genes, regulating for exam-
ple the production of specific antibodies and immune receptors [197]. While it has been shown to
play an important role in growth, development and di erentiation between tissues, little is known
about the specific loci as well as the genome-wide character of allele-specific expression. Also,
to date, most e ects of aberrant monoallelic expression on cancer have been studied at single
imprinted loci with association studies in humans or mutation analysis in mice [238]. Thus, there
is need for a genome-wide method to (i) address the profile of monoallelically expressed loci and
(ii) to characterize its instability and e ect in tumor formation.
In 2014, our lab created a data-analytical framework based on the Hardy-Weinberg theorem [201]
that - using enrichment-based sequencing data (e.g. MethylCap-seq) - screens for regions featured
by monoallelic DNA methylation in a genome-wide manner [149]. Although this methodology
succesfully identified well-known as well as novel imprinted regions, it also had some drawbacks,
such as high computational load and the fact that it is very conservative. Recently, Baran et
al. [243] provoked a method to characterize imprinting by examining allele-specific expression.
Using both RNA-seq and genotype data from population samples, they were able to identify
imprinted genes in a diverse set of adult human tissues. However, although they succesfully de-
tected some known and new imprinted genes, their methodology is rather prone to false positives,
e.g. when heterozygous samples are incorrectly genotyped as homozygous, requiring the need for
extensive a posteriori filtering and further validation [243].
To overcome these and previous issues, we optimized and further improved the rationale of
our Hardy-Weinberg method [149] and developed a novel framework. This methodology uses a
mixture distribution model including Maximum Likelihood Estimation (MLE) and the Likelihood
Ratio Test (LRT). In contrast to the framework of Baran et al. [243], our method does not
rely on prior genotyping making it more generally applicable. Using this methodology on 113
healthy control samples of the The Cancer Genome Atlas (TCGA) breast cancer RNA-seq data,
we were able to identify 140 imprinted SNP loci, corresponding with 60 genes. Interestingly, these
included some of the well-known imprinted loci, such as IGF2 and PEG3, but also several novel
loci (not detected by Baran et al. or others), e.g. MIR6723 and BCR. In addition, the method was
extended to study di erential imprinting between control and cancer samples (LOI), leading to
the observation of three potentially ‘deregulated’ SNP loci. Overall, our results demonstrate the
e cacy of our method for the identification of allele-specifically expressed regions and underline
that deregulation of these loci is present in breast cancer, and likely in other human cancers.
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3.3 Materials & Methods
3.3.1 Samples & data preprocessing
A total of 113 human healthy control and 506 diseased RNA-seq samples of the TCGA breast in-
vasive carcinoma dataset were downloaded from the TCGA data portal (Appendix A.2.1). Down-
loaded data was already mapped and preprocessed according to the guidelines used by Genomic
Data Commons (GDC) to harmonize the data, and each phase of processing was standardized
into common pipelines of open source sequence analysis tools. The GDC mRNA-seq alignment
workflow follows the International Cancer Genome Consortium (ICGC) STAR [160] 2-pass RNA-
seq alignment (Figure A.4). For a description of the specific steps in this data preprocessing
workflow, see Appendix A.2.3. For all cancer samples, additional expression subtypes based on
the PAM50 classifier were obtained from the UCSC cancer genome browser [244] (Appendix
A.2.1).
After downloading the data, in all samples, variants were called for the non-duplicate uniquely
mapped reads with Samtools mpileup/bcftools (v0.1.19) [163] whereby variant sites with a raw
read depth lower than 10 in all samples were filtered out. Next, only SNP positions called by
Samtools mpileup and present in the public NCBI SNP-archive dbSNP (version 137) were kept.
Additionally, loci with only one reference allele in dbSNP (deletions and insertions) and/or loci
corresponding with mutations from the Human Gene Mutation Database [245] were filtered out
as well. Afterwards, the found SNP positions for all samples were merged and the corresponding
nucleotide sequences were determined.
3.3.2 Data-analytical framework
The rationale behind the proposed methodology is that biallelic expression yields RNA-seq data
(or other similar sequencing data) that is in Hardy-Weinberg equilibrium (HWE) for each locus
[201], i.e. if SNPs are present for a locus, both homozygous and heterozygous subjects will be
detected at a predictable rate [201]. However, in case of monoallelic expression, heterozygous
samples will no longer be detected resulting in deviation from the HWE, which can be measured.
Note that the same is true for enrichment-based sequencing data. Indeed, monoallelic histone
modifications as well as monoallelic DNA methylation lead to ChIPseq and MethylCap-seq data,
respectively, that no longer is in HWE [149]. Importantly, in practice these assumptions are
expected to generally hold for appropriate study designs, even to an extent that deviation of
HWE is often used as an indication for genotyping errors - also in TCGA data - rather than
assumption violation [229, 246].
Here, we outline our data-analytical framework that based on Maximum Likelihood Estimation
(MLE) and the Likelihood Ratio Test (LRT) allows the identification of imprinting. In addition,
we developed a methodology to enable the detection of possible di erential imprinting between
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two groups, e.g. two subsets of samples. For a more detailed explanation of each step in this
framework, see Appendix A.2.4. As our developed methodology to detect imprinted regions is
based on MLE and LRT, and these concepts are important to understand the following framework,
a basic introduction can be found in Appendix A.2.4.3.
Genotype calling & Filtering
After SNP calling, for each SNP position samples were filtered and corrected to obtain nucleotide
sequences containing a maximum of two alleles. Using a maximum of two alleles per locus
ensures high quality sequences, but was also a prerequisite for the genotype calling step later on
(by SeqEM, see below).
Calculation of genotype probabilities and corresponding nucleotide-read/sequencing error rate was
done using SeqEM (v1.0) [165], a Bayesian genotype-calling algorithm based on the Expectation
Maximization (EM) algorithm to estimate the prior genotype frequencies and the nucleotide-read
error rate in an iterative way. Given the goal to identify deviation from HWE (see next sections),
the option to calculate genotype frequencies taking into account this equilibrium was not used.
As the model-based approach is prone to false positives due to preprocessing induced artefacts
(e.g. alignment errors), only reliable loci were used for further analysis. The standard approach of
filtering is based on HWE and not applicable here, leading to the necessity to use a combination
of alternative criteria [165]. Therefore, after obtaining estimates of both the allele frequencies
and sequencing error rate, the SNP loci were subjected to extra filtering steps: (i) minor allele
frequency > 0.1, (ii) median coverage > 4, (iii) estimated sequencing error rate Æ 0.035 and
finally, (iv) the amount of samples covering the specific locus had to be at least 75.
Loci which succesfully passed these previous filters were subsequently tested with two final quality
checks based on ‘goodness of fit’ criteria. See Appendix A.2.4.2 for an explanation of these two
methods.
Detection of imprinting
After prior filtering of the data, the remaining SNPs were screened for imprinted regions by a
LRT.
PMF calculation First, the probability mass function (PMF) describing the probability of observ-
ing specific coverages for each allele for a specific SNP locus was established. As the probabilities
depend on the underlying genotypes, we established the PMF as a mixture model of genotype-
dependent binomial distributions with weights corresponding to the by Hardy-Weinberg expected
chances (Figure 3.1(a)) [201]. Importantly, in these binomial probabilities, sequencing error rates,
degree of imprinting as well as the specific genotypes are taken into account. Ultimately this
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leads to the following PMF for e.g. a locus with two alleles A and T (equivalent for any other
combination of two alleles) (Figure 3.1(b)):
PMF (x) = P 2AB(x; 1≠ SE) + P 2TB(x;SE) + PAPTB(x; p) + PAPTB(x; 1≠ p) (3.1)
With:
• x the coverages for alleles A and T, i.e. x = (nA, nT )
• PA and PT the estimated population allele frequencies for a specific locus over all samples
(obtained by SeqEM)
• SE the estimated sequencing error rate (obtained by SeqEM)
• i the degree of imprinting (varying from not (i = 0) to fully (i = 1) imprinted)
• B(x; ) the binomial probability for x
• p = 0.5≠
i
2
1≠ i2
(1≠ SE) + 0.51≠ i2 SE
A detailed discussion of each individual element of this formula can be found in Appendix A.2.4.4.
Note that this PMF can be easily extended towards four alleles by considering a mixture of
multinomial instead of binomial distributions (Appendix equation A.16). However, for simplicity
- and as SeqEM can only handle two alleles per locus - we considered only two alleles (see section
3.3.2).
Imprinting factor In a next step, the degree of imprinting (or imprinting factor) i for a specific
SNP locus is estimated using MLE. The likelihoods are calculated as the sum of the logarithmic
values of the PMF-derived probabilities (Formula 3.1) over all samples. In summary, for each
locus, i is varied from 0 to 1 (stepsize = 0.01), retaining the value of i corresponding to the
highest likelihood. Hence, for every SNP locus a degree of imprinting is obtained (Appendix
A.2.4.5).
Likelihood Ratio Test Finally, in order to screen for imprinted loci a likelihood ratio test is
performed. The respective null and alternative hypotheses for a locus are:
H0 : the locus is not imprinted
H1 : the locus is imprinted
(3.2)
With the previous definitions this translates into:
H0 : i = 0
H1 : i > 0
(3.3)
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(a)
(b)
Figure 3.1: Graphical representation of rationale PMF. (a) The PMF is defined as a mixture
model of genotype-dependent binomial distributions and describes the probability of observing
specific RNA-seq coverages for each allele for a specific SNP locus. In these binomial probabilities,
sequencing error rates, degree of imprinting as well as the specific genotype are taken into ac-
count. (b) PMF for di erent degrees of imprinting. In this mixture model, the genotype-dependent
binomial distributions have weights corresponding to their Hardy-Weinberg expected chances.
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Thus, the null hypothesis of no imprinting (i = 0) is compared to the alternative hypothesis that
the locus is imprinted (i > 0). Practically, in a first step, the PMF (Formula 3.1) for the locus
under study is calculated with i equal to 0. Next, the PMF is determined with the estimated
value of i as explained in the previous section. The obtained PMFs are then used in a LRT:
 (X) = f(X|H0)
f(X|H1) =
L(H0|X)
L(H1|X)
= PMF (x1, i = 0)PMF (x2, i = 0)...PMF (xn, i = 0)
PMF (x1, i = iˆ)PMF (x2, i = iˆ)...PMF (xn, i = iˆ)
=
rn
a=1 PMF (xa, i = 0)rn
a=1 PMF (xa, i = iˆ)
(3.4)
As the null hypothesis is a special case of the alternative hypothesis, the test statistic for nested
models ≠2ln( ) can be used [247, 248]. This test statistic is ‰2 distributed and H0 will be
rejected if its value is greater than ‰2–. However, because we are testing at the border of a
constrained parameter space (i equal to 0), a mixture of ‰2 distributions is used: under the null
hypothesis, the test statistic is distributed as an equal mixture of two ‰2 distributions, namely ‰20
and ‰21 with 0 and 1 degrees of freedom, respectively [249]. Finally, a locus is called imprinted
if the corresponding P-value was smaller than the P-value corresponding with an FDR of 0.05
(Benjamini-Hochberg correction for multiple testing [175]).
Median imprinting
A robust measure for degree of imprinting, called median imprinting, was developed to enable
the identification of a robust set of imprinted loci. For each SNP locus, sample-specific ratios
(= Ri,s for locus i and sample s) are calculated as the lowest allele count over the highest allele
count, yielding values between 0 (only one allele expressed) and 1 (both alleles expressed to an
equal extent). Next, the values of these ratios are sorted over all samples and the value of the
‘median putatively heterozygous sample (sm)’ is calculated. This sample corresponds with rank
round(samplesize ú (1 ≠ P 2A ≠ P 2T ≠ PAPT )) = round(samplesize ú (PAPT )). The median
imprinting value is then calculated as 2 ú (0.5 ≠ Ri,sm). In a last step, SNP positions with a
median imprinting level Ø 0.8 were considered as robust.
Detection of differential imprinting
Apart from the detection of imprinted loci, we also wanted to examine possible deregulation of
imprinting in cancer. This was done by testing re-expression of the silenced allele, here termed
di erential imprinting. Briefly, for each sample and for each locus, ratios of the lowest allele
count on the highest allele count (i.e. Ri,s) are calculated for each nucleotide sequence. Similar
to the detection of robust imprinting - but now separately for control ratios and tumor ratios -
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these ratios are sorted in an ascending order. As the lowest ratios are expected for homozygous
samples (ratios theoretically equal to 0, yet slightly higher due to the presence of sequencing
errors), one can consider samples with the highest 2pq ratios as putative heterozygous samples
for that specific locus (in practice: samples with rank higher than round(samplesizeú(P 2A+P 2T ))
are considered the heterozygous samples for a specific locus). After determining the mean ratio
of these heterozygotes (Ri,stumor and Ri,scontrol), parameter Ri,di  is calculated as the di erence
between these values, i.e.Ri,di  =Ri,stumor -Ri,scontrol . Upon random assignment of the tumor and
control labels to the present samples by permutation, 10,000 random values of Ri,di  are simulated
to generate a null distribution. Loci with a P-value smaller than the P-value corresponding with
a selected FDR of 0.1 were assumed to be di erentially imprinted between control and tumor
samples (LOI) (Appendix A.2.4.6). Here, it should be noted that considering the ratios allows
for detecting di erences independent of alterations in expression levels of imprinted genes, which
are also prominent in breast cancer [250].
Assumptions
It is important to note that several assumptions are made for these models:
(i) The basic assumption for the detection of imprinting using the proposed methodology is
that under the null hypothesis SNP loci are in HWE, which only holds for a panmictic
population and for variants that are not under selection, i.e. a single population that is
long-term mating (see Discussion).
(ii) In the model developed to screen for imprinted loci, it is assumed that the degree of imprin-
ting is equal in all samples. This translates in the assumption that the cell type composition
of each sample is similar.
For the robust measure of imprinting as well as the detection of di erential imprinting, samples
with the lowest and highest fractions of alternative alleles are considered as putatively homozygous
resp. heterozygous. Yet, particularly in the case of 100% imprinting, homozygous and heterozy-
gous samples cannot be discriminated using this approach. However, this will not bias the results
as (i) in case of 100% imprinting, the robust imprinting criterion will have no practical impact on
detection, (ii) to detect di erential imprinting, both sample groups are treated equally, implying
no bias as long as the genotype frequencies are not associated with the case-control status.
3.3.3 Overlap with monoallelic methylation & 27/450k Infinium HumanMethyla-
tion Array validation
In order to evaluate the loci detected by this novel framework, a comparison was made with the
(putatively) monoallelically methylated loci detected with our previous methodology [149]. Over-
lap between (some of) these monoallelically methylated genes and our found loci might indicate
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that the found monoallelic expression is regulated by monoallelic methylation. To further validate
whether these loci are indeed characterized by monoallelic methylation in our samples, additional
Infinium HumanMethylation Array data was downloaded from the TCGA data portal. For the
here used 113 normal RNA-seq samples, there were in total 55 samples for which matching methy-
lation data (= normalized beta-values) were available (34 samples with 450k, and 21 samples
with 27k Infinium HumanMethylation Array data, https://gdc.cancer.gov/). After downloading
the beta-values, it was assessed if the overlapping genes were characterized by probes with a
median beta-value between 0.4 and 0.6 over all 55 samples.
3.4 Results
3.4.1 SNP tracing & data filtering
After SNP calling and additional filtering (see Materials & Methods section 3.3.2), for the 113
normal breast samples a total of 23,190 SNPs were retained. Table 3.1 shows the number of SNP
positions after SNP calling and filtering as well as the fraction per chromosome (see Appendix
Table A.15 for a more detailed table). Note that sex chromosomes were not taken into account
in our analysis.
Table 3.1: Amount of SNP positions found after SNP calling that overlapped with SNV positions
of dbSNP (Overlap dbSNP), the amount of retained loci after filtering (fSNPs) and as well as the
amount of significantly imprinted SNPs (iSNPs) per chromosome.
Chr Overlap dbSNP fSNPs iSNPs
1 38,200 2,290 2
2 26,873 1,588 6
3 23,093 1,505 2
4 16,806 977 3
5 17,778 1,166 1
6 24,094 1,338 20
7 19,472 1,268 5
8 13,816 871 0
9 17,025 998 1
10 16,627 981 0
11 20,130 1,210 13
12 18,417 1,221 1
13 7,104 426 0
14 13,828 840 26
15 12,239 819 29
16 15,537 967 6
17 20,071 1,286 5
18 6,091 455 0
19 23,714 1,377 12
20 9,983 656 7
21 5,948 374 0
22 10,274 577 1
TOTAL 377,120 23,190 140
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3.4.2 Detection of imprinting
After prior filtering of the data and establishing the corresponding PMFs per SNP position for
each detected allele, the loci were screened for imprinted regions by a LRT. Of the 23,190 SNPs
present in exons and retained upon filtering, 140 (0.6%) SNPs had an FDR-corrected P-value
< 0.05 and were thus considered to be putatively imprinted, i.e. characterized by allele-specific
expression (Table 3.1, last column). These 140 putatively imprinted SNPs corresponded with
60 genes, of which at least 35 were already known to be imprinted. Table 3.2 lists all found
imprinted SNP loci and corresponding genes.
Table 3.2: Genes featured by monoallelic expression. The columns show the gene symbol (Gene
symbol) and the ID of significantly imprinted SNP locus falling in these genes (iSNPs) with its
FDR-adjusted P-value between brackets. Genes which are known to be imprinted or for which
there is already (some) evidence of imprinting are marked in red.
Gene symbol iSNPs Gene symbol iSNPs
MIR6723 rs112232512 (1.42E-75) MEG3 rs3742390 (6.24E-31)
LINC01139 rs61746209 (6.14E-29) MEG3 rs4906022 (8.42E-204)
ZDBF2 rs7582864 (1.02E-21) SNRPN/SNURF rs2554426 (9.39E-16)
ZDBF2 rs3732084 (6.54E-26) SNRPN/SNURF rs705 (1.81E-71)
ZDBF2 rs1975597 (7.97E-30) PWAR5 rs2732028 (3.33E-15)
ZDBF2 rs1448902 (2.02E-17) PWAR5/SNHG14/SNORD108 rs2732029 (6.71E-28)
ZDBF2 rs4673350 (2.56E-23) PWAR5/SNHG14/SNORD108 rs765438 (1.96E-28)
PAX8/PAX8-AS1 rs7585510 (0.0068) PWAR5/SNHG14/SNORD108 rs2732030 (9.43E-12)
PTX3/VEPH1 rs73158510 (5.44E-07) PWAR5/SNHG14 rs10451029 (6.14E-22)
CPHL1P rs12497062 (0.00027) PWAR5/SNHG14 rs2052723 (1.14E-25)
ATP8A1 rs11940243 (3.21E-08) SNHG14 rs2554419 (7.96E-31)
HERC3/NAP1L5 rs8605 (3.77E-22) SNHG14 rs719704 (3.32E-22)
HERC3/NAP1L5 rs710834 (9.10E-21) SNHG14 rs34316840 (1.13E-25)
ZNF300P1 rs17800987 (4.87E-11) SNHG14 rs2732031 (1.23E-26)
LOC105369230 rs41287328 (6.34E-18) PWAR6 rs2732041 (1.60E-12)
PLAGL1 rs2328535 (3.09E-10) PWAR6 rs2732043 (1.78E-13)
PLAGL1 rs9373409 (1.40E-27) PWAR6 rs2732044 (1.42E-26)
PLAGL1 rs73006222 (2.41E-15) PWAR6 rs1030389 (1.68E-28)
PLAGL1 rs17615967 (1.76E-14) PWAR6 rs62001981 (1.41E-26)
PLAGL1 rs77203559 (3.76E-15) PWAR6 rs62001982 (1.09E-19)
PLAGL1 rs9321953 (1.48E-21) PWAR6 rs1045935 (6.76E-29)
LOC100294145 rs241407 (2.71E-07) SNORD116-10/SNORD116-9 rs11637436 (1.44E-11)
PEG10 rs35237090 (1.69E-17) SNORD116-13/SNORD116-14 rs4344720 (7.48E-20)
PEG10 rs13073 (3.35E-13) SNORD116-21/SNORD116-22 rs3863396 (2.68E-19)
PEG10 rs7810469 (6.18E-29) IPW rs62002013 (3.83E-12)
COPG2/MEST rs10863 (<detection limit) IPW rs2356294 (4.96E-24)
HOTAIRM1 rs706018 (5.67E-36) IPW rs1043164 (6.41E-12)
H19/MIR675/MRPL23 rs2075745 (6.63E-34) IPW rs691 (6.11E-33)
H19/MIR675/MRPL23 rs2075744 (3.21E-27) IPW rs13526 (3.74E-29)
H19/MIR675/MRPL23 rs2839698 (3.18E-57) PLIN1 rs4578621 (3.29E-06)
H19/MIR675/MRPL23 rs2067051 (1.94E-57) ZNF597 rs37822 (1.47E-18)
H19/HOTS/MRPL23 rs2839701 (3.29E-61) ZNF597 rs37823 (3.08E-18)
H19/HOTS/MRPL23 rs2839704 (1.40E-44) ZNF597 rs11639510 (3.42E-25)
H19/HOTS/MRPL23 rs2839702 (2.94E-50) ZNF597 rs37824 (3.21E-18)
H19/HOTS/MRPL23 rs2839703 (1.10E-46) ZNF597 rs12737 (1.01E-21)
H19/HOTS/MRPL23 rs10840159 (2.28E-50) TPSB2 rs77309587 (1.52E-08)
H19/HOTS/MRPL23 rs3741219 (1.01E-107) USP32P2 rs141915702 (0.0093)
RP11-109L13.1 rs201284359 (4.97E-10) LOC102723754/MTRNR2L1 rs3931649 (3.16E-28)
IGF2/INS-IGF2 rs7873 (1.08E-268) LOC102723754/MTRNR2L1 rs113014658 (6.82E-09)
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Table 3.2: Continued
Gene symbol iSNPs Gene symbol iSNPs
IGF2/INS-IGF2 rs2585 (<detection limit) LOC102723754/MTRNR2L1 rs113626706 (5.74E-12)
GLIPR1/KRR1 rs1056905 (1.20E-06) LOC102723754/MTRNR2L1 rs3931650 (7.67E-29)
MEG3 rs78793760 (4.16E-21) ZNF331 rs113983639 (1.99E-13)
MEG3 rs35458454 (5.16E-21) ZNF331 rs8110350 (4.12E-106)
MEG3 rs35431412 (1.62E-29) ZNF331 rs8110538 (1.74E-109)
MEG3 rs10147988 (1.07E-26) ZNF331 rs8109631 (8.52E-175)
MEG3 rs3087918 (5.47E-27) PEG3-AS1/PEG3/ZIM2 rs4801386 (0.00011)
MEG3 rs3087917 (1.64E-30) PEG3-AS1/PEG3/ZIM2 rs1558355 (0.00027)
MEG3 rs3742391 (2.13E-19) PEG3-AS1/PEG3/ZIM2 rs723082 (1.62E-31)
MEG3 rs12897172 (2.31E-17) PEG3-AS1/PEG3/ZIM2 rs3143 (7.86E-06)
MEG3 rs1884540 (1.78E-26) PEG3-AS1/PEG3/ZIM2 s1055359 (9.07E-20)
MEG3 rs2400941 (1.64E-29) PEG3-AS1/PEG3/ZIM2 rs11666110 (8.06E-28)
MEG3 rs77658190 (2.45E-17) PEG3-AS1/ZIM2 rs1860565 (1.02E-21)
MEG3 rs10132552 (4.26E-17) PEG3-AS1/ZIM2 rs33931963 (6.73E-28)
MEG3 rs3194464 (1.43E-23) HM13 rs6058058 (1.33E-10)
MEG3 rs11160606 (1.53E-23) HM13 rs6059869 (4.04E-14)
MEG3 rs1950628 (1.01E-26) HM13 rs6059873 (1.29E-19)
MEG3 rs1053900 (4.91E-34) HM13 rs6059874 (4.88E-14)
MEG3 rs1054000 (7.58E-27) HM13/MCTS2P rs1115713 (7.94E-09)
MEG3 rs8013873 (6.63E-27) L3MBTL1 rs2269621 (1.84E-18)
MEG3 rs11859 (2.17E-25) GNAS/GNAS-AS1 rs1800900 (5.02E-16)
MEG3 rs74080162 (1.15E-24) MCTS2P rs1115713 (7.94E-09)
MEG3 rs4378559 (8.76E-25) BCR rs550197 (7.93E-50)
MEG3 rs12890215 (8.74E-25) DLK1 rs1802710 (2.68E-28)
MEG3 rs55996894 (5.63E-21)
Note that several HLA, HLA-DR and HLA-DQ genes - important players in immune reactions -
also were identified as putatively imprinted. However, these are known to be regulated by random
monoallelic expression instead of parent-of-origin expression [243]. Therefore, these genes are
excluded from further analyses and are also not included in the comparisons discussed in next
sections. The remaining genes (Table 3.2) are considered to represent the final list of imprinted
loci in normal human breast tissue. Genes which are known to be imprinted or for which there is
already (some) evidence of imprinting are marked in red. As an example, the resulting mixture
distributions of IGF2 and SNRPN/SNURF are shown in Figures 3.2(a) and 3.2(b), respectively.
The distributions show that these loci are clearly depleted of heterozygous samples and enriched
for apparently homozygous samples. Mixture distributions of imprinted loci for the other genes
can be found in Appendix A.2.6. These plots also demonstrate that the genotype frequencies
predicted by HWE and modified according to equation 3.1 provide good approximations for the
population under study, though the observed fraction of heterozygous samples often appears
to be slightly underestimated. Figure 3.2 also clearly demonstrates the advantage of using a
methodology that allows for partial imprinting. IGF2 can be arguably considered as the most
well-known example of an imprinted gene, yet a very low fraction of the imprinted allele appears to
be expressed (Figure 3.2(a)) rather than to reflect sequencing errors (cf. Figure 3.2(b)). Methods
strictly discarding loci with (even very limited) expression of the alternative allele could have failed
to detect IGF2 as imprinted gene. In addition, Figure 3.3 depicts a circular representation of the
genomic distribution of the found imprinted loci for chromosome 15. As expected, the imprinted
genes are mostly clustered together.
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(a) (b)
Figure 3.2: Resulting binomial distributions of two significantly imprinted SNP positions. (a)
IGF2 (rs2585). (b) SNRPN/SNURF (rs705).
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Figure 3.3: Genomic distribution of the loci of chromosome 15 for which allele-specific expression
was called significant. Left panel: Chromosome 15 is shown on a circular representation and divided
in regions of 1,000,000bp. The inner circle shows the histogram of the significantly imprinted SNPs
found in a specific region (highlighted in yellow). Right panel: An additional close-up of the
hot-spot region with annotation of the imprinted genes [212].
3.4.3 Validation of putative imprinted regions
Comparison with external references
To independently validate our methodology, we compared our found imprinted loci with the loci
found by Baran et al. [243]. By using RNA-seq data combined with genotype data from 1,582
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primary tissue samples - including 27 samples from primary breast tissue - originating from 178
individuals (Genotype Tissue Expression (GTEx) project), they were able to establish imprinting in
42 genes, including both novel (12) and previously identified genes (30). Next to these 42 genes,
they also detected a lot of HLA genes, but as already stated in previous paragraph, these are not
taken into account. Importantly, of these 42 genes, 15 were found to be (partially) imprinted in
breast tissue (based on tissue-specific heatmap and supplementary data, see [243]). Appendix
Table A.16 shows the overlap between both methods. In summary, 14 genes were also found to
be imprinted in breast tissue by our methodology, whereas 1 (= PPIEL) was not detected due
to too low coverage in our samples. Figure 3.4 shows mixture distributions of our data for three
cases: (i) two known imprinted genes both detected by Baran et al. and our methodology, (ii) a
gene found to be imprinted by Baran et al., but not with our method due to too low coverage in
our samples, (iii) a gene found to imprinted by our framework, but not detected by Baran et al.
Next, an additional comparison was made with Geneimprint - a species-specific database con-
taining already known imprinted or predicted imprinted genes with some (preliminary) evidence
over all tissues [217] - for which our samples contained heterozygous position(s). Our method-
ology succesfully detected 35 of these genes to be monoallelically expressed in the 113 normal
breast tissue samples (colored in red in Table 3.2). Interestingly, 25 genes were not yet included
in Geneimprint, thus representing novel candidate imprinted genes. It should be noted that for
several genes, alternative independent evidence for imprinting is available. For example, PWAR5
and PWAR6 are two genes lying in the Prader-Willi/Angelman region (PWAR), a region on
chromosome 15 for which deregulation of the imprinting pattern is known to result in imprinting
disorders, i.e. Prader-Willi and Angelman syndromes [251].
Comparison with previously found monoallelically methylated loci
In 2014, our lab defined a framework to detect monoallelically methylated loci (see Introduction
and section 3.3.3) [149]. Applied on 334 MethylCap-seq samples of diverse origin, 80 genomic
regions were identified that featured significant monoallelic methylation, of which 49 were located
in genic regions. As an additional evaluation, these results were combined with here reported
monoallelically expressed genes (Table 3.3).
The presence of genes overlapping between both datasets suggests that monoallelic methylation
of these loci is associated with - and is possibly involved in the mechanism of - the imprinted
expression pattern. Here, 14 overlapping genes were found featuring both monoallelic methylation
as well as monoallelic expression. To assess whether these genes can indeed be characterized by
monoallelic methylation, matching methylation data was downloaded from the TCGA data portal
for the breast control samples. This data was available for 55 of our samples. After downloading
the methylation data, the presence of putative monoallelically methylated probes was determined
for each overlapping gene. Monoallelically methylated probes were defined as probe locations
with a median beta-value between 0.4 and 0.6 over all 55 samples. For 13 genes monoallelically
methylated probes were found (genes marked with an asterix (*) in Table 3.3), suggesting that
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(a) (b)
(c) (d)
Figure 3.4: Resulting mixture distributions of some SNP positions. (a) MEG3 (rs1053900). (b)
H19 (rs2075745). (c) MIR6723 (rs112232512). (d) PPIEL (rs12023084). Distributions of three
cases are shown: imprinted genes both detected by Baran et al. and our methodology (a+b), a
gene found to imprinted by our framework, but not detected by Baran et al. (c) and a gene found
to be imprinted by Baran et al., but not by our method due to too low coverage (d).
these genes are indeed characterized by monoallelic methylation in normal breast tissue. Only
for one gene (ZDBF2) no monoallelically methylated probes were found, yet this may still be
attributed to the selected probe locations for the Infinium assay. Additionally, to investigate the
distribution of monoallelic methylation in our found imprinted loci, a Pearson’s chi-square test was
performed. With a chi-square test, it may be assessed whether imprinted and non-imprinted genes
have an equal distribution of monoallelically methylated probes or whether these are enriched in
the imprinted group. Indeed, the chi-square test resulted in a P-value of virtually 0 (< 2.2E-16),
suggesting that the found imprinted loci are heavily enriched for putative monoallelic methylation
and thus that monoallelic expression is putatively linked with monoallelic methylation. Of course,
as a limitation it should be pointed out that monoallelic methylation will result in methylation
degrees of 50%, yet that the opposite is not necessarily true.
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Table 3.3: Overlap between monoallelically methylated regions found by Steyaert et al. [149] and
the imprinted genes identified by the current methodology. Shown are the genes found by the former
method. Genes also identified as allele-specifically expressed by our framework are colored in green,
whereas genes not detected as imprinted by our method are colored in red. In case monoallelically
methylated probes are found in the Infinium data for the respective gene, the gene is additionally
marked with an asterisk (*). Genes which were not covered by heterozygous samples in our dataset
(as in the current RNA-seq data only exons are considered) - and thus were not analyzed by our
framework - are shown in grey.
DUSP5P RN5S6 ZDBF2 ANTXR1 CDC27P1
MFI2 SORCS2 HERC3* NAP1L5* ADAMTS2
FAM50B RP11-420L9.4.1 WDR27 AC007091.1.1 PTPRN2
SEC31 NDUFB8 KCNQ1 KCNQ10T1 MIR675*
H19* C13ORF33 LINC00351 RP11-1152H15.1.1 SNURF*
SNRPN* NAA60* ZNF597* RMI2 AC136932.1
ACCN1 PEG3* ZIM2* NOTCH3 AC092279.1
ZNF331* GNAS-AS1* GNAS* TMPRSS3 WRB
MX2 FAM19A5 NHP2L1
3.4.4 Differential imprinting
To examine possible deregulation of imprinting in cancer, alterations in allele-specific expression
levels of imprinted genes were investigated between control and cancer samples. If cancer samples
are featured by a higher frequency of biallelic expression, this indicates LOI in breast cancer. After
applying the approach explained in section 3.3.2 and using an FDR of 0.1, three SNP loci were
found with significant LOI, i.e. re-expression of the silenced allele. These SNPs correspond with
three genes, namely MEST, H19 and HM13. Figure 3.5 shows the mixture distributions of these
genes (same SNP locations) for both the 113 control and 506 tumor samples.
In addition, the same approach was used for the di erent breast cancer subtypes, namely the
Basal-like (BL), HER2-enriched (HER2), Luminal A (LumA) and Luminal B (LumB) subtypes.
Note that as there were only 8 Normal-like samples, this subtype was not taken into account.
Again, the permutation test was used to check for di erences between the control samples and
each of these four subtypes, resulting in the second identification of the previously identified
deregulated loci. Compared to the results for all tumor samples, for H19 and HM13 significant
LOI was detected at the same SNP positions in all subtypes expect for LumA (with borderline
significance in LumB), whereas MEST was only significantly deregulated in HER2 and LumB.
In summary, a total of 23 significant and 18 borderline significant deregulated loci were detected
over all di erent subtypes, with most deregulation in HER2 and to a lesser extent in BL. These
loci corresponded with 8 genic regions, i.e. ZDBF2, PEG10, MEST, H19, IGF2, MEG3, ZNF331
and HM13. For LumB only in MEST, H19 and HM13 LOI was found whereas for LumA no
3.4 RESULTS 127
di erential imprinting could be identified. Plots for the same loci as in Figure 3.5, but now found
to be significantly deregulated in (some) subtypes are shown below in Figure 3.6. Distributions
of the other loci featured by LOI in cancer subtypes are displayed in Appendix A.2.8. Especially
the H19/IGF2 locus showed strong LOI in HER2 and BL samples: all 6 SNPs were found to be
deregulated in HER2, whereas for BL 5 SNPs were di erentially imprinted (borderline significant).
Interestingly, in HER2 also MEG3 showed signs of LOI (3 significant SNP positions).
For the three loci featured by LOI over all tumor samples, it was evaluated whether the cor-
responding putatively imprinting-associated probes (with 0.4 < median beta < 0.6 in controls)
exhibited significant di erential methylation (two-sided Wilcoxon rank sum test) in tumors versus
control samples. Methylation data was also downloaded for tumor samples (total of 470 Infinium
HumanMethylation Array datasets) and Table 3.4 lists the resulting median beta values for the
MEST gene (see Appendix A.2.8 for the values of H19 and HM13). Significant hypermethy-
lation (FDR < 0.05) was detected for all 39 probes in MEST and several probes in H19 and
HM13, resp. 20 and 5. For H19 and HM13 also 2 and 1 probes, respectively, were found with
significant hypomethylation (data not shown). This demonstrates that in general re-expression
of the second allele is not associated with overall hypomethylation, yet that locus-specific e ects
cannot be excluded.
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Table 3.4: Median beta values for control and tumor samples for probes in the MEST gene that
are monoallelically methylated over all control samples (i.e. median beta value between 0.4 and
0.6).
Probe Control Tumor Probe Control Tumor
cg00286878 0.55 0.62 cg16511229 0.40 0.26
cg02665037 0.43 0.56 cg17079325 0.56 0.61
cg02490034 0.55 0.41 cg17347253 0.52 0.69
cg02501418 0.58 0.83 cg17580798 0.56 0.66
cg03588221 0.56 0.62 cg19344806 0.54 0.63
cg04344875 0.60 0.67 cg19386484 0.53 0.69
cg04678950 0.52 0.69 cg20050761 0.50 0.52
cg04786207 0.58 0.69 cg20826277 0.51 0.69
cg05260959 0.56 0.70 cg21200654 0.57 0.63
cg05369791 0.41 0.49 cg21667116 0.42 0.54
cg05556276 0.57 0.62 cg22705386 0.56 0.66
cg05862114 0.52 0.59 cg23156962 0.41 0.50
cg06100421 0.43 0.58 cg23714917 0.59 0.65
cg06212135 0.59 0.69 cg25407198 0.50 0.57
cg07224147 0.51 0.87 cg25519926 0.54 0.65
cg07870293 0.53 0.56 cg26708559 0.51 0.56
cg08734637 0.45 0.52 cg27338480 0.60 0.68
cg10249538 0.59 0.75 cg27417677 0.56 0.79
cg12347392 0.55 0.64 cg14584935 0.56 0.79
cg13917504 0.52 0.64
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Control Tumor
(a)
Control Tumor
(b)
Control Tumor
(c)
Figure 3.5: SNP positions di erentially imprinted between normal and cancer samples. (a)MEST
(rs10863, adj P-value = 0.016). (b) H19 (rs2839701, adj P-value = 0.078). (c) HM13 (rs6059873,
adj P-value = 0.078).
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HER2-enriched Luminal B
adj P-value = 0.00019 adj P-value = < 2.2E-16
(a)
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adj P-value = 0.00393 adj P-value = 0.06857
(b)
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adj P-value = 0.06969 adj P-value = 0.02625
HER2-enriched
adj P-value = 0.00906 
(c)
Figure 3.6: SNP positions di erentially imprinted between normal and cancer substypes samples.
(a) MEST (rs10863). (b) H19 (rs2839701). (c) HM13 (rs6059873).
3.5 Discussion
Monoallelic gene expression is typically initiated early in the development of an organism and
stably maintained. The term ‘imprinting’ is used when monoallelic expression is based on the
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parental origin. Research has shown the importance of imprinting in cell di erentiation and
normal development as well as in diseases such as cancer, resulting in extensive e orts to study
these imprinting patterns [252]. Based on our previous Hardy-Weinberg methodology to detect
monoallelic methylated loci [149], here, we developed a novel framework to identify imprinted
regions based on RNA-seq data. In addition, a novel HWE-based test was introduced to enable
detection of di erential imprinting (LOI).
Using public RNA-seq data of 113 healthy control samples of the TCGA breast cancer repository,
our method allowed the identification of 60 (putatively) imprinted genes, of which 35 are already
known or linked to imprinting such as H19, IGF2 and GNAS (Table 3.2). Compared to the recent
study of Baran et al., which used 1,582 RNA-seq samples - including 27 samples from primary
breast tissue - combined with genotype data from multiple tissues (GTEx project) [243], 15 genes
were found to be imprinted by both methods. As our framework relies on high-quality loci, for 1
gene found by the former study, no evidence of imprinting was found by our methodology (too
low coverage). Interestingly, for only 35 genes of our imprinted set evidence of imprinting already
exists and/or are also identified by Baran et al., so that with our new data-analytical framework
25 novel genes putatively imprinted in breast tissue are detected. Though our methodology
cannot assess whether the expression status of each allele is indeed determined by the parent of
origin, visual evaluation of the di erent mixture distribution plots as well as the clearly significant
adjusted P-values strongly supports at least monoallelic expression. Of special note, for some of
these novel genes, alternative independent evidence is available. For example, it is well-known
that deletion and/or deregulation of SNRPN and clusters of SNORD-genes are causative to the
Prader-Willi/Angelman syndromes (PW/AS), two imprinting disorders both resulting in physical,
mental and behavioral problems [251]. These genes are on chromosome 15 located in the 15q11-
13 region. In this ‘PW/AS’ region, the maternally inherited copies of these genes are silenced
and only paternal copies are expressed. While loss of the paternal copies results in the Prader-
Willi syndrome, deletion of the same region in the maternal chromosome causes the Angelman
syndrome [253]. Two of our novel putatively imprinted genes, i.e. PWAR5 and PWAR6 (Prader-
Willi/Angelman region RNA 5/6), are also located in this PW/AS region and evidence indeed
suggests that next to the already known genes these transcripts are also paternally expressed,
adding extra value to our results [254].
Monoallelic DNA methylation is likely to bare an essential role in the regulation of monoallelic gene
expression. Using enrichment-based sequencing data, our lab previously developed a methodol-
ogy to screen for genomic regions featured by monoallelic methylation [149]. Applied on data
originating from a mixture of samples, 80 putatively monoallelically methylated loci were iden-
tified. Overlap with our loci resulted in 14 genes for which both monoallelic methylation and
expression are identified (Table 3.3). To verify that these genes might indeed also be featured by
monoallelic methylation in our samples, matching methylation data (Infinium HumanMethylation
Arrays) were downloaded and screened for probes featured by ≥50% methylation, indicative of
monoallelically methylated probes. Indeed, apart from ZDBF2, for the remaining 13 genes the
presence of putative monoallelic methylation was established. Moreover, using a chi-square test
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strong enrichment for monoallelically methylated probes in our imprinted genes was found. In
conclusion, these results suggest that the found allele-specific expression is associated with and
probably regulated by monoallelic methylation, at least for some of our loci.
In addition, an extra feature was added to the framework allowing the identification of putative
deregulation of imprinting in cancer (i.e. di erential imprinting (LOI)). Indeed, (epigenetic) in-
stability of imprinted genes is known to occur in a plethora of human cancers [252]. It has been
revealed that the expression levels of imprinted genes are mostly downregulated in tumors com-
pared to normal cells, especially for breast cancer [252]. Generally, these changes in expression
levels are accompanied by changes in DNA methylation levels in corresponding imprinted domains.
For example, the imprinting control regions of PEG3, MEST, IGF2 and GNAS are often a ected
in breast, lung and ovarian cancers leading to aberrant expression [252, 255, 256]. Using both
normal and tumor RNA-seq data, we identified 1 gene to be significantly di erentially imprinted
- MEST - as well as 2 ‘borderline’ significant genes - H19 and HM13 between both groups. As
stated above, the former gene is already known to be characterized by deregulated imprinting in
breast cancer, whereas for the latter two there also is (preliminary) evidence of their involvement
in (breast) carcinogenesis. Actually, for H19 this is an understatement with its presence in a
plethora of cancers - which is not a surpise given its role in regulation of cell proliferation and
gene expression. Indeed, apart from the imprinting disorders Beckwith-Wiedemann and Silver-
Russel syndrome [257], aberrant expression of the H19 long non-coding RNA can be involved
in the pathology of several cancers, such as for example bladder, lung, ovarian and esophageal
cancer [258]. Also in breast cancer H19 is identified as a putative oncogene: multiple studies
have shown that H19 displays increased expression compared to normal breast tissue and that
in most cases it also promotes proliferation [259, 260]. While the exact functions of H19 RNA
are not fully revealed, its presence in many types of carcinoma cells suggests its potential use
as a tumor marker [261]. Also for HM13, a gene involved in the catalyzation of intramembrane
proteolysis, there exists some indication that this gene is indeed deregulated in breast cancer. In
2010, a study found that this gene was one of the genes with di erential protein expression in
breast tumor cells and likely involved in breast carcinogenesis [262], corroborating the outcome
of this study.
While breast cancer is often thought of as a single disease, increasing evidence suggests that there
are multiple subtypes of breast cancer. These di erent subtypes respond to di erent treatments
and have di erent risk factors and survival rates. Generally, breast cancer is divided into four
major molecular subtypes, namely LumA, LumB, BL and HER2. This classification is based
on a number of biological markers that have already been associated with specific mechanisms
of breast cancer. For example, the BL subtype is negative for three common markers: estrogen
receptors (ER), progestin receptors (PR), and human epidermal growth factor receptor 2 (HER2).
In contrast, as the name suggests, the HER2-enriched subtype has extra copies of the HER2 -
gene, while LumA and LumB are both ER-positive. The di erence between the latter two lies
in the tumor growth and/or the state of the HER2-receptor [263]. At this point, these subtypes
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are mainly used for research applications and not yet (or rarely) used for guiding treatment
decisions. However, they seem to be very useful to predict prognosis, plan a specific treatment
and develop new therapies [264]. Here, we also tested subtypes of breast cancer for di erential
imprinting, of which the HER2-enriched subtype was most characterized by LOI. Apart from the
3 genes found above, over all subtypes, 5 additional di erentially imprinted genic regions were
found, i.e. ZDBF2, PEG10, IGF2, MEG3 and ZNF331. Of these, especially the H19/IGF2 locus
displayed strong deregulation in both the HER2-enriched and Basal-like subtype. These results
directly demonstrate the relevance of also performing such analyses per subtype: every subtype
has it own characteristics and deregulated (expression) profile.
Also here, the possible link with DNA methylation was investigated. Next to browsing into the
matching methylation data of the control samples, the same was done for the tumor samples.
Comparing beta methylation values of MEST, H19 and HM13 between both groups as described
in section 3.4.4, showed that next to di erential expression there also seems to be additional
deregulation of the (monoallelic) methylation profile in tumors, although this can be most likely
explained by di erences in general expression levels. Importantly, although here we only screened
the genic methylation patterns of these genes, for some genes also the ICRs should be investigated
for possible aberrant monoallelic methylation, although until now the exact location of only a
small set of ICRs is already known.
In summary, the developed HWE-based methodology was able to succesfully identify both known
and novel imprinted genomic regions as well as di erential imprinting between two groups. Al-
ternative models have been developed, of which the approach by Baran et al. [243] was most
successful. Basically, they identify heterozygous samples by genotyping, and determine whether
the allelic expression ratio significantly deviates from the expected 1:1 ratio. As with our model,
partial imprinting can be detected, which we demonstrated to be particularly relevant, e.g. for
IGF2. As discussed by the developers, there are several functional and technical problems that
complicate this approach and require several post hoc filtering approaches. Here, we largely over-
come the most relevant problems by (i) not relying on genotyping, avoiding next to extra cost
the impact of associated errors (e.g. incorrectly labeled heterozygous samples will demonstrate
‘imprinting-like’ monoallelic expression), (ii) creating a unified model that describes both the nor-
mal as well as the imprinted situation (i.e. the latter is explicitly modeled rather than identified
by deviation of the normal situation), (iii) goodness of fit based a priori removal of aberrant loci,
which can be both technical (e.g. mapping errors) and biological (e.g. eQTLs) in nature. Never-
theless, next to the fact that no method can discriminate between random monoallelic expression
and imprinting without family data, there are still several assumptions and potential issues that
should be taken into account:
(i) The basic assumption that RNA-seq data from biallelically expressed SNP loci are generally
in HWE only holds for samples from a panmictic population (i.e. a single population that
is long-term randomly mating). If the samples are not panmictic and the data are not in
equilibrium, the weights used in the mixture distribution are not fully accurate. In theory,
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inbreeding can lead to the (virtually) complete disappearance of heterozygous samples
falsely resulting in detection of significant imprinting, yet this is very unlikely to occur in
the observational studies this methodology was created for. In realistic scenarios, such as
for the data here, there is only slight deviation from HWE and the impact is minimal.
Moreover, if visual inspection or goodness of fit testing would indeed demonstrate relevant
deviation, this can be solved by prior estimation of the inbreeding coe cient and subsequent
correction in the used weights of the mixture model. As it can be assumed that most loci are
not imprinted and that alleles present in the expression data thus represent the underlying
genotypes - with no bias due to genotype frequencies associated with case-control status
(see assumptions), this additional estimation is rather straightforward to implement. Note
that it is also possible to use alternative weights in case extra information of the genotypes
would be available (e.g. SNP arrays). In this scenario, one can solely focus on the putative
heterozygous samples and use weights based on the genotyping error rate, cf. the strategy
by Baran et al., yet additional work is required to evaluate this strategy.
(ii) As sequencing includes a PCR step, initial amplification errors are exponentially magnified
in the data. Furthermore, the studied samples may be heterogeneous with variable sub-
populations of imprinted and non-imprinted cell types. Although the latter di culty is
partially covered by prior estimation of the imprinting factor i, allowing ‘partial imprinting’,
the binomial distribution cannot capture a large amount of variance, leading to potential
underestimation of the variance for the heterozygous fraction. In our work this particularly
led to situations where a single but broad heterozygotes peak was modelled as a mixture
of the two imprinted binomial peaks (with low degree of imprinting), which could be easily
remediated by imposing a robust measure of imprinting. Alternatively, a beta-binomial
distribution may be considered more appropriate to model data. As in a beta-binomial dis-
tribution the probability of success is not fixed - but follows a beta distribution - this model
can capture putative additional variance providing a better fit to the data, yet at the cost
of a complexer model (additional parameter per locus) as well as increased computation
time.
(iii) Estimation of allele frequencies and the corresponding sequencing error rate was done with
a Bayesian genotype-calling algorithm, i.e. SeqEM. However, loci with more than two alleles
caused a problem as SeqEM cannot cope with these sequences. For that reason, a prior
correction step was included correcting these nucleotide sequences resulting in a maximum
of two alleles per locus. However, although SeqEM proved e cient for the developed
methodology, this necessary filtering step significantly increased the computational intensity.
Therefore, for future analyses it would be beneficial - and preferred - to include another
genotype caller able to handle three or four alleles thereby removing the necessity of a prior
sequence correction. Luckily, alternative genotype callers exist, such as GATK, where the
allele frequency spectrum is estimated using maximum likelihood estimation [265, 266].
(iv) Another computational intensive step is the estimation of the imprinting factor i by means
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of a basic line search. In fact, it was the most demanding step of the algorithm. As more
and more data will be analyzed in the future, improvement of this step is desirable.
(v) Finally, an obvious but important remark that comes with our methodology: only loci which
are expressed ànd have a SNP at su ciently high frequencies are picked up, making that
only imprinted loci carrying variant alleles in the dataset are picked up and analyzed.
Of course, there is still room to implement extra features. Next to LOI, loss of heterozygosity
(LOH) is also an important phenomenon in cancers. Indeed, a locus can seem homozygous
due to only one parental copy being present. If this occurs in a tumor suppressor gene, and
the other copy is silenced by for example a mutation or DNA methylation, the gene becomes
non-functional with a lack of tumor suppressor activity as a result. Our developed methodology
for the detection of LOI can be easily modified towards the detection of LOH: it is equivalent
to testing whether the fraction of heterozygous samples is decreased in cases (vs. controls) and
shifted to both homozygous peaks. In other words, this corresponds to testing whether there
are significant di erences in weights between both sample groups, where weights are no longer
determined by HWE (imprinting) but directly determined from the data. Normally, the level of
imprinting i can be considered 0 for this approach. Similarly, the framework can also be used to
detect loci featured by allele-specific expression imbalance (i.e. where present SNPs themselves
are associated with higher or lower expression, independent of parent of origin).
In conclusion, the results of this study demonstrate the e ectiveness of our newly developed
method for the identification of imprinted regions. As imprinting is an important biological
process, which is often deregulated in diseases such as cancer, also a HWE-based statistical
test was developed to enable the identification of LOI in cancer. Using RNA-seq data of breast
samples from TCGA, here, we provide an overview of both known and novel imprinted loci in
normal breast tissue as well as regions that are putatively deregulated in breast cancer.
3.6 Author’s contributions
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A genome-wide search for epigenetically
regulated genes in zebra finch using
MethylCap-seq and RNA-seq
1.1 Abstract
Learning and memory formation are known to require dynamic CpG (de)methylation and gene
expression changes. Here, we aimed at establishing a genome-wide DNA methylation map of the
zebra finch genome, a model organism in neuroscience, as well as identifying putatively epigenet-
ically regulated genes. RNA- and MethylCap-seq experiments were performed on two zebra finch
cell lines in presence or absence of 5-aza-2’-deoxycytidine (AZA) induced demethylation. First,
the MethylCap-seq methodology was validated in zebra finch by comparison with RRBS-generated
data. To assess the influence of (variable) methylation on gene expression, RNA-seq experiments
were performed as well. Comparison of RNA-seq and MethylCap-seq results showed that at least
357 of the 3,457 AZA-upregulated genes are putatively regulated by methylation in the promoter
region, for which a pathway analysis showed remarkable enrichment for neurological networks. A
subset of genes was validated using Exon Arrays, quantitative RT-PCR and CpG pyrosequencing
on bisulfite-treated samples. To our knowledge, this study provides the first genome-wide DNA
methylation map of the zebra finch genome as well as a comprehensive set of genes of which
transcription is under methylation control.
1.2 Introduction
In the past few decades, songbirds have become a widely used model system in the behavioral
neurobiology of learning [84], evolutionary genetics [85], neuroendocrinology [267] - particularly
the sexual di erentiation of the brain - and adult neurogenesis [86]. Songbirds evolved the ability
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to learn vocalizations by copying a singing adult. Vocal learning is a trait that songbirds share
with humans, where it forms the basis of spoken language acquisition, but which is absent in
traditional model organisms such as rodents and non-human primates [87]. The presence of
multiple behavioral parallels between song learning and human speech learning makes it plausible
that there are similar underlying neurobiological pathways involved [268, 269]. Indeed, it has
become apparent that there are striking homologies between the brains of birds and mammals,
leading to the identification of common neuronal and molecular substrates [98].
One songbird in particular, the zebra finch (Taeniopygia guttata), has been the focus of many
studies because of its rapid maturation and its tendency to sing and breed in captivity [87,
269], highlighted by the availability of its complete genome sequence [99]. Although numerous
genomic resources are becoming available for this animal model, several in vivo experiments
(e.g. knockdowns or manipulation of gene expression) are still impossible or very laborious and
expensive. Fortunately, two immortalized zebra finch cell lines were recently established, i.e. the
diploid male G266 and tetraploid female ZFTMA cell line, both obtained from spontaneous, non-
neuronal tumors, providing an e cient alternative to whole-animal manipulations [270]. Although
these cell lines are not derived from brain tissue, it has previously been observed that they express
many neurobiologically relevant genes [97].
Epigenetic modifications, including DNA methylation, have been shown to play an important
role in several neurobiological and cognitive processes, such as learning and memory [271, 272].
Epigenetics is defined as the study of inheritable chromatin modifications that have an impact
on gene expression without altering the underlying DNA sequence [273]. DNA methylation is a
well-known epigenetic mark that is essential for normal development. It is established by DNA
methyltransferases (DNMTs) and involves the transfer of a methyl group to cytosine residues
at the carbon 5 position, predominantly in a CpG context. This methylation mark is known to
regulate gene expression and when located in the promoter region, it generally leads to tran-
scriptional silencing of the corresponding gene [40]. DNA methylation has traditionally been
regarded as a highly stable epigenetic mark in post-mitotic cells, defining their cellular identity.
However, it has been observed that the postnatal brain shows stimulus-induced de novo CpG
methylation or active DNA demethylation at specific loci during the process of learning and
memory formation [53, 274, 275]. For example, there is accumulating evidence that the expres-
sion of brain-derived neurotrophic factor (BDNF ) is regulated by epigenetic modifications, and
in particularly by promoter DNA methylation [276]. BDNF is a neurotrophic factor important for
neuronal activity-dependent processes such as long term-potentiation, neuronal survival, develop-
ment, memory formation and synaptic plasticity, which is linked to several neurological disorders
(e.g. schizophrenia and mood disorders) [277, 278].
Even though zebra finches are an attractive model to study the molecular basis of (vocal) learning,
a genome-wide DNA methylation pattern in this species is currently lacking. In order to assess a
first ‘draft of the zebra finch methylome’, we performed methyl-CpG binding domain protein se-
quencing (MethylCap-seq) experiments on the G266 as well as the ZFTMA cell line, in presence or
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absence of the DNA methylation inhibitor 5-aza-2’deoxycytidine (AZA) that, when incorporated
in the genome, inhibits DNMTs resulting in a net demethylation e ect [279]. MethylCap-seq is
based on the specific enrichment of methylated portions of the genome (i.e. enrichment-based
method) by Methyl-CpG Binding Domain (MBD)-based a nity purification followed by mas-
sively parallel sequencing [148, 280]. Contrasting whole-genome bisulfite sequencing, it provides
a cost-e cient option to assess genome-wide DNA methylation profiles [281]. However, until
now MethylCap-seq has primarily been used for human and mouse genomes, and its e ectiveness
has not yet been demonstrated in zebra finch. Here, we evaluate the quality and sensitivity of this
methodology for zebra finch by comparison with a species-independent, though not genome-wide,
methodology, i.e. Reduced Representation Bisulfite Sequencing (RRBS) [282]. By comparing the
MethylCap-seq data of dimethyl sulfoxide (DMSO, solvent control) and AZA-treated samples, it
was possible to identify genomic regions that are substantially demethylated due to the treat-
ment. Moreover, to assess the e ect of AZA-induced demethylation on gene expression, RNA-seq
experiments were performed, which were validated by performing zebra finch Exon Array analysis.
Subsequently, a pathway analysis was done on the resulting set of loci, and a subset was vali-
dated by independent methodologies, i.e. CpG pyrosequencing and quantitative Real-Time PCR
(qPCR).
To our knowledge, this study provides the first genome-wide draft methylome of the zebra finch.
The inclusion of AZA-treated samples allows the identification of loci, which are nearly always
methylated, or - more importantly - for which the methylation status is highly variable in di erent
settings. We provide an overview of loci featured by dynamic methylation degrees as well as a list
of genes for which expression is putatively regulated by DNA methylation in the promoter region.
1.3 Materials & Methods
Cell cultures and treatments
Two zebra finch cell lines were used: the diploid male G266 cell line and the tetraploid female
ZFTMA cell line, both derived from spontaneous tumors [270]. These cell lines were a kind
gift of Dr. David Clayton (Queen Mary University of London). Cells were cultured in DMEM
high glucose medium (Life Technologies 41965039) supplemented with 10% heat inactivated
fetal bovine serum (Life Technologies 102070106), 2% heat inactivated chicken serum (Life
Technologies 15140122) and 1% penicillin streptomycin (Life Technologies 15070063). Cultures
were maintained at 37°C, 5% CO2 and 95-98% humidity.
Cells were treated for 72 hours with 1 µM concentration of AZA (= demethylation treatment,
Sigma-Aldrich A3656), with DMSO as a solvent control, or left untreated. Both AZA and DMSO
inductions were repeated every 24 hours, as AZA is known to be relative unstable in aqueous
solution. Genomic DNA (gDNA) was extracted from an untreated ZFTMA cell line as well as
from AZA- and DMSO-treated G266 and ZFTMA cell lines using the DNAeasy mini kit (Qiagen
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69506) while RNA was extracted from AZA- and DMSO-treated G266 and ZFTMA cell lines using
Trizol and RNeasy mini kit (Qiagen 74106), both according to the manufacturer’s instructions.
DNA and RNA concentrations were measured using Nanodrop 1000 (Thermo Fisher Scientific).
Library preparation and sequencing
Reduced Representation Bisulfite Sequencing
Bisulfite treatment, library preparation and sequencing of the untreated ZFTMA DNA sample
were performed as a commercial service by BaseClear, using the Zymo Research EpiQuest bisulfite
and library preparation procedures. For this sample, 500ng gDNA was checked for integrity and
lack of degradation by agarose gel electrophoresis, and the concentration was measured by a non-
UV method. The DNA was subsequently fragmented, size selected (150-450bp) and a bisulfite
conversion was performed. Next, Illumina adapters were added and the fragments amplified via
PCR amplification. The length distribution of the resulting library was checked on a BioAnalyzer
(Agilent Technologies G2940CA) and quantified. Quantified and converted DNA libraries were
loaded on the Illumina HiSeq2000 platform and a paired-end sequencing run was performed as
described in the Illumina protocol ‘performing a multiplexed paired-end run’ (2 times 50 cycles).
Methyl-CpG binding domain protein sequencing
Methyl-CpG binding domain protein sequencing (MethylCap-seq), which combines enrichment of
methylated DNA fragments by MBD-based a nity purification with massively parallel sequenc-
ing [148], was used to profile the DNA methylation pattern of the DMSO-, AZA- and untreated
zebra finch cell lines, i.e. G266 and ZFTMA. The gDNA was sheared using Covaris S2 equipment
with following settings: duty cycle 10%, intensity 5, 200 cycles per burst during 190 seconds to
obtain fragments with an envisaged average length of 200bp. The power mode was frequency
sweeping, temperature 6-8°C and water level of 12. 2 µg was loaded in 130 µl TE (1:5) in a mi-
crotube with AFA intensifier. After DNA fragmentation, the methylated fragments were captured
using Diagenode’s MethylCapTM kit (Diagenode AF-100-0048) according to the manufacturer’s
instructions starting from a DNA concentration between 250 and 500 ng. Captured DNA was
eluted in a 150 µl High Elution bu er and purified with MinElute PCR purification columns (Qi-
agen 28006). Purified DNA was used for library preparation, which was performed on the Apollo
324TM (IntegenX) using the Multiplexing Sample Preparation Oligonucleotide Kit (Illumina PE-
400-1001). Size selection (100-350bp) was done with Agencourt AMPure XP beads (Beckman
Coulter Inc. (Analis Sa) A63882) in combination with polyethylene glycol (PEG). 22 µl of DNA
was subjected to PCR following the Illumina Library Amplification Index Protocol (Illumina) with
21 cycles of PCR amplification using Phusion High-Fidelity PCR Master Mix (New England Bi-
olabs (NEB) M0532L) with primers of the Multiplexing Sample Preparation Oligonucleotide Kit
(Illumina). PCR products were purified with the High Pure PCR Cleanup Micro Kit (Roche
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Applied Science 04983912001). Next, libraries were assessed using an Agilent DNA 1000 Chip
(Agilent Technologies 5067-1504). The concentration was determined following Illumina’s qPCR
Quantification Protocol Guide (Illumina SY-930-1010). After pooling the libraries, paired-end
sequencing was performed as a commercial service by BaseClear on one lane (8 samples/lane) of
the Illumina HiSeq2000 following the Illumina protocol ‘performing a multiplexed paired-end run’
(2 times 50 cycles).
RNA-sequencing
RNA-seq experiments were performed on DMSO- and AZA-treated G266 and ZFTMA cell lines.
RNA samples were analyzed with both the Quant-iTTM RiboGreen RNA Assay Kit (Invitrogen
R11491) and the Agilent Eukaryote Total RNA 6000 Pico Chip (Agilent 5067-1513) to ensure
adequate quality and quantity of total RNA. Prior to the library preparation, an rRNA depletion
step was performed on 3 µg input RNA (RiboGreen measurement) using the Ribo-ZeroTM Mag-
netic Kit (Human/Mouse/Rat, Epicentre MRZH11124). Next, cDNA libraries for the ZFTMA
and G266 rRNA depleted samples (6 µl/sample) were prepared using the ScriptSeqTM v2 RNA-
seq Library Preparation Kit (Epicentre SSV21124) following the manufacturer’s protocol. Library
amplification was performed with 15 PCR cycles. Quality control of the libraries was assessed us-
ing an Agilent High Sensitivity DNA Chip (Agilent Technologies 5067-4526). The concentration
was determined following Illumina’s qPCR Quantification Protocol Guide (Illumina SY-930-1010).
After pooling the libraries, paired-end sequencing was again performed by BaseClear on one lane
(4 samples/lane) of the Illumina HiSeq2000 again following Illumina’s protocol ‘performing a
multiplexed paired-end run’ (2 times 50 cycles).
Sequence read mapping
For each sample, MethylCap-seq paired-end reads were mapped with BOWTIE2 (v2.1.0) [158].
The mapping parameters were chosen so that only paired-end reads that mapped uniquely and
concordantly on the zebra finch reference genome (assembly taeGut3.2.4, Ensembl release 72)
within a maximum of 400bp of each other were retained. Seed mismatches, length and interval
during multiseed alignment were set to the default values. For RRBS, paired-end reads were
mapped with Bismark (v0.9.0) in BOWTIE2-mode [162]. Again, default values were chosen
for the multiseed alignment and only concordantly, uniquely mapped reads with a maximum
insert size of 500bp were withheld. Paired-end RNA-seq reads were mapped with STAR (v2.3.0)
[160]. Here, reads mapping up to 10 places on the zebra finch genome were allowed with a
maximum of 6 mismatches per fragment, i.e. read pair. For MethylCap-seq, duplicate fragments,
i.e. fragments with the exact same location of both paired-end reads, were disposed as these
are most likely the result of amplification of the same sequence reads during library preparation.
As for RNA-seq and RRBS duplicate reads are expected - they arise from both the enzymatic
cutting (RRBS)/limited library complexity (RNA-seq) as well as from the PCR step and there is
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no simple way to distinguish between these two sources of duplicate reads - they were retained
for further analysis.
Quality control of MethylCap-seq
As our study is the first to use MethylCap-seq - which employs a human-derived MBD - on
zebra finch samples, it was necessary to first assess the accuracy of this methodology in this non-
mammal species. MethylCap-seq specifically enriches for methylated genomic regions. Hence,
a higher amount of MethylCap-seq fragments covering a particular region reflects in general a
higher methylation degree. Though limited regarding genome-wide information, RRBS is based
on bisulfite treatment - and therefore species-independent - and can yield a quantitative estimate
of the percentage of methylation. As bisulfite treatment only converts non-methylated cytosine
residues to uracil, which will be read as a thymine when sequenced, whereas methylated cytosine
residues remain identified as cytosine, it is possible to summarize the methylation state of each
sequenced cytosine and CG dinucleotide (= CpG methylation degree). In order to evaluate the
e cacy of the performed MethylCap-seq in zebra finch, the MethylCap-seq data of the untreated
ZFTMA cell line was compared to its corresponding RRBS data. For each RRBS-covered CpG (at
least 10 RRBS reads), the CpG methylation degree was determined as well as its coverage obtained
by MethylCap-seq. Finally, to indicate the sensitivity of MethylCap-seq, it was examined if higher
RRBS CpG methylation degrees are indeed associated with more MethylCap-seq fragments.
Read summarization
Prior to the di erential expression/methylation analysis, the sequencing reads needed to be as-
signed to genomic features of interest. The mapped RNA-seq reads were converted to fragment
counts per exon and grouped per gene with the R-package Rsubread (v1.12.0) [283]. Gene an-
notations were obtained from Ensembl (release 72).
In order to summarize the MethylCap-seq reads, it was necessary to first identify all possibly
methylated regions in the zebra finch genome (Methylation Peaks), which could subsequently be
used as units for statistical analysis, cf. the use of genes in RNA-seq data analysis. As MethylCap-
seq data consists of a mixture of DNA methylation signal and (relatively low amounts of) noise,
only loci that exhibit a su ciently high signal intensity (i.e. pass a certain threshold) qualify as
‘potentially methylated’. This classification was done by taking the summed coverage of both
ZFTMA and G266 cell line control sample results (i.e. DMSO-treated), and by evaluating di erent
coverage thresholds - ranging from 1 to 20 - for ‘significant’ methylation. Instead of imposing an
arbitrary signal intensity threshold, an optimal threshold was identified by using the RRBS data
as ‘gold standard’. Consequently, for threshold identification, only those loci for which RRBS
data was available were considered, but the reasonable assumption was made that the identified
threshold can be applied on the complete MethylCap-seq dataset.
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In a first step, the MethylCap-seq data for both the ZFTMA and G266 DMSO-treated samples
was piled up for an unbiased selection, hereby making the common assumption that the large
majority of methylation events are conserved between both cell lines. Second, for each CpG
measured by RRBS and MethylCap-seq coverage threshold under study, it was assessed whether
this CpG was categorized as ‘methylated’ (= MethylCap-seq intensity above threshold), or ‘un-
methylated’ (= vice versa). Third, the optimal coverage threshold was determined by comparing
the RRBS methylation degrees between both categories using the Kruskal-Wallis rank sum test.
Subsequently, the MethylCap-seq threshold for which this comparison yielded the clearest di er-
ence (i.e. lowest P-value) was selected as optimal threshold. In other words, for this threshold
MethylCap-seq results correspond best with the RRBS results.
In a next step, the Methylation Peaks were defined as all genomic regions where every position
has a total coverage larger than or equal to this optimal coverage threshold. Additionally, these
regions were trimmed at both ends so that the final regions start and end with a CpG. Finally,
for each sample, the non-duplicate, uniquely mapped MethylCap-seq reads were summarized into
fragment counts per Methylation Peak.
The corresponding functional genomic annotation (i.e. promoter, exon, intron and intergenic) of
the identified Methylation Peaks was determined using Ensembl (release 72), with the promoter
was defined as starting from 2,000bp upstream until 500bp downstream of the transcriptional
start site. Only if a Methylation Peak had none of the genic categories (i.e. promoter, exon and
intron) it was defined as intergenic.
Both circular plots (Circos tool [212]) and an in-house developed genome browser (H2G2,
http://h2g2.ugent.be/biobix.html) were used for visualization of the experimental data.
Differential methylation and expression analysis
To test whether the methylation pattern in intergenic regions was di erent between gene-deserts
(i.e. gene-poor/intergenic regions > 500kb) and no-gene-deserts (i.e. intergenic regionsÆ 500kb),
the amount of reads in the Methylation Peaks belonging to each group was determined. Per chro-
mosome, the read count of each group was normalized for its respective length, after which a
t-test was performed comparing the methylation level of both gene-deserts and no-gene-deserts.
Subsequently, we used the R-package EdgeR (v3.4.2.) [171] to test for both di erential methyla-
tion degrees as well as di erential gene expression between the DSMO- and AZA-treated samples.
Normalization of the Methylcap-seq counts between the two treatments was performed based on
the reads that mapped in non-Methylation Peaks, i.e. the library size of ‘noise reads’. The ra-
tionale of this in-house method was that despite the performed treatment, the observed noise,
i.e. amount of reads between Methylation Peaks, should be similar between the two G266 samples
as well as between the two ZFTMA samples. Since the putative noise regions might still contain
some signal as well, this can be considered a conservative approach. Normalization of the RNA-seq
gene counts was performed with the PoissonSeq package implemented in R (v1.1.2.) [178]. This
normalization method is based on a chi-square-like goodness of fit statistic and has been shown
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to perform better than other existing methods (e.g. trimmed mean of M-values (TMM) [284],
DESeq [179], quantile and library size normalization). Because the global di erences between
the DSMO- (= control) and AZA-treated (= demethylation treatment) samples are of primary
interest, and not the di erences between the two cell lines nor the treatment e ect that occurs
for only one cell line, a paired design was chosen - which also accounts for the di erent ploidy
levels between the two cell lines. Resulting P-values were adjusted using the Benjamini-Hochberg
correction and only Methylation Peaks (or genes) that were significant at a false discovery rate
(FDR) of 0.1 were considered as di erentially methylated (or expressed).
Enrichment analysis
Next, we tested the list of di erentially methylated genomic regions between DMSO- and AZA-
treated samples for enrichment in one or more functional categories (i.e. promoter, exon, intron
and intergenic). By random sampling from the total amount of Methylation Peaks and counting
the occurrences of the respective annotations, a null distribution was generated. During this
sampling procedure, the number of Methylation Peaks sampled for each chromosome was equal to
the number of significantly down-methylated Methylation Peaks for that chromosome. Sampling
was repeated 1,000 times. Based on the null distribution obtained for promoter, exonic, intronic
and intergenic regions, it was possible to calculate a two-sided P-value for each of these categories.
For Methylation Peaks that were featured by more than one genic annotation (i.e. overlapping
genes and/or di erent transcripts and/or sense and antisense strand and/or peaks overlapping
di erent locations on the same strand), the attributed score of the functional location was divided
by the amount of di erent categories for this peak (the sum always being one). For example, if
a Methylation Peak is located in an exon on the sense strand but is also located in an intron on
the other strand, both ‘exon’ and ‘intron’ categories were attributed a score of 0.5.
As the AZA-treatment normally leads to demethylation and we were particularly interested in
demethylation that results in upregulated expression, a similar analysis was performed only on
those genomic regions which were significantly down-methylated and located in genes significantly
upregulated by AZA-treatment. The functional genic annotation (i.e. promoter, exon and intron)
of these Methylation Peaks was determined as described above. Likewise, two-sided P-values were
calculated for each genic annotation, after random sampling from the whole set of Methylation
Peaks located in upregulated genes.
Ingenuity Pathway Analysis
To interpret the results in the context of biological processes, regulatory networks and other path-
ways, Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, www.ingenuity.com) was performed.
The IPA software provides a comprehensive database of known networks and pathways that are
constantly being updated based on published literature on gene functions and interactions. After
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providing the Ensembl gene identifiers of the target genes to IPA (fall release 2015), the most
a ected/involved biological processes and networks are listed and scored based on significance.
In addition, also possible relationships with diseases and disorders are shown. The provided gene
list consisted of genes that upon AZA-treatment were significantly upregulated and featured by
at least one Methylation Peak exhibiting significant AZA-induced demethylation in the promoter
region (i.e. genes that are under putative DNA methylation control). P-values were corrected for
multiple testing using the Benjamini-Hochberg method.
Validation: Zebra finch Exon Arrays and Quantitative Real-Time PCR
To confirm the RNA-seq findings, we performed zebra finch Exon Arrays (A ymetrix custom
designed) on independent samples. Total RNA was extracted using Trizol and the RNeasy Mini
Kit (#74104, Qiagen Inc., Valencia, CA, USA) according to the manufacturer’s protocol includ-
ing the optional DNA digestion step. RNA quality was assessed using an Agilent Model 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) and the RNA concentration was deter-
mined with a Nanodrop 1000 spectrometer (Thermo Fisher Scientific, Wilmington, MA, USA).
For each sample, 100ng of total RNA was processed for hybridization on the microarray using the
Ambion WT Expression Kit (#4411974, Thermo Fisher Scientific Inc.), the GeneChip WT Ter-
minal Labeling and Controls Kit (#901524, A ymetrix Microarray Solutions) and the GeneChip
Hybridization, Wash, and Stain Kit (#900720, A ymetrix Microarray Solutions). The resulting
cDNA was hybridized to the custom designed A ymetrix GeneChip MPIO-ZF1s520811 Exon Ar-
ray as described by Frankl-Vilches et al. [285] and scanned with the GeneChip Scanner 3000 7G
(#00-0210, A ymetrix Microarray Solutions). CEL files generated by the A ymetrix GeneChip
Command Console Software (AGCC) were imported into ChipInspector software, version 21 (El
Dorado Database version: E30R1410 Genomatix GmbH). Di erential expression between DMSO
and AZA (500 nM) treated samples was analyzed using the group-wise exhaustive analysis with
FDR set to zero and 10-significant probe minimum coverage. CEL files, raw data and additional
statistical information have been deposited in NCBI’s Gene Expression Omnibus [213] and are
accessible through GEO Series accession number GSE71344.
In order to determine whether the expression level correlates to the methylation status, 7 genes
were selected that showed a significant increase in gene expression (both RNA-seq and Exon
Arrays) and decrease in promoter DNA methylation (MethylCap-seq): BDNF [286], neuroglobin
(NGB) [287], HES family BHLH transcription factor 1-4 (HES1-4) [288], GABA(A) receptor
subunit delta (GABRD) [289], ankyrin 1 (ANK1) [290], matrix metallopeptidase 9 (MMP9)
[291] and inhibitor of kappa light polypeptide gene enhancer in B-cells kinase epsilon (IKBKE ).
Three independent biological replicates of DMSO- and AZA-treated samples were used for the
validation experiments. Gene-specific qPCR primers were designed using PrimerBlast (NCBI)
(Table 1.1). Total RNA was isolated as described above. 1 µg of RNA was subsequently converted
into cDNA using oligodT primers and M-MLV Reverse transcriptase (Promega). SYBR Green
qPCR was performed in triplicate on the Rotor-GeneQ instrument (Qiagen) using the Rotor-Gene
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SYBR Green Fast PCR kit, as follows: 95°C for 5 min, followed by 45 cycles of 95°C for 5 s
and 60°C for 10 s. Dissociation curves were checked to ensure amplification of a single PCR
product. Moreover, standard curves were run to check the amplification e ciency of each assay.
All amplification e ciencies were between 100% and 111%, with no major di erences between
test genes and housekeeping genes.
For each independent biological sample, all cycle threshold (Ct) values for the target genes were
normalized to the corresponding geometric mean of three housekeeping genes: ribosomal protein
L30 (RPL30), ribosomal protein S13 (RPS13), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). To compare the expression levels between di erent treatments, the 2≠  Ct method
[292] was used and corresponsing gene-specific P-values were calculated with a two-way ANOVA
- using treatment and sample (= 1, 2 or 3) as factors - on the normalized Ct values instead of
the 2≠  Ct values.
Table 1.1: qPCR primer sequences.
Gene Forward primer Reverse primer
GAPDH TCCCATGTTCGTGATGGGTG GATGGCATGGACAGTGGTCA
RPS13 CAGCTCTCCAGAGGAACTCAAGAT CGCTTGAACACGTTCTTGATGG
RPL30 ATGCTTGCCAAGACTGGTGT GTCAGAGTCACCTGGGTCAA
BDNF CACATCCCGAGTCATGCTAA ATGTTTGCAGCATCCAGGTA
NGB GGTGATGCTGGTGATTGATG TCTTCCAGGCAGGACAAGTT
HES1-4 CAGCTGAAGACGCTCATCCT TTGGAATGCCGGGAGCTATC
GABRD ACCAGAGCTGGAGAGACGAT GCTTGTCCACAAACCTGCTG
ANK1 CAGCGAGATCGTCAACATGC GTGTGTAATGCAGGGAGGCA
MMP9 TTGGTAGCCAAGAGCATGGG CATCGCTGTTGCCACCATTG
IKBKE ATCGTGGTGGACGTGTTCTC GCTGCTCTCTGTGGTTTTGC
Validation: Single locus specific DNA methylation quantification by CpG pyro-
sequencing
Additionally, the MethylCap-seq profiles of BDNF, NGB, HES1-4, GABRD, ANK1, MMP9 and
IKBKE were validated with CpG pyrosequencing of bisulfite-treated samples (same three inde-
pendent samples used for qPCR validation). PCR amplification and sequencing primers were
designed using the Pyromark Assay Design v2.0 software (Qiagen). The primers (Table 1.2) were
designed at significant Methylation Peaks in the promoter region of the genes of interest. To
ensure su cient bisulfite conversion, a bisulfite conversion control was included in each assay.
First, 2 µg of gDNA was bisulfite converted using EpiTect Fast Bisulfite Kit (Qiagen). 20ng of
this bisulfite converted DNA was then used as a PCR template (reverse primer was biotinylated),
using PyroMark PCR kit (Qiagen). Primer annealing temperatures were optimized: 56°C for
BDNF, GABRD, ANK1 and MMP9, 58°C for HES1-4, 59°C for IKBKE and 60°C for NGB.
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Next, 15 µl of the PCR product was used for CpG pyrosequencing on the PyroMark Q24 Instru-
ment (Qiagen). Finally, the results were analyzed using the PyroMark Q24 software. Methylation
values of each cell line were summarized per CpG for both the DMSO- and AZA-treatment and
gene-specific P-values, i.e. including all CpGs tested for the gene, were obtained using a two-way
ANOVA with treatment and CpG as factors.
1.4 Results
Experimental design
MethylCap-seq and RNA-seq analyses were performed on DMSO- and AZA-treated samples
(Figure 1.1). AZA is a chemical analogue of cytidine, that, when incorporated in the genome,
inhibits DNMTs resulting in a net demethylation e ect [279]. In addition, an untreated ZFTMA
sample was analyzed with MethylCap-seq and RRBS to validate the MethylCap-seq methodology
in zebra finch (quality control).
ZFTMA & G266
cell lines
DMSO treatment AZA treatment
MethylCap-seq RNA-seq MethylCap-seq RNA-seq
DNA- 
extraction
DNA- 
extraction
RNA- 
extraction
RNA- 
extraction
No treatment
EPIGENETIC TREATMENT
QUALITY CONTROL
MethylCap-seq
& RRBS
DNA- 
extraction
Figure 1.1: Overview of experimental design.
Sequence read mapping
Table 1.3 lists the results of the sequence alignment for all libraries. For the five MethylCap-seq
samples, removal of the duplicate fragments resulted in a lower fraction of non-duplicate, uniquely
mapped reads for the AZA-treated experiments. Note that mapping of the RRBS paired-end reads
resulted in a rather low percentage of uniquely mapped reads (28.42%), similar to Chatterjee et
al. [293], who obtained percentages ranging from 27% to 32.7% when uniquely mapping four
non-mammal zebrafish RRBS libraries. In contrast, RRBS mapping of another non-model species
Table 1.2: CpG pyrosequencing primer sequences.
Gene Forward primer Reverse primer Sequencing primer
(1biotinylated)
BDNF GTAGAGTTGAGTTGGATAGATGT 1ACAATAATTCTACTACTATCCCTTCAA TGGATAGATGTTTGTATTATATGA
NGB GAGTTAGAATTGATGGGATTAAATAAGG 1CCTTACAAAAATAACCAAAAATAACACTTC GGGTAGTTGGGAGATATA
HES1-4 GGTGGGGTTATAAGTTTTTTGAT 1CTCCAAAAACATACTACAATTTTCACA GATAAATTAGAGTGAGGAAAAGAT
GABRD GTAGAAAGTATTTTTGGGTAAAAGTGGTAT 1AAGTGGTATTATTTATTTTAGTTAT TATACACCCAACAACACAAATATATCAA
ANK1 TAGTTTATGGGTTAGAAGGATAGGT 1ATAAAATCAACACATATTTCCCCTACA TAGGTGGTGGAGGGT
MMP9 AAGTGAGGGTTTATTTTTGAGGTAGTAT 1CCCCTAATTTCTCACCATTACTTCCTT GGTGGGATTTATTTTAGAGT
IKBKE GGGTGAGGGTGTTTGGTATAGT 1CCAACCCCTTCTCTTCCTATCA TGGGAGGGGGTGGTA
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(sheep) resulted in an average unique mapping e ciency of 60% [294]. These mapping e ciencies
depend on both the specific characteristics of the reads and reference genome, as well as the used
stringency during mapping (see Discussion). After RRBS alignment, the CpG dinucleotides were
filtered based on coverage. Only CpG sites covered by 10 or more RRBS reads were retained for
further analysis. For the RRBS library, this resulted in 1,074,648 CpGs (approximately 11% of
total number of genomic CpG sites), with a mean coverage of 123 for which subsequently CpG
methylation degrees were calculated (Figure 1.2).
Table 1.3: Summary of mapping statistics. (a) MethylCap-seq and RRBS. (b) RNA-seq.
Non-duplicate,
Uniquely mapped uniquely mapped Mapping
a Cell line Treatment Input reads reads reads percentage
MethylCap-seq G266 DMSO 34,794,421 19,678,423 12,273,057 56.56%
G266 AZA 36,064,631 15,632,019 5,263,239 43.34%
ZFTMA DMSO 29,975,474 13,788,246 9,407,497 46.00%
ZFTMA AZA 33,496,076 17,508,214 4,741,451 52.25%
ZFTMA Untreated 35,015,944 15,617,024 11,173,357 44.60%
RRBS ZFTMA Untreated 73,660,217 20,939,730 NA 28.42%
Total Mapping
b Cell line Treatment Input reads mapped reads percentage
G266 DMSO 59,068,389 43,896,990 74.31%
G266 AZA 60,093,607 45,342,201 75.45%
ZFTMA DMSO 94,390,205 66,146,096 70.07%RNA-seq
ZFTMA AZA 63,714,282 45,870,652 71.99%
Figure 1.2: Histogram of %CpG methylation. CpG methylation degrees obtained with RRBS
of an untreated ZFTMA cell line (CpG sites with a RRBS coverage Ø10). Values above the bars
indicate the frequency of the specific interval (in percentages).
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MethylCap-seq is an appropriate methodology for studying DNA methylation in
zebra finch
Since this is the first study performing MethylCap-seq on zebra finch samples, prior to the genome-
wide DNA methylation analysis, it was necessary to evaluate the e ectiveness of this technique
in zebra finch. Therefore, as a quality control, the untreated ZFTMA sample was also analyzed
with RRBS, demonstrating that higher RRBS CpG methylation degrees are clearly associated with
more MethylCap-seq fragments (Figure 1.3), whereas for very high methylation percentages, on
average a high coverage is obtained (Figure 1.3(a)). Note that Figure 1.3(b) also illustrates that
even for ≥100% methylated loci, no fragments may be picked up by MethylCap-seq, most likely
due to several known biases inherent to the methodology [295]. Taken altogether, these results
indicate that MethylCap-seq is an appropriate methodology for genome-wide mapping of DNA
methylation in zebra finch, though only semi-quantitatively.
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Figure 1.3: Comparison of MethylCap-seq and RRBS for the RRBS-covered CpGs (coverage
Ø10). (a) Plot of the obtained RRBS CpG methylation degree and the average MethylCap-seq
coverage. (b) Boxplots of the observed MethylCap-seq fragments for RRBS-covered CpGs with a
CpG methylation degree starting from Æ1% to Ø99%, respectively.
(Differential) methylation and expression analysis
By combining the MethylCap-seq data with the RRBS data, we identified 719,917 possibly methy-
lated genomic regions, i.e. Methylation Peaks, of which 60.29%, 31.32%, 5.39% and 3% are
distributed in intergenic, intronic, exonic and promoter regions, respectively (see Appendix Fig-
ure B.1(a)). This peak distribution is not at all surprising, given the overall higher share of
intronic/intergenic regions compared to exonic/promoter regions in the genome.
Examination of the methylation level per chromosome revealed overall similar methylation degrees
between chromosomes (online Supplementary Table S6 (All Supplementary Tables can be found
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at the author’s website, see Data Submission)). Furthermore, the distribution of methylation
between exons, introns, promoters and intergenic regions showed only slight di erences between
chromosomes (Appendix Figures B.2 and B.3). Additionally, it was examined if the intergenic
methylation pattern distinguishes gene-deserts (gene-poor regions > 500kb) from other intergenic
regions. Indeed, after determining the methylation level of each group per chromosome, a t-test
showed that gene-deserts are clearly less methylated than other intergenic regions (P-value =
0.0079 for the 21 chromosomes characterized by gene-deserts) (data not shown).
In a next step, a quantitative comparison was made between the DMSO- (= control) and AZA-
treated (= demethylation treatment) samples with the R-package EdgeR [171]. Normalization
was based on the reads that mapped between Methylation Peaks. Using an FDR of 10% (corre-
sponding with a P-value of 0.0043), 30,700 Methylation Peaks (= 4.26%) showed significantly
less methylation after AZA-treatment. 1,996 of the 18,318 annotated zebra finch genes (=
10.90%) had at least one of these 30,700 Methylation Peaks in their promoter region (2000bp
up- and 500bp downstream of transcription start site) (online Supplementary Table S1).
To assess the impact of (variable) methylation on gene expression and to identify genes that
are under DNA methylation control, RNA-seq experiments were performed. Of the mapped
RNA-seq reads, only approximately 50% were located in genomic regions that are annotated
by Ensembl as coding regions, i.e. exons, likely reflecting a still incomplete annotation of the
zebra finch genome. For each sample, on average 70% of the known 18,318 genes were covered
with at least 10 reads in their coding region. Next, data normalization was performed with
PoissonSeq [178] as this method performed better upon visual inspection - profile of the scaling
factor line through the scatterplot of the data points - compared to other normalization methods
(e.g. TMM [284], quantile and library size normalization) (data not shown). After normalization
and EdgeR analysis (FDR = 0.1, corresponding P-value = 0.0205), we identified 147 and 3,679
genes that were significantly down- and upregulated after AZA-treatment, respectively (online
Supplementary Tables S3 and S4).
Next, RNA- and MethylCap-seq results were compared. 357 of the 3,679 upregulated genes (=
10.35%) were featured by at least one Methylation Peak exhibiting significant AZA-dependent
demethylation in the promoter region, and are thus under putative DNA methylation control
(online Supplementary Table S2). As an example, the data tracks of a couple of these genes are
depicted for both cell lines in two circular plots [212]. Figure 1.4 shows the methylation profile
(= MethylCap-seq tracks) of the promoter regions of 4 genes that are putatively epigenetically
regulated (i.e. HES1-4, herapin-binding EGF-like growth factor (HBEGF ), ANK1 and IKBKE ),
while Figure 1.5 also shows the corresponding expression profile (= RNA-seq tracks) for these
genes. As songbirds are an ideal model to study memory formation, brain development and
neuroplasticity, two of the depicted genes are neurobiologically relevant (HES1-4 and ANK1),
but in order to provide a general overview also two other genes (HBEGF and IKBKE ) were
added to the circular plots. These figures clearly show that these genes are characterized by
AZA-induced demethylation of the promoter as well as re-expression.
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In addition, also the MethylCap- and RNA-seq tracks of BDNF are shown. As stated earlier,
it has been shown that BDNF is involved in synaptic plasticity with an expression inversely
correlated with promoter DNA methylation. In our analysis, although BDNF expression was
significantly upregulated after AZA-treatment (P-value = 5.31E-11, Figure 1.5), we found no
significantly demethylated Methylation Peaks in the BDNF promoter. However, visual inspec-
tion of the methylation profiles of the promoter region (Figure 1.4) suggests considerable AZA-
induced demethylation. Indeed, one particular Methylation Peak (highlighted in yellow in Figure
1.4) received a P-value of 0.01, and despite the fact that this was just above the FDR thresh-
old (corresponding with a P-value of 0.0043), this still suggests methylation-dependent gene
expression.
Enrichment analysis
As we wanted to identify epigenetically regulated genes, we were particularly interested in DNA
demethylation leading to upregulated gene expression. Therefore, we determined the global
distribution of the functional genic locations (i.e. promoter, exon and intron) of those AZA-
demethylated Methylation Peaks that are located in genes upregulated after AZA-treatment
(Figure 1.6(a)). Not unexpectedly - given the higher share of intronic regions compared to
exonic/promoter regions in the genome - the majority of these Methylation Peaks is located in
intronic regions (68.27%). Additionally, a considerable number was found in the exonic (21.37%)
and promoter regions (10.36%). In order to investigate whether one of these genic locations
was relatively under- or overrepresented compared to random data, i.e. significantly decreased
or enriched, we performed an enrichment analysis. By comparing the genomic distributions of
1,000 random samples (Figure 1.6(b)) with the distribution shown in Figure 1.6(a), a significant
overrepresentation of AZA-demethylated loci was found for promoter and exonic regions whereas
a significant underrepresentation was found for intronic regions (P-values < 0.001). No significant
enrichment was found for a particular exon number (data not shown).
When looking only at the genome-wide methylation data, i.e. including intergenic regions and
not taking into account the RNA-seq expression data, similar results were obtained: compared to
random data, AZA-induced demethylation was relatively enriched in exonic and promoter regions,
but decreased in intronic and intergenic regions (P-values < 0.001, see Appendix Figure B.1(b)).
Ingenuity Pathway Analysis
Table 1.4 shows the top overrepresented disease and function categories resulting from an
IPA of the 357 putatively epigenetically regulated genes (i.e. upregulated expression and down-
methylated promoter after AZA-treatment). As can be noted from Table 1.4, neurological disease
is classified as the top overrepresented disease category (Benjamini-Hochberg adjusted P-values
between 6.1E-5 and 6.41E-2). Next to neurological diseases, this gene cluster also shows sig-
nificant association with cancer and psychological disorders. A list of genes that contribute to
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Figure 1.4: Circular representation of the normalized methylation profiles of 5 genes (BDNF,
ANK1, HBEGF, HES4 and IKBKE). Promoter regions of the 5 depicted genes with the corre-
sponding methylation profiles for both DMSO- and AZA-treatments. From inner to outer circle:
(i, ii) MethylCap-seq data of DMSO- treated ZFTMA and G266 cell lines, respectively. (iii, iv)
MethylCap-seq data of AZA-treated ZFTMA and G266 cell lines, respectively. (v) Gene promoter
annotation. Significantly down-methylated Methylation Peaks are highlighted in grey. Apart from
BDNF, all genes are part of the 357 genes found to be putatively regulated by promoter methylation
(i.e. AZA-induced down-methylated promoter methylation and upregulated expression), while for
BDNF only expression was significantly upregulated. For BDNF, the defined Methylation Peak in
the promoter region for which methylation was clearly reduced – yet not significant at FDR 0.1 – is
highlighted in yellow. From this figure it is clear that these genes are characterized by AZA-induced
demethylation of the promoter region.
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Figure 1.5: Circular representation of the normalized expression profiles of 5 genes (BDNF, ANK1,
HBEGF, HES4 and IKBKE). Genic regions with the corresponding expression profiles for both
DMSO- and AZA-treatments. From inner to outer circle: (i, ii) RNA-seq data of DMSO-treated
ZFTMA and G266 cell lines, respectively. (iii, iv) RNA-seq data of AZA-treated ZFTMA and
G266 cell lines, respectively. (v) Genic annotation (Ensembl). Due to the large extent of some
genes, instead of the whole genic range, a subregion of HBEGF, ANK1 and IKBKE is shown. In
both figures, the two G266 tracks are equally scaled, as well as both ZFTMA tracks. Apart from
BDNF, all genes are part of the 357 genes found to be putatively regulated by promoter methylation
(i.e. AZA-induced down-methylated promoter methylation and upregulated expression), while for
BDNF only the expression was significantly upregulated. From this figure it is clear that these
genes are characterized by AZA-induced re-expression.
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Figure 1.6: Genic distribution of the Methylation Peaks located in the upregulated genes after
AZA-treatment. (a) Distribution of the Methylation Peaks featured by significant AZA-induced
demethylation. (b) Mean genic classification of random Methylation Peaks resulting from 1,000
iterations.
each of the significant categories as well as a list of genes that contribute to each of the specific
diseases or functions in each of the categories can be found in the online Supplementary Table
S7 and Table S8, respectively.
Validation: Zebra finch Exon Arrays, qPCR and single locus specific DNA methyla-
tion quantification by CpG pyrosequencing
In order to confirm the RNA-seq findings using a larger number of biological replicates, we
performed zebra finch Exon Array analysis (A ymetrix, custom designed). In addition, the inverse
correlation between DNA methylation and expression levels was validated using pyrosequencing
and qPCR for a subset of genes. 14 AZA-treated RNA samples, corresponding to 7 ZFTMA and 7
G266 samples, were compared to 11 controls (DMSO-treated), 5 from ZFTMA and 6 from G266,
using Exon Arrays. With this platform, it is possible to detect expression of 17,882 Ensembl-
NCBI annotated genes. 3,826 genes were found to be di erentially expressed in the RNA-seq
experiment, out of which 3,533 are present on the array. Hence, the validation covered 92.3% of
the RNA-seq di erentially expressed genes. Genes were considered di erentially expressed when
the P-value was lower than or equal to 0.05. This way, di erential expression could be confirmed
for 2,398 out of 3,826 (62.7%) genes: 109 out of 147 (74.1%) down-regulated genes and 2,289
out of 3,679 (62.2%) upregulated genes.
In order to determine whether the expression level correlates to the methylation status, 7 genes
were selected that showed a significant increase in gene expression and decrease in promoter DNA
methylation in both RNA-seq and Exon Arrays and in MethylCap-seq experiments, respectively:
BDNF, NGB, HES1-4, GABRD, ANK1, MMP9 and IKBKE. To validate our findings, three
independent biological samples were treated with either DMSO or AZA and for these 7 genes (i)
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qPCR was carried out to validate the induction of mRNA expression and (ii) CpG pyrosequencing
was performed to validate DNA methylation changes in the promoter region of the corresponding
genes.
For each gene, qPCR results were consistent with the obtained RNA-seq results, i.e. the mRNA
expression of these genes is significantly upregulated by AZA-treatment in both cell lines (Figure
1.7 and Table 1.5). Also, for 6 genes, the change in DNA methylation levels in the promoter
was confirmed by pyrosequencing, even for di erentially methylated BDNF peaks, which revealed
borderline statistical significance in the MethylCap-seq results (Figure 1.8, Appendix Figure B.3
and Table 1.5). Note that for MMP9 the change in promoter methylation was only confirmed in
one cell line (ZFTMA). Although IKBKE was found to be di erentially expressed between both
treatments - both with RNA-seq and qPCR - the methylation di erences found with MethylCap-
seq could not be validated with CpG pyrosequencing (see Discussion).
Table 1.4: Top overrepresented disease and function categories as determined by pathway analysis
(IPA). Categories, corresponding P-values and false discovery rates are shown for the analysis done
on the list of 357 AZA-induced upregulated zebra finch genes with at least one significantly down-
methylated Methylation Peak in their promoter region.
Category P-value - FDR
Neurological Disease 6.10E-05-6.41E-02
Cancer 3.89E-03-6.41E-02
Organismal Injury and Abnormalities 3.89E-03-6.41E-02
Respiratory Disease 8.51E-03-6.41E-02
Inflammatory Disease 1.03E-02-6.41E-02
Hereditary Disorder 1.03E-02-6.41E-02
Psychological Disorders 1.03E-02-6.41E-02
Skeletal and Muscular Disorders 1.03E-02-6.41E-02
Cell Cycle 1.03E-02-6.41E-02
Amino Acid Metabolism 1.03E-02-6.41E-02
Molecular Transport 1,03E-02-6.41E-02
Small Molecule Biochemistry 1.03E-02-6.41E-02
Gastrointestinal Disease 1.16E-02-6.41E-02
Cardiovascular System Development and Function 1.16E-02-6.41E-02
Organismal Development 1.16E-02-6.41E-02
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Figure 1.7: qPCR validation of RNA-seq results. For validation 7 genes were selected that showed
a significant increase in gene expression and decrease in promoter DNA methylation in RNA-seq,
Exon Arrays and MethylCap-seq experiments, respectively. This figure shows the impact of AZA
(1 µM) treatment on BDNF, NGB, HES1-4, GABRD, ANK1, MMP9 and IKBKE gene expression
in ZFTMA and G266 cell lines, relative to a DMSO solvent control. Results were normalized to the
geometric mean of reference genes RPS13, RPL30 and GAPDH. The bar graphs represent relative
mRNA expression (mean ± SEM) of three independent experiments. In all cases, the changes in
mRNA expression after AZA treatment could be validated by qPCR (2-way ANOVA).
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Table 1.5: Results of qPCR and CpG pyrosequencing validation. 7 genes were selected that showed
a significant increase in gene expression (both in RNA-seq and Exon Arrays) and decrease in pro-
moter DNA methylation (MethylCap-seq). qPCR and CpG-pyrosequencing validation experiments
were performed comparing expression and methylation values between DMSO- and AZA-treated
samples. The obtained gene-specific P-values per cell line clearly show a significant di erence in
expression for each of the genes for the two treatments. Methylation di erences between treatments
could be validated by CpG pyrosequencing in all genes except for IKBKE. For MMP9 the change
in promoter methylation was only confirmed in the ZFTMA cell line.
qPCR CpG pyrosequencing
Gene ZFTMA G266 ZFTMA G266
BDNF 1.09E-11 6.22E-11 2.03E-04 2.55E-04
NGB 3.25E-06 2.12E-08 6.74E-03 3.53E-02
HES1-4 3.25E-06 2.12E-08 6.97E-03 8.85E-03
GABRD 1.41E-11 3.82E-02 1.09E-03 2.60E-02
ANK1 2.03E-05 1.12E-07 6.40E-08 5.03E-08
MMP9 7.96E-13 1.71E-14 3.81E-02 2.80E-01
IKBKE 1.34E-09 8.06E-08 3.41E-01 5.69E-01
Figure 1.8: CpG pyrosequencing validation of MethylCap-seq results. For validation 7 genes
were selected that showed a significant increase in gene expression and decrease in promoter DNA
methylation in RNA-seq, Exon Arrays and MethylCap-seq experiments, respectively. This figure
depicts changes in DNA methylation of specific CpG sites in the promoters of BDNF, NGB, HES1-
4, GABRD, ANK1, MMP9 and IKBKE after AZA (1 µM) treatment in ZFTMA and G266 cell
lines, relative to DMSO solvent control. The shown DNA methylation levels represent the mean of
three independent experiments. Only CpG sites that passed quality control were considered. The
NGB gene was found to contain a SNP in the G266 cell line at position chr5:39,429,316, which was
corrected for in the analysis. Methylation changes could be validated for each of the genes, except
for IKBKE (2-way ANOVA). For MMP9 the change in promoter methylation was only confirmed
in the ZFTMA cell line.
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1.5 Discussion
The methylomes of two zebra finch cell lines were profiled by MethylCap-seq. Both G266 (male,
diploid) and ZFTMA (female, tetraploid) cell lines were obtained from spontaneous, non-neuronal
tumors and provide an e cient alternative for whole-animal manipulations. As this study is the
first to use MethylCap-seq to provide a genome-wide DNA methylation profile of DNA origi-
nating from zebra finch samples, we first evaluated the e ectiveness of this technique on an
untreated ZFTMA cell line. By comparing the MethylCap-seq data with RRBS CpG methyla-
tion degrees, MethylCap-seq indeed proved to be an appropriate methodology for genome-wide
mapping of DNA methylation in zebra finches. The fact that CpG pyrosequencing validated
promoter methylation changes in 6 out of the 7 selected genes further supports our conclusion
regarding MethylCap-seq as a suitable methodology in zebra finches, though it only provides a
semi-quantitative indication of the degree of methylation.
Based on MethylCap-seq data of AZA-treated samples and controls (solvent, DMSO), an in-house
peak calling method identified 719,917 Methylation Peaks of which 30,700 showed significantly
less methylation after AZA-treatment. Not unexpectedly, these down-methylated Methylation
Peaks were significantly enriched for exonic and promoter regions. Complemented with addi-
tional RNA-seq data, we subsequently identified 357 genes featured by expression under putative
DNA methylation control, including ANK1 (online Supplementary Table S2). Interestingly, two
independent studies recently demonstrated hypermethylation of ANK1 in the brain of Alzheimer’s
patients [290, 296]. ANK1 produces ankyrin 1, an essential structural component of the cell outer
membranes. Furthermore, this epigenetic alteration appears to occur early on in the disease, mak-
ing them potential biomarkers. Our results further confirm that ANK1 expression is regulated by
promoter DNA methylation, at least in zebra finch.
Subsequent pathway analysis of the obtained list of genes regulated by DNA methylation showed
pronounced enrichment for neurological pathways/networks and associations with neurological
diseases. Besides neurological diseases and organismal survival, cancer is also in the top three
of overrepresented diseases and function categories. This is not surprising, as (i) we are working
with cell lines derived from tumor material and (ii) AZA has been shown to have anti-cancer
e ects by reactivating tumor suppressor genes that are silenced by aberrant DNA methylation
[297]. Due to these anti-cancer properties, AZA has already been used in some clinical trials for
leukemia, myelodysplastic syndrome and non-small cell lung carcinoma [298].
Exon Array validation of RNA-seq results confirmed di erential expression for 62.7% of genes,
indicating a high level of agreement between RNA-seq and Exon Array results. The possibility of
100% cross-platform agreement is precluded by di erences specific to each platform. In contrast
to RNA-seq, microarrays have for example the inherent limitation that they can only detect a
limited number of genes (in this case 92% of the target genes are detectable by the array) and
have a limited dynamic detection range, owing to both background and saturation of signals
[127]. Moreover, the statistical power and the number of replicates used was di erent for both
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platforms, which can further explain the di erences in results between platforms.
For a subset of genes putatively regulated by DNA methylation, expression and methylation
changes following AZA-treatment were validated using respectively qPCR and CpG pyrosequenc-
ing on bisulfite-treated samples. For 6 of the 7 selected genes - BDNF, NGB, HES1-4, GABRD,
ANK1 and MMP9 - we could validate both promoter methylation and gene expression changes
caused by AZA-mediated demethylation. However, whereas the demethylation of AZA is very
clear in MethylCap-seq data, only modest e ects (change of 1-19%) could be observed by pyro-
sequencing (Appendix Figure B.3). Of special note, though pyrosequencing results demonstrated
only moderate methylation changes, subsequent analysis still showed a significant distinction
between the DMSO- and AZA-treated samples (Table 1.5). One possible explanation for this
observation is that accumulation of small individual methylation changes in multiple subsequent
CpG sequences may culminate in drastic changes in a nity of MethylCap-seq. In contrast, CpG
pyrosequencing relies on nucleotide-based sequencing of individual CpG motifs in a stretch of less
than 100bp within a Methylation Peak, so there is always the possibility that there are bigger
CpG methylation changes up/downstream of the pyrosequencing amplicon - which could explain
why the pyrosequencing results of IKBKE were not significant. Alternatively, secondary DNA
damage in AZA-treated samples may further reduce the a nity for MBD and overestimate the
absolute decrease in DNA methylation levels [299, 300]. Besides, mixed changes in DNA methy-
lation and hydroxymethylation by AZA-treatment can di erentially a ect MBD binding a nity,
whereas bisulfite CpG pyrosequencing can not discriminate between both epigenetic modifications
[301, 302].
Nevertheless, the magnitude of DNA methylation changes following AZA-treatment is similar to
e ects reported in gene promoter-specific pyrosequencing assays performed in cancer (patient)
samples (human, mouse) [303].
As already noted in the introduction, songbirds - and zebra finches in particular - are inten-
sively studied by neuroscientists. Dynamic CpG (de)methylation and subsequent gene expression
changes play an important role in neuronal functions like learning and memory formation, high-
lighting the relevance of this study. There are however a couple of important concerns that limit
straightforward extrapolation of here reported results to the zebra finch brain:
(i) A first note worth considering is that the used cell lines do not originate from brain tissue but
from spontaneous, non-neuronal, tumors. However, by comparing the expression profile of
these cell lines with the expression profile of the zebra finch auditory lobule, Balakrishnan
et al. [97] demonstrated that many neurobiologically relevant genes are expressed in both
G266 and ZFTMA cell lines. Moreover, additional overlap with microarray data of Drnevich
et al. (Songbird Neurogenomics (SoNG 20K microarray), 488 songbird brain samples [304]),
showed that 104 of the found 357 epigenetically regulated genes were significantly di eren-
tially expressed (P-value < 2.6E-06) in the zebra finch microarray contrasts. This number
increased to 134 out of 357 when a less stringent P-value of 0.001 was used to call a gene
di erentially expressed in the microarray data. A list of these genes is added in the online
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Supplementary Table S5. Finally, the fact that ‘neurological diseases’ is the most over-
represented disease category in the pathway analysis together with the plethora of genes
associated with brain function in our epigenetic analysis further illustrate the utility of these
cell lines to study neurobiologically relevant genes.
(ii) A subset of tissue-related genes may need tissue-specific transcription factors to be expressed.
When these transcription factors are not present in the cell lines, these genes will not be
expressed, even if the promoter is demethylated. As a result, our list of 357 genes under
putative DNA methylation control could be incomplete for the brain. Therefore, a list of
genes with changes in promoter methylation, independent of a change in expression, is also
included as Supplementary Table S1 at the author’s website (see Data Submission).
(iii) As G266 and ZFTMA are immortalized cell lines, it is possible that some of the found
epigenetically regulated genes are involved in tumorigenesis, particularly when taking into
account that (i) DNA methylation deregulation is common in cancer [305] and (ii) AZA-
treatment has been shown to reactivate tumor suppressor genes [297].
(iv) The zebra finch reference genome and its annotation are currently still incomplete. This is
partially reflected in the rather ‘low’ unique mapping e ciency of the RRBS library. Indeed,
besides sequencing quality, also the quality of the reference genome (particularly complete-
ness) and intrinsic features of the studied species (e.g. overall degree of methylation) are
anticipated to have a profound impact on mapping percentages. In high quality human
RRBS data for example, mapping percentages are approaching 80% [306]. One possibility
to increase RRBS mapping e ciencies in this study was to lower the mapping stringency,
but as RRBS was particularly used to validate the MethylCap-seq approach rather than to
give biological insight as such, this option was not further explored.
We believe that this study can be an important starting point for future epigenetic studies in
zebra finch. The genome-wide map of the zebra finch methylome, for both control and AZA-
treated samples, allows the identification of sites that are practically always methylated, or for
which the methylation status is highly variable in di erent settings. Furthermore, we provide a
list of genes that are putatively regulated by DNA methylation in the promoter region. The next
step will be to investigate whether DNA methylation also regulates the expression of these genes
in vivo and under which circumstances. DNA methylation changes are e.g. known to play an
important role during learning processes [307], brain development [53] and ageing [308], and are
known to occur in response to (sex) hormone exposure [309] or environmental cues [310]. Since
epigenetic regulation is emerging as an important mechanism in sexual di erentiation [311, 312],
in our future work we will focus on the underlying epigenetic mechanisms of sexual dimorphic
brain development during vocal learning in the zebra finch.
In conclusion, using two zebra finch cell lines, were were able to validate the MethylCap-seq
methodology in zebra finch samples. To the best of our knowledge, this study provides the
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first genome-wide DNA methylation map of the zebra finch genome as well as a comprehensive
set of genes for which transcription is under putative DNA methylation control. Interestingly,
this subset included many neurobiologically relevant genes, further supported by the pathway
analysis showing obvious enrichment for neurological pathways/networks and associations with
neurological diseases. As such, this zebra finch draft methylome may become an attractive
data-mining tool for (neuro)epigenetic studies in songbirds.
1.6 Data submission
The data discussed in this publication have been deposited in NCBI’s Gene Expression Om-
nibus and are accessible through GEO Series accession numbers GSE61060 and GSE71344
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61060,
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71344). Next to these files, Supple-
mentary Tables and RRBS data (BAM-format) has also been made available, which can be
downloaded from the author’s website: http://www.biobix.be/data-2/zebrafinch/. Supplemen-
tary information accompanies this work at http://www.nature.com/srep.
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1
Conclusion & future perspectives
Decoding the precise order of A, C, T and Gs in our DNA has become indispensable for biological
and medical research. DNA and RNA sequencing not only enables the detection of genomic
variation but also permits investigating the regulatory link between genotype and phenotype by
quantification of transcription/translation. The true era of DNA sequencing started with the
development of (first generation) Sanger sequencing in 1977. However, after completing the
Human Genome Project in 2001, interest in novel and especially faster and cheaper technologies
emerged, leading to the development of second or next-generation sequencing (NGS) technologies.
The rise of NGS technologies did not only allow sequencing at a dramatically increased speed, it
also allowed more complex diseases and more samples to be analyzed at a fraction of the cost.
The past decade, the high demand to low-cost sequencing strategies has driven the development
of high-throughput sequencing in a way that NGS has become a self-evident commodity. The
development of complex sample preparations and creative sequencing strategies makes it now
possible to investigate an abundance of divergent and exciting research questions even on top
of the DNA such as splicing events, DNA methylation and histone modifications. Yet, the size
of NGS data can be huge. NGS methods are yielding a plethora of sequencing data, resulting
in the need for the right computational methods that can keep up with these enormous and
ever-growing datasets. Nowadays, the bottleneck of genomic analyses lies not anymore in the
technologies to obtain the raw data, but gradually shifted to their subsequent maintenance,
analysis and downstream data interpretation, which is often complex and laborious [313].
The core of this doctoral thesis comprises the influence of epigenetics - and in particular DNA
methylation - on the transcription and translation of genes, with the main focus on imprinting
and neuroepigenetics. While the former is a well-known and investigated phenomenon, the latter
topic is a rather new research field. The term ‘imprinting’ is used when monoallelic expression is
based on parental origin. Monoallelic DNA methylation is deemed to be an important regulator
of monoallelic gene expression. However, although imprinting is indeed already a familiar concept
that has been (and still is) intensively researched, until now only a handful of imprinted regions are
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well-characterized [195, 196]. E ective high-throughput screening of imprinted genes has been a
continuing challenge for the community, due to both the biological complexity of the phenomenon
and technical caveats. As monoallelic gene expression is a defining feature of cellular identity
and essential for normal development, dysregulation of both monoallelic methylation and gene
expression have already been linked to several genetic disorders as well as to diseased phenotypes
such as cancer, explaining the extensive e orts to study these imprinted patterns [243].
The arrival of NGS makes it now possible to screen genomes for such features in a genome-
wide manner. When it comes to methylation profiling, bisulfite sequencing is still the gold
standard. By combining bisulfite treatment of the DNA with a sequencing procedure, it allows
to readily identify (monoallelically) methylated nucleotides at the highest possible resolution.
Extensive e orts improving library preparations recently made it possible to perform whole-genome
bisulfite sequencing (WGBS), enabling methylation profiles in a genome-wide manner at single
base pair resolution. However, next to the di cult/complex post-NGS analysis (e.g. alignment),
the application of this approach remains costly for organisms with large genomes, including
humans [314, 315]. One alternative is RRBS, where restriction enzymes and bisulfite sequencing
are combined to enrich for genomic loci with a high CpG content. But, given its targeted
approach it is evidently quite limited regarding genome-wide information. Luckily, even more
cost-e cient and genome-wide alternative methods such as MethylCap-seq and MeDIP-seq exist
that in addition also avoid the disadvantages that come with bisulfite-treatment. These methods
are based on prior enrichment of methylated DNA fragments by methylation-specific antibodies or
proteins and hence are termed ‘enrichment-based sequencing methods’. By reducing the overall
cost of sequencing while still providing a genome-wide profile, these enrichment-based methods
are better a ordable for smaller projects. But, there are some drawbacks as well. The most
important one in context of imprinting is that, in contrast to bisulfite sequencing, they do not
provide single base pair resolution nor information regarding the unmethylated fraction of the
genome. However, as we still wanted to take advantage of their utility, our goal was to devise
a method that circumvents these issues and that by solely using data from enrichment-based
sequencing is still able to identify imprinted regions.
In 2014, we developed a first methodology based on classical population genetic theory, i.e. Hardy-
Weinberg theorem, and combines methylomic data (MethylCap-seq) with associated SNP profiles
to identify monoallelically methylated loci, thereby achieving our first research goal. Next
to MethylCap-seq, this approach can also be used for other applications, such as ChIP-seq-
based detection of monoallelic protein-DNA binding events and histone modifications. However,
although additional validation proved the e ectiveness and reliability of the developed method, we
felt that there was still room for further optimization. Indeed, the method also has some downsides
that are briefly outlined in the intermezzo, of which computational load and the inability to allow
(some) flexibility in the degree of imprinting are the most important. Consequently, giving in
to our never stopping need to optimize, we began to develop a new novel methodology that
starts from the same rationale as the previous one, but with some improvements, such as possible
presence of partial imprinting and detection of di erential imprinting.
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The phenomenon of genomic imprinting with abnormal imprinting and loss of imprinting/heterozy-
gosity contributes to a wide range of malignancies, with the number of detected human diseases or
disorders due to aberrant imprinting already greater than 100 conditions [316]. These range from
classical genetic disorders such as Beckwith-Wiedemann, Angelman and Prader-Willi syndromes
to cancer, obesity and diabetes. In addition, imprinted genes a ect animal growth, development
and viability and may also contribute to behavior and language development, alcohol depen-
dency, schizophrenia, and possibly bipolar a ective disorders. It has already been reported that
the incidence of these disorders are increased in individuals conceived with assisted reproductive
technology [316, 317].
Almost all imprinted genes identified to date are involved in growth processes such as embryonic
growth, placental growth or adult metabolism, and IGF2 is involved in all three. The IGF2 gene
is one of the most intensively studied imprinted genes, reflected in the very well-characterized
mechanisms and regions of its imprinting regulation. With respect to LOI in cancer, most studies
also focused on IGF2 and its e ects after misregulation. LOI occurs at high frequency in a large
variety of human tumors. At present, it is even considered to be the most common alteration
in cancer. Although LOI is an early event in most cancers studied, making it of obvious interest
from both a diagnostic and prognostic point of view. The importance of imprinting and the
loss of proper imprinted gene regulation is further illustrated by the existence of genetic diseases
with altered expression of an imprinted gene pair (e.g. Beckwith-Wiedemann, Angelman and
Prader-Willi). Such patients are significantly more susceptible to tumors leading to an increased
cancer risk. This latter feature strongly suggests that dysregulation of imprinted genes is not
just a ‘by-product’ of cancer phenotypes, but is likely to be involved in tumor growth and/or
progression. Taken together, a greater understanding of imprinting and LOI will constitute an
important medical advance, opening new avenues of diagnosis and treatment [318].
The mouse is still the leading organism for disease research. However, humans are predicted to
have fewer imprinted genes than mice and the types of human genes involved are often markedly
di erent from mice. Therefore, questions have been raised about the use of mice as models for
human diseases involved with imprinted genes, underlining the relevance of directly focusing on
human data (where possible) [191].
Although our first method was applied on MethylCap-seq samples of a challenging experimental
set-up (= mixture of di erent tissues, mostly cancer tumors) this framework allowed the identi-
fication of loci known to be generally imprinted, but also novel candidate imprinted genes. The
second method was first tested on RNA-seq data - establishing its e cacy and applicability on
other data types - from the TCGA breast cancer control dataset. Recent evidence suggests that
monoallelic DNA methylation and expression are often tissue- or cell-type specific, emphasizing
the relevance of applying this framework on samples of normal, single-tissue origin. Not only
did this framework detect regions known to be imprinted in breast tissue (e.g. IGF2, GNAS,
H19 and MEST ), it also identified novel putative monoallelically expressed regions. Interest-
ingly, for several of these novel loci there is already some independent evidence for imprinting
(e.g. PWAR5/6).
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Additionally, comparison with samples originating from breast cancer tumors showed deregulation
of three loci known to be involved in breast cancer, particularly in the HER2-positive subtype
of breast cancer. Cancer subtypes are useful to predict prognosis, plan a specific treatment and
develop new therapies. The complex profile of each subtype is determined using molecular and
genetic information from tumor cells. For molecular subtyping of breast cancer, the PAM50 panel
(microarray expression profiling) is most frequently used. Generally, breast cancer is divided in four
major molecular subtypes: Luminal A (LumA), Luminal B (LumB), Basal-like (BL) and HER2-
enriched (HER2) [319]. LumA tends to be estrogen-receptor positive and HER2-receptor negative
while LumB is estrogen-receptor positive but can be HER2-receptor positive or negative. BL on
the other hand is negative to both estrogen- en HER2-receptors, while HER2 is estrogen-receptor
negative and mostly HER2-receptor positive. Treatment and prognosis is highly dependent on
these specific cancer subtypes. For example, LumA tumors are treated with hormone therapy
(due to their estrogen-receptor) and tend to have the best prognosis, with fairly high survival
rates and fairly low recurrence rates, while for BL-tumors hormone therapy is not e ective and
often a combination of surgery, radio- and chemotherapy is used. Tumors of this latter subtype
are often aggressive and have a poorer prognosis compared to the estrogen-receptor positive
subtypes LumA/B [264, 320]. Our observations directly validate the relevance of also performing
such imprinting analyses per subtype: every subtype has its own characteristics and deregulated
(expression) profile.
Overall, our results demonstrate the e cacy of our methods for the identification of monoallelic
expressed regions known to be generally imprinted and involved in genetic and/or imprinting
disorders (e.g. IGF2/H19, SNURF/SNRPN, MEST, ... ) as well as novel imprinted genes and
underline that deregulation of these loci is present in breast cancer, thereby completing research
goal 2. Of course, there is still room for further optimization, like including extra features to (i)
detect LOH and to (ii) better cope with heterogeneous samples, but our results already present
an interesting, potential data-mining tool for future imprinting studies.
In a time where sequencing becomes less and less expensive, and third-generation sequencing
methods are already knocking at our door, one might wonder if it is still relevant to develop
methods for enrichment-based sequencing methods or NGS-based RNA-seq. The answer - at
least in my opinion - is yes, because of the following three reasons:
(i) With the decreased sequencing cost, why not just perform WGBS to detect monoallelic
methylation? Of course, with unlimited resources and time, whole-genome sequencing
(WGS) is a clear winner. However, enrichment-based methods still cost far less than WGS.
It is important to note that next to the cost of the actual sequencing itself, this also
holds for the post data storage and analysis costs. The reduced costs per sample of the
enrichment/targeted approach thus makes it feasible to increase both the sequencing depth
as well as the number of samples to be sequenced, an important factor for large popultation
studies [321].
(ii) Third or next-next-generation sequencing (NNGS) promises (1) to increase sequencing
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throughput and read lengths, (2) decrease costs, run times and error rates, (3) elimi-
nate biases inherent in NGS (e.g. PCR amplification and reverse transcription) and (4)
o er capabilities beyond nucleic acid sequencing [322]. But, despite these improvements -
and already a couple of years after the commercial release of Pacific Bioscience (PacBio)
SMRT systems - NNGS still hasn’t taken over the sequencing world. And it is very unlikely
that NNGS will replace NGS anytime soon. Firstly, from a technological standpoint, NNGS
systems are far from mature. For example, till now, the PacBio instrument produces reads
with a very high error rate (sometimes with an average accuracy less than 85%), a feature
regarded as the primary limitation slowing down the share of the technology. Especially
for imprinting detection based on SNPs, major improvements are be required to detect
imprinted loci in a cost-e cient manner. Another important holdback related to this is
that NNGS instruments are generating an entirely new type of sequencing data, requiring
a complete change in the focus of software development. Currently, the software is not in
place yet for the scientific community to easily analyze this new type of data. Secondly,
from a business standpoint, companies developing and o ering NNGS technologies are at a
disadvantage. The past years, there were significant investments from both pharmaceutical
and academic facilities, making that at this moment the sequencing market may be satu-
rated with high-throughput NGS sequencers. In conclusion, although it is clear that NNGS
provides several unique capabilities that cannot be matched by NGS technologies, overall,
they cannot meet the demands of today’s research and diagnostics market as well as NGS
does. However, it stands no reason that in 10 to 15 years, when the technology more
matures, NNGS will take at least a part of the sequencing market, but instead of replacing
NGS, it is more expected to peacefully coexist with NGS. Indeed, given the preliminary
results and costs of the first NNGS experiments, population studies that require a high
depth of sequencing will remain best studied with NGS, while NNGS will be more suited
for applications where particularly read length is important, such as genome assembly or
genome-wide structural variation studies (e.g. copy number variations) [322, 323].
(iii) A last item in big favor of the development of tools for NGS-based data is the advent
of genomic databases collecting overwhelming treasures of data. Indeed, the inherent
potential underlying these databases with data from all sorts of sequencing projects, such
as amongst others TCGA and GTEx, is tremendous. Researchers now have the ability to
navigate through this publicly available information spaces containing lots of di erent data
types that are just waiting for us to be analyzed [324]. For example, our second method is
currently being applied on all tissues and associated tumor types present in TCGA to obtain
a comprehensive overview of imprinting in the human body as well as its deregulation in
cancer.
DNA methylation has been thought to be a static epigenetic mark for over 20 years. However, the
last couple of years, a lot of papers have been published concerning (dynamic) epigenetic mech-
anisms in the nervous system. Indeed, emerging evidence highlights the unique involvement of
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dynamic (hydroxy) DNA methylation in brain plasticity. As this separates the role of methylation
in neurons, from its role in developmental biology (e.g. genomic imprinting), a distinction was
necessary between these phenomena, leading to a novel research field termed neuroepigenetics.
The 5-mCG landscape of postnatal neurons is generally quite similar to other cell types, meaning
that intergenic regions and repeats contain high levels of 5-mCG while regulatory elements such
as active promoters are depleted of 5-mCG. Therefore, methylation of neuronal CG-dinucleotides
is also thought to regulate gene expression by promoting trancriptional repression. Importantly,
it has recently become apparent that next to 5-mCG, neurons also accumulare other types of
methylation, namely 5-hmC and non-CpG methylation. These two alternative forms seem to be
significantly more present in the neuronal genome relative to other cell types, thereby expanding
the role of DNA methylation [325].
Songbirds o er an unique opportunity to understand the (epi)genetics behind the plasticity of
learning and memory. Due to several advantages, particularly the zebra finch has been used as
a model organism in neurobiological studies. However, a genome-wide methylation profile of the
zebra finch genome was still lacking. Here, we aimed at establishing the first genome-wide DNA
methylation map of the zebra finch genome, as well as the identification of epigenetically regulated
genes. RNA- and MethylCap-seq experiments were performed on two zebra finch cell lines in
presence or absence of 5-aza-2’-deoxycytidine (AZA) induced demethylation. After establishing
that MethylCap-seq (developed for mammals) is indeed an appropriate methodology for genome-
wide mapping of DNA methylation in zebra finch, genes were identified for which transcription is
putatively regulated by methylation. Interestingly, these included many neurobiologically relevant
genes, underscoring the relevance of the here completed research goal 3.
Of course, cell lines are not perfect substitutes for primary samples. Like all model systems,
there are limitations that must be considered. One - and probably the biggest - limitation of in
vitro models is the di culty in translating the relevance in vitro results to in vivo outcomes -
although this limitation holds for every model organism. (Epi)Genomic di erences between cell
lines and tissues of interest have already been pointed out in several studies. In addition, not all
cell lines express all pathways of interest/importance, which again limits the ability to extrapolate
the relevance of some of the findings. For these reasons, researchers want (and need) to use cell
lines that most closely resemble the (epi)genomic landscape of interest [326, 327].
Unfortunately, this is not always feasible for some studies. In our study, we used the only two
zebra finch cell lines that are currently available. As these do not originate from brain tissue, one
needs to be extra cautious when extrapolating our reported results to the brain. Note that it is
important to consider the limitations of specific cell lines in context of the study. Our primary
goal was to assess the applicability of the MethylCap-seq methodology in zebra finch tissue,
independent of the origin of the samples, which we did.
Despite the limitations of the used cell lines, they o er a good starting point to investigate
(methylation) biology and identify putative markers. Therefore, in an additional step, we showed
that the MethylCap-seq approach was successful in identifying a large set of loci under epigenetic
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control and demonstrated overall relevance of epigenetics towards neuroplasticity. An enrichment
was found for genes associated with brain function, suggesting that this first genome-wide map of
the zebra finch together with the list of methylation-regulated genes can be an important starting
point for future (neuro)epigenetic studies in zebra finch.
Note that as the exact promoter locations were not available, we defined the promoter as ranging
from 2000bp upstream to 500bp downstream of the TSS. For our zebra finch experiments, this
definition will a ect the size of the found ‘functional methylome’. More specifically, a broader
definition would lead to more genes identified as featured by di erential promoter methylation
and thereby also lead to more genes featured by both di erential promoter methylation and
di erential expression upon AZA treatment. Vice versa, a more narrow definition may lead to
a smaller functional methylome. However, although the exact promoter definition will probably
impact the final results, overall conclusions will remain the same. In fact, when gene-specific
promoter information would become available in the future, using these improved definitions
would likely result in an even higher enrichment for promoter regions.
Yet, where possible (i.e. su cient amount of material), an in vivo approach will lead to far more
biological insight. The logical next step will be to investigate whether DNA methylation indeed
regulates these genes in vivo and under which circumstances. Therefore, we planned to perform
methylation and expression studies on zebra finch brain tissue (telencephalon) harvested at critical
timepoints in its the development. Though the MethylCap-seq approach was successful for the
cell lines, the anticipated low (hydroxy-)methylation degrees in the developing telencephalon may
compromise the sensitivity of this methodology. Therefore, we choose to use a combination
of standard and oxidative RRBS (oxRRBS). These were applied on a total of 24 samples, i.e.
three replicates of telencephalon 1, 20 and 65 days post hatch as well as adults, for both sexes.
Moreover, each sample consisted of a pool of three independent telencephalons to additionally
reduce variance and increase power.
By now, the first sequencing runs are finished and are currently being analyzed and inter-
preted. Preliminary results already made clear that in all samples, average telencephalon (hy-
droxy)methylation levels are overall low. Yet, a clear, consistent and significant (all P-values
< 0.01) increase over development could be observed, which was similar for both sexes. In
addition, we detected methylation changes in many genes involved in neurogenesis and nervous
system development, including several genes that were already identified using the cell line work.
Interestingly, we found an enrichment of both estrogen and androgen response elements in the
promoters of genes displaying methylation changes as compared to random promoters, which
suggests an interplay between hormones and DNA methylation. Currently, also non-CpG context
DNA methylation is under evaluation.
These results will guide us to evaluate the functional impact of (di erential) methylation of
identified genes in specific song control nuclei. Hopefully, identified genes and pathways will also
yield relevant insight in human diseases associated with learning problems, but that will be the
topic of another PhD.
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Last but not least - en eigenlijk vaak zelfs het eerste (maar ik hoop niet het enige?) stuk dat
gelezen wordt - een paar grote woorden van dankbaarheid. Want het werk dat hierin beschreven
staat, is uiteraard niet enkel en alleen te danken aan mij, maar het resultaat van veel gezamenlijke
inspanningen van allerlei aard. In tegenstelling tot de pagina’s hiervoor, is er hier niet veel inleiding
nodig, dus laat ik er maar direct invliegen.
Adriaan, je zou Adriaan niet zijn als je niet zou verwachten om als eerste vermeld te worden in
dit dankwoord! En uiteraard volledig terecht. My Splinter, my partner in crime. We hebben de
afgelopen 4 jaar zij aan zij het Gentse doctoraatsgebeuren mogen ervaren. Ik op ons vertrouwde
Boerekot, jij aan de andere kant van de Coupure als overloper naar de faculteit Geneeskunde.
De periode van het onstaan van Team Awesome! Zalige momenten! De eerste jaren nog groen
achter onze oren met volle moed pendelend tussen De Panne en Gent. Het voelde vaak aan
als een treinrit naar Hogwarts, maar dan helaas zonder tovenarij, magische beesten of snoepjes.
Eigenlijk gewoon heel erg lang, onvoorspelbaar, onwetend welke zaken ons spoor die dag zouden
kruisen. Een periode waarin ik ook mijn eerste West-Vlaams woord geleerd heb: ‘tsjollinge’. Maar
gelukkig konden we altijd op elkaar rekenen en nu nog steeds, maar dan vanuit het Izegemse.
Bedankt voor de steun, het luisterend wetenschappelijk oor en het geduld. Wat een luxe om
mijn lieveling en beste vriend in één enkele persoon te hebben! Mijn rots in de branding! Zeker
ook de laatste paar weken, waarin jij die twee flu y leeuwen vaak in je eentje moest temmen,
terwijl ik ‘nog maar een paar minuutjes’ ging werken, maar die door een vreemde kronkeling in
het ruime-tijd continuum vaak een paar uur bleken te zijn. Je zou een marathon lopen voor mij.
Twee zelfs. Maar nu is het jouw beurt om de komende weken bij het schrijven/finaliseren van
je PhD op diezelfde manier ‘misbruik’ te maken van mij, en aan mij om te proberen diezelfde
houvast te zijn voor jou. Gaan!
Mama en papa, ook voor jullie is er hier een glansrol. Jullie hebben de voorbije decennia zoveel
opgeo erd, enkel en alleen opdat Nicola en ik dat niet zouden moeten doen. Nooit was jullie
iets teveel, zolang wij maar niets tekort kwamen en onze dromen konden najagen. Jullie vormen
de fundamenten van mijn persoonlijkheid. Ik heb zoveel van jullie geleerd. Levenswijsheid, hard
werken, niet opgeven, voetjes op de grond. Ik heb werkelijk alles aan jullie te danken. Er zijn weinig
woorden die kunnen omschrijven hoe dankbaar ik ben. Zonder jullie onvoorwaardelijke steun zou
dit boekje nooit een feit zijn geweest. Bedankt voor alle kansen die ik door jullie gekregen
heb! Nicola, Niësto, whatever. Hoe vaak hebben we niet bij een kopje ko e gefilosofeerd/weg-
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gedroomd over de stomste zaken eerst. Momenten die alles zo relatief maken en jezelf weer
opladen om erin te vliegen en nieuwe uitdagingen aan te gaan. Merci bro!
Een immens grote danku aan jou, Tim. Zonder jouw coaching zou dit werk er niet geweest zijn.
Je inbreng was immens. Je stond telkens klaar om me met raad en daad bij te staan, hoe druk
je het ook had. Ongeacht hoe dom of complex de vraag was. Geen moeite was teveel. En
meer dan eens stond ik versteld van je capaciteiten en intellect. Je bent een voorbeeld om naar
op te kijken. En vooral door jou heb ik lang gepiekerd om al dan niet academisch te blijven.
Jouw enthousiasme en je oprecht pure drang naar goede wetenschap deed mij verlangen om ooit
in je voetsporen te treden. En de keuze was niet gemakkelijk. En hoewel ik uiteindelijk toch
de niet-academische richting gekozen heb, hoop ik dat we in de toekomst ooit nog eens mogen
samenwerken! En dat je veel toekomstige studenten kan inspireren, net zoals je bij mij gedaan
hebt!
Ook jij, Wim VC, ontsnapt niet. Eerst en vooral bedankt om mij tijdens de masterjaren het pad
naar de bioinformatica wereld te tonen en mij later de kans te geven dit te bewandelen. Het was
een eer om met iemand als jou te mogen samenwerken. Je hebt een zeer grote rol gespeeld in
hoe ik nu naar de wereld kijk en waar ik naartoe wil. Ik heb enorm veel opgestoken van jouw
visies, aanpak en enthousiasme. Bedankt voor alle opportuniteiten!
En ook vanuit het Antwerpse kon ik - vooral bij het derde luik van dit werk - rekenen op extra hulp.
Wim VDB, bedankt voor de ondersteuning bij alle (wet-lab) experimenten die hierbij kwamen
kijken. Je ervaring kwam ten zeerste van pas bij dit voor ons vaak nog onbekende terrein!
Bij het schrijven van dit dankwoord besef ik plots ook dat al mijn promoters hun namen bestaan
uit drie letters. Toeval? Nee ik denk het niet!
Geen aangenaam werk zonder to e collega’s! Biobixers, bedankt voor de aangename werksfeer!
Joachim, Simon, Jeroen, Alexander, Klaas, Geert, Jeroen, Elvis, Volodimir, Tine, Steven, Daisy...
Stuk voor stuk fantastische persoonlijkheden. Amongst others harde werkers, eveneens verslaafd
aan ko e, levensgenieters, zalige humor. Ik denk nu soms al nostalgisch terug aan die periode
op ‘den bureau’. Good times! Ook mijn ‘collega’s’ van het Plastoscine project verdienen hier een
plaats. Gent, Luik, Anwerpen, Leuven. Veel universiteiten en verschillende expertises samen in
één project. Wat het uiteraard niet altijd eenvoudig maakt om gestroomlijnd te communiceren
of te werken, maar wat we naar mijn mening zeer goed gedaan hebben. Zeer leerrijke periode.
Bedankt voor de aangename collaboratie! Een extra merci ook voor Jolien, mijn Antwerpse
collega in het labo. Jij drijvende kracht in het wet-lab, ik van het dry-lab. Bedankt voor de vlotte
samenwerking!
Yvan, Brigitte en Sander, jullie steun was eveneens niet te onderschatten de afgelopen tijd. Jullie
ervaringen, raad en bijstand waren meer dan welkom! Fantastisch om te weten dat ik ook bij
jullie steeds terecht kan voor levenswijsheid, rust, (wetenschappelijke) discussies en een helpende
hand bij zaken die voor mij (vaak) wereldvreemd zijn.
En nee, lieve vrienden. Ik ben jullie zeker niet vergeten! Mijn bio-ir vriendjes, Laurens, Eveline,
Kaat, Eva, Dieter, Bieke, Aaron en Ste e. Wat een memorabele momenten op het Boerekot!
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(Gluten-vrije) lasagne hier, biertje daar, olé! Wat een geluk dat deze momenten nu - nu we wat
ouder en wijzer (geacht) worden - even memorabel blijven. Zij het tegenwoordig wel met wat
hoogstaandere culinaire verwennerij (bedankt Laurens om die lat hoog te leggen)...
Mijn lieve doc-vriend(inn)en, wat uniek dat onze vriendschap na al die jaren nog steeds zo hecht
is. Ik ben enorm dankbaar dat jullie mij niet uit het oog zijn verloren tijdens de unief-jaren toen
ik als enkeling geen geneeskunde, maar (bio-)ingenieur wou gaan studeren. Extra fantastisch dat
we die fascinatie voor ko e, taart en wijn (3x vrouwelijk cliché) delen!
Aan mijn Gentse bu alo vrienden, ondanks jullie wat vreemde smaak in voetbalploegen, bedankt
voor de zalige momenten. Niets beter om te ontstressen dan ‘s morgens, ‘s middags, ‘s avonds
of eender welk moment samen enen te gaan drinken en te chillen met jullie! En hetzelfde geldt
ook voor mijn ‘nieuwe’ Izegemse gang! Wanneer gaan we nog eens eentje gaan klinken in den
Sinte-Pieter, of ‘t Vlaams Huis, of ‘t potje (of was het kannetje? of tasje?) ko e? Kersttruien
toegestaan!
EXTRA SPOTLIGHT ook op Joost, Jeroen & Adriaan. Hoewel jullie helemaal niet vertrouwd zijn
met deze materie, was het bewonderingswaardig hoe vlot en enthousiast jullie dit spontaan wilden
en hebben nagelezen. Super professioneel ook! Woorden als ‘Bowtie’ die vervangen werden door
‘David Bowie’, of mopjes over het TET-eiwit, ... Super dikke merci! I owe you one!
Source: [342].
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Appendix A
A.1 Detection of monoallelic DNA methylation
A.1.1 Samples
Table A.1: List of the 334 samples with their ID, sequencing Platform, originating Tissue, sample
Origin, Disease state, Gender (M: male, F: female) and resulting mapping percentage (MP).
ID Platform Tissue Origin Disease Gender MP (%)
1 GAIIx kidney primary cancer F 67.43
2 GAIIx kidney primary cancer M 71.62
3 GAIIx kidney primary cancer F 71.97
4 GAIIx kidney primary cancer M 71.44
5 GAIIx kidney primary cancer M 68.74
6 GAIIx kidney primary cancer M 68.89
7 GAIIx kidney primary cancer M 67.70
8 GAIIx kidney primary cancer F 71.60
9 GAIIx kidney primary cancer M 71.85
10 GAIIx kidney primary cancer M 69.16
11 GAIIx kidney primary cancer M 67.29
12 GAIIx kidney primary cancer M 75.30
13 GAIIx kidney primary cancer M 71.89
14 GAIIx kidney primary cancer M 72.13
15 GAIIx melanoma cell line cancer F 76.73
16 GAIIx melanoma cell line cancer F 76.38
17 GAIIx melanoma cell line cancer F 74.27
18 GAIIx melanoma cell line cancer F 74.04
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Table A.1: Continued
ID Platform Tissue Origin Disease Gender MP (%)
19 GAIIx melanoma cell line cancer F 78.34
20 GAIIx melanoma cell line cancer F 76.97
21 GAIIx stem cell cell line normal M 71.87
22 GAIIx stem cell cell line cancer F 72.31
23 GAIIx breast primary normal F 63.15
24 GAIIx breast cell line cancer F 60.38
25 GAIIx breast cell line cancer F 62.58
26 GAIIx breast cell line cancer F 67.77
27 GAIIx brain primary normal M 75.25
28 GAIIx colon primary cancer M 20.86
29 GAIIx colon primary cancer M 23.26
30 GAIIx colon primary cancer M 31.88
31 GAIIx colon primary cancer M 20.14
32 GAIIx colon primary cancer F 72.61
33 GAIIx colon primary cancer M 71.85
34 GAIIx colon primary cancer M 71.26
35 GAIIx colon primary cancer F 72.86
36 GAIIx colon primary cancer F 71.00
37 GAIIx colon primary cancer F 71.94
38 GAIIx colon primary cancer F 73.44
39 GAIIx colon primary cancer M 71.51
40 GAIIx colon primary cancer M 27.70
41 GAIIx colon primary cancer M 29.48
42 GAIIx colon primary cancer M 22.84
43 GAIIx lung primary cancer F 78.15
44 GAIIx lung primary cancer F 77.07
45 GAIIx lung primary cancer F 78.89
46 GAIIx lung primary cancer M 74.05
47 GAIIx lung primary cancer F 75,79
48 GAIIx lung primary cancer F 75.05
49 GAIIx lung primary cancer F 74.21
50 GAIIx kidney primary cancer M 73.04
51 GAIIx kidney primary cancer M 71.29
52 GAIIx kidney primary cancer F 71.40
53 GAIIx kidney primary cancer M 70.15
54 GAIIx kidney primary cancer F 3.45
55 GAIIx bladder cell line cancer F 74.68
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Table A.1: Continued
ID Platform Tissue Origin Disease Gender MP (%)
56 GAIIx bladder cell line cancer M 78.90
57 GAIIx bladder cell line cancer M 75.12
58 GAIIx bladder cell line cancer M 72.42
59 GAIIx lung primary cancer M 73.42
60 GAIIx lung primary cancer F 80.95
61 HiSeq white blood cells cell line cancer F 41.37
62 HiSeq white blood cells cell line cancer F 41.66
63 HiSeq head & neck primary cancer F 50.16
64 HiSeq head & neck primary cancer M 50.50
65 HiSeq head & neck primary cancer F 54.55
66 HiSeq head & neck primary cancer F 51.93
67 HiSeq head & neck primary cancer F 49.45
68 HiSeq head & neck primary cancer M 48.63
69 HiSeq head & neck primary cancer F 50.44
70 HiSeq head & neck primary cancer F 50.55
71 HiSeq head & neck primary cancer M 50.56
72 HiSeq head & neck primary cancer F 51.62
73 HiSeq head & neck primary cancer M 49.15
74 HiSeq cervix primary cancer F 57.61
75 HiSeq cervix primary cancer F 56.48
76 HiSeq cervix primary cancer F 58.12
77 HiSeq cervix primary cancer F 56.81
78 HiSeq cervix primary cancer F 55.57
79 HiSeq cervix primary cancer F 59.27
80 HiSeq cervix primary cancer F 56.21
81 HiSeq cervix primary cancer F 57.07
82 HiSeq cervix primary cancer F 57.01
83 HiSeq cervix primary cancer F 56.32
84 HiSeq cervix primary cancer F 56.65
85 GAIIx lung primary cancer F 78.84
86 GAIIx colon primary normal M 74.16
87 GAIIx colon primary normal M 73.64
88 GAIIx colon primary normal M 71.25
89 GAIIx colon primary normal F 75.28
90 GAIIx colon primary normal F 74.66
91 GAIIx colon primary cancer M 75.28
92 GAIIx colon primary cancer M 74.03
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Table A.1: Continued
ID Platform Tissue Origin Disease Gender MP (%)
93 GAIIx colon primary cancer F 77.53
94 GAIIx colon primary cancer F 78.59
95 GAIIx colon primary cancer M 77.11
96 GAIIx cervix cell line cancer F 70.53
97 GAIIx cervix cell line cancer F 75.05
98 GAIIx cervix cell line cancer F 76.53
99 HiSeq cervix cell line cancer F 28.20
100 HiSeq cervix cell line cancer F 65.45
101 HiSeq cervix cell line cancer F 71.56
102 HiSeq cervix cell line cancer F 71.93
103 HiSeq cervix cell line cancer F 70.60
104 HiSeq cervix cell line cancer F 71.04
105 HiSeq cervix cell line cancer F 70.04
106 HiSeq cervix cell line cancer F 72.81
107 HiSeq cervix cell line cancer F 70.25
108 HiSeq cervix cell line cancer F 73.39
109 HiSeq ovaries primary cancer F 72.24
110 HiSeq ovaries primary cancer F 74.18
111 HiSeq ovaries primary cancer F 73.99
112 HiSeq ovaries primary cancer F 72.72
113 HiSeq ovaries primary cancer F 74.79
114 HiSeq ovaries primary cancer F 76.82
115 HiSeq ovaries primary cancer F 69.06
116 HiSeq ovaries primary cancer F 76.17
117 HiSeq ovaries primary cancer F 70.27
118 HiSeq ovaries primary cancer F 72.46
119 HiSeq ovaries primary cancer F 69.94
120 HiSeq ovaries primary cancer F 76.62
121 HiSeq ovaries primary cancer F 76.15
122 HiSeq ovaries primary cancer F 72.38
123 HiSeq ovaries primary cancer F 71.08
124 HiSeq ovaries primary cancer F 70.85
125 HiSeq ovaries primary cancer F 67.03
126 HiSeq ovaries primary cancer F 71.25
127 HiSeq ovaries primary cancer F 71.47
128 HiSeq ovaries primary cancer F 73.20
129 GAIIx brain primary cancer M 62.79
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Table A.1: Continued
ID Platform Tissue Origin Disease Gender MP (%)
130 GAIIx brain primary cancer M 72.60
131 GAIIx brain primary cancer F 67.13
132 GAIIx brain primary cancer M 67.96
133 GAIIx brain primary cancer M 62.43
134 GAIIx brain primary cancer M 63.67
135 GAIIx brain primary cancer F 66.44
136 GAIIx brain primary cancer M 63.60
137 GAIIx brain primary cancer M 68.32
138 GAIIx brain primary cancer M 63.30
139 GAIIx brain primary cancer M 61.88
140 GAIIx brain primary cancer M 62.01
141 GAIIx brain primary cancer M 41.84
142 GAIIx brain primary cancer F 42.62
143 GAIIx brain primary cancer M 61.50
144 GAIIx brain primary cancer M 59.55
145 GAIIx brain primary cancer M 62.10
146 GAIIx brain primary cancer M 59.28
147 GAIIx brain primary cancer M 67.33
148 GAIIx brain primary cancer M 65.14
149 GAIIx brain primary cancer F 64.74
150 GAIIx brain primary cancer M 64.43
151 GAIIx brain primary cancer M 64.51
152 GAIIx brain primary cancer M 61.76
153 GAIIx brain primary cancer M 57.75
154 GAIIx brain primary cancer M 59.86
155 GAIIx brain primary cancer F 67.84
156 GAIIx brain primary cancer M 67.67
157 GAIIx brain primary cancer F 70.62
158 GAIIx brain primary cancer M 66.80
159 GAIIx brain primary cancer M 68.06
160 GAIIx brain primary cancer M 61.65
161 GAIIx brain primary cancer M 62.65
162 GAIIx brain primary cancer M 63.52
163 GAIIx brain primary cancer M 66.21
164 GAIIx brain primary cancer F 63.22
165 GAIIx brain primary cancer M 63.62
166 GAIIx brain primary cancer M 63.75
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Table A.1: Continued
ID Platform Tissue Origin Disease Gender MP (%)
167 GAIIx brain primary cancer M 65.47
168 GAIIx brain primary cancer F 65.91
169 GAIIx brain primary cancer M 65.09
170 GAIIx brain primary cancer M 63.00
171 GAIIx brain primary cancer F 62.76
172 GAIIx brain primary cancer M 64.28
173 GAIIx brain primary cancer F 65.77
174 GAIIx brain primary cancer M 67.25
175 GAIIx brain primary cancer F 66.07
176 GAIIx brain primary cancer F 67.27
177 GAIIx brain primary cancer M 69.91
178 GAIIx brain primary cancer M 64.30
179 GAIIx brain primary cancer M 64.62
180 GAIIx brain primary cancer M 67.31
181 GAIIx brain primary cancer M 65.64
182 GAIIx brain primary cancer M 65.76
183 GAIIx brain primary cancer F 68.25
184 GAIIx brain primary cancer M 61.99
185 GAIIx brain primary cancer M 63.75
186 GAIIx brain primary cancer M 61.41
187 GAIIx brain primary cancer M 61.68
188 GAIIx brain primary cancer F 64.04
189 GAIIx brain primary cancer M 69.46
190 GAIIx brain primary cancer M 64.92
191 GAIIx brain primary cancer M 66.29
192 GAIIx brain primary cancer M 66.95
193 GAIIx brain primary cancer M 70.29
194 GAIIx brain primary cancer F 70.96
195 GAIIx brain primary cancer M 62.04
196 GAIIx brain primary cancer F 68.41
197 GAIIx brain primary cancer M 70.76
198 GAIIx brain primary cancer M 67.79
199 HiSeq ascites primary cancer F 71.49
200 HiSeq ascites primary cancer F 73.07
201 HiSeq ascites primary cancer F 66.10
202 HiSeq ascites primary cancer F 69.89
203 HiSeq ascites primary cancer F 67.63
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Table A.1: Continued
ID Platform Tissue Origin Disease Gender MP (%)
204 HiSeq ascites primary cancer F 68.62
205 HiSeq ascites primary cancer F 70.74
206 HiSeq ascites primary cancer F 69.34
207 HiSeq ascites primary cancer F 66.89
208 HiSeq ascites primary cancer F 67.50
209 HiSeq ascites primary cancer F 65.96
210 HiSeq ascites primary cancer F 71.78
211 HiSeq ascites primary cancer F 67.14
212 HiSeq ascites primary cancer F 69.82
213 HiSeq ascites primary cancer F 68.46
214 HiSeq ascites primary cancer F 70.46
215 HiSeq ascites primary cancer F 68.17
216 HiSeq ascites primary cancer F 70.99
217 HiSeq ascites primary cancer F 70.70
218 HiSeq ascites primary cancer F 71.09
219 HiSeq ascites primary cancer F 71.73
220 HiSeq ascites primary cancer F 69.85
221 HiSeq ascites primary cancer F 67.93
222 HiSeq ascites primary cancer F 70.06
223 HiSeq ascites primary cancer F 70.15
224 HiSeq ascites primary cancer F 74.94
225 HiSeq ascites primary cancer F 71.40
226 HiSeq ascites primary cancer F 68.55
227 HiSeq ascites primary cancer F 69.46
228 HiSeq ascites primary cancer F 71.08
229 HiSeq ascites primary cancer F 68.35
230 HiSeq ascites primary cancer F 70.36
231 HiSeq ascites primary cancer F 72.40
232 HiSeq ascites primary cancer F 71.15
233 HiSeq ascites primary cancer F 72.97
234 HiSeq ascites primary cancer F 73.75
235 GAIIx prostate cell line cancer M 63.84
236 GAIIx prostate cell line cancer M 61.72
237 GAIIx prostate cell line cancer M 57.46
238 GAIIx blood plasma primary normal M 66.27
239 GAIIx blood plasma primary cancer M 66.49
240 GAIIx stem cell primary normal M 66.47
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Table A.1: Continued
ID Platform Tissue Origin Disease Gender MP (%)
241 GAIIx kidney primary normal M 60.52
242 GAIIx melanocytes primary normal M 60.76
243 GAIIx kidney primary cancer M 62.77
244 GAIIx kidney primary cancer M 60.81
245 GAIIx basal cell primary cancer M 60.44
246 GAIIx basal cell primary cancer F 57.64
247 GAIIx basal cell primary cancer F 62.19
248 GAIIx basal cell primary cancer F 63.02
249 GAIIx basal cell primary cancer F 70.96
250 GAIIx basal cell primary cancer F 73.39
251 GAIIx basal cell primary cancer M 67.94
252 GAIIx basal cell primary cancer F 58.43
253 GAIIx basal cell primary cancer F 66.57
254 GAIIx monocytes primary normal M 42.24
255 GAIIx nose polyps primary normal M 62.49
256 GAIIx nose polyps primary normal M 55.49
257 GAIIx nose polyps primary normal M 61.92
258 GAIIx breast cell line cancer F 66.87
259 GAIIx breast cell line cancer F 68.00
260 GAIIx breast cell line cancer M 72.84
261 GAIIx colon primary cancer M 64.02
262 GAIIx colon primary cancer M 65.70
263 GAIIx colon primary cancer M 61.80
264 GAIIx colon primary cancer M 59.52
265 GAIIx colon primary cancer F 56.77
266 GAIIx thyroid primary normal F 57.23
267 HiSeq breast primary normal F 72.73
268 HiSeq breast primary normal F 74.05
269 HiSeq breast primary normal F 72.11
270 HiSeq breast primary normal F 77.77
271 HiSeq breast primary normal F 77.01
272 HiSeq breast primary normal F 76.65
273 HiSeq breast primary normal F 76.74
274 HiSeq breast primary normal F 77.35
275 HiSeq breast primary normal F 76.69
276 HiSeq breast primary normal F 78.80
277 HiSeq breast primary normal F 74.80
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Table A.1: Continued
ID Platform Tissue Origin Disease Gender MP (%)
278 HiSeq breast primary normal F 75.30
279 HiSeq breast primary normal F 73.72
280 HiSeq breast primary normal F 70.58
281 HiSeq breast primary normal F 74.52
282 HiSeq breast primary normal F 69.27
283 HiSeq breast primary normal F 77.08
284 HiSeq breast primary normal F 75.11
285 HiSeq breast primary normal F 74.81
286 HiSeq breast primary normal F 75.51
287 HiSeq head & neck primary cancer F 47.77
288 HiSeq head & neck primary cancer F 45.93
289 HiSeq head & neck primary cancer F 46.80
290 HiSeq head & neck primary cancer F 47.56
291 HiSeq head & neck primary cancer F 49.87
292 HiSeq head & neck primary cancer M 45.62
293 HiSeq head & neck primary cancer F 48.19
294 HiSeq head & neck primary cancer M 49.03
295 HiSeq cervix primary cancer F 27.30
296 HiSeq cervix primary cancer F 26.44
297 HiSeq cervix primary cancer F 26.93
298 HiSeq cervix primary cancer F 27.60
299 HiSeq cervix primary cancer F 27.33
300 HiSeq cervix primary cancer F 27.80
301 HiSeq cervix primary cancer F 28.61
302 HiSeq cervix primary cancer F 27.54
303 HiSeq cervix primary cancer F 27.27
304 HiSeq cervix primary cancer F 27.97
305 HiSeq cervix primary cancer F 27.25
306 HiSeq cervix primary cancer F 28.00
307 HiSeq cervix primary cancer F 49.61
308 HiSeq cervix primary cancer F 49.72
309 HiSeq cervix primary cancer F 49.28
310 HiSeq cervix primary cancer F 50.27
311 HiSeq cervix primary cancer F 49.84
312 HiSeq cervix primary cancer F 48.65
313 HiSeq cervix primary cancer F 50.00
314 HiSeq cervix primary cancer F 49.78
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Table A.1: Continued
ID Platform Tissue Origin Disease Gender MP (%)
315 HiSeq cervix primary cancer F 48.22
316 HiSeq cervix primary cancer F 47.74
317 HiSeq cervix primary cancer F 48.80
318 HiSeq cervix primary cancer F 48.32
319 HiSeq cervix primary cancer F 46.64
320 HiSeq cervix primary cancer F 49.49
321 HiSeq cervix primary cancer F 48.47
322 HiSeq cervix primary cancer F 49.27
323 HiSeq cervix primary cancer F 47.85
324 HiSeq cervix primary cancer F 49.45
325 HiSeq cervix primary cancer F 49.50
326 HiSeq cervix primary cancer F 49.21
327 HiSeq cervix primary cancer F 48.73
328 HiSeq cervix primary cancer F 49.43
329 HiSeq cervix primary cancer F 48.83
330 HiSeq cervix primary cancer F 50.19
331 HiSeq cervix primary cancer F 46.53
332 HiSeq cervix primary cancer F 45.77
333 HiSeq cervix primary cancer F 44.93
334 HiSeq cervix primary cancer F 45.33
A.1.2 Additional methods
Here we present the methodology of the data-analytical framework to screen for monoallelic
DNA methylation in sequencing data obtained from MethylCap-seq. In summary, MethylCap-
seq, which combines precipitation and thereby enrichment of methylated DNA-fragments by a
recombinant methyl-binding domain (MBD) with massively parallel sequencing of the isolated
DNA, was used to profile the DNA methylation pattern of 334 human samples, mostly cancer
samples. Preliminary to the sequencing step, the DNA was fragmented to pieces of approximately
200 nucleotides making use of a Covaris S2 instrument. The resulting fragments of the di er-
ent samples were subsequently multiplexed, followed by paired-end sequencing on the Illumina
Genome Analyzer IIx (GAIIx) or the Illumina HiSeq. Depending on the sequencing platform, the
resulting reads had a length of 45 and 50bp, respectively. Upon mapping of sequenced reads and
SNP identification, loci were filtered based on major allele frequency and coverage, and additional
data correction for sequencing errors was performed. Subsequently, the SNP profiles were com-
bined with the methylome profiles to detect regions that display monoallelic DNA methylation. In
the next sections, the global idea and strategy of both the additional sequencing error correction
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and the data-analytical framework will be discussed in detail. The developed approach will also
be illustrated with two hypothetical examples.
A.1.2.1 Data-analytical framework: general discussion
Besides the description of the data preprocessing, the di erent steps of the statistical methodology
and the procedure followed to correct for possible sequencing errors, a global overview as well as
a discussion of the practical implementation will also be presented.
Data preprocessing: mapping and SNP identification The paired-end reads were mapped using
BOWTIE [209] to the human reference genome (NCBI build 37). During the mapping process,
no more than three mismatches were allowed. Based on the SNP database of NCBI (dbSNP,
version 137), in the obtained non-duplicate, uniquely mappable sequence reads the SNPs were
tracked down so that, in addition to the methylome profile, also the SNP profile of the methylated
fragments became available for each sample. Sequencing errors are characterized by their low
frequency of appearance, i.e. a very low frequency of the ‘minor allele’ (= high frequency of the
major allele). Both for computational reasons and to remove possible sequencing errors from
the found SNPs, it was opted to filter the data based on a predetermined maximal frequency for
the major allele (0.9) as well as a minimal total coverage threshold (250 for the X-chromosome,
350 for other chromosomes ≥ number of analyzed samples). Note that real SNPs with such a
low allele frequency and/or coverage contribute very little to the identification of monoallelically
methylated loci (too low power). As a second filter for sequencing errors, an additional data
correction was performed (cf. infra).
Estimation of the allele and genotype frequencies Firstly, by parsing the mapping output and
using dbSNP, the obtained MethylCap-seq data is screened for SNPs. These SNPs make it
possible to discriminate between homo- and heterozygous samples for each locus. Suppose there
are S samples with L loci in which SNPs were found. For each sample s (1 to S) and for each
locus l (1 to L) nsl sequences are observed with nsl Ø 0. In these, there are nsl,t sequences with
a thymine, nsl,c sequences with a cytosine, nsl,a sequences with an adenine and nsl,g sequences
with a guanine for the relevant SNP position (= locus), so that consequently nsl,t + nsl,c + nsl,a
+ nsl,g = nsl. As the human genome is diploid, at least two of these numbers are zero, with the
possible exception of sequencing errors. If for a locus both alleles are observed in a sample, then
this sample is called heterozygous. If on the other hand only one allele is observed, this sample
is called homozygous for this locus. From these observed genotypes, the allele frequencies
can be estimated.
The estimation of these frequencies might however be complicated by a limited coverage for
a specific locus, resulting in heterozygous samples appearing as putative homozygous samples.
When for example both allele A and allele B are present, and both alleles are methylated, it
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might occur that only allele A will be observed due to limited coverage for this locus. However,
ignoring the putatively very limited e ect of sequencing bias on SNP coverage, the observation
of a specific allele can be considered to be the result of a random sampling process. Therefore,
with a su cient amount of samples, errors will be averaged yielding an unbiased estimate of the
allele frequencies. For example, assume that there are 20 heterozygous samples wherein 10 of
the samples the coverage was too low to observe both alleles, A and B. Because every allele has
an equal chance of being picked up, it is expected that in 5 cases only A and in the other 5
cases only B will be observed. If in each case these samples are considered to be homozygous,
the estimated allele frequency (10 AB + 5 AA + 5 BB = 20 A and 20 B) is equal to
the actual allele frequency (20 AB = 20 A and 20 B). When sequencing errors are not taken
into account, real homozygotes will always be observed as homozygotes and thus the estimation
remains correct. The possible extension to three or four alleles in the population doesn’t have a
further impact on the determination of the allele frequencies.
The remainder of this analysis will work with the observed fraction of heterozygotes. Un-
der the null hypothesis, i.e. no presence of monoallelic methylation, using the Hardy-Weinberg
theorem [201], it is possible to calculate the expected genotype frequencies. For the homozy-
gous fractions TT, AA, CC and GG, the resulting theoretically expected genotype fre-
quencies (i.e. the expected genotype frequencies under the null hypothesis) are (nsl,t/nsl)2,
(nsl,a/nsl)2, (nsl,c/nsl)2 and (nsl,g/nsl)2, respectively, while for the di erent x,y heterozygotes this
gives 2*(nsl,x*nsl,y)/(nsl)2.
Additional data correction Candidate SNPs identified in the previous paragraph are either real
SNPs or the result of sequencing errors. An additional data correction step was performed to
reduce noise caused by possible sequencing errors. This correction makes sure that for every
individual sample there are at most two values of nsl,t, nsl,c, nsl,a and nsl,g bigger than zero. For
computational reasons a heuristic approach was chosen rather than an advanced analysis of the
FASTQ quality scores. Remaining variation in the sequence reads, like for example indels, usually
results in the inability to map these reads on the reference genome using BOWTIE. Therefore,
this kind of variation will not be taken into account.
For a particular locus l and a particular sample s, the obtained sequencing data can have a similar
format like one of the following three questionable situations:
• Situation 1: AAAAAAAAAAAAAAAT
In this situation, the data consists of two alleles but one allele is overrepresented (A).
Although the determination of the genotype will result in a heterozygote (AT), this was
most likely a homozygous sample for allele A where allele T was probably the result of a
sequencing error. To correct for these ‘false’ heterozygotes, for every heterozygous sample
two probabilities are calculated: (i) the probability that this sequence list is the result of
a homozygote (ho) in which there is a sequencing error (se) present (Pho&se) and (ii). the
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possibility that this sequence list is indeed the result of a heterozygous (he) sample (sa)
(Phe&sa).
The calculation of Pho&se and Phe&sa goes as follows:
– Pho&se = Pse|ho * Pho
Where:
  Pse|ho = the probability of success (i.e. that you observe this sequence) in a
Bernoulli experiment given the coverage of the allele with the lowest frequency
(= number of successes, here: coverage of allele T), the sample coverage (=
number of trials, here: coverage of allele A + coverage of allele T) and the
possibility of a sequencing error (= hypothesized probability of success). The
sequencing error rate was set to the most conservative (= lowest) value found in
literature, namely 0.25% [211].
  Pho = the probability of having a homozygote in the population (i.e. all samples),
given the population frequency of the most frequent allele in the sample (=
freqmost, here: frequency of allele A). Thus, Pho = (freqmost)2.
– Phe&sa = Psa|he * Phe
Where:
  Psa|he = the probability of success (i.e. that you observe this sequence) in a
Bernoulli experiment given the coverage of the allele with the lowest frequency
(= number of successes, here: coverage of allele T), the sample coverage (=
number of trials, here: coverage of allele A + coverage of allele T) and finally
the possibility of having a heterozygous sample (= hypothesized probability of
success) which was assumed to be 50%.
  Phe = the probability of having a heterozygote in the population (i.e. all samples),
given the frequencies of both alleles (= freq1 and freq2, here: frequencies of alleles
A and T) in the whole population. Thus, Phe = 2*freq1*freq2.
If Pho&se is bigger than Phe&sa the putative sequencing error will be removed and the data
is corrected to AAAAAAAAAAAAAAA.
• Situation 2: AAAAAATTTTTTC
Although this data is obtained from a diploid sample, the resulting genotype is a triploid.
Intuitively, the genotype would be AT, so that also here one detected allele (C) is due
to a sequencing error. These situations are adjusted by removing the nucleotides of the
allele with the lowest coverage in the sample from the obtained sequencing data. Here,
this results in AAAAAATTTTTT and now consists only of two alleles instead of three.
The corresponding genotype is AT. As this is now a (diploid) heterozygote, in a next step,
Pho&se and Phe&sa are also determined for this sequence using the same procedure as the
one described in situation 1.
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• Situation 3: AAAATC
In this situation, again three di erent alleles are picked up, but here the two alleles with
the lowest frequencies (T and C) have an equal coverage. The correction method for
this situation is thus less straightforward than the triploid of situation 2. Nevertheless,
these kinds of dubious situations can be corrected in a likewise manner as for situation 2:
remove the allele which has the lowest allele frequency throughout all the samples (i.e. the
population frequency). The resulting data will now consist of two alleles and again will go
through the same procedure as in situation 1.
Because after each correction round the allele frequencies of the population are updated, an
iterative approach was used. Due to the computational load, this correction procedure of the
data was only performed twice, but in most cases this was already su cient to obtain stable
results. It should also be noted that this procedure is relatively conservative, i.e. the observed
fraction of heterzygotes will likely be overestimated.
Identification of loci with significant monoallelic methylation Taken altogether, the identifica-
tion of SNP loci with significant monoallelic methylation results in finding a significant discrepancy
between the observed and the theoretically expected heterozygous fractions. Indeed, in
case of perfect monoallelic methylation, the observed heterozygous fraction equals zero.
However, due to the low coverage that can occur for some loci, there can be a bias in the
observed fraction of heterozygotes: due to stochastic e ects, only a single allele might be
captured from biallelically methylated samples, resulting in the latter to be observed as homozy-
gous. Note that this e ect does not a ect the estimation of the allele frequencies (cf. supra).
In order to correct for this bias, an iterative sampling procedure is used, where data is simu-
lated under the null hypothesis for the locus l under study. Practically, S genotypes are sampled
from the total pool of possible genotypes with probability weights equal to the theoretically
expected genotypes for l. Subsequently, the S observed coverages for locus l are permuted
and attributed to the S created genotypes. For each created heterozygous genotype, an amount
of alleles equal to the attributed coverage is sampled from both alleles (with equal chance). This
sampling procedure will result in a lower amount of heterozygotes in these coverage adjusted
expected genotype fractions. By using this coverage filter and obtaining the coverage ad-
justed expected genotype frequencies, the bias that is intrinsically present in the observed
data is also introduced in the frequencies of the theoretical expected genotypes.
This sampling procedure was conducted in two phases, with 1,000 and 1,000,000 iterations,
respectively. Subsequently, with the obtained coverage adjusted expected heterozygous
fractions (e.g. 1,000 or 1,000,000 data points) a null distribution is made. If for a specific
locus the observed heterozygous fraction shows a significant discrepancy with, and thus will
be smaller than, the coverage adjusted expected heterozyous fraction, this locus will be
considered as monoallelically methylated.
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Overview and practical implementation All things considered, this leads to the following sta-
tistical test for locus l, for which two examples can be viewed in section A.1.2.2:
• For all S samples, determine the observed allele frequencies and the total coverage for locus
l. In case these both su ce with respect to the predetermined thresholds, proceed to the
next step, if not: proceed with the next locus.
• For each sample s, determine the coverage for locus l (Csl) and perform the additional data
correction .
• Determine the observed fraction of heterozygotes.
• Based on the allele frequencies, calculate the theoretically expected genotype frequen-
cies.
• Subsequently, repeat m times:
– For s going from 1 to S:
  Select a random genotype according to chances equal to the theoretical genotype
frequencies.
  If the selected genotype is homozygous, s = s + 1.
  Else, if the selected genotype is heterozygous, select from both alleles (here A
and B) Csl alleles, with equal chances for A and B. When Csl is low, it is expected
that a fraction of the heterozygotes will be observed as homozygotes due to the
fact that by coincidence one of both alleles will never be picked. Thus, it is in
this step that the coverage dependent bias, present in the observed fraction of
heterozygotes, is also introduced in the theoretically expected fraction.
– Determine the coverage adjusted expected heterozygous fraction.
• Finally, with the aid of the m coverage adjusted expected heterozygous fractions, it is
possible to construct a null distribution, calculate a corresponding P-value for the observed
frequency of heterozygotes and ultimately observe a possible significant discrepancy and
thus the presence of monoallelic DNA methylation.
This new statistical methodology was developed in the R statistical environment (R 2.15.2). In
a first stage, the procedure was executed with 1,000 iterations (= m). For loci with a P-value of
0.005 or smaller the analysis was performed a second time, but now with 1,000,000 iterations. If
the final P-value was smaller than the P-value corresponding with a false discovery rate (FDR)
of 0.1, the monoallelic methylation on this SNP locus was called significant.
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A.1.2.2 Examples
Here, two hypothetical examples are presented to provide further insight into the data-analytical
framework. These examples don’t consider the additional preprocessing steps of the data (filtering
and correction) but only illustrate the strategy explained in previous sections. The first example
involves a situation where there is monoallelic DNA methylation present at the hypothetical locus,
whereas the second example illustrates the same procedure but for a situation with biallelic DNA
methylation.
Example 1: presence of monoallelic DNA methylation Suppose that for locus l there are
fourteen samples available, for which the following information is picked up (see Table A.2):
Table A.2: Hypothetically detected nucleotides for each sample at locus l.
Sample Locus l Sample Locus l
1 AAAA 8 AA
2 A 9 TTTTT
3 TTT 10 AAA
4 AA 11 AA
5 AAAAAAA 12 TT
6 A 13 AAA
7 AAA 14 TTT
Taking into account that if in a sample only one allele is detected, this sample is considered
homozygous (despite the possible low coverage), the observed genotypes are shown in Table
A.3:
Table A.3: Observed genotypes per sample.
Sample Locus l Sample Locus l
1 AA 8 AA
2 AA 9 TT
3 TT 10 AA
4 AA 11 AA
5 AA 12 TT
6 AA 13 AA
7 AA 14 TT
Apparently, the observed heterozygous fraction is zero in this set-up. Subsequently, based on
these observed genotypes, the allele frequencies can be determined (p = frequency of A; q =
frequency of T).
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Number of nucleotides = nsl = 28
Prevalence of A = nsl,a = 20
Prevalence of T = nsl,t = 8
æ p = 2028 en q = 828
With these allele frequencies and using the Hardy-Weinberg theorem, the theoretically expected
genotype frequencies are calculated.
AA æ p2 = (2028)2 = 400784
TT æ q2 = ( 828)2 = 64784
AT æ 2pq = 2*2028* 828 = 320784 ƒ 25
With the theoretically expected genotype frequencies it is easy to determine the theoretically
expected genotypes: they are randomly chosen according to possibilities equal to the theo-
retically expected genotype frequencies. Table A.4 shows the resulting theoretically expected
genotypes for five of those sampling procedures.
Table A.4: Theoretically expected genotypes resulting from five sampling procedures.
Sampling 1 Sampling 2 Sampling 3 Sampling 4 Sampling 5
1 AT AA AA AA AT
2 AA TT AA AT AA
3 AA AT AT AT AT
4 TT AT TT AT AA
5 AA AA TT TT AA
6 AT AT TT AA AA
7 AA AT AA AT TT
8 AT AT AA TT AT
9 AA AA AA AA AT
10 AT AA AA AT AA
11 AA AA TT AT AA
12 AA AT AT AT AT
13 AA AT AT AT TT
14 TT AT AA AT AA
The order in which these genotypes are presented is of no importance and hence is at random.
As a result, the theoretically expected heterozygous fraction for these five samplings is 414 ,
8
14 , 314 , 914 , 514 , respectively, and are all bigger than the observed heterozygous fraction.
As explained in the previous paragraphs, now the coverage adjusted expected genotypes are
determined. This is achieved by introducing a similar coverage bias in the theoretically expected
genotypes. For the fourteen samples, the observed coverages are 4, 1, 3, 2, 7, 1, 3, 2, 5, 3, 2, 2,
3 and 3, respectively. These coverages are for every sampling iteration randomly assigned to each
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one of the theoretically expected genotypes. Once more, the order in which these coverages are
assigned is of no importance. For example, take the theoretically expected genotypes of sampling
1 in Table A.4 and assign each of the observed coverages to one of the genotypes (see columns
1 and 2 of Table A.5). Based on these coverages, alleles are sampled from the corresponding
genotype where each has an even chance of being selected. A possible outcome of this allele
sampling is shown in the third column of Table A.5. From this outcome it is now possible to
determine the coverage adjusted expected genotypes (last column of Table A.5).
Table A.5: Rendering of the theoretically expected genotypes of sampling 1 from Table A.4, the
assigned coverages, the outcome of the allele sampling as well as the coverage adjusted expected
genotypes.
Theoretically Assigned Possible Coverage adjusted
expected coverage outcome of expected
genotypes allele sampling genotypes
AT 4 AATA AT
AA 1 A AA
AA 3 AAA AA
TT 2 TT TT
AA 7 AAAAAAA AA
AT 1 A AA
AA 3 AAA AA
AT 2 AT AT
AA 5 AAAAA AA
AT 3 TTT TT
AA 2 AA AA
AA 2 AA AA
AA 3 AAA AA
TT 3 TTT TT
From this table it is clear that in this situation the coverage adjusted expected heterozygous frac-
tion is 214 and hence is smaller than the theoretically expected heterozygous fraction of sampling
1 ( 414). The coverage adjusted expected fraction of heterozygotes can now be compared to the
observed heterozygous fraction. In order to establish the presence of monoallelic methylation,
the observed heterozygous fraction has to be smaller than the coverage adjusted expected het-
erozygous fraction, which is true for this example. To settle this in a more liable and statistical
manner, the procedure starting from the step where the theoretically expected genotypes are
determined out of the theoretically expected genotype frequencies (Table A.4), till the final step
including the determination of the coverage adjusted expected genotypes, is repeated m times.
This way it is feasible to respectively construct a null distribution of the coverage adjusted ex-
pected heterozygous fraction, calculate a corresponding P-value for the observed heterozygous
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fraction and finally determine the presence or absence of monoallelic DNA methylation. If the P-
value is smaller than a selected FDR, the monoallelic methylation of the locus is called significant.
For these fourteen samples and using 1,000 iterations, our methodology resulted in a P-value
of 0.016. The corresponding null distribution of the coverage adjusted expected heterozygous
fractions is shown in Figure A.1.
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Figure A.1: Null distribution of the coverage adjusted expected heterozygous fraction for Example
1 after 1,000 iterations.
Example 2: absence of monoallelic DNA methylation In this example the same procedure will
be used as in the previous example, but now for a situation in which there is no monoallelic DNA
methylation present at the hypothetical locus. Assume that the fourteen samples of locus l hold
the following information (see Table A.6):
Table A.6: Hypothetically detected nucleotides for each sample at locus l.
Sample Locus l Sample Locus l
1 AATA 8 AT
2 TTT 9 TTTAA
3 T 10 AAA
4 AA 11 AT
5 AAATTTT 12 TT
6 ATAA 13 AAT
7 TTT 14 TTT
The corresponding observed genotypes are illustrated in Table A.7.
In this situation, the observed heterozygous fraction is equal to 714 = 12 . Based on these
observed genotypes the allele frequencies can be determined (p = frequency of A; q = frequency
of T).
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Table A.7: Observed genotypes per sample.
Sample Locus l Sample Locus l
1 AT 8 AT
2 TT 9 AT
3 TT 10 AA
4 AA 11 AT
5 AT 12 TT
6 AT 13 AT
7 TT 14 TT
Number of nucleotides = nsl = 28
Prevalence of A = nsl,a = 11
Prevalence of T = nsl,t = 17
æ p = 1128 and q = 1728
In the next step, the theoretically expected frequencies of the genotypes are calculated.
AA æ p2 = (1128)2 = 121784
TT æ q2 = (1728)2 = 289784
AT æ 2pq = 2*1128*1728 = 374784
Subsequently, the theoretically expected genotypes are determined. These are randomly cho-
sen according to chances that are equal to the theoretically expected genotype frequencies. Table
A.8 lists the theoretically expected genotypes resulting from five of those sampling procedures.
Thus, the theoretically expected heterozygous fractions are 914 , 414 , 814 , 914 and 514 , respectively.
For this example, the observed coverages are 4, 3, 1, 2, 7, 4, 3, 2, 5, 3, 2, 2, 3 and 3, respectively,
and as in Example 1, these are now for each sampling procedure randomly assigned to one of the
theoretically expected genotypes. The first two columns of Table A.9 show a possible result of this
random assignment for the theoretically expected genotypes of sampling 1 of Table A.8. Taking
these coverages into account, alleles are sampled from the theoretically expected genotypes where
each allele has an even chance of being selected (see third column of Table A.9). Finally, the
last column of Table A.9 shows the corresponding coverage adjusted expected genotypes of
these sampled sequences.
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Table A.8: Theoretically expected genotypes after five sampling procedures.
Sampling 1 Sampling 2 Sampling 3 Sampling 4 Sampling 5
1 TT TT TT AT AA
2 AT TT TT AA AT
3 AT AA AT AT AT
4 TT TT AT TT AT
5 AT AT AT AT AA
6 AT AT TT AT TT
7 AT TT AT TT AT
8 AA TT AT AT TT
9 AT AA AT AT AT
10 AT TT TT AT AA
11 TT AA TT TT TT
12 AT AA AT AT TT
13 TT AT AT AA TT
14 AT AT TT AT TT
Table A.9: Rendering of the theoretically expected genotypes, the assigned coverages, the outcome
of the sampling procedure as well as the coverage adjusted expected genotypes.
Theoretically Assigned Possible Coverage adjusted
expected coverage outcome of expected
genotypes allele sampling genotypes
TT 4 TTTT TT
AT 3 AAT AT
AT 1 A AA
TT 2 TT TT
AT 7 AATATTA AT
AT 4 TAAT AT
AT 3 ATT AT
AA 2 AA AA
AT 5 TTATA AT
AT 3 TAT AT
TT 2 TT TT
AT 2 AA AA
TT 3 TTT TT
AT 3 TTA AT
In this example, the coverage adjusted expected heterozygous fraction is equal to 714 ,
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again smaller than the theoretically expected heterozygous fraction of sampling 1 ( 914). The
steps starting from the determination of the theoretically expected genotypes till the step where
the coverage adjusted expected heterozygous fraction is determined, are repeated m times so
that again a null distribution can be constructed from these m coverage adjusted expected
heterozygous fractions. From this null distribution, a corresponding P-value can be obtained
for the observed heterozygous fraction. For this example, the resulting null distribution of the
coverage adjusted expected heterozygous fractions after 1,000 iterations is shown in Figure A.2.
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Figure A.2: Null distribution of the coverage adjusted expected heterozygous fraction for Example
2 after 1,000 iterations.
The final P-value of the observed heterozygous fraction is 0.953. The monoallelic methylation of
this locus is consequently not proven to be significantly present and is assumed to be biallelically
methylated.
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A.1.3 WGBS datasets
Table A.10: Summary of the 14 publicly available whole-genome bisulfite sequencing data sets
with their name, description and GEO accession numbers, respectively.
ID Sample name Sample description GEO/SRA ID
1 colon colon adjacent normal GSE46644
2 colonTumor colon primary tumor GSE46644
3 cortexNormal1 mid frontal cortex normal GSE46644
4 cortexNormal2 mid frontal cortex normal GSE46644
5 cortexAD1 mid frontal cortex alzheimer GSE46644
6 cortexAD2 mid frontal cortex alzheimer GSE46644
7 fFF newborn foreskin fibroblasts SRX015769,SRX015770,
SRX015771,SRX015772
8 IMR90 IMR90 GSE46644
9 HepG2 HepG2 GSE46644
10 HSCP HSCP SRX096521,SRX096518
11 bcell bcell SRX096520,SRX096517
12 dMesenchy H1 derived mesenchymal stem cells SRX116603,SRX116604
13 dMEEN H1+BMP4 derived mesendoderm cells GSM818003,GSM818004,
GSM818005,GSM818006
14 dNPC H1 derived neuronal progenitor cells GSM675542,GSM675543,
GSM675544,GSM675545,GSM675546
A.1.4 Illumina Human Body Map 2.0
Table A.11: Illumina Human BodyMap 2.0. Sample description of RNA-Seq of 16 human individual tissues. ASE genes 1: genes with Ø 1 variant
site showing significant deviation from equal allelic expression. ASE genes 2: genes with Ø 2 variant sites showing significant deviation from equal
allelic expression.
uniquely significant
Source Age #raw mapped # variant variant ASE ASE
Name Organism (years) Sex Ethnic Tissue reads reads (%) sites sites (fdr 1%) genes 1 genes 2
HCT20142 Homo Sapiens 60 female Caucasian kidney 80397337 72.31 13091 2974 1684 784
HCT20143 Homo Sapiens 77 male Caucasian heart 82918784 77.75 15431 3997 2121 1070
HCT20144 Homo Sapiens 37 male Caucasian liver 80048623 73.23 10416 2850 1488 739
HCT20145 Homo Sapiens 56 male Caucasian lung 79296905 75.72 10953 2755 1462 677
HCT20146 Homo Sapiens 86 female Caucasian lymph node 82078157 72.64 9985 2246 1208 563
HCT20147 Homo Sapiens 73 male Caucasian prostate 82334076 77.00 14348 3142 1858 845
HCT20148 Homo Sapiens 77 male Caucasian skeletal muscle 82111139 75.55 6323 1825 944 444
HCT20149 Homo Sapiens 58 male Caucasian leukocyte 81217148 76.58 10006 2634 1430 681
HCT20150 Homo Sapiens 47 female African American ovary 80946260 74.73 27693 6416 3531 1822
HCT20151 Homo Sapiens 19 male Caucasian testis 81836199 76.00 19730 4973 3073 1467
HCT20152 Homo Sapiens 60 female Caucasian thyroid 81912887 74.03 19093 4838 2791 1383
HCT20158 Homo Sapiens 73 female Caucasian adipose 77300072 71.51 14363 4165 2180 1044
HCT20159 Homo Sapiens 60 male Caucasian adrenal 74472871 73.39 18230 4618 2537 1266
HCT20160 Homo Sapiens 77 female Caucasian brain 73513047 78.07 18797 15488 6749 4292
HCT20161 Homo Sapiens 29 female Caucasian breast 75862215 72.84 15645 4361 2367 1191
HCT20162 Homo Sapiens 68 female Caucasian colon 82437443 73.68 11234 2947 1631 780
76.50 235338 70229 37054 19048
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A.1.5 SNP tracing and data filtering
Table A.12: Amount of SNP positions that overlapped with SNV positions of dbSNP (Overlap
dbSNP) and the amount of retained loci after filtering based on sample coverage and the major
allele frequency (fSNPs) per chromosome.
Chr Overlap dbSNP fSNPs Relative %
1 1587302 37259 2.35
2 1555395 34184 2.20
3 1260034 22065 1.75
4 1172419 26442 2.26
5 1111028 20500 1.85
6 1157413 25708 2.22
7 1128561 31450 2.79
8 1011641 20868 2.06
9 847923 19908 2.35
10 977071 30138 3.08
11 949203 19255 2.03
12 918704 20484 2.23
13 609862 11709 1.92
14 615814 12297 2.00
15 588324 11829 2.01
16 778319 29432 3.78
17 703214 24824 3.53
18 504029 11783 2.34
19 646421 25066 3.88
20 529745 16201 3.06
21 302657 11977 3.96
22 371385 15012 4.04
X 524426 7699 1.47
TOTAL 19850890 486090 2.45
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A.1.6 Detection of monoallelically methylated loci
Figure A.3: Genomic distribution of the 80 loci for which the monoallelic DNA methylation was
called significant. Chromosomes are shown on a circular representation and divided in regions of
5,000,000bp. The inner circle shows the histogram of all SNPs found in a specific region, whereas
the outer circle shows the histograms of the significant SNPs in that same region.
A.1.7 Functional location
Table A.13: Functional annotation of the 80 loci with significant monoallelic DNA methylation.
Next to the functional annotation, the corresponding (Ensembl) gene ID is shown (GeneID).
Chr SNP position Functional annotation GeneID
1 90844629 INTERGENIC
1 90844662 INTERGENIC
1 228757936 PROMOTER ENSG00000200624
1 228757936 INTRON ENSG00000183929
2 69347244 INTRON ENSG00000169604
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Table A.13: Continued
Chr SNP position Functional annotation GeneID
2 133018988 PROMOTER ENSG00000233786
2 133020085 EXON ENSG00000233786
2 133023691 INTERGENIC
2 133023703 INTERGENIC
2 133023711 INTERGENIC
2 133029769 INTERGENIC
2 133032580 INTERGENIC
2 133033524 INTERGENIC
2 207122438 INTERGENIC
3 5156139 INTERGENIC
3 5156149 INTERGENIC
3 162561619 INTERGENIC
3 196722009 INTRON ENSG00000163975
4 7635629 INTRON ENSG00000184985
4 49099668 INTERGENIC
4 89618837 INTRON ENSG00000138641
4 89618837 EXON ENSG00000177432
5 178650557 INTRON ENSG00000087116
6 3849305 PROMOTER ENSG00000145945
6 3849305 INTRON ENSG00000238158
6 168784228 INTERGENIC
6 170055316 INTRON ENSG00000184465
7 19534519 INTRON ENSG00000223838
7 56437045 INTERGENIC
7 57554497 INTERGENIC
7 61080848 INTERGENIC
7 64895556 INTERGENIC
7 157923845 INTRON ENGS00000155093
7 158041458 INTRON ENSG00000155093
7 158041459 INTRON ENSG00000155093
10 39086215 INTERGENIC
10 39086885 INTERGENIC
10 39086905 INTERGENIC
10 39086907 INTERGENIC
10 42800026 INTERGENIC
10 102279294 INTRON ENSG00000075826
10 102279294 INTRON ENSG00000255339
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Table A.13: Continued
Chr SNP position Functional annotation GeneID
10 102279294 INTRON ENSG00000166136
10 102279295 INTRON ENSG00000075826
10 102279295 INTRON ENSG00000255339
10 102279295 INTRON ENSG00000166136
11 2019496 PROMOTER ENSG00000130600
11 2019496 INTRON ENSG00000130600
11 2019496 PROMOTER ENSG00000211502
11 2019618 PROMOTER ENSG00000130600
11 2019618 INTRON ENSG00000130600
11 2019618 PROMOTER ENSG00000211502
11 2021164 INTRON ENSG00000130600
11 2021206 INTRON ENSG00000130600
11 2021980 INTRON ENSG00000130600
11 2022023 INTRON ENSG00000130600
11 2721568 PROMOTER ENSG00000258492
11 2721568 INTRON ENSG00000053918
11 51579458 INTERGENIC
13 31481030 INTRON ENSG00000102802
13 85969909 INTRON ENSG00000226317
13 85969941 INTRON ENSG00000226317
14 88237822 INTRON ENSG00000258807
15 25123472 INTRON ENSG00000128739
15 25201659 INTRON ENSG00000128739
15 25201659 INTRON ENSG00000214265
16 3493495 EXON ENSG00000167981
16 3493495 PROMOTER ENSG00000122390
16 11415785 INTRON ENSG00000175643
16 33960762 PROMOTER ENSG00000207986
16 46411729 INTERGENIC
17 22252007 INTERGENIC
17 22259640 INTERGENIC
17 31340444 EXON ENSG00000108684
18 18517029 INTERGENIC
19 15279411 INTRON ENSG00000074181
19 24184564 PROMOTER ENSG00000251948
19 54040861 PROMOTER ENSG00000130844
19 54040861 INTRON ENSG00000130844
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Table A.13: Continued
Chr SNP position Functional annotation GeneID
19 54040861 EXON ENSG00000130844
19 54041242 PROMOTER ENSG00000130844
19 54041242 INTRON ENSG00000130844
19 54057156 INTRON ENSG00000130844
19 54057156 PROMOTER ENSG00000130844
19 54057515 INTRON ENSG00000130844
19 54057515 PROMOTER ENSG00000130844
19 54057777 INTRON ENSG00000130844
19 54057777 PROMOTER ENSG00000130844
19 57350463 INTRON ENSG00000198300
19 57350463 INTRON ENSG00000259486
20 55658479 INTERGENIC
20 55658481 INTERGENIC
20 57415110 INTRON ENSG00000235590
20 57415110 EXON ENSG00000235590
20 57415110 PROMOTER ENSG00000087460
20 57415110 EXON ENSG00000087460
20 57426449 PROMOTER ENSG00000235590
20 57426449 PROMOTER ENSG00000087460
20 57426449 INTRON ENSG00000087460
20 57426726 PROMOTER ENSG00000235590
20 57426726 PROMOTER ENSG00000087460
20 57426726 INTRON ENSG00000087460
20 57427132 PROMOTER ENSG00000235590
20 57427132 PROMOTER ENSG00000087460
20 57427132 INTRON ENSG00000087460
20 57431165 INTRON ENSG00000087460
20 57431165 EXON ENSG00000087460
21 40757887 INTRON ENSG00000160183
21 40757887 INTRON ENSG00000182093
21 40757887 PROMOTER ENSG00000182093
21 44011806 INTRON ENSG00000183486
22 42078666 PROMOTER ENSG00000100138
22 42078666 INTRON ENSG00000100138
22 49077801 INTRON ENSG00000219438
A.2.2 Allele-specific expression validation
Table A.14: Validation of allele-specific expression (ASE). Results are shown for the 28 genes with one (or more) monoallelic methylated SNP(s) in their genic regions and with at least 1 variant site showing
a significant deviation from equal allelic expression. 7 genes exclusively show ASE in one or multiple tissues, 14 genes have both ASE and biallelic expression (BE) in di erent tissues and 7 genes only show BE. The
following columns are indicated: (Ensembl) Gene ID, Gene symbol, number and annotation of tissues for which ASE/BE could be examined (# Tissues and Tissues, respectively) and the Type of expression found for
these tissues (ASE of BE). *: known imprinted region; **: predicted imprinted genomic region.
GeneID Gene symbol # Tissues Tissues Type of expression
ENSG00000219438 FAM19A5 1 testis ASE
ENSG00000255339 NDUFB8 1 heart ASE
ENSG00000198300 PEG3/ZIM2* 3 brain,ovary,testis, ASE
ENSG00000169604 ANTXR1 7 adipose,brain,colon,lung,ovary,testis,thyroid, ASE
ENSG00000166136 NDUFB8 10 adipose,adrenal,brain,breast,colon,heart,ovary,prostate,testis,thyroid, ASE
ENSG00000130600 H19* 11 adipose,adrenal,breast,colon,heart,kidney,ovary,prostate,skeletal_muscle,testis,thyroid, ASE
ENSG00000087460 GNAS* 16 adipose,adrenal,brain,breast,colon,heart, ASE
kidney,leukocyte,liver,lung,lymph_node,ovary,prostate,skeletal_muscle,testis,thyroid,
ENSG00000175643 RMI2 1 testis ASE
1 ovary BE
ENSG00000184985 SORCS2 1 brain ASE
1 testis BE
ENSG00000238158 RP11-420L9.4.1 1 thyroid ASE
1 testis BE
ENSG00000075826 SEC31B 1 heart ASE
1 testis BE
ENSG00000122390 NAA60** 1 brain ASE
11 adipose,adrenal,breast,colon,heart,kidney,liver,lymph_node,ovary,testis,thyroid, BE
ENSG00000138641 HERC3 1 brain ASE
8 adipose,adrenal,colon,heart,leukocyte,lung,ovary,prostate, BE
ENSG00000155093 PTPRN2 1 brain ASE
2 kidney,prostate, BE
ENSG00000183486 MX2 2 adipose,leukocyte, ASE
4 breast,ovary,testis,thyroid, BE
ENSG00000130844 ZNF331 2 brain,ovary, ASE
2 adrenal,lung, BE
ENSG00000182093 WRB 3 brain,liver,testis, ASE
6 adrenal,heart,leukocyte,ovary,skeletal_muscle,thyroid, BE
ENSG00000214265 SNURF* 4 brain,lymph_node,prostate,testis, ASE
2 heart,thyroid, BE
ENSG00000128739 SNRPN* 7 adrenal,colon,leukocyte,lymph_node,ovary,prostate,testis, ASE
1 brain BE
ENSG00000074181 NOTCH3 8 adipose,adrenal,breast,heart, lymph_node,ovary,testis,thyroid, ASE
2 colon,skeletal_muscle, BE
ENSG00000100138 NHP2L1 15 adipose,adrenal,brain,breast, ASE
colon,heart,kidney,leukocyte,liver,lung,lymph_node, ovary,prostate,testis,thyroid,
1 skeletal muscle BE
ENSG00000235590 GNAS-AS1* 1 testis BE
ENSG00000184465 WDR27 1 testis BE
ENSG00000160183 TMPRSS3 1 thyroid BE
ENSG00000102802 C13-ORF33 1 ovary BE
ENSG00000163975 MFI2 2 adipose,breast, BE
ENSG00000053918 KCNQ1* 3 prostate,testis,thyroid, BE
ENSG00000087116 ADAMTS2 3 adipose,breast,ovary, BE
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A.2 A mixture model for the omics-based identification of monoal-
lelically expressed loci and their deregulation in cancer
A.2.1 Samples
To detect (di erential) imprinting, samples from the breast cancer RNA-seq data from The Cancer
Genome Atlas (TCGA) were used. The aligned RNA-seq data for 113 healthy control samples and
506 breast cancer samples were downloaded from the TCGA data portal. The expression subtypes
(8 normal-like samples, 92 basal-like, 227 luminal A, 122 luminal B and 57 Her2-enriched) for all
cancer samples were obtained from the UCSC cancer genome browser.
A.2.3 Data preprocessing
In summary, the GDC used FASTQ or BAM formatted sequence data to generate analysis data.
BAM files were first validated with Picard Tools (ValidateSamFile function) [153], after which
they were split and converted to FASTQ files - taking into account di erent read groups - using
Biobambam’s bamtofastq functionality [344]. Next, FASTQC [152] was used in order to check
read qualities on these converted or directly submitted FASTQ files. If necessary, 3’ and 5’ read
ends were soft-clipped to remove low quality bases. In a next-step, data-type specific alignment
pipelines realigned sequence reads to the same human reference genome (GRCh37) using the
STAR mapper [160] for RNA-seq data. After alignment, additional quality control was performed
with RNA-SeQC [328]. To ensure best practice of data generation, the GDC collects both raw
read quality measurements as well as multiple post-alignment quality control metrics, such as
number of (uniquely) mapped reads, duplicates and properly paired reads (Figure A.4).
A.2.4 Detection of (differential) imprinting
A.2.4.1 Additional data filtering using an empirical Bayes approach
As dbSNP was used for SNP calling, the dbSNP alleles were chosen as the two standard alleles.
In case dbSNP contained three or more alleles for a particular SNP position, the standard alleles
were chosen as the two dbSNP alleles with the highest mean allele frequencies for that locus over
all samples. A quality filtering procedure was included to retain only those samples featuring one
(homoyzgous) or both (heterozygous) standard alleles (= reference alleles defined by dbSNP for
that particular SNP position). By default, samples already containing the two standard alleles as
most frequent alleles were retained, whereas samples where the allele with the highest frequency
was not a standard allele were filtered out. However, for samples characterized by a non-standard
allele as the second most abundant allele, an empirical Bayes approach was implemented to filter
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Figure A.4: RNA-seq processing workflow used by GDC for the TCGA data. See main text for
an explanation of the di erent steps.
out putative heterozygous samples (one standard allele and one non-standard allele) yet keeping
homozygous samples (one standard allele and sequencing errors). This procedure goes as follows:
(i) • The posterior probability of obtaining a specific observation given a heterozygous sample
was determined using a multinomial distribution:
P (data|heterozygous) = M(data;x1, x2, x3, x4) (A.1)
with both x1 and x2 equal to the sum of the two highest allele frequencies of the
sample divided by two, and x3 and x4 are equal to the sum of the two lowest sample
allele frequencies divided by two. Note that the two alleles corresponding to these
latter two frequencies could only be obtained due to sequencing errors.
• The probability that the sample is heterozygous is calculated as:
P (heterozygote) = 2pq (A.2)
with p and q the mean allele frequencies over all samples of the standard and non-
standard allele, respectively.
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(ii) • Similar to the approach for heterozygous samples, the posterior probability of the
obtained nucleotide sequence in case of a homozygous sample is again defined with a
multinomial distribution:
P (data|homozygous) = M(data;x1, x2, x3, x4) (A.3)
However, here only one allele is genuine while the other three are the result of sequenc-
ing errors. Therefore, x2, x3, x4 are determined as the sum of the lowest three allele
frequencies divided by three, while x1 represents the allele frequency of the ‘true’,
standard allele (having the highest sample allele frequency).
• The probability of the sample originally being homozygous is next defined as:
P (homozygote) = p2 (A.4)
as in formula A.2, p again represents the mean allele frequency of the standard allele
over all samples.
(iii) Finally, following criterion was used to identify putative heterozygous samples:
P (heterozygote|data) Ø P (homozygote|data) (A.5)
Using Bayes’ theorem and knowing that P (data) is equal for both P (heterozygote|data)
and P (homozygote|data), this can also be written as:
P (data|heterozygous)úP (heterozygous) Ø P (data|homozygous)úP (homozygous) (A.6)
Next, identified putative heterozygous samples are removed from the dataset for the locus under
study.
A.2.4.2 Additional data filtering using a goodness of fit test
SNPs that already passed the basic filtering steps were subjected to two final checks based
on two methods assessing their goodness of fit in the model, independent of the presence of
(partial) imprinting. This approach is particularly aimed to remove loci exhibiting good sequencing
characteristics, yet with properties that indicate deviation from the standard genetic models. This
may be due to technical (e.g. mismapping) but also biological (e.g. presence of SNP dependent
expression di erences) reasons.
As a first control, the ‰2 test is used for goodness of fit. Though the exact distribution depends
on the level of imprinting, this is not the case for the fractions of samples with respectively a
higher reference allele (expected p2 + p*q) resp. alternative allele count (expected q2 + p*q).
Upon comparison of the observed and expected sample counts using the ‰2 test, only loci with
a resulting P-value > 0.05 were retained.
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Next to a ‰2 test, likelihoods are also a benchmark for goodness of fit. As likelihoods strongly
depend on coverage (e.g. impact binomial coe cient), the likelihood of each individual measure-
ment was multiplied by its coverage+1. The mean of these corrected log-likelihoods was next
used as measure for the goodness of fit: loci with a mean Æ 1.2 were filtered out. Though
empirical in nature, this filter setting largely removed remaining loci featured by aberrant allelic
distributions.
A.2.4.3 An introduction to Likelihood Ratio Tests
The ‘likelihood’ of a sample can be defined as the likeliness, given the data, to observe this specific
sample as a function of its parameter values [329, 330]. In MLE, the goal is to find values for
the parameters (or coe cients) that maximize the value of the likelihood function, that is, to
find the set of parameter estimates that make the observed data most likely [331]. Thus, the
data are fixed and the parameter estimates are continuously changed in order to maximize the
likelihood. Typically, the log likelihood function is preferred, because it is easier to work with
(products become summations).
The LRT is a statistical test often used to compare two models, most commonly when both the
null and alternative hypotheses are composite (= nested), i.e. when the former is a special case
of the latter. The test is based on the likelihood ratio (or its logarithm)  . Consider a sample
X = (x1,x2,...,xn,) depending on a set of parameters ◊1, ◊2, ..., ◊m in parameter space  . The
likelihood ratio   is then defined as [247]:
 (X) = L(◊ˆ0|X)L(◊ˆ1|X)
= f(X|◊ˆ0)
f(X|◊ˆ1)
= sup 0L(◊0|X))
sup L(◊|X))
(A.7)
Where ◊ˆ0 is the MLE of ◊ in parameter space  0 and ◊ˆ1 is the MLE of ◊ in parameter space
 . Note that  0 µ  . f(X|◊ˆ0) and f(X|◊ˆ1) represent the probability mass functions (PMF) of
the first and second model, respectively. The corresponding null and alternative hypotheses for
obtaining the best model are:
H0 : ◊ œ  0
H1 : ◊ œ  
(A.8)
Testing H0 against H1 can now be done using the LRT [248]. If the two models are nested, the
test statistic ≠2ln (X) can be used: ≠2ln (X) is then asymptotically ‰2 distributed with q
degrees of freedom, where q is the di erence between the number of free parameters under H0
and H1. The null hypothesis H0 will be rejected if ≠2ln (X) > c with c = ‰2q,1≠– [247, 331].
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A.2.4.4 PMF calculation: population allele frequency, binomial test and sequencing
error rate
In our framework, the PMF is defined as the probability of observing specific coverages for
each allele for a specific SNP locus and established as a mixture of genotype-dependent binomial
distributions with weights corresponding to the by Hardy-Weinberg expected chances [201]. When
considering two possible alleles A and T for a specific SNP position, and taking into account
sequencing error rates, degree of imprinting as well as the specific genotype, the PMF becomes:
PMF (x) = P 2AB(x; pA = 1≠ SE, pT = SE) + P 2TB(x; pA = SE, pT = 1≠ SE)
+PAPTB(x; pA =
0.5≠ i2
1≠ i2
(1≠ SE) + 0.51≠ i2
SE, pT =
0.5
1≠ i2
(1≠ SE) + 0.5≠
i
2
1≠ i2
SE)
+PAPTB(x; pA =
0.5
1≠ i2
(1≠ SE) + 0.5≠
i
2
1≠ i2
SE, pT =
0.5≠ i2
1≠ i2
(1≠ SE) + 0.51≠ i2
SE)
(A.9)
With:
• x the coverages for alleles A and T, i.e. x = (nA, nT )
• PA and PT the population allele frequencies for a specific locus over all samples (obtained
by SeqEM)
• SE the sequencing error rate (obtained by SeqEM)
• i the degree of imprinting
• B(x; pA, pT ) the binomial probability for x given the probabilities for each allele, i.e. pA
and pT , which depend on the specific genotype, SE and imprinting factor i
One already familiar with binomial distributions will notice that this is a somewhat alternative
representation than typically used. However, it is simple to see that here, the chance of ‘success’
is represented by pA (indeed, pA + pT = 1) whereas the ‘total number of trials’ equals nA + nT .
From a practical point of view, the binomial coe cient is identical for each binomial distribution
(within a sample, not between samples) and expressed as:
b = (nA + nT )!
nA!nT !
(A.10)
As ideally only a single allele is observed for homozygous samples, potential imprinting cannot be
deduced from the allelic coverages. Here, the binomial probability will depend only on the SE -
which is obtained by SeqEM. Because this error rate is assumed to be equal for all loci but can
be ill-estimated when imprinting is present, the median SE over all loci is used. For homozygote
AA, for example, the chance of observing allele A (=pA) is 1-SE, while the chance of observing
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allele T (= pT ) is equal to SE, as T can only be present in the data due to a sequencing error.
P (nA, nT ) then becomes:
P (nA, nT ) = B(x; pA = 1≠ SE, pT = SE)
= bpnAA pnTT
= b(1≠ SE)nASEnT
(A.11)
In the PMF this value of P (nA, nT ) is multiplied by the probability of the sample being homozy-
gous AA. Assuming Hardy-Weinberg equilibrium (HWE), this equals the respective population
allele frequency squared, i.e. P 2A.
For heterozygotes, for example AT, potential imprinting has to be taken into account. This is
done by including an imprinting factor i that can vary between 0 (no imprinting) and 1 (fully
imprinted) and is estimated using MLE (see below). Without imprinting, in theory both alleles
A and T will be expressed to a similar extent so that pA and pT can be estimated as 0.5.
However, when imprinting is present, the probability of observing the imprinted allele diminishes
with a factor i2 . As the probabilities for both alleles need to sum to one, both probabilities are
normalized by dividing them by a factor 1 - i2 (= 0.5 + 0.5- i2). Also sequencing error rates have
to be taken into account, as a fraction SE of the normalized probability of one allele will be
observed as the other allele and vice versa. Thus, when allele A is imprinted, the probability of
observing allele A (= pA) equals:
0.5≠ i2
1≠ i2
(1≠ SE) + 0.51≠ i2
SE (A.12)
while for probability pT this becomes:
0.5
1≠ i2
(1≠ SE) + 0.5≠
i
2
1≠ i2
SE (A.13)
Leading to the following formula:
P (nA, nT |A imprinted) =
b(0.5≠
i
2
1≠ i2
(1≠ SE) + 0.51≠ i2
SE)nA( 0.51≠ i2
(1≠ SE) + 0.5≠
i
2
1≠ i2
SE)nT
(A.14)
However, the possibility of imprinting of allele T also has to be taken into account:
P (nA, nT |T imprinted) =
b( 0.51≠ i2
(1≠ SE) + 0.5≠
i
2
1≠ i2
SE)nA(0.5≠
i
2
1≠ i2
(1≠ SE) + 0.51≠ i2
SE)nT
(A.15)
Likewise as for homozygotes, the binomial probability for the heterozygous fraction has to be
multiplied by the genotype frequency 2PAPB. As from the underlying biology both alleles can
be assumed to have an equal chance of imprinting (= 50%), this ultimately leads to the mixture
PMF denoted in Formula A.9 and 3.1.
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When the more complicated case of four alleles is considered, instead of binomial, a mixture of
multinomial distributions is used in the PMF:
PMF (x) = P 2AM(x; pA = 1≠ SE, pT = SE/3, pC = SE/3, pG = SE/3)+
P 2TM(x; pA = SE/3, pT = 1≠ SE, pC = SE/3, pG = SE/3)+
P 2CM(x; pA = SE/3, pT = SE/3, pC = 1≠ SE, pG = SE/3)+
P 2GM(x; pA = SE/3, pT = SE/3, pC = SE/3, pG = 1≠ SE)+
PAPTM(x; pA = c1, pT = c2, pC = SE/3, pG = SE/3)+
PAPTM(x; pA = c2, pT = c1, pC = SE/3, pG = SE/3)+
PAPCM(x; pA = c1, pT = SE/3, pC = c2, pG = SE/3)+
PAPCM(x; pA = c2, pT = SE/3, pC = c1, pG = SE/3)+
PAPGM(x; pA = c1, pT = SE/3, pC = SE/3, pG = c2)+
PAPGM(x; pA = c2, pT = SE/3, pC = SE/3, pG = c1)+
PTPCM(x; pA = SE/3, pT = c1, pC = c2, pG = SE/3)+
PTPCM(x; pA = SE/3, pT = c2, pC = c1, pG = SE/3)+
PTPGM(x; pA = SE/3, pT = c1, pC = SE/3, pG = c2)+
PTPGM(x; pA = SE/3, pT = c2, pC = SE/3, pG = c1)+
PCPGM(x; pA = SE/3, pT = SE/3, pC = c1, pG = c2)+
PCPGM(x; pA = SE/3, pT = SE/3, pC = c2, pG = c1)+
(A.16)
With
c1 =
(0.5≠ i2)
(1≠ i2)
(1≠ SE) + 0.5(1≠ i2)
(SE3 )
c2 =
0.5
(1≠ i2)
(1≠ SE) + (0.5≠
i
2)
(1≠ i2)
(SE3 )
(A.17)
Next, the multinomial coe cient is defined as:
m = (nA + nT + nC + nG)!
nA!nT !nC !nG!
(A.18)
Finally, the multinomial probability is calculated as:
P (nA, nT , nC , nG) = mpnAA pnTT pnCC pnGG (A.19)
For example,
• For homozygote AA:
P (nA, nT , nC , nG) = m(1≠ SE)nA(SE3 )
nT (SE3 )
nC (SE3 )
nG (A.20)
• For heterozygote AT,
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– where allele A is imprinted:
P (nA, nT , nC , nG|A imprinted) =
m(0.5≠
i
2
1≠ i2
(1≠ SE) + 0.51≠ i2
SE
3 )
nA( 0.51≠ i2
(1≠ SE) + 0.5≠
i
2
1≠ i2
SE
3 )
nT
SE
3
nC SE
3
nG
(A.21)
– where allele T is imprinted:
P (nA, nT , nC , nG|T imprinted) =
m(( 0.51≠ i2
(1≠ SE) + 0.5≠
i
2
1≠ i2
SE
3 )
nA(0.5≠
i
2
1≠ i2
(1≠ SE) + 0.51≠ i2
SE
3 )
nT
SE
3
nC SE
3
nG
(A.22)
Likewise as for the case of two alleles, these values are multiplied by their corresponding genotype
frequency (assuming HWE).
A.2.4.5 Imprinting factor calculation
To determine the amount of imprinting (= i) of a specific SNP locus (varying from not (i = 0)
to fully (i = 1) imprinted), MLE is used:
i = supi
nŸ
a=1
PMF (xa) (A.23)
This is done in R via a line search. In summary, for each locus i is varied from 0 to 1 (in steps of
0.01) and the value of i corresponding to the highest likelihood is retained. For each sample, this
likelihood is calculated for each locus as the product of the PMF-derived probabilities. However,
because of the potential occurence of small probabilities the sum of the logarithmic values is
preferred:
i = supi
nÿ
a=1
log(PMF (xa)) (A.24)
This way, an imprinting value is obtained for every locus.
A.2.4.6 Detection of differential imprinting
Di erential imprinting between two groups can be tested by comparing the obtained sequencing
data of these subsets of samples (e.g. tumor versus control cases). A possible approach is to
calculate the ratio (i.e. Ri,s) of the coverage of the least frequent allele (= nominator) on the
coverage of most frequent allele (= denominator). For homozygous samples, this ratio will be
approximately 0, while the ratios of heterozygotes will be close to 1. Likewise as for the detection
of imprinting - but now separated for control ratios and tumor ratios - these ratios are sorted in
an ascending order. The samples after the sample with rank round(samplesize ú (P 2A + P 2T ))
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are the heterozygous samples for a specific locus. After determining the mean ratio of these
heterozygotes (Ri,stumor and Ri,scontrol), parameter Ri,di  is calculated as the di erence between
these values, i.e. Ri,di  = Ri,stumor - Ri,scontrol . Finally, using a permutation approach (10,000
permutations randomly dividing the ratios between subset 1 and subset 2), values of Ri,di  are
simulated and loci with a P-value smaller than the P-value corresponding with an FDR of 0.1
can be assumed to harbor di erential imprinting (LOI) between the two groups. The rationale of
our approach is as follows: if a locus is imprinted in one of the subsets but not in the other, all
ratios for this former subset can be expected to be around 0 (as they appear to be homozygous).
However, in the case of loss of imprinting on at least some samples of one subset, ratios will
be close to 1 in this subset due to biallelic expression. Hence, the distribution of ratios of both
subsets will be di erent, which can be tested for by a permutation test.
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A.2.5 SNP tracing & data filtering
Table A.15: Amount of SNP positions found after SNP calling that overlapped with SNV positions
of dbSNP (Overlap dbSNP), the amount of retained loci after prior filtering (fSNPs), additional
filtering on (i) FDR-adjusted P-value (adjP SNPs) and (ii) median imprinting i (miSNPs) as well
as the amount of significantly imprinted SNPs (iSNPs) per chromosome.
Chr Overlap dbSNP fSNPs adjP SNPs miSNPs iSNPs
1 38,200 2,290 1653 5 2
2 26,873 1,588 1079 6 6
3 23,093 1,505 1064 2 2
4 16,806 977 682 4 3
5 17,778 1,166 845 1 1
6 24,094 1,338 913 20 20
7 19,472 1,268 898 6 5
8 13,816 871 660 0 0
9 17,025 998 642 1 1
10 16,627 981 683 1 0
11 20,130 1,210 860 13 13
12 18,417 1,221 874 1 1
13 7,104 426 312 0 0
14 13,828 840 551 26 26
15 12,239 819 538 29 29
16 15,537 967 687 7 6
17 20,071 1,286 921 5 5
18 6,091 455 315 0 0
19 23,714 1,377 888 13 12
20 9,983 656 445 7 7
21 5,948 374 277 0 0
22 10,274 577 427 1 1
TOTAL 377,120 23,190 16,214 148 140
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A.2.6 Mixture distributions
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure A.5: Resulting mixture distributions of significantly imprinted SNP positions. (a)
MIR6723 (rs112232512). (b) LINC01139 (rs61746209). (c) ZDBF2 (rs1975597). (d) PAX8(-
AS1) (rs7585510). (e) PTX3/VEPH1 (rs73158510). (f) CPHL1P (rs12497062). (g) ATP8A1
(rs11940243). (h) HERC3/NAP1L5 (rs8605).
A.2 A MIXTURE MODEL FOR THE OMICS-BASED IDENTIFICATION OF MONOALLELICALLY
EXPRESSED LOCI AND THEIR DEREGULATION IN CANCER 44
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure A.6: Resulting mixture distributions of significantly imprinted SNP positions. (a)
ZNF300P1 (rs17800987). (b) PLAGL1 (rs9373409). (c) LOC100294145 (rs241407). (d)
PEG10 (rs35237090). (e) COPG2/MEST (rs10863). (f) HOTAIRM1 (rs706018). (g)
H19/HOTS/MRPL23 (rs2075745). (h) H19/HOTS/MRPL23 (rs2839701).
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure A.7: Resulting mixture distributions of significantly imprinted SNP positions. (a)
RP11-109L13.1 (rs201284359). (b) IGF2/INS-IGF2 (rs2585). (c) GLIPR1/KRR1 (rs1056905).
(d) DLK1 (rs1802710). (e) MEG3 (rs1053900). (f) SNRPN/SNURF (rs705). (g)
SNHG14/SNORD108/PWAR5 (rs765438). (h) PWAR6 (rs1045935).
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure A.8: Resulting mixture distributions of significantly imprinted SNP positions. (a)
SNORD116-9/10 (rs11637436). (b) SNORD116-13/14 (rs4344720). (c) SNORD115-21/22
(rs3863396). (d) IPW (rs691). (e) PLIN1 (rs4578621). (f) ZNF597 (rs11639510). (g) TPSB2
(rs77309587). (h) USP32P2 (rs141915702).
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(a) (b)
(c) (d) (e)
(f) (g)
Figure A.9: Resulting mixture distributions of significantly imprinted SNP positions. (a)
LOC102723754/MTRNR2L1 (rs3931650). (b) ZNF331 (rs8110350). (c) PEG3(-AS1)/ZIM1
(rs3143). (d) HM13 (rs6059874). (e) GNAS(-AS1) (rs1800900). (e) MCTS2P (rs1115713). (g)
BCR (rs550197).
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A.2.7 Comparison with external references
Table A.16: Overview of the overlap between imprinted genes identified by our methodology and
the one of Baran et al. [243]. Shown are the 42 genes found by the latter method. Genes also
identified as allele-specifically expressed by our framework are colored in green, whereas genes not
detected by our method are colored in red. Genes that were not covered by heterozygous samples
in our dataset - and thus were not analyzed by our framework - are shown in grey. Only genes
marked with an asterix (*) are found to be imprinted in breast tissue by Baran et al.
CPA4 CST1 DIRAS3 DLK1* FAM50B GBR10 H19*
IGF2-AS1 IGF2* INPP5F_V2 KCNQ1 KIF25 L3MBTL1* LPAR6
MAGEL2 MAGI2 MEG3* MEG8 MEG9 MEST* NAP1L5
NDN NTM PEG10* PEG3* PLAGL1* PPIEL* PRSS50
PWRN1 RP11-7F17.7 SGK2 SNHG14* SNRPN* SNURF* SYCE1
THEGL UBE3A UGT2B4 UTS2 ZDBF2* ZNF331* ZNF597
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A.2.8 Differential imprinting
HER2-enriched Basal-like
adj P-value = 0.09519 adj P-value = 0.04953 
(a)
Basal-like
adj P-value = 0.07617
(b)
adj P-value = 0.05883
HER2-enriched
(c)
HER2-enriched Basal-like
adj P-value = 0.00175 adj P-value = 0.04953 
(d)
Figure A.10: SNP positions di erentially imprinted between normal and cancer subtypes samples.
(a) ZDBF2 (rs3732084). (b) PEG10 (rs35237090). (c) PEG10 (rs7810469). (d) H19 (rs2075745).
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HER2-enriched Basal-like
adj P-value = 0.07145 adj P-value = 0.04953 
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Figure A.11: SNP positions di erentially imprinted between normal and cancer subtypes samples.
(a) H19 (rs2075744). (b) H19 (rs2839703). (c) H19 (rs2839704). (d) H19 (rs2839702).
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HER2-enriched Basal-like
adj P-value = 0.00393 adj P-value = 0.04953 
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Figure A.12: SNP positions di erentially imprinted between normal and cancer subtypes samples.
(a) H19 (rs10840159). (b) H19 (rs2839698). (c) H19 (rs2067051). (d) H19 (rs3741219).
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Figure A.13: SNP positions di erentially imprinted between normal and cancer subtypes samples.
(a) IGF2 (rs7873). (b) IGF2 (rs2585). (c) MEG3 (rs1053900). (d) MEG3 (rs4378559).
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Figure A.14: SNP positions di erentially imprinted between normal and cancer subtypes sam-
ples. (a) MEG3 (rs12890215). (b) ZNF331 (rs8110350). (c) ZNF331 (rs8110538). (d) HM13
(rs6059869).
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Table A.17: Median beta values for control and tumor samples for probes in the HM13 gene that
are monoallelically methylated over all control samples (i.e. median beta value between 0.4 and
0.6).
Probe Control Tumor
cg02146091 0.42 0.44
cg15815607 0.42 0.46
cg18471488 0.55 0.41
cg19617948 0.42 0.46
cg24607140 0.55 0.61
cg25359645 0.42 0.45
Table A.18: Median beta values for control and tumor samples for probes in the HG19 gene that
are monoallelically methylated over all control samples (i.e. median beta value between 0.4 and
0.6).
Probe Control Tumor Probe Control Tumor
cg00237904 0.48 0.45 cg16303279 0.55 0.61
cg01539474 0.58 0.60 cg17769238 0.52 0.42
cg01895612 0.48 0.45 cg17985533 0.54 0.36
cg02694715 0.59 0.60 cg18362496 0.46 0.39
cg04975775 0.54 0.45 cg18454954 0.44 0.40
cg06765785 0.43 0.31 cg22172494 0.53 0.61
cg09701145 0.53 0.47 cg23476401 0.52 0.48
cg10154633 0.58 0.59 cg24510613 0.52 0.53
cg10602543 0.55 0.51 cg24605090 0.49 0.44
cg11492040 0.56 0.45 cg25281616 0.53 0.51
cg11735853 0.51 0.55 cg25437674 0.40 0.37
cg11753499 0.42 0.30 cg25579157 0.53 0.51
cg13581483 0.53 0.54 cg25821896 0.57 0.48
cg15317267 0.56 0.56 cg25838645 0.55 0.55
cg15886040 0.57 0.58 cg25852472 0.54 0.44
cg15922305 0.51 0.39 cg26469586 0.47 0.49
B
Appendix B
B.1 Characterization of DNA methylation dynamics in the
ontogeny of a songbird
B.1.1 (Differential) methylation and expression analysis & enrichment analysis
Promoter 3%
Exon 5.39%
Intron 31.32%
Intergenic 60.29%
Methylation Peaks
(a)
Promoter 4.4%
Exon 10.52%
Intron 31.93%
Intergenic 53.15%
down−methylated Methylation Peaks
(b)
Figure B.1: Genomic distribution of the identified Methylation Peaks. (a) Distribution of the
full set of 719,917 Methylation Peaks. (b) Distribution of the 30,700 significantly down-methylated
Methylation Peaks.
B.1 CHARACTERIZATION OF DNA METHYLATION DYNAMICS IN THE
ONTOGENY OF A SONGBIRD 56
2.15%
4.18%
28.97%
64.7%
1
2.55%
4.99%
33.2%
59.26%
1A
5.43%
10.93%39.07%
44.57%
1B
1.94%
3.59%
30.14%
64.33%
2
2.26%
4.33%
31.68%
61.73%
3
2.29%
4.5%
29.28%
63.92%
4
3.86%
6.35%
28.1%
61.69%
4A
3.07%
5.83%
33.74%
57.36%
5
3.17%
5.95%
35.52%
55.36%
6
2.93%
6.53%
35.04%
55.5%
7
3.19%
6.12%
33.04%
57.66%
8
3.83%
6.36%
30.08%
59.72%
9
3.7%
7.68%
33.49%
55.13%
10
3.47%
5.93%
28.15%
62.45%
11
3.38%
7.86%
37.54%
51.22%
12
4.01%
6.62%
32.11%
57.26%
13
4.72%
8.7%
36.36%
50.22%
14
4.88%
10.18%
34.26%
50.68%
15
0%100%
16
5.37%
9.34%
40.12%
45.18%
17
5.09%
9.45%
40.59%
44.87%
18
5.14%
9.98%45.19%
39.69%
19
4.59%
8.2%
29.34%
57.88%
20
5.39%
11.11%39.76%
43.74%
21
6.37%
9.85%
32.26%
51.52%
22
6.42%
9.43%
31.52%
52.64%
23
4.73%
6.7%
28.54%
60.03%
24
10.74%
13.3%
46.41%
29.54%
25
7.24%
11.24%39.89%
41.63%
26
9.44%
12.75%
42.52%
35.29%
27
7.68%
12.77%
44.44%
35.11%
28
2.35%
3.89%
29.23%
64.53%
Z
4.7%
3.42%2.14%
89.74%
LG2
16.67%
5.95%13.1%
64.29%
LG5
6.35%
4.29%
8.34%
81.01%
Un
promoter  exon intron intergenic
Figure B.2: Genomic distribution of the 719,917 identified Methylation Peaks per chromosome.
Corresponding chromosome names are stated above each piechart. Apart from some exceptions
like chromosomes 16, LG2, LG5 and Un, overall, the distribution of the Methylation Peaks follows
a general trend.
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Figure B.3: Genomic distribution of the summed G266 and ZFTMA coverage of the control
(i.e. DMSO-treated) samples per chromosome. Corresponding chromosome names are stated above
each piechart. Not unexpectedly, this distribution is very similar to the distribution of Figure B.2.
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(b)
Figure B.3: CpG pyrosequencing validation of MethylCap-seq results. This figure shows the
changes in DNA methylation of specific CpG sites in the promoters of BDNF, NGB, HES1-4,
GABRD, ANK1, MMP9 and IKBKE after AZA (1 µM) treatment in ZFTMA and G266 cell lines,
relative to DMSO solvent control. The shown DNA methylation levels represent the mean of three
independent experiments. Only CpG sites that passed quality control were considered. The NGB
gene was found to contain a SNP in the G266 cell line at position chr5:39,429,316, which was
corrected for in the analysis. The methylation changes could be validated for each of the genes,
except for IKBKE (2-way ANOVA). For MMP9 the change in promoter methylation was only
confirmed in the ZFTMA cell line. (a) BDNF, NGB, HES1-4 and GABRD. (b) ANK1, MMP9
and IKBKE.
